Neutron capture therapy

International Nuclear Information System (INIS)

Jun, B. J.

1998-11-01

The overall state of the art related with neutron capture therapy(NCT) is surveyed. Since the field related with NCT is very wide, it is not intended to survey all related subjects in depth. The primary objective of this report is to help those working for the installation of a NCT facility and a PGNAA(prompt gamma ray neutron activation analysis) system for the boron analysis understand overall NCT at Hanaro. Therefore, while the parts of reactor neutron source and PGNAA are dealt in detail, other parts are limited to the level necessary to understand related fields. For example, the subject of chemical compound which requires intensive knowledge on chemistry, is not dealt as a separated item. However, the requirement of a compound for NCT, currently available compounds, their characteristics, etc. could be understood through this report. Although the subject of cancer treated by NCT is out of the capability of the author, it is dealt focussing its characteristics related with the success of NCT. Each detailed subject is expected to be dealt more detail by specialists in future. This report would be helpful for the researchers working for the NCT to understand related fields. (author). 128 refs., 3 tabs., 12 figs

Gadolinium neutron capture therapy

International Nuclear Information System (INIS)

Akine, Yasuyuki; Tokita, Nobuhiko; Tokuuye, Koichi; Satoh, Michinao; Churei, Hisahiko

1993-01-01

Gadolinium neutron capture therapy makes use of photons and electrons produced by nuclear reactions between gadolinium and lower-energy neutrons which occur within the tumor. The results of our studies have shown that its radiation effect is mostly of low LET and that the electrons are the significant component in the over-all dose. The dose from gadolinium neutron capture reactions does not seem to increase in proportion to the gadolinium concentration, and the Gd-157 concentration of about 100 μg/ml appears most optimal for therapy. Close contact between gadolinium and the cell is not necessarily required for cell inactivation, however, the effect of electrons released from intracellular gadolinium may be significant. Experimental studies on tumor-bearing mice and rabbits have shown that this is a very promising modality though further improvements in gadolinium delivery to tumors are needed. (author)

Preclinical studies on gadolinium neutron capture therapy

International Nuclear Information System (INIS)

Akine, Yasuyuki

1994-01-01

Gadolinium neutron capture therapy is based on radiations (photons and electrons) produced in the tumor by a nuclear reaction between gadolinium and lower-energy neutrons. Studies with Chinese hamster cells have shown that the radiation effect resulting from gadolinium neutron capture reactions is mostly of low LET and that released electrons are the significant component in the over-all dose. Biological dosimetry revealed that the dose does not seem to increase in proportion to the gadolinium concentration, leading to a conclusion that there is a range of gadolinium concentrations most efficient for gadolinium neutron capture therapy. The in vivo studies with transplantable tumors in mice and rabbits have revealed that close contact between gadolinium and the cell is not necessarily required for cell inactivation and that gadolinium delivery selective to tumors is crucial. The results show that the potential of gadolinium neutron capture therapy as a therapeutic modality appears very promising. (author)

An accelerator-based Boron Neutron Capture Therapy (BNCT) facility based on the 7Li(p,n)7Be

Science.gov (United States)

Musacchio González, Elizabeth; Martín Hernández, Guido

2017-09-01

BNCT (Boron Neutron Capture Therapy) is a therapeutic modality used to irradiate tumors cells previously loaded with the stable isotope 10B, with thermal or epithermal neutrons. This technique is capable of delivering a high dose to the tumor cells while the healthy surrounding tissue receive a much lower dose depending on the 10B biodistribution. In this study, therapeutic gain and tumor dose per target power, as parameters to evaluate the treatment quality, were calculated. The common neutron-producing reaction 7Li(p,n)7Be for accelerator-based BNCT, having a reaction threshold of 1880.4 keV, was considered as the primary source of neutrons. Energies near the reaction threshold for deep-seated brain tumors were employed. These calculations were performed with the Monte Carlo N-Particle (MCNP) code. A simple but effective beam shaping assembly (BSA) was calculated producing a high therapeutic gain compared to previously proposed facilities with the same nuclear reaction.

A comparison of the COG and MCNP codes in computational neutron capture therapy modeling, Part I: boron neutron capture therapy models.

Science.gov (United States)

Culbertson, C N; Wangerin, K; Ghandourah, E; Jevremovic, T

2005-08-01

The goal of this study was to evaluate the COG Monte Carlo radiation transport code, developed and tested by Lawrence Livermore National Laboratory, for neutron capture therapy related modeling. A boron neutron capture therapy model was analyzed comparing COG calculational results to results from the widely used MCNP4B (Monte Carlo N-Particle) transport code. The approach for computing neutron fluence rate and each dose component relevant in boron neutron capture therapy is described, and calculated values are shown in detail. The differences between the COG and MCNP predictions are qualified and quantified. The differences are generally small and suggest that the COG code can be applied for BNCT research related problems.

Analytical dosimetry for spontaneous tumor dogs receiving boron neutron capture therapy

International Nuclear Information System (INIS)

Wheeler, F.J.; Atkinson, C.A.; Gavin, P.R.

1992-01-01

The dog irradiation project of the Power Burst Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program is administered by Washington State University (WSU) with analytical and physical dosimetry provided by the Idaho National Engineering Laboratory (INEL). One subtask of this project includes BNCT safety studies for dogs with spontaneously-occurring brain tumors. The boron compound (Na 2 B 12 H 11 SH or BSH) was administered and single irradiations performed using the epithermal-neutron beam at the Brookhaven Medical Research Reactor (BMRR). The main goal of the study was not to provide therapy, but to determine tumorcidal effect while administering a subtolerance dose to healthy tissue. Irradiation times were based on delivery of 19 Gy peak physical dose to the blood

Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer

Energy Technology Data Exchange (ETDEWEB)

Haapaniemi, Aaro, E-mail: aaro.haapaniemi@hus.fi [Department of Otorhinolaryngology–Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki (Finland); Kankaanranta, Leena [Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki (Finland); Saat, Riste [Department of Radiology, Helsinki University Hospital and University of Helsinki, Helsinki (Finland); Koivunoro, Hanna; Saarilahti, Kauko [Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki (Finland); Mäkitie, Antti; Atula, Timo [Department of Otorhinolaryngology–Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki (Finland); Joensuu, Heikki [Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki (Finland)

2016-05-01

Purpose: To investigate the safety and efficacy of boron neutron capture therapy (BNCT) as a larynx-preserving treatment option for patients with recurrent laryngeal cancer. Methods and Materials: Six patients with locally recurrent squamous cell laryngeal carcinoma and 3 patients with persistent laryngeal cancer after prior treatment were treated with BNCT at the FiR1 facility (Espoo, Finland) in 2006 to 2012. The patients had received prior radiation therapy with or without concomitant chemotherapy to a cumulative median dose of 66 Gy. The median tumor diameter was 2.9 cm (range, 1.4-10.9 cm) before BNCT. Boron neutron capture therapy was offered on a compassionate basis to patients who either refused laryngectomy (n=7) or had an inoperable tumor (n=2). Boronophenylalanine-fructose (400 mg/kg) was used as the boron carrier and was infused over 2 hours intravenously before neutron irradiation. Results: Six patients received BNCT once and 3 twice. The estimated average gross tumor volume dose ranged from 22 to 38 Gy (W) (mean; 29 Gy [W]). Six of the 8 evaluable patients responded to BNCT; 2 achieved complete and 4 partial response. One patient died early and was not evaluable for response. Most common side effects were stomatitis, fatigue, and oral pain. No life-threatening or grade 4 toxicity was observed. The median time to progression within the target volume was 6.6 months, and the median overall survival time 13.3 months after BNCT. One patient with complete response is alive and disease-free with a functioning larynx 60 months after BNCT. Conclusions: Boron neutron capture therapy given after prior external beam radiation therapy is well tolerated. Most patients responded to BNCT, but long-term survival with larynx preservation was infrequent owing to cancer progression. Selected patients with recurrent laryngeal cancer may benefit from BNCT.

Optimal Neutron Source and Beam Shaping Assembly for Boron Neutron Capture Therapy

International Nuclear Information System (INIS)

Vujic, J.; Greenspan, E.; Kastenber, W.E.; Karni, Y.; Regev, D.; Verbeke, J.M.; Leung, K.N.; Chivers, D.; Guess, S.; Kim, L.; Waldron, W.; Zhu, Y.

2003-01-01

There were three objectives to this project: (1) The development of the 2-D Swan code for the optimization of the nuclear design of facilities for medical applications of radiation, radiation shields, blankets of accelerator-driven systems, fusion facilities, etc. (2) Identification of the maximum beam quality that can be obtained for Boron Neutron Capture Therapy (BNCT) from different reactor-, and accelerator-based neutron sources. The optimal beam-shaping assembly (BSA) design for each neutron source was also to e obtained. (3) Feasibility assessment of a new neutron source for NCT and other medical and industrial applications. This source consists of a state-of-the-art proton or deuteron accelerator driving and inherently safe, proliferation resistant, small subcritical fission assembly

Background suppression by the DRAGON radiative capture facility at TRIUMF/ISAC

International Nuclear Information System (INIS)

Hutcheon, D.; Buchmann, L.; Chen, A.A.; D'Auria, J.M.; Davis, C.A.; Greife, U.; Hussein, A.; Ottewell, D.F.; Ouellet, C.V.; Parikh, A.; Parker, P.; Pearson, J.; Ruiz, C.; Ruprecht, G.; Trinczek, M.; Vockenhuber, C.

2008-01-01

The DRAGON facility at TRIUMF/ISAC detects reaction products following radiative capture of a hydrogen or helium target nucleus by an accelerated heavy ion. Capture reactions of interest in nuclear astrophysics may have reaction rates 10-14 orders of magnitude lower than the intensity of the incident beam: as well as efficiently transporting the heavy reaction product from the target to a suitable particle detector, the separator must provide most of the suppression of unreacted beam. We describe the features of beam background encountered in a range of proton- and alpha-capture experiments at the DRAGON facility.

Neutron capture therapy. Principles and applications

International Nuclear Information System (INIS)

Sauerwein, Wolfgang A.G.; Moss, Raymond; Wittig, Andrea; Nakagawa, Yoshinobu

2012-01-01

State of the art report on neutron capture therapy. Summarizes the progress made in recent decades. Multidisciplinary approach. Written by the most experienced specialists Neutron capture therapy (NCT) is based on the ability of the non-radioactive isotope boron-10 to capture thermal neutrons with very high probability and immediately to release heavy particles with a path length of one cell diameter. This in principle allows for tumor cell-selective high-LET particle radiotherapy. NCT is exciting scientifically but challenging clinically, and a key factor in success is close collaboration among very different disciplines. This book provides a comprehensive summary of the progress made in NCT in recent years. Individual sections cover all important aspects, including neutron sources, boron chemistry, drugs for NCT, dosimetry, and radiation biology. The use of NCT in a variety of malignancies and also some non-malignant diseases is extensively discussed. NCT is clearly shown to be a promising modality at the threshold of wider clinical application. All of the chapters are written by experienced specialists in language that will be readily understood by all participating disciplines.

Development of a Tandem-ElectroStatic-Quadrupole accelerator facility for Boron Neutron Capture Therapy (BNCT)

International Nuclear Information System (INIS)

Kreiner, A.J.; Thatar Vento, V.; Levinas, P.; Bergueiro, J.; Burlon, A.A.; Di Paolo, H.; Kesque, J.M.; Valda, A.A.; Debray, M.E.; Somacal, H.R.; Minsky, D.M.; Estrada, L.; Hazarabedian, A.; Johann, F.; Suarez Sandin, J.C.; Castell, W.; Davidson, J.; Davidson, M.; Repetto, M.; Obligado, M.; Nery, J.P.; Huck, H.; Igarzabal, M.; Fernandez Salares, A.

2008-01-01

There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). An ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.4-2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.20-1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. This machine is conceptually shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. This electrostatic machine is one of the technologically simplest and cheapest solutions for optimized AB-BNCT. At present there is no BNCT facility in the world with the characteristics presented in this work. For the accelerator, results on its design, construction and beam transport calculations are discussed. Taking into account the peculiarities of the expected irradiation field, the project also considers a specific study of the treatment room. This study aims at the design of the treatment room emphasizing aspects related to patient, personnel and public radiation protection; dose monitoring; patient positioning and room construction. The design considers both thermal (for the treatment of shallow tumors) and epithermal (for deep-seated tumors) neutron beams entering the room through a port connected to the accelerator via a moderation and neutron beam shaping assembly. Preliminary results of dose calculations for the treatment room design, using the MCNP program, are presented

Design of a boron neutron capture enhanced fast neutron therapy assembly

Energy Technology Data Exchange (ETDEWEB)

Wang, Zhonglu [Georgia Inst. of Technology, Atlanta, GA (United States)

2006-12-01

The use of boron neutron capture to boost tumor dose in fast neutron therapy has been investigated at several fast neutron therapy centers worldwide. This treatment is termed boron neutron capture enhanced fast neutron therapy (BNCEFNT). It is a combination of boron neutron capture therapy (BNCT) and fast neutron therapy (FNT). It is believed that BNCEFNT may be useful in the treatment of some radioresistant brain tumors, such as glioblastoma multiform (GBM). A boron neutron capture enhanced fast neutron therapy assembly has been designed for the Fermilab Neutron Therapy Facility (NTF). This assembly uses a tungsten filter and collimator near the patient's head, with a graphite reflector surrounding the head to significantly increase the dose due to boron neutron capture reactions. The assembly was designed using Monte Carlo radiation transport code MCNP version 5 for a standard 20x20 cm² treatment beam. The calculated boron dose enhancement at 5.7-cm depth in a water-filled head phantom in the assembly with a 5x5 cm² collimation was 21.9% per 100-ppm ¹⁰B for a 5.0-cm tungsten filter and 29.8% for a 8.5-cm tungsten filter. The corresponding dose rate for the 5.0-cm and 8.5-cm thick filters were 0.221 and 0.127 Gy/min, respectively; about 48.5% and 27.9% of the dose rate of the standard 10x10 cm² fast neutron treatment beam. To validate the design calculations, a simplified BNCEFNT assembly was built using four lead bricks to form a 5x5 cm² collimator. Five 1.0-cm thick 20x20 cm² tungsten plates were used to obtain different filter thicknesses and graphite bricks/blocks were used to form a reflector. Measurements of the dose enhancement of the simplified assembly in a water-filled head phantom were performed using a pair of tissue-equivalent ion chambers. One of the ion chambers is loaded with 1000-ppm natural boron (184-ppm ¹⁰B) to measure dose due to boron neutron capture. The

Neutron capture therapy: Years of experimentation---Years of reflection

International Nuclear Information System (INIS)

Farr, L.E.

1991-01-01

This report describes early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments. This work carried out over eighteen years, beginning over forty years ago. Yet, it is only fitting to start by relating how neutron capture therapy became part of Brookhaven's Medical Research Center program

Development of cancer therapy facility of HANARO

International Nuclear Information System (INIS)

Jun, Byung Jin; Hwang, S. Y.; Kim, M. J. and others

2000-04-01

Facilities of the research and clinical treatments of neutron capture therapy using HANARO are developed, and they are ready to install. They are BNCT irradiation facility and prompt gamma neutron activatiion analysis facility. Since every horizontal neutron facility of HANARO is long and narrow tangential beam tube, it is analysed that sufficient epithermal neutrons for the BNCT cannot be obtained but sufficient thermal neutrons can be obtained by a filter composed of silicon and bismuth single crystals. Since the thermal neutron penetaration increases significantly when the crystals are cooled, a filter cooled by liquid nitrogen is developed. So as to avoid interference with the reactor operation, a water shutter is developed. The irradiation room is designed for the temporary surgical operation as well. Handling tools to remove activated beam port plug and to install water shutter and filter are developed. The basic structure of the irradiation room is already installed and most of other parts are ready to install. Since no free beam port is available for the prompt gamma neutron activation analysis, a method obtaining almost pure thermal neutrons by the vertical diffraction of extra beam for the polarized neutron spectrometer is developed. This method is confirmed by analysis and experiments to give high enough neutron beam. Equipment and devices are provided to install this facility

Development of cancer therapy facility of HANARO

Energy Technology Data Exchange (ETDEWEB)

Jun, Byung Jin; Hwang, S. Y.; Kim, M. J. and others

2000-04-01

Facilities of the research and clinical treatments of neutron capture therapy using HANARO are developed, and they are ready to install. They are BNCT irradiation facility and prompt gamma neutron activatiion analysis facility. Since every horizontal neutron facility of HANARO is long and narrow tangential beam tube, it is analysed that sufficient epithermal neutrons for the BNCT cannot be obtained but sufficient thermal neutrons can be obtained by a filter composed of silicon and bismuth single crystals. Since the thermal neutron penetaration increases significantly when the crystals are cooled, a filter cooled by liquid nitrogen is developed. So as to avoid interference with the reactor operation, a water shutter is developed. The irradiation room is designed for the temporary surgical operation as well. Handling tools to remove activated beam port plug and to install water shutter and filter are developed. The basic structure of the irradiation room is already installed and most of other parts are ready to install. Since no free beam port is available for the prompt gamma neutron activation analysis, a method obtaining almost pure thermal neutrons by the vertical diffraction of extra beam for the polarized neutron spectrometer is developed. This method is confirmed by analysis and experiments to give high enough neutron beam. Equipment and devices are provided to install this facility.

In vivo evaluation of neutron capture therapy effectivity using calcium phosphate-based nanoparticles as Gd-DTPA delivery agent.

Science.gov (United States)

Dewi, Novriana; Mi, Peng; Yanagie, Hironobu; Sakurai, Yuriko; Morishita, Yasuyuki; Yanagawa, Masashi; Nakagawa, Takayuki; Shinohara, Atsuko; Matsukawa, Takehisa; Yokoyama, Kazuhito; Cabral, Horacio; Suzuki, Minoru; Sakurai, Yoshinori; Tanaka, Hiroki; Ono, Koji; Nishiyama, Nobuhiro; Kataoka, Kazunori; Takahashi, Hiroyuki

2016-04-01

A more immediate impact for therapeutic approaches of current clinical research efforts is of major interest, which might be obtained by developing a noninvasive radiation dose-escalation strategy, and neutron capture therapy represents one such novel approach. Furthermore, some recent researches on neutron capture therapy have focused on using gadolinium as an alternative or complementary for currently used boron, taking into account several advantages that gadolinium offers. Therefore, in this study, we carried out feasibility evaluation for both single and multiple injections of gadolinium-based MRI contrast agent incorporated in calcium phosphate nanoparticles as neutron capture therapy agent. In vivo evaluation was performed on colon carcinoma Col-26 tumor-bearing mice irradiated at nuclear reactor facility of Kyoto University Research Reactor Institute with average neutron fluence of 1.8 × 10(12) n/cm(2). Antitumor effectivity was evaluated based on tumor growth suppression assessed until 27 days after neutron irradiation, followed by histopathological analysis on tumor slice. The experimental results showed that the tumor growth of irradiated mice injected beforehand with Gd-DTPA-incorporating calcium phosphate-based nanoparticles was suppressed up to four times higher compared to the non-treated group, supported by the results of histopathological analysis. The results of antitumor effectivity observed on tumor-bearing mice after neutron irradiation indicated possible effectivity of gadolinium-based neutron capture therapy treatment.

Physical engineering and medical physics on boron neutron capture therapy

International Nuclear Information System (INIS)

Sakurai, Yoshinori

2011-01-01

The contents of physical engineering and medical physics that support boron neutron capture therapy (BNCT) can be roughly classified to the four items, (1) neutron irradiation system, (2) development and improvement of dose assessment techniques, (3) development and improvement of dose planning system, and (4) quality assurance and quality control. This paper introduces the BNCT at Kyoto University Research Reactor Institute, with a focus on the basic physics of BNCT, thermal neutron irradiation and epithermal neutron irradiation, heavy water neutron irradiation facilities of KUR, and medical irradiation system of KUR. It also introduces the world's first BNCT clinical cyclotron irradiation system (C-BENS) of Kyoto University Research Reactor Institute, BNCT dose assessment techniques, dose planning system, and quality assurance and quality control. (A.O.)

The national carbon capture center at the power systems development facility

Energy Technology Data Exchange (ETDEWEB)

None, None

2012-09-01

The Power Systems Development Facility (PSDF) is a state-of-the-art test center sponsored by the U.S. Department of Energy and dedicated to the advancement of clean coal technology. In addition to the development of advanced coal gasification processes, the PSDF features the National Carbon Capture Center (NCCC) to study CO2 capture from coal-derived syngas and flue gas. The NCCC includes multiple, adaptable test skids that allow technology development of CO2 capture concepts using coal-derived syngas and flue gas in industrial settings. Because of the ability to operate under a wide range of flow rates and process conditions, research at the NCCC can effectively evaluate technologies at various levels of maturity. During the Budget Period Three reporting period, efforts at the NCCC/PSDF focused on testing of pre-combustion CO2 capture and related processes; commissioning and initial testing at the post-combustion CO2 capture facilities; and operating the gasification process to develop gasification related technologies and for syngas generation to test syngas conditioning technologies.

THE NATIONAL CARBON CAPTURE CENTER AT THE POWER SYSTEMS DEVELOPMENT FACILITY

Energy Technology Data Exchange (ETDEWEB)

None, None

2011-05-11

The Power Systems Development Facility (PSDF) is a state-of-the-art test center sponsored by the U.S. Department of Energy and dedicated to the advancement of clean coal technology. In addition to the development of advanced coal gasification processes, the PSDF features the National Carbon Capture Center (NCCC) to study CO2 capture from coal-derived syngas and flue gas. The NCCC includes multiple, adaptable test skids that allow technology development of CO2 capture concepts using coal-derived syngas and flue gas in industrial settings. Because of the ability to operate under a wide range of flow rates and process conditions, research at the NCCC can effectively evaluate technologies at various levels of maturity. During the Budget Period Two reporting period, efforts at the PSDF/NCCC focused on new technology assessment and test planning; designing and constructing post-combustion CO2 capture facilities; testing of pre-combustion CO2 capture and related processes; and operating the gasification process to develop gasification related technologies and for syngas generation to test syngas conditioning technologies.

Microdosimetry for Boron Neutron Capture Therapy

International Nuclear Information System (INIS)

Maughan, R.L.; Kota, C.

2000-01-01

The specific aims of the research proposal were as follows: (1) To design and construct small volume tissue equivalent proportional counters for the dosimetry and microdosimetry of high intensity thermal and epithermal neutron beams used in BNCT, and of modified fast neutron beams designed for boron neutron capture enhanced fast neutron therapy (BNCEFNT). (2) To develop analytical methods for estimating the biological effectiveness of the absorbed dose in BNCT and BNCEFNT based on the measured microdosimetric spectra. (3) To develop an analytical framework for comparing the biological effectiveness of different epithermal neutron beams used in BNCT and BNCEFNT, based on correlated sets of measured microdosimetric spectra and radiobiological data. Specific aims (1) and (2) were achieved in their entirety and are comprehensively documented in Jay Burmeister's Ph.D. dissertation entitled ''Specification of physical and biologically effective absorbed dose in radiation therapies utilizing the boron neutron capture reaction'' (Wayne State University, 1999). Specific aim (3) proved difficult to accomplish because of a lack of sufficient radiobiological data

Neutron Therapy Facility

Data.gov (United States)

Federal Laboratory Consortium — The Neutron Therapy Facility provides a moderate intensity, broad energy spectrum neutron beam that can be used for short term irradiations for radiobiology (cells)...

Biological Tests for Boron Neutron Capture Therapy Research at the TRIGA Mark II Reactor in Pavia

Energy Technology Data Exchange (ETDEWEB)

Protti, N.; Ballarini, F.; Bortolussi, S.; De Bari, A.; Stella, S.; Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); Nuclear Physics National Institute (INFN), Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); Bakeine, J.G.; Cansolino, L.; Clerici, A.M. [Laboratory of Experimental Surgery, Department of Surgery, University of Pavia, Pavia (Italy)

2011-07-01

The thermal column of the TRIGA Mark II reactor of the Pavia University is used as an irradiation facility to perform biological tests and irradiations of living systems for Boron Neutron Capture Therapy (BNCT) research. The suitability of the facility has been ensured by studying the neutron flux and the photon background in the irradiation chamber inside the thermal column. This characterization has been realized both by flux and dose measurements as well as by Monte Carlo simulations. The routine irradiations concern in vitro cells cultures and different tumor animal models to test the efficacy of the BNCT treatment. Some results about these experiments will be described. (author)

Neutron capture therapy for melanoma

Energy Technology Data Exchange (ETDEWEB)

Coderre, J.A.; Glass, J.D.; Micca, P.; Fairchild, R.G.

1988-01-01

The development of boron-containing compounds which localize selectively in tumor may require a tumor-by-tumor type of approach that exploits any metabolic pathways unique to the particular type of tumor. Melanin-producing melanomas actively transport and metabolize aromatic amino acids for use as precursors in the synthesis of the pigment melanin. It has been shown that the boron-containing amino acid analog p-borono-phenylalanine (BPA) is selectively accumulated in melanoma tissue, producing boron concentrations in tumor that are within the range estimated to be necessary for successful boron neutron capture therapy (BNCT). We report here the results of therapy experiments carried out at the Brookhaven Medical Research Reactor (BMRR). 21 refs., 5 figs., 3 tabs.

Neutron capture therapy for melanoma

International Nuclear Information System (INIS)

Coderre, J.A.; Glass, J.D.; Micca, P.; Fairchild, R.G.

1988-01-01

The development of boron-containing compounds which localize selectively in tumor may require a tumor-by-tumor type of approach that exploits any metabolic pathways unique to the particular type of tumor. Melanin-producing melanomas actively transport and metabolize aromatic amino acids for use as precursors in the synthesis of the pigment melanin. It has been shown that the boron-containing amino acid analog p-borono-phenylalanine (BPA) is selectively accumulated in melanoma tissue, producing boron concentrations in tumor that are within the range estimated to be necessary for successful boron neutron capture therapy (BNCT). We report here the results of therapy experiments carried out at the Brookhaven Medical Research Reactor (BMRR). 21 refs., 5 figs., 3 tabs

Gadolinium atom on neutron capture therapy

International Nuclear Information System (INIS)

Oda, Y.; Takagaki, M.; Miyatake, S.; Kikuchi, H.

1994-01-01

This report describes our measurements of gadolinium concentrations in several brain tumors obtained from fresh surgical specimens, as compared with corresponding concentrations in the blood. Moreover we tried to find out if the gadolinium concentration is high enough to use this compound in the treatment of brain tumors by neutron capture therapy. (J.P.N.)

Advances in neutron capture therapy 2006. Proceedings of 12th international congress on neutron capture therapy

International Nuclear Information System (INIS)

Nakagawa, Yoshinobu; Kobayashi, Tooru; Fukuda, Hiroshi

2006-01-01

The Twelfth International Congress on Neutron Capture Therapy (ICNCT-12) is being held from October 9th to 13th, 2006 at the Kagawa International Congress Hall in Takamatsu, Kagawa, Japan. The main theme of the congress is From the past to the Future'. Five symposiums were organized to accommodate all the contributions from the international scientific committees of the International Society for Neutron Capture Therapy (ISNCT), and two symposiums were added to balance the number of fields of specialties. The seven symposiums for ICNCT-12 are as follows: 1) Clinical Results of BNCT for Brain Tumors, 2) Dosimetry, 3) Treatment Planning system, 4) Drug Delivery System, 5) Biomedical and General Matters, 6) BNCT Systems using Accelerators, 7) New Applications and Protocols for BNCT. There are a total of 195 presentations in this congress: 3 special lectures, 34 symposium presentations, 10 presentations in two special sessions from the recipients of the Ralph G. Fairchild Award, 70 presentations in the oral parallel sessions and 78 presentations in the poster sessions. A compilation of 169 papers are published in this proceedings. The 165 of the presented papers are indexed individually. (J.P.N.)

Clinical considerations for neutron capture therapy of brain tumors

International Nuclear Information System (INIS)

Madoc-Jones, H.; Wazer, D.E.; Zamenhof, R.G.; Harling, O.K.; Bernard, J.A. Jr.

1990-01-01

The radiotherapeutic management of primary brain tumors and metastatic melanoma in brain has had disappointing clinical results for many years. Although neutron capture therapy was tried in the US in the 1950s and 1960s, the results were not as hoped. However, with the newly developed capability to measure boron concentrations in blood and tissue both quickly and accurately, and with the advent of epithermal neutron beams obviating the need for scalp and skull reflection, it should not be possible to mount such a clinical trial of NCT again and avoid serious complications. As a prerequisite, it will be important to demonstrate the differential uptake of boron compound in brain tumor as compared with normal brain and its blood supply. If this can be done, then a trial of boron neutron capture therapy for brain tumors should be feasible. Because boronated phenylalanine has been demonstrated to be preferentially taken up by melanoma cells through the biosynthetic pathway for melanin, there is special interest in a trial of boron neutron capture therapy for metastatic melanoma in brain. Again, the use of an epithermal beam would make this a practical possibility. However, because any epithermal (or thermal) beam must contain a certain contaminating level of gamma rays, and because even a pure neutron beam cases gamma rays to be generated when it interacts with tissue, they think that it is essential to deliver treatments with an epithermal beam for boron neutron capture therapy in fractions in order to minimize the late-effects of low-LET gamma rays in the normal tissue

Epithermal neutron beam design for neutron capture therapy at the Power Burst Facility and the Brookhaven Medical Research Reactor

International Nuclear Information System (INIS)

Wheeler, F.J.; Parsons, D.K.; Rushton, B.L.; Nigg, D.W.

1990-01-01

Nuclear design studies have been performed for two reactor-based epithermal neutron beams for cancer treatment by neutron capture therapy (NCT). An intermediate-intensity epithermal beam has been designed and implemented at the Brookhaven Medical Research Reactor (BMRR). Measurements show that the BMRR design predictions for the principal characteristics of this beam are accurate. A canine program for research into the biological effects of NCT is now under way at BMRR. The design for a high-intensity epithermal beam with minimal contamination from undesirable radiation components has been finalized for the Power Burst Facility (PBF) at the Idaho National Engineering Laboratory. This design will be implemented when it is determined that human NCT trials are advisable. The PBF beam will exhibit approximately an order of magnitude improvement in absolute epithermal flux intensity over that available in the BMRR, and its angular distribution and spectral characteristics will be more advantageous for NCT. The combined effects of beam intensity, angular distribution, spectrum, and contaminant level allow the desired tumor radiation dose to be delivered in much shorter times than are possible with the currently available BMRR beam, with a significant reduction (factor of 3 to 5) in collateral dose due to beam contaminants

Neutron capture therapy with thermal neutrons at IRT MIFI

International Nuclear Information System (INIS)

Zajtsev, K.N.; Portnov, A.A.; Savkin, V.A.; Kulakov, V.N.; Khokhlov, V.F.; Shejno, I.N.; Vajnson, A.A.; Kozlovskaya, N.G.; Meshcherikova, V.V.; Mitin, V.N.; Yarmonenko, S.P.

2001-01-01

Combined preclinical investigations into neutron capture therapy are conducted. Malignant melanoma was adopted as the line of investigation; boron-containing and gadolinium-containing preparations were used during the neutron capture therapy working off. Preparations produce secondary varying radiations when used in tumor. Dogs with spontaneous melanoma were used for the experiments. Procedures for the irradiation of dogs by neutron beam as the stage before use for the treatment of oncology patients were finished off; efficiency of neutron beam influence on normal tissues during the irradiation of dogs with melanoma (and without it) in antitumor and side effect sense was estimated [ru

Radiation therapy facilities in the United States

International Nuclear Information System (INIS)

Ballas, Leslie K.; Elkin, Elena B.; Schrag, Deborah; Minsky, Bruce D.; Bach, Peter B.

2006-01-01

Purpose: About half of all cancer patients in the United States receive radiation therapy as a part of their cancer treatment. Little is known, however, about the facilities that currently deliver external beam radiation. Our goal was to construct a comprehensive database of all radiation therapy facilities in the United States that can be used for future health services research in radiation oncology. Methods and Materials: From each state's health department we obtained a list of all facilities that have a linear accelerator or provide radiation therapy. We merged these state lists with information from the American Hospital Association (AHA), as well as 2 organizations that audit the accuracy of radiation machines: the Radiologic Physics Center (RPC) and Radiation Dosimetry Services (RDS). The comprehensive database included all unique facilities listed in 1 or more of the 4 sources. Results: We identified 2,246 radiation therapy facilities operating in the United States as of 2004-2005. Of these, 448 (20%) facilities were identified through state health department records alone and were not listed in any other data source. Conclusions: Determining the location of the 2,246 radiation facilities in the United States is a first step in providing important information to radiation oncologists and policymakers concerned with access to radiation therapy services, the distribution of health care resources, and the quality of cancer care

A conceptual design of neutron tumor therapy reactor facility with a YAYOI based fast neutron source reactor

International Nuclear Information System (INIS)

Wakabayashi, Hiroaki; An, Shigehiro.

1983-01-01

Fast neutron is known as one of useful radiations for radiation therapy of tumors. Boron neutron capture therapy (BNCT) of tumors which makes use of 10 B(n, α) 7 Li reaction of 10 B compounds selectively attached to tumor cells with thermal and intermediate neutrons is another way of neutron based radiation therapy which is, above all, attractive enough to kill tumor cells selectively sparing normal tissue. In Japan, BNCT has already been applied and leaned to be effective. After more than a decade operational experiences and the specific experiments designed for therapeutical purposes, in this paper, a conceptual design of a special neutron therapy reactor facility based on YAYOI - fast neutron source reactor of Nuclear Engineering Research Laboratory, Faculty of Engineering, the University of Tokyo - modified to provide an upward beam of fast and intermediate neutrons is presented. Emphasis is placed on the in-house nature of facility and on the coordinating capability of biological and physical researches as well as maintenances of the facility. (author)

Neutron spectrum for neutron capture therapy in boron

International Nuclear Information System (INIS)

Medina C, D.; Soto B, T. G.; Baltazar R, A.; Vega C, H. R.

2016-10-01

Glioblastoma multiforme is the most common and aggressive of brain tumors and is difficult to treat by surgery, chemotherapy or conventional radiation therapy. One treatment alternative is the Neutron Capture Therapy in Boron, which requires a beam modulated in neutron energy and a drug with 10 B able to be fixed in the tumor. When the patients head is exposed to the neutron beam, they are captured by the 10 B and produce a nucleus of 7 Li and an alpha particle whose energy is deposited in the cancer cells causing it to be destroyed without damaging the normal tissue. One of the problems associated with this therapy is to have an epithermal neutrons flux of the order of 10 9 n/cm 2 -sec, whereby irradiation channels of a nuclear research reactor are used. In this work using Monte Carlo methods, the neutron spectra obtained in the radial irradiation channel of the TRIGA Mark III reactor are calculated when inserting filters whose position and thickness have been modified. From the arrangements studied, we found that the Fe-Cd-Al-Cd polyethylene filter yielded a ratio between thermal and epithermal neutron fluxes of 0.006 that exceeded the recommended value (<0.05), and the dose due to the capture gamma rays is lower than the dose obtained with the other arrangements studied. (Author)

Role of gel dosimeters in boron neutron capture therapy

International Nuclear Information System (INIS)

Khajeali, Azim; Farajollahi, Ali Reza; Khodadadi, Roghayeh; Kasesaz, Yaser; Khalili, Assef

2015-01-01

Gel dosimeters have acquired a unique status in radiotherapy, especially with the advent of the new techniques in which there is a need for three-dimensional dose measurement with high spatial resolution. One of the techniques in which the use of gel dosimeters has drawn the attention of the researchers is the boron neutron capture therapy. Exploring the history of gel dosimeters, this paper sets out to study their role in the boron neutron capture therapy dosimetric process. - Highlights: • Gel dosimeters have been investigated. • Conventional dosimetric proses of BNCT has been investigated. • Role of gel dosimeters in BNCT has been investigated

The National Carbon Capture Center at the Power Systems Development Facility

Energy Technology Data Exchange (ETDEWEB)

None, None

2014-12-30

The National Carbon Capture Center (NCCC) at the Power Systems Development Facility supports the Department of Energy (DOE) goal of promoting the United States’ energy security through reliable, clean, and affordable energy produced from coal. Work at the NCCC supports the development of new power technologies and the continued operation of conventional power plants under CO₂ emission constraints. The NCCC includes adaptable slipstreams that allow technology development of CO₂ capture concepts using coal-derived syngas and flue gas in industrial settings. Because of the ability to operate under a wide range of flow rates and process conditions, research at the NCCC can effectively evaluate technologies at various levels of maturity and accelerate their development path to commercialization. During its first contract period, from October 1, 2008, through December 30, 2014, the NCCC designed, constructed, and began operation of the Post-Combustion Carbon Capture Center (PC4). Testing of CO₂ capture technologies commenced in 2011, and through the end of the contract period, more than 25,000 hours of testing had been achieved, supporting a variety of technology developers. Technologies tested included advanced solvents, enzymes, membranes, sorbents, and associated systems. The NCCC continued operation of the existing gasification facilities, which have been in operation since 1996, to support the advancement of technologies for next-generation gasification processes and pre-combustion CO₂ capture. The gasification process operated for 13 test runs, supporting over 30,000 hours combined of both gasification and pre-combustion technology developer testing. Throughout the contract period, the NCCC incorporated numerous modifications to the facilities to accommodate technology developers and increase test capabilities. Preparations for further testing were ongoing to continue advancement of the most promising technologies for

Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

Energy Technology Data Exchange (ETDEWEB)

Pozzi, E. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)], E-mail: epozzi@cnea.gov.ar; Nigg, D.W. [Idaho National Laboratory, Idaho Falls (United States); Miller, M.; Thorp, S.I. [Instrumentation and Control Department, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Heber, E.M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Zarza, L.; Estryk, G. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Monti Hughes, A.; Molinari, A.J.; Garabalino, M. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Itoiz, M.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina); Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Aromando, R.F. [Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires (Argentina); Quintana, J. [Research and Production Reactors, National Atomic Energy Commission, Ezeiza Atomic Center (Argentina); Trivillin, V.A.; Schwint, A.E. [Department of Radiobiology, National Atomic Energy Commission, Constituyentes Atomic Center (Argentina)

2009-07-15

The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10{sup 9} n cm{sup -2} s{sup -1} and the fast neutron flux was 2.5x10{sup 6} n cm{sup -2} s{sup -1}, indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in {sup 6}Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of experimental oral cancer

International Nuclear Information System (INIS)

Pozzi, E.; Nigg, D.W.; Miller, M.; Thorp, S.I.; Heber, E.M.; Zarza, L.; Estryk, G.; Monti Hughes, A.; Molinari, A.J.; Garabalino, M.; Itoiz, M.E.; Aromando, R.F.; Quintana, J.; Trivillin, V.A.; Schwint, A.E.

2009-01-01

The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1x10 9 n cm -2 s -1 and the fast neutron flux was 2.5x10 6 n cm -2 s -1 , indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in 6 Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

Accelerator conceptual design and needs of nuclear data for boron neutron capture therapy

International Nuclear Information System (INIS)

Sasaki, Makoto; Yamanaka, Toshiyuki; Yokobori, Hitoshi

1999-01-01

An optimization study has been made on an accelerator-based facility for the boron neutron capture therapy. The energy of the incident proton and the arrangement of the moderator assemblies are optimized. The beam current and the accelerating voltage are determined so that the accelerator power becomes minimum. The proposed facility is equipped with a 2.5 MeV proton accelerator of 10-25 mA, a lithium target, and a heavy water moderator contained in an aluminum tank. Each of these equipment is feasible, if proper R and D works have been done. Our new design requires the beam power of less than a hundred kW for the accelerator, although that of our previous design was 1 MW. The reduction of the beam power makes the cooling system for the target much simpler. The essential issues for realization of this concept are long-life lithium targets under high heat flux and high current proton accelerators with average currents of more than 10 mA. It is necessary for the reasonable design of a small-sized and low cost facility to get good accuracy nuclear reaction data. Especially, the latest Li/Be(p, n) neutron yield data in a range of threshold energy - few MeV are required for exact evaluation of neutron energy spectrum used therapy. And damage data by low energy proton beam are also important to evaluate integrity of target material. (author)

The National Carbon Capture Center at the Power Systems Development Facility

Energy Technology Data Exchange (ETDEWEB)

None, None

2014-07-14

The Power Systems Development Facility (PSDF) is a state-of-the-art test center sponsored by the U.S. Department of Energy (DOE) and dedicated to the advancement of clean coal technology. In addition to the development of high efficiency coal gasification processes, the PSDF features the National Carbon Capture Center (NCCC) to promote new technologies for CO2 capture from coal-derived flue gas and syngas. The NCCC includes multiple, adaptable test skids that allow technology development of CO2 capture concepts using coal-derived flue gas and syngas in industrial settings. Because of the ability to operate under a wide range of flow rates and process conditions, research at the NCCC can effectively evaluate technologies at various levels of maturity and accelerate their development paths to commercialization. During the calendar year 2013 portion of the Budget Period Four reporting period, efforts at the NCCC focused on post-combustion CO2 capture, gasification, and pre-combustion CO2 capture technology testing. Preparations for future testing were on-going as well, and involved facility upgrades and collaboration with numerous technology developers. In the area of post-combustion, testing was conducted on an enzyme-based technology, advanced solvents from two major developers, and a gas separation membrane. During the year, the gasification process was operated for three test runs, supporting development of water-gas shift and COS hydrolysis catalysts, a mercury sorbent, and several gasification support technologies. Syngas produced during gasification operation was also used for pre-combustion capture technologies, including gas separation membranes from three different technology developers, a CO2 sorbent, and CO2 solvents.

Anesthetic management of Boron Neutron Capture Therapy for glioblastoma

International Nuclear Information System (INIS)

Shinomura, T.; Furutani, H.; Osawa, M.; Ono, K.; Fukuda, K.

2000-01-01

General anesthesia was given to twenty-seven patients who received Boron Neutron Capture Therapy (BNCT) under craniotomy at Kyoto University Research Reactor from 1991 to 1999. Special considerations are required for anesthesia. (author)

Proton linacs for boron neutron capture therapy

International Nuclear Information System (INIS)

Lennox, A.J.

1993-08-01

Recent advances in the ability to deliver boron-containing drugs to brain tumors have generated interest in ∼4 MeV linacs as sources of epithermal neutrons for radiation therapy. In addition, fast neutron therapy facilities have been studying methods to moderate their beams to take advantage of the high cross section for epithermal neutrons on boron-10. This paper describes the technical issues involved in each approach and presents the motivation for undertaking such studies using the Fermilab linac. the problems which must be solved before therapy can begin are outlined. Status of preparatory work and results of preliminary measurements are presented

Boron containing compounds and their preparation and use in neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Gabel, D.

1992-09-01

The present invention pertains to boron containing thiouracil derivatives, their method of preparations, and their use in the therapy of malignant melanoma using boron neutron capture therapy. No Drawings

Development of lithium target for accelerator based neutron capture therapy

International Nuclear Information System (INIS)

Taskaev, Sergey; Bayanov, Boris; Belov, Victor; Zhoorov, Eugene

2006-01-01

Pilot innovative accelerator based neutron source for neutron capture therapy of cancer is now of the threshold of its operation at the BINP, Russia. One of the main elements of the facility is lithium target producing neutrons via threshold 7 Li(p,n) 7 Be reaction at 25 kW proton beam with energies 1.915 MeV or 2.5 MeV. The main problems of lithium target were determined to be: 7 Be radioactive isotope activation keeping lithium layer solid, presence of photons due to proton inelastic scattering on lithium nuclei, and radiation blistering. The results of thermal test of target prototype were presented as previous NCT Congress. It becomes clear that water is preferable for cooling the target, and that lithium target 10 cm in diameter is able to run before melting. In the present report, the conception of optimal target is proposed: thin metal disk 10 cm in diameter easy for detaching, with evaporated thin layer of pure lithium from the side of proton beam exposure, its back being intensively cooled with turbulent water flow to maintain lithium layer solid. Design of the target for the neutron source constructed at BINP is shown. The results of investigation of radiation blistering and lithium layer are presented. Target unit of facility is under construction now, and obtaining neutrons is expected in nearest future. (author)

OPTIMIZATION OF THE EPITHERMAL NEUTRON BEAM FOR BORON NEUTRON CAPTURE THERAPY AT THE BROOKHAVEN MEDICAL RESEARCH REACTOR.

Energy Technology Data Exchange (ETDEWEB)

HU,J.P.; RORER,D.C.; RECINIELLO,R.N.; HOLDEN,N.E.

2002-08-18

Clinical trials of Boron Neutron Capture Therapy for patients with malignant brain tumor had been carried out for half a decade, using an epithermal neutron beam at the Brookhaven's Medical Reactor. The decision to permanently close this reactor in 2000 cut short the efforts to implement a new conceptual design to optimize this beam in preparation for use with possible new protocols. Details of the conceptual design to produce a higher intensity, more forward-directed neutron beam with less contamination from gamma rays, fast and thermal neutrons are presented here for their potential applicability to other reactor facilities. Monte Carlo calculations were used to predict the flux and absorbed dose produced by the proposed design. The results were benchmarked by the dose rate and flux measurements taken at the facility then in use.

The National Carbon Capture Center at the Power Systems Development Facility: Topical Report

Energy Technology Data Exchange (ETDEWEB)

None, None

2011-03-01

The Power Systems Development Facility (PSDF) is a state-of-the-art test center sponsored by the U.S. Department of Energy and dedicated to the advancement of clean coal technology. In addition to the development of advanced coal gasification processes, the PSDF features the National Carbon Capture Center (NCCC) to study CO2 capture from coal-derived syngas and flue gas. The newly established NCCC will include multiple, adaptable test skids that will allow technology development of CO2 capture concepts using coal-derived syngas and flue gas in industrial settings. Because of the ability to operate under a wide range of flow rates and process conditions, research at the NCCC can effectively evaluate technologies at various levels of maturity. During the Budget Period One reporting period, efforts at the PSDF/NCCC focused on developing a screening process for testing consideration of new technologies; designing and constructing pre- and post-combustion CO2 capture facilities; developing sampling and analytical methods; expanding fuel flexibility of the Transport Gasification process; and operating the gasification process for technology research and for syngas generation to test syngas conditioning technologies.

Monte Carlo based dosimetry and treatment planning for neutron capture therapy of brain tumors

International Nuclear Information System (INIS)

Zamenhof, R.G.; Brenner, J.F.; Wazer, D.E.; Madoc-Jones, H.; Clement, S.D.; Harling, O.K.; Yanch, J.C.

1990-01-01

Monte Carlo based dosimetry and computer-aided treatment planning for neutron capture therapy have been developed to provide the necessary link between physical dosimetric measurements performed on the MITR-II epithermal-neutron beams and the need of the radiation oncologist to synthesize large amounts of dosimetric data into a clinically meaningful treatment plan for each individual patient. Monte Carlo simulation has been employed to characterize the spatial dose distributions within a skull/brain model irradiated by an epithermal-neutron beam designed for neutron capture therapy applications. The geometry and elemental composition employed for the mathematical skull/brain model and the neutron and photon fluence-to-dose conversion formalism are presented. A treatment planning program, NCTPLAN, developed specifically for neutron capture therapy, is described. Examples are presented illustrating both one and two-dimensional dose distributions obtainable within the brain with an experimental epithermal-neutron beam, together with beam quality and treatment plan efficacy criteria which have been formulated for neutron capture therapy. The incorporation of three-dimensional computed tomographic image data into the treatment planning procedure is illustrated

Neutron dosimetry in boron neutron capture therapy

International Nuclear Information System (INIS)

Fairchild, R.G.; Miola, U.J.; Ettinger, K.V.

1981-01-01

The recent development of various borated compounds and the utilization of one of these (Na 2 B 12 H 11 SH) to treat brain tumors in clinical studies in Japan has renewed interest in neutron capture therapy. In these procedures thermal neutrons interact with 10 B in boron containing cells through the 10 B(n,α) 7 Li reaction producing charged particles with a maximum range of approx. 10μm in tissue. Borated analogs of chlorpromazine, porphyrin, thiouracil and deoxyuridine promise improved tumor uptake and blood clearance. The therapy beam from the Medical Research Reactor in Brookhaven contains neutrons from a modified and filtered fission spectrum and dosimetric consequences of the use of the above mentioned compounds in conjunction with thermal and epithermal fluxes are discussed in the paper. One of the important problems of radiation dosimetry in capture therapy is determination of the flux profile and, hence, the dose profile in the brain. This has been achieved by constructing a brain phantom made of TE plastic. The lyoluminescence technique provides a convenient way of monitoring the neutron flux distributions; the detectors for this purpose utilize 6 Li and 10 B compounds. Such compounds have been synthesized specially for the purpose of dosimetry of thermal and epithermal beams. In addition, standard lyoluminescent phosphors, like glutamine, could be used to determine the collisional component of the dose as well as the contribution of the 14 N(n,p) 14 C reaction. Measurements of thermal flux were compared with calculations and with measurements done with activation foils

MODELING THE RADIATION SHIELDING OF BORON NEUTRON CAPTURE THERAPY BASED ON 2.4 MEV D-D NEUTRON GENERATOR FACILITY

Directory of Open Access Journals (Sweden)

Muhammad Mu’Alim

2018-01-01

PEMODELAN PERISAI RADIASI PADA FASILITAS BORON NEUTRON CAPTURE THERAPY BERBASIS GENERATOR NEUTRON D-D 2,4 MeV. Telah dimodelkan perisai radiasi pada fasilitas Boron Neutron Capture Therapy (BNCT berbasis reaksi D-D pada Neutron Generator 2,4 MeV dengan Beam Shaping Assembly (BSA yang telah didesain sebelumnya. Pemodelan ini dilakukan untuk memperoleh suatu desain perisai radiasi untuk fasilitas BNCT berbasis generator neutron 2,4 MeV. Pemodelan dilakukan dengan cara memvariasikan bahan dan ketebalan perisasi radiasi. Bahan yang dipilih adalah beton barit, parafin, polietilen terborasi dan timbal. Perhitungan dilakukan menggunakan program MCNPX dengan tally F4 untuk menentukan laju dosis yang keluar dari perisai radiasi. Desain periasi radiasi dinyatakan optimal jika radiasi yang dihasilkan diluar perisai radiasi tidak melebihi Nilai Batas Dosis (NBD yang telah ditentukan oleh BAPETEN. Hasilnya, diperoleh suatu desain perisai radiasi menggunakan lapisan utama beton barit setebal 100 cm yang mengelilingi ruangan 100 cm x 100 cm x 166,4 cm dan polietilen terborasi 40 cm yang mengelilingi bahan beton barit. Kemudian ditambahkan beton barit 10 cm dan polietilen terborasi 10 cm untuk mengurangi radiasi primer yang lurus dari BSA setelah keluar dari lapisan utama. Laju dosis terbesar adalah 4,58 μSv·jam-1 pada sel 227 dan laju dosis rata-rata yang dihasilkan adalah sebesar 0,65 µSv·jam-1. Nilai laju dosis tersebut masih dibawah ambang batas NBD yang diperbolehkan oleh BAPETEN untuk pekerja radiasi. Kata kunci: Perisai radiasi, tally, laju dosis radiasi, BSA, BNCT

Carborane derivative development for boron neutron capture therapy. Final report

International Nuclear Information System (INIS)

Barnum, Beverly A.; Yan Hao; Moore, Roger; Hawthorne, M. Frederick; Baum, Kurt

1999-01-01

Boron Neutron Capture Therapy [BNCT] is a binary method of cancer therapy based on the capture of neutrons by a boron-10 atom [ 10 B]. Cytotoxic 7 Li nuclei and α-particles are emitted, with a range in tissue of 9 and 5 microm, respectively, about one cell diameter. The major obstacle to clinically viable BNCT is the selective localization of 5-30 ppm 10 B in tumor cells required for effective therapy. A promising approach to BNCT is based on hydrophilic boron-rich oligomeric phosphate diesters, or ''trailers'' that have been shown to concentrate selectively in tumor tissue. Examples of these compounds were prepared previously at high cost using an automated DNA synthesizer. Direct synthesis methods are needed for the production of gram-scale quantities for further biological evaluation. The work accomplished as a result of the collaboration between Fluorochem, Inc. and UCLA demonstrates that short oligomers containing at least five carborane units with four phosphodiester linkages can be prepared in substantial quantities. This work was accomplished by the application of standard phosphoramidite coupling chemistry

The National Carbon Capture Center at the Power Systems Development Facility

Energy Technology Data Exchange (ETDEWEB)

Mosser, Morgan [Southern Company Services, Inc., Wilsonville, AL (United States)

2012-12-31

The Power Systems Development Facility (PSDF) is a state-of-the-art test center sponsored by the U.S. Department of Energy and dedicated to the advancement of clean coal technology. In addition to the development of high efficiency coal gasification processes, the PSDF features the National Carbon Capture Center (NCCC) to promote new technologies for CO₂ capture from coal-derived syngas and flue gas. The NCCC includes multiple, adaptable test skids that allow technology development of CO₂ capture concepts using coal-derived syngas and flue gas in industrial settings. Because of the ability to operate under a wide range of flow rates and process conditions, research at the NCCC can effectively evaluate technologies at various levels of maturity and accelerate their development path to commercialization. During the calendar year 2012 portion of the Budget Period Four reporting period, efforts at the NCCC focused on testing of pre- and post-combustion CO₂ capture processes and gasification support technologies. Preparations for future testing were on-going as well, and involved facility upgrades and collaboration with numerous technology developers. In the area of pre-combustion, testing was conducted on a new water-gas shift catalyst, a CO₂ solvent, and gas separation membranes from four different technology developers, including two membrane systems incorporating major scale-ups. Post-combustion tests involved advanced solvents from three major developers, a gas separation membrane, and two different enzyme technologies. An advanced sensor for gasification operation was evaluated, operation with biomass co-feeding with coal under oxygen-blown conditions was achieved, and progress continued on refining several gasification support technologies.

Study on the dose distribution of the mixed field with thermal and epi-thermal neutrons for neutron capture therapy

International Nuclear Information System (INIS)

Kobayashi, Tooru; Sakurai, Yoshinori; Kanda, Keiji

1994-01-01

Simulation calculations using DOT 3.5 were carried out in order to confirm the characteristics of depth-dependent dose distribution in water phantom dependent on incident neutron energy. The epithermal neutrons mixed to thermal neutron field is effective improving the thermal neutron depth-dose distribution for neutron capture therapy. A feasibility study on the neutron energy spectrum shifter was performed using ANISN-JR for the KUR Heavy Water Facility. The design of the neutron spectrum shifter is feasible, without reducing the performance as a thermal neutron irradiation field. (author)

Phantom experiment of depth-dose distributions for gadolinium neutron capture therapy

International Nuclear Information System (INIS)

Matsumoto, T.; Kato, K.; Sakuma, Y.; Tsuruno, A.; Matsubayashi, M.

1993-01-01

Depth-dose distributions in a tumor simulated phantom were measured for thermal neutron flux, capture gamma-ray and internal conversion electron dose rates for gadolinium neutron capture therapy. The results show that (i) a significant dose enhancement can be achieved in the tumor by capture gamma-rays and internal conversion electrons but the dose is mainly due to capture gamma-rays from the Gd(n, γ) reactions, therefore, is not selective at the cellular level, (ii) the dose distribution was a function of strongly interrelated parameters such as gadolinium concentrations, tumor site and neutron beam size (collimator aperture size), and (iii) the Gd-NCT by thermal neutrons appears to be a potential for treatment of superficial tumor. (author)

A standardized method for beam design in neutron capture therapy

International Nuclear Information System (INIS)

Storr, G.J.: Harrington, B.V.

1993-01-01

A desirable end point for a given beam design for Neutron Capture Therapy (NCT) should be quantitative description of tumour control probability and normal tissue damage. Achieving this goal will ultimately rely on data from NCT human clinical trials. Traditional descriptions of beam designs have used a variety of assessment methods to quantify proposed or installed beam designs. These methods include measurement and calculation of open-quotes free fieldclose quotes parameters, such as neutron and gamma flux intensities and energy spectra, and figures-of-merit in tissue equivalent phantoms. The authors propose here a standardized method for beam design in NCT. This method would allow all proposed and existing NCT beam facilities to be compared equally. The traditional approach to determining a quantitative description of tumour control probability and normal tissue damage in NCT research may be described by the following path: Beam design → dosimetry → macroscopic effects → microscopic effects. Methods exist that allow neutron and gamma fluxes and energy dependence to be calculated and measured to good accuracy. By using this information and intermediate dosimetric quantities such as kerma factors for neutrons and gammas, macroscopic effect (absorbed dose) in geometries of tissue or tissue-equivalent materials can be calculated. After this stage, for NCT the data begins to become more sparse and in some areas ambiguous. Uncertainties in the Relative Biological Effectiveness (RBE) of some NCT dose components means that beam designs based on assumptions considered valid a few years ago may have to be reassessed. A standard method is therefore useful for comparing different NCT facilities

Treatment facilities, human resource development, and future prospect of particle beam therapy

International Nuclear Information System (INIS)

Tamaki, Tomoaki; Nakano, Takashi

2015-01-01

The number of particle beam therapy facilities is increasing globally. Among the countries practicing particle beam therapy, Japan is one of the leading countries in the field with four operating carbon-ion therapy facilities and ten operating proton therapy facilities. With the increasing number of particle beam therapy facilities, the human resource development is becoming extremely important, and there has been many such efforts including the Gunma University Program for Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering, which aimed to educate and train the radiation oncologists, medical physicists, accelerator engineers, and radiation biologists to become global leaders in the field of particle beam therapy. In the future, the benefit and effectiveness of particle beam therapy should be discussed and elucidated objectively in a framework of comprehensive cancer care. (author)

Recent advances in neutron capture therapy (NCT)

International Nuclear Information System (INIS)

Fairchild, R.G.

1985-01-01

The application of the 10 B(n,α) 7 Li reaction to cancer radiotherapy (Neutron Capture therapy, or NCT) has intrigued investigators since the discovery of the neutron. This paper briefly summarizes data describing recently developed boronated compounds with evident tumor specificity and extended biological half-lives. The implication of these compounds to NCT is evaluated in terms of Therapeutic Gain (TG). The optimization of NCT using band-pass filtered beams is described, again in terms of TG, and irradiation times with these less intense beams are estimated. 24 refs., 3 figs., 3 tabs

Investigation on the neutron beam characteristics for boron neutron capture therapy with 3D and 2D transport calculations

International Nuclear Information System (INIS)

Kodeli, I.; Diop, C.M.; Nimal, J.C.

1994-01-01

In the framework of future Boron Neutron Capture Therapy (BNCT) experiments, where cells and animals irradiations are planned at the research reactor of Strasbourg University, the feasibility to obtain a suitable epithermal neutron beam is investigated. The neutron fluence and spectra calculations in the reactor are performed using the 3D Monte Carlo code TRIPOLI-3 and the 2D SN code TWODANT. The preliminary analysis of Al 2 O 3 and Al-Al 2 O 3 filters configurations are carried out in an attempt to optimize the flux characteristics in the beam tube facility. 7 figs., 7 refs

Workshop on neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Fairchild, R.G.; Bond, V.P. (eds.)

1986-01-01

Potentially optimal conditions for Neutron Capture Therapy (NCT) may soon be in hand due to the anticipated development of band-pass filtered beams relatively free of fast neutron contaminations, and of broadly applicable biomolecules for boron transport such as porphyrins and monoclonal antibodies. Consequently, a number of groups in the US are now devoting their efforts to exploring NCT for clinical application. The purpose of this Workshop was to bring these groups together to exchange views on significant problems of mutual interest, and to assure a unified and effective approach to the solutions. Several areas of preclinical investigation were deemed to be necessary before it would be possible to initiate clinical studies. As neither the monomer nor the dimer of sulfhydryl boron hydride is unequivocally preferable at this time, studies on both compounds should be continued until one is proven superior.

Workshop on neutron capture therapy

International Nuclear Information System (INIS)

Fairchild, R.G.; Bond, V.P.

1986-01-01

Potentially optimal conditions for Neutron Capture Therapy (NCT) may soon be in hand due to the anticipated development of band-pass filtered beams relatively free of fast neutron contaminations, and of broadly applicable biomolecules for boron transport such as porphyrins and monoclonal antibodies. Consequently, a number of groups in the US are now devoting their efforts to exploring NCT for clinical application. The purpose of this Workshop was to bring these groups together to exchange views on significant problems of mutual interest, and to assure a unified and effective approach to the solutions. Several areas of preclinical investigation were deemed to be necessary before it would be possible to initiate clinical studies. As neither the monomer nor the dimer of sulfhydryl boron hydride is unequivocally preferable at this time, studies on both compounds should be continued until one is proven superior

Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

Energy Technology Data Exchange (ETDEWEB)

Ackermann, A.L. (ed.); Dorn, R.V. III.

1990-09-01

This monthly bulletin describes activities in the following project areas during this reporting period: supporting technology development, large animal model studies, neutron source and facility preparation, administration and common support, and PBF operations. (FI)

Radionuclide therapy practice and facilities in Europe

International Nuclear Information System (INIS)

Hoefnagel, C.A.; Clarke, S.E.M.; Fischer, M.; Chatal, J.F.; Lewington, V.J.; Nilsson, S.; Troncone, L.; Vieira, M.R.

1999-01-01

Using a questionnaire the EANM Task Group Radionuclide Therapy in 1993 collected data on the current practice of radionuclide therapy in European countries. Subsequently, at the request of the EANM Executive Committee, the EANM Radionuclide Therapy Committee has made an inventory of the distribution of facilities for radionuclide therapy and undertaken an assessment of the total number of patients treated throughout Europe and of the types of treatment provides, with the aim of supporting the development of policy to adjust the available capacity to the needs by the year 2000. For this purpose, a second, more detailed questionnaire was sent out the members and national advisors of the Committee (see below), who gathered the data for each country that was a member of the EANM at the time. It is concluded that a wide bariation in therapy practice exists across Europe, particularly in the utilisation of radionuclide therapy, the requirement and availability of proper isolation facilities and the background training of those undertaking therapy. More uniform guidelines and legislation are required, although changes in legislation may have a significant impact in some countries. Although there is wide variation in the therapies used in each country, one the whole it appears that there is an underutilisation of nuclear medicine as a therapeutic modality. A rapidly increasing role may be expected, in particular for oncological indications requiring high-dose radionuclide treatment. Therefore there is an urgent need for a greater number of isolation beds in dedicated centers throughout Europe

Medical and biological requirements for boron neutron capture therapy

International Nuclear Information System (INIS)

Gahbauer, R.; Goodman, J.H.; Kanellitsas, C.; Clendenon, N.; Blue, J.

1986-01-01

In conventional radiation therapy, tumor doses applied to most solid tumors are limited by the tolerance of normal tissues. The promise of Boron Neutron Capture Therapy lies in its potential to deposit high doses of radiation very specifically to tumor tissue. Theoretically ratios of tumor to normal tissue doses can be achieved significantly higher than conventional radiotherapeutic techniques would allow. Effective dose distributions obtainable are a complex function of the neutron beam characteristics and the macro and micro distributions of boron in tumor and normal tissues. Effective RBE doses are calculated in tumors and normal tissue for thermal, epithermal and 2 keV neutrons

Neutron therapy coupling brachytherapy and boron neutron capture therapy (BNCT) techniques

International Nuclear Information System (INIS)

Chaves, Iara Ferreira.

1994-12-01

In the present dissertation, neutron radiation techniques applied into organs of the human body are investigated as oncologic radiation therapy. The proposal treatment consists on connecting two distinct techniques: Boron Neutron Capture Therapy (BNCT) and irradiation by discrete sources of neutrons, through the brachytherapy conception. Biological and radio-dosimetrical aspects of the two techniques are considered. Nuclear aspects are discussed, presenting the nuclear reactions occurred in tumoral region, and describing the forms of evaluating the dose curves. Methods for estimating radiation transmission are reviewed through the solution of the neutron transport equation, Monte Carlo methodology, and simplified analytical calculation based on diffusion equation and numerical integration. The last is computational developed and presented as a quickly way to neutron transport evaluation in homogeneous medium. The computational evaluation of the doses for distinct hypothetical situations is presented, applying the coupled techniques BNTC and brachytherapy as an possible oncologic treatment. (author). 78 refs., 61 figs., 21 tabs

Microdosimetric investigations at the fast neutron therapy facility at Fermilab

International Nuclear Information System (INIS)

Langen, K.M.

1997-01-01

Microdosimetry was used to investigate three issues at the neutron therapy facility (NTF) at Fermilab. Firstly, the conversion factor from absorbed dose in A-150 tissue equivalent plastic to absorbed dose in ICRU tissue was determined. For this, the effective neutron kerma factor ratios, i.e., oxygen tissue equivalent plastic and carbon to A-150 tissue equivalent plastic, were measured in the neutron beam. An A-150 tissue equivalent plastic to ICRU tissue absorbed dose conversion factor of 0.92 ± 0.04 was determined. Secondly, variations in the radiobiological effectiveness (RBE) in the beam were mapped by determining variations in two related quantities, e * and R, with field size and depth in tissue. Maximal variation in e * and R of 9% and 15% respectively were determined. Lastly, the feasibility of utilizing the boron neutron capture reaction on boron-10 to selectively enhance the tumor dose in the NTF beam was investigated

Experimental and Simulated Characterization of a Beam Shaping Assembly for Accelerator- Based Boron Neutron Capture Therapy (AB-BNCT)

International Nuclear Information System (INIS)

Burlon, Alejandro A.; Valda, Alejandro A.; Girola, Santiago; Minsky, Daniel M.; Kreiner, Andres J.

2010-01-01

In the frame of the construction of a Tandem Electrostatic Quadrupole Accelerator facility devoted to the Accelerator-Based Boron Neutron Capture Therapy, a Beam Shaping Assembly has been characterized by means of Monte-Carlo simulations and measurements. The neutrons were generated via the 7 Li(p, n) 7 Be reaction by irradiating a thick LiF target with a 2.3 MeV proton beam delivered by the TANDAR accelerator at CNEA. The emerging neutron flux was measured by means of activation foils while the beam quality and directionality was evaluated by means of Monte Carlo simulations. The parameters show compliance with those suggested by IAEA. Finally, an improvement adding a beam collimator has been evaluated.

Proceedings of the first international symposium on neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Fairchild, R.G.; Brownell, G.L. (eds.)

1982-01-01

This meeting was arranged jointly by MIT and BNL in order to illuminate progress in the synthesis and targeting of boron compounds and to evaluate and document progress in radiobiological and dosimetric aspects of neutron capture therapy. It is hoped that this meeting will facilitate transfer of information between groups working in these fields, and encourage synergistic collaboration.

Proceedings of the first international symposium on neutron capture therapy

International Nuclear Information System (INIS)

Fairchild, R.G.; Brownell, G.L.

1982-01-01

This meeting was arranged jointly by MIT and BNL in order to illuminate progress in the synthesis and targeting of boron compounds and to evaluate and document progress in radiobiological and dosimetric aspects of neutron capture therapy. It is hoped that this meeting will facilitate transfer of information between groups working in these fields, and encourage synergistic collaboration

Recombination methods for boron neutron capture therapy dosimetry

International Nuclear Information System (INIS)

Golnik, N.; Tulik, P.; Zielczynski, M.

2003-01-01

The radiation effects of boron neutron capture therapy (BNCT) are associated with four-dose-compartment radiation field - boron dose (from 10 B(n,α) 7 Li) reaction), proton dose from 14 N(n,p) 14 C reaction, neutron dose (mainly fast and epithermal neutrons) and gamma-ray dose (external and from capture reaction 1 H(n,γ) 2 D). Because of this the relation between the absorbed dose and the biological effects is very complex and all the above mentioned absorbed dose components should be determined. From this point of view, the recombination chambers can be very useful instruments for characterization of the BNCT beams. They can be used for determination of gamma and high-LET dose components for the characterization of radiation quality of mixed radiation fields by recombination microdosimetric method (RMM). In present work, a graphite high-pressure recombination chamber filled with nitrogen, 10 BF 3 and tissue equivalent gas was used for studies on application of RMM for BNCT dosimetry. The use of these gases or their mixtures opens a possibility to design a recombination chamber for determination of the dose fractions due to gamma radiation, fast neutrons, neutron capture on nitrogen and high LET particles from (n, 10 B) reaction in simulated tissue with different content of 10 B. (author)

Real-time monitoring of emissions from monoethanolamine-based industrial scale carbon capture facilities.

Science.gov (United States)

Zhu, Liang; Schade, Gunnar Wolfgang; Nielsen, Claus Jørgen

2013-12-17

We demonstrate the capabilities and properties of using Proton Transfer Reaction time-of-flight mass spectrometry (PTR-ToF-MS) to real-time monitor gaseous emissions from industrial scale amine-based carbon capture processes. The benchmark monoethanolamine (MEA) was used as an example of amines needing to be monitored from carbon capture facilities, and to describe how the measurements may be influenced by potentially interfering species in CO2 absorber stack discharges. On the basis of known or expected emission compositions, we investigated the PTR-ToF-MS MEA response as a function of sample flow humidity, ammonia, and CO2 abundances, and show that all can exhibit interferences, thus making accurate amine measurements difficult. This warrants a proper sample pretreatment, and we show an example using a dilution with bottled zero air of 1:20 to 1:10 to monitor stack gas concentrations at the CO2 Technology Center Mongstad (TCM), Norway. Observed emissions included many expected chemical species, dominantly ammonia and acetaldehyde, but also two new species previously not reported but emitted in significant quantities. With respect to concerns regarding amine emissions, we show that accurate amine quantifications in the presence of water vapor, ammonia, and CO2 become feasible after proper sample dilution, thus making PTR-ToF-MS a viable technique to monitor future carbon capture facility emissions, without conventional laborious sample pretreatment.

Proton beam therapy facility

International Nuclear Information System (INIS)

1984-01-01

It is proposed to build a regional outpatient medical clinic at the Fermi National Accelerator Laboratory (Fermilab), Batavia, Illinois, to exploit the unique therapeutic characteristics of high energy proton beams. The Fermilab location for a proton therapy facility (PTF) is being chosen for reasons ranging from lower total construction and operating costs and the availability of sophisticated technical support to a location with good access to patients from the Chicago area and from the entire nation. 9 refs., 4 figs., 26 tabs

Proton beam therapy facility

Energy Technology Data Exchange (ETDEWEB)

1984-10-09

It is proposed to build a regional outpatient medical clinic at the Fermi National Accelerator Laboratory (Fermilab), Batavia, Illinois, to exploit the unique therapeutic characteristics of high energy proton beams. The Fermilab location for a proton therapy facility (PTF) is being chosen for reasons ranging from lower total construction and operating costs and the availability of sophisticated technical support to a location with good access to patients from the Chicago area and from the entire nation. 9 refs., 4 figs., 26 tabs.

SBNCT plan: A 3-dimensional treatment planning system for boron neutron capture therapy

International Nuclear Information System (INIS)

Reinstein, L.E.; Ramsay, E.B.; Gajewski, J.; Ramamoorthy, S.; Meek, A.G.

1993-01-01

The need for accurate and comprehensive 3-dimensional treatment planning for boron neutron capture therapy (BNCT) has been debated for the past several years. Although many argue against the need for elaborate and expensive treatment planning programs which mimic conventional radiotherapy planning systems, it is clear that in order to realize significant gains over conventional fractionated radiation therapy, patients must be treated to the edge of normal tissue tolerance. Just how close to this edge is dictated by the uncertainties in dosimetry. Hence the focus of BNCT planning is the determination of dose distribution throughout normal tissue volumes. Although precise geometric manipulation of the epithermal neutron beam is not achievable, the following variables play an important role in BNCT optimization: patient orientation, dose fractionation, number of fields, megawatt-minutes per fraction, use of surface bolus, and use of collimation. Other variables which are not as easily adjustable and would not, therefore, be part of treatment planning optimization, include external patient contour, internal patient heterogeneities, boron compound distributions, and RBE's. The boron neutron capture therapy planning system developed at SUNY Stony Brook (SBNCT-Plan) was designed as an interactive graphic tool to assist the radiation oncologist in generating the optimum plan for a neutron capture treatment

Thiourea derivatives, methods of their preparation and their use in neutron capture therapy of malignant melanoma

Energy Technology Data Exchange (ETDEWEB)

Gabel, D.

1991-06-04

The present invention pertains to boron containing thiouracil derivatives, their method of preparations, and their use in the therapy of malignant melanoma using boron neutron capture therapy. No Drawings

A physical and engineering study on the irradiation techniques in neutron capture therapy aiming for wider application

International Nuclear Information System (INIS)

Sakurai, Y.; Ono, K.; Suzuki, M.; Katoh, I.; Miyatake, S.-I.; Yanagie, H.

2003-01-01

The solo-irradiation of thermal neutrons has been applied for brain cancer and malignant melanoma in the boron neutron capture therapy (BNCT) at the medical irradiation facility of Kyoto University Reactor (KUR), from the first clinical trial in 1974. In 1997, after the facility remodeling, the application of the mix-irradiation of thermal and epi-thermal neutrons was started, and the depth dose distribution for brain cancer has been improved in some degree. In 2001, the solo-irradiation of epi-thermal neutrons also started. It is specially mentioned that the application to oral cancers started at the same time. The BNCT clinical trial using epi-thermal neutron irradiation at KUR, amounts to twelve as of March 2003. The seven trials; more than a half of the total trials, are for oral cancers. From this fact, we think that the wider application to the other cancers is required for the future prosperity of BNCT. The cancers applied for BNCT in KUR at the present time, are brain cancer, melanoma and oral cancers, as mentioned above. The cancers, expected to be applied in near future, are liver cancer, pancreas cancer, lung cancer, tongue cancer, breast cancer, etc.. Any cancer is almost incurable by the other therapy including the other radiation therapy. In the wider application of BNCT to these cancers, the dose-distribution control suitable to each cancer and/or each part, is important. The introduction of multi-directional and/or multi-divisional irradiation is also needed. Here, a physical and engineering study using two-dimensional transport calculation and three-dimensional Monte-Carlo simulation for the irradiation techniques in BNCT aiming for wider application is reported

Boron neutron capture therapy for malignant melanoma: An experimental approach

Energy Technology Data Exchange (ETDEWEB)

Larsson, B.S.; Larsson, B.; Roberto, A. (Uppsala Univ. (Sweden))

1989-07-01

Previous studies have shown that some thioamides, e.g., thiouracil, are incorporated as false precursors into melanin during its synthesis. If boronated analogs of the thioamides share this property, the melanin of melanotic melanomas offers a possibility for specific tumoural uptake and retention of boron as a basis for neutron capture therapy. We report on the synthesis of boronated 1H-1,2,4-triazole-3-thiol (B-TZT), boronated 5-carboxy-2-thiouracil (B-CTU), and boronated 5-diethylaminomethyl-2-thiouracil (B-DEAMTU) and the localization of these substances in melanotic melanomas transplanted to mice. The distribution in the mice was studied by boron neutron capture radiography. B-TZT and B-CTU showed the highest tumour:normal tissue concentration ratios, with tumour:liver ratios of about 4 and tumour:muscle ratios of about 14; B-DEAMTU showed corresponding ratios of 1.4 and 5, respectively. The absolute concentration of boron in the tumours, however, was more than three times higher in the mice injected with B-TZT, compared with B-CTU. The results suggest that B-TZT may be the most promising compound of the three tested with regard to possible therapy of melanotic melanomas.

Iodine neutron capture therapy

Science.gov (United States)

Ahmed, Kazi Fariduddin

A new technique, Iodine Neutron Capture Therapy (INCT) is proposed to treat hyperthyroidism in people. Present thyroid therapies, surgical removal and 131I treatment, result in hypothyroidism and, for 131I, involve protracted treatment times and excessive whole-body radiation doses. The new technique involves using a low energy neutron beam to convert a fraction of the natural iodine stored in the thyroid to radioactive 128I, which has a 24-minute half-life and decays by emitting 2.12-MeV beta particles. The beta particles are absorbed in and damage some thyroid tissue cells and consequently reduce the production and release of thyroid hormones to the blood stream. Treatment times and whole-body radiation doses are thus reduced substantially. This dissertation addresses the first of the several steps needed to obtain medical profession acceptance and regulatory approval to implement this therapy. As with other such programs, initial feasibility is established by performing experiments on suitable small mammals. Laboratory rats were used and their thyroids were exposed to the beta particles coming from small encapsulated amounts of 128I. Masses of 89.0 mg reagent-grade elemental iodine crystals have been activated in the ISU AGN-201 reactor to provide 0.033 mBq of 128I. This activity delivers 0.2 Gy to the thyroid gland of 300-g male rats having fresh thyroid tissue masses of ˜20 mg. Larger iodine masses are used to provide greater doses. The activated iodine is encapsulated to form a thin (0.16 cm 2/mg) patch that is then applied directly to the surgically exposed thyroid of an anesthetized rat. Direct neutron irradiation of a rat's thyroid was not possible due to its small size. Direct in-vivo exposure of the thyroid of the rat to the emitted radiation from 128I is allowed to continue for 2.5 hours (6 half-lives). Pre- and post-exposure blood samples are taken to quantify thyroid hormone levels. The serum T4 concentration is measured by radioimmunoassay at

Neutron capture therapy beams at the MIT Research Reactor

International Nuclear Information System (INIS)

Choi, J.R.; Clement, S.D.; Harling, O.K.; Zamenhof, R.G.

1990-01-01

Several neutron beams that could be used for neutron capture therapy at MITR-II are dosimetrically characterized and their suitability for the treatment of glioblastoma multiforme and other types of tumors are described. The types of neutron beams studied are: (1) those filtered by various thicknesses of cadmium, D2O, 6Li, and bismuth; and (2) epithermal beams achieved by filtration with aluminum, sulfur, cadmium, 6Li, and bismuth. Measured dose vs. depth data are presented in polyethylene phantom with references to what can be expected in brain. The results indicate that both types of neutron beams are useful for neutron capture therapy. The first type of neutron beams have good therapeutic advantage depths (approximately 5 cm) and excellent in-phantom ratios of therapeutic dose to background dose. Such beams would be useful for treating tumors located at relatively shallow depths in the brain. On the other hand, the second type of neutron beams have superior therapeutic advantage depths (greater than 6 cm) and good in-phantom therapeutic advantage ratios. Such beams, when used along with bilateral irradiation schemes, would be able to treat tumors at any depth in the brain. Numerical examples of what could be achieved with these beams, using RBEs, fractionated-dose delivery, unilateral, and bilateral irradiation are presented in the paper. Finally, additional plans for further neutron beam development at MITR-II are discussed

Boron analysis for neutron capture therapy using particle-induced gamma-ray emission

International Nuclear Information System (INIS)

Nakai, Kei; Yamamoto, Yohei; Okamoto, Emiko; Yamamoto, Tetsuya; Yoshida, Fumiyo; Matsumura, Akira; Yamada, Naoto; Kitamura, Akane; Koka, Masashi; Satoh, Takahiro

2015-01-01

The neutron source of BNCT is currently changing from reactor to accelerator, but peripheral facilities such as a dose-planning system and blood boron analysis have still not been established. To evaluate the potential application of particle-induced gamma-ray emission (PIGE) for boron measurement in clinical boron neutron capture therapy, boronophenylalanine dissolved within a cell culture medium was measured using PIGE. PIGE detected 18 μgB/mL f-BPA in the culture medium, and all measurements of any given sample were taken within 20 min. Two hours of f-BPA exposure was required to create a boron distribution image. However, even though boron remained in the cells, the boron on the cell membrane could not be distinguished from the boron in the cytoplasm. - Highlights: • PIGE was evaluated for measuring blood boron concentration during clinical BNCT. • PIGE detected 18 μgB/mL f-BPA in culture medium. • All measurements of any given sample were taken within 20 min. • Two hours of f-BPA exposure is required to create boron distribution image by PIGE. • Boron on the cell membrane could not be distinguished from boron in the cytoplasm.

Slow neutron capture therapy for malignant glioma (boron or lithium neutron capture therapy)

International Nuclear Information System (INIS)

Hatanaka, Hiroshi

1981-01-01

In recurrent glioblastoma, the mean survival period is approx. 6 months by the routine methods of treatment, but is extended more than 3-fold by neutron capture therapy. This method and a routine method with 60 Co or an accelerator were used for comparison in the clinical treatment of 26 patients with supratentorial malignant glioma. There were no significant differences as for prognostic factors of the group treated by this method and those of the control group; No. of cases 14 and 12, the mean age 46 and 53.5 yr, and the stage (TNM) 3.14 and 2.83, respectively. As of the end of Feb. 1980, this method showed a lifeprolonging effect 3 times that of the control, the mean survival period being 67 weeks for this method and 21 for the control. Although 100% improvement was observed in about one half of the cases by this method, the control group showed improvement of only 80% at maximum. It is also possible to treat any deep portion of the brain with thermal neutrons. As a Boron compound, mercaptoundecahydrododecarborate with a low toxicity has been put into practical use for brain tumors, and as Li, the use of 6 LiCl for lung cancer is under examination. (Chiba, N.)

Dose modification factors in boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Allen, B.J. (Australian Nuclear Science and Technology Organization (ANSTO), Menai (Australia))

1993-01-01

The effective treatment depth and therapeutic ratio in boron neutron capture therapy (BNCT) depend on a number of macroscopic dose factors such as boron concentrations in the tumor, normal tissue and blood. However, the role of various microscopic dose modification factors can be of critical importance in the evaluation of normal tissue tolerance levels. An understanding of these factors is valuable in designing BNCT experiments and the selection of appropriate boron compounds. These factors are defined in this paper and applied to the case of brain tumors with particular attention to capillary endothelial cells and oligodendrocytes. (orig.).

Novel amino-carboxy-dihydroboranes for neutron capture therapy

International Nuclear Information System (INIS)

Boehmel, T.

1985-01-01

The thesis discusses the following topics: I. Synthesis of boron compounds for the neutron capture therapy which are to meet the following requirements: 1. Low toxicity; 2. High boron content; 3. High enrichment and long retention time in the neoplastic tissue and simultaneous low concentration in blood and normal tissue; 4. Independent cytostatic effects; 5. Functional groups which allow a connection with polymers. II. Presentation of compounds with increased 10 B content. III. Examination of the distribution of boric substances in living organisms by means of a quantitative analysis of the boron content. (orig./PW) [de

Monte Carlo based dosimetry and treatment planning for neutron capture therapy of brain tumors

International Nuclear Information System (INIS)

Zamenhof, R.G.; Clement, S.D.; Harling, O.K.; Brenner, J.F.; Wazer, D.E.; Madoc-Jones, H.; Yanch, J.C.

1990-01-01

Monte Carlo based dosimetry and computer-aided treatment planning for neutron capture therapy have been developed to provide the necessary link between physical dosimetric measurements performed on the MITR-II epithermal-neutron beams and the need of the radiation oncologist to synthesize large amounts of dosimetric data into a clinically meaningful treatment plan for each individual patient. Monte Carlo simulation has been employed to characterize the spatial dose distributions within a skull/brain model irradiated by an epithermal-neutron beam designed for neutron capture therapy applications. The geometry and elemental composition employed for the mathematical skull/brain model and the neutron and photon fluence-to-dose conversion formalism are presented. A treatment planning program, NCTPLAN, developed specifically for neutron capture therapy, is described. Examples are presented illustrating both one and two-dimensional dose distributions obtainable within the brain with an experimental epithermal-neutron beam, together with beam quality and treatment plan efficacy criteria which have been formulated for neutron capture therapy. The incorporation of three-dimensional computed tomographic image data into the treatment planning procedure is illustrated. The experimental epithermal-neutron beam has a maximum usable circular diameter of 20 cm, and with 30 ppm of B-10 in tumor and 3 ppm of B-10 in blood, it produces a beam-axis advantage depth of 7.4 cm, a beam-axis advantage ratio of 1.83, a global advantage ratio of 1.70, and an advantage depth RBE-dose rate to tumor of 20.6 RBE-cGy/min (cJ/kg-min). These characteristics make this beam well suited for clinical applications, enabling an RBE-dose of 2,000 RBE-cGy/min (cJ/kg-min) to be delivered to tumor at brain midline in six fractions with a treatment time of approximately 16 minutes per fraction

Considerations for boron neutron capture therapy studies

International Nuclear Information System (INIS)

Faria Gaspar, P. de.

1994-01-01

Radiotherapy is indispensable as a mean to eradicate deeply or infiltrating tumor tissue that can not be removed surgically. Therefore, it is not selective and may also kill the surrounding health tissue. The principle of BNCT (Boron Neutron Capture Therapy) consist in targeting a tumor selectively with a boron-10 compound. This nuclide has a large capture cross section for thermal neutrons and the nuclear reaction and the delivered energy in locus will selective the tumor. Since its initial proposal in 1963 BNCT has made much progress, however it is not used in a routine treatment. In this work it was approached some complex procedures, as the obtention of selective boron compounds, the adequate set up of neutron beams, the biodistribution, the in vivo and in vitro studies, and also human patients treatments. This work provide fundamentals about BNCT to professional of different areas of knowledge since it comprises multidisciplinary study. It includes appendixes for the ones not related to the field for a better comprehension of the many aspects involved. It is also presented a glossary containing technical and basic aspects involved. It is also presented a glossary containing technical and basic terms referred in the work. (author). 174 refs, 1 fig, 12 apps

Neutron capture therapy of ocular melanoma: dosimetry and microdosimetry approaches

International Nuclear Information System (INIS)

Pignol, J.P.; Methlin, G.; Abbe, J.C.; Lefebvre, O.; Sahel, J.

1994-01-01

Neutron capture therapy (NCT) aims at destroying cancerous cells with the α and 7 Li particles produced by the neutron capture reaction on 10 B. This note reports on the study of the boron distribution in tissues on an animal model (nude mice) xenografted with a human ocular melanoma after an i.p.injection of 2g/kg of 10 B-BPA and in cells cultured in the presence of 530 μmol/l of 10 B-BPA. A concentration of 64 ppm of 10 B in the active part of the tumour with a ratio of concentrations versus the skin of 3.7 are observed. Investigations on cells reveal the presence of boron in the cytoplasm. The biological, dosimetric and microdosimetric consequences of these findings are discussed. (authors). 15 refs., 2 tabs., 2 figs

Physico-technical progress in neutron-capture therapy method

International Nuclear Information System (INIS)

Kanda, Keiji; Furubayashi, Toru; Aoki, Kazuhiko

1985-01-01

This paper describes mainly development studies on the determination method of in vivo 10 B for the purpose of employment for neutron capture therapy for malignant melanoma and other tumors. To darify the efficacy of the neutron capture therapy, it is necessary to determine 10 B concentration in the diseased part. This study aimed at in vivo 10 B concention determination in living sample to the level of ppm order with 10 % of analytical error within 1 hour, and these determination conditions were satified by prompt γ-ray (478 keV) determination of 10 B (n, αγ) 7 Li reaction. This method required no sample pretreatment. Further, data normalization by γ-ray of H(n, γ)D reaction permitted no disturbance by sample shape or size. Lower limit of detection of the proposed method was estimated in terms of measuring time and statistical error by the equations of 10 B concentration and error analysis derived by the authors. As for the effect of prompt γ-rays of 23 Na(n, γ) 24 Na and 6 Li(n, γ) 7 Li reactions, it was clarified that the former showed no disturbance but some correction was necessary in case of less than 0.1 g of smaple size owing to the latter reaction. In vivo sample determination showed the proposed method was practical. In this paper some results of phantom experiment for in vivo non-destructive 10 B measurement and related simulation calculation, and examination of effect of (γ, n) reaction in heavy water of biomedical irradiation equipment on radiation quality were also described. (Takagi, S.)

TU-G-BRCD-01: Will the High Cost of Proton Therapy Facilities Limit the Availability of Proton Therapy Treatment?

Science.gov (United States)

Maughan, R

2012-06-01

The potential dose distribution advantages associated with proton therapy, and particularly with pencil beam scanning (PBS) techniques, have lead to considerable interest in this modality in recent years. However, the large capital expenditure necessary for such a project requires careful financial consideration and business planning. The complexity of the beam delivery systems impacts the capital expenditure and the PBS only systems presently being advocated can reduce these costs. Also several manufacturers are considering "one-room" facilities as less expensive alternatives to multi-room facilities. This presentation includes a brief introduction to beam delivery options (passive scattering, uniform and modulated scanning) and some of the new technologies proposed for providing less expensive proton therapy systems. Based on current experience, data on proton therapy center start-up costs, running costs and the financial challenges associated with making this highly conformal therapy more widely available will be discussed. Issues associated with proton therapy implementation that are key to project success include strong project management, vendor cooperation and collaboration, staff recruitment and training. Time management during facility start up is a major concern, particularly in multi-room systems, where time must be shared between continuing vendor system validation, verification and acceptance testing, and user commissioning and patient treatments. The challenges associated with facility operation during this period and beyond are discussed, focusing on how standardization of process, downtime and smart scheduling can influence operational efficiency. 1. To understand the available choices for proton therapy facilities, the different beam delivery systems and the financial implications associated with these choices. 2. To understand the key elements necessary for successfully implementing a proton therapy program. 3. To understand the challenges

Experience of boron neutron capture therapy in Japan

International Nuclear Information System (INIS)

Kanda, K.

2004-01-01

Four research reactors are currently licensed for medical application in Japan. As of July 1995, approximately 210 clinical irradiations using these research reactors have been done for brain and skin tumors as shown. The number of chief medical doctors certified by the Government is eleven so far. Among them, eight doctors have already treated tumor patients using the Kyoto University Reactor (KUR, 5MW). Recently in USA clinical trials have been restarted using epithermal neutrons at MIT and BNL. In this paper, the experience of clinical trials of boron neutron capture therapy (BNCT) which have been performed in Japan, mainly physics studies, are reviewed, and current studies are also introduced

Antitumor potential induction and free radicals production in melanoma cells by Boron Neutron Capture Therapy

Energy Technology Data Exchange (ETDEWEB)

Faiao-Flores, F. [Biochemical and Biophysical Laboratory, Butantan Institute, 1500 Vital Brasil Avenue, Sao Paulo (Brazil)] [Faculty of Medicine, University of Sao Paulo, 455 Doutor Arnaldo Avenue, Sao Paulo (Brazil); Coelho, P.R.P.; Muniz, R.O.R.; Souza, G.S. [Institute for Nuclear and Energy Research, 2242 Lineu Prestes Avenue, Sao Paulo (Brazil); Arruda-Neto, J. [Physics Institute, University of Sao Paulo, 187 Matao Street, Sao Paulo (Brazil)] [FESP, Sao Paulo Engineering School, 5520 Nove de Julho Avenue, Sao Paulo (Brazil); Maria, Durvanei A., E-mail: durvaneiaugusto@yahoo.com.br [Biochemical and Biophysical Laboratory, Butantan Institute, 1500 Vital Brasil Avenue, Sao Paulo (Brazil)

2011-12-15

Antiproliferative and oxidative damage effects occurring in Boron Neutron Capture Therapy (BNCT) in normal fibroblasts and melanoma cell lines were analyzed. Melanoma cells and normal fibroblasts were treated with different concentrations of Boronophenylalanine and irradiated with thermal neutron flux. The cellular viability and the oxidative stress were determined. BNCT induced free radicals production and proliferative potential inhibition in melanoma cells. Therefore, this therapeutic technique could be considered efficient to inhibit growth of melanoma with minimal effects on normal tissues. - Highlights: Black-Right-Pointing-Pointer Boron Neutron Capture Therapy (BNCT) induces melanoma cell death. Black-Right-Pointing-Pointer BNCT stimulates free radicals production and proliferative inhibition in melanoma cells. Black-Right-Pointing-Pointer It produces tumor membrane degeneration and destruction with apoptotic bodies formation. Black-Right-Pointing-Pointer This therapy damages tumor cells selectively, with minimum effects on normal adjacent tissue.

Boron neutron capture therapy: Brain Tumor Treatment Evaluation Program

International Nuclear Information System (INIS)

Griebenow, M.L.; Dorn, R.V. III; Gavin, P.R.; Spickard, J.H.

1988-01-01

The United States (US) Department of Energy (DOE) recently initiated a focused, multidisciplined program to evaluate Boron Neutron Capture Therapy (BNCT) for the treatment of brain tumors. The program, centered at the DOE/endash/Idaho National Engineering Laboratory (INEL), will develop the analytical, diagnostic and treatment tools, and the database required for BNCT technical assessment. The integrated technology will be evaluated in a spontaneously-occurring canine brain-tumor model. Successful animal studies are expected to lead to human clinical trials within four to five years. 2 refs., 3 figs

Research needs for neutron capture therapy

International Nuclear Information System (INIS)

1995-01-01

Key issues and questions addressed by the workshop related to optimization of Boron Neutron Capture Therapy (BNCT), in general, and to the possibility of success of the present BNCT trials at Brookhaven National Laboratory (BNL) and Massachusetts Institute of Technology (MIT), in particular. Both trials use nuclear fission reactors as neutron sources for BNCT of glioblastoma multiforme (BNL) and of deep seated melanoma (MIT). Presentations and discussions focussed on optimal boron-labeled compounds, mainly for brain tumors such as glioblastoma multiforme, and the best mode of compound delivery to the tumor. Also, optimizing neutron irradiation with dose delivery to the tumor cells and the issues of dosimetry of BNCT especially in the brain were discussed. Planning of treatment and of follow-up of patients, coordination of BNCT at various treatment sites, and the potential of delivering BNCT to various types of cancer with an appropriately tailored protocol were additional issues. The need for multicentric interdisciplinary cooperation among the different medical specialties was highlighted

Opening and construction of facilities in succession for particle beam therapy of cancer

International Nuclear Information System (INIS)

Nakano, Takashi; Yamamoto, Kazutaka; Hishikawa, Yoshio; Totoki, Tadahide; Hoshino, Junichi; Aoki, Takashi; Yoshiyuki, Takeshi; Hirabayashi, Masayuki; Nakamura, Fumito

2011-01-01

This feature article describes the current state of practical particle beam therapy of cancer, its future prospect, recent opening/construction of its facilities and manufacturers' view with following 9 topics presented by relevant experts. Gunma University (topic 1) started the carbon ion therapy from Mar., 2010, and has treated more than 100 cancer patients to aim the treatment of about 600 patients/year after several years. Fukui Prefectural Hospital Proton Therapy Center (topic 2) started from this March with proton beams for patients with its therapeutic standard, in cooperation with insurance companies and hotels for patients' convenience. Medipolis Proton Therapy and Research Center (Kagoshima Pref.) (topic 3) started this year with proton beams for 13 patients hitherto with reference protocol of Hyogo Ion Beam Medical Center. A new stereotactic irradiation system of proton beams for breast cancer has been developed. Construction of Saga Heavy Ion Medical Accelerator in Tosu (Saga Pref.) (topic 4) began this year to be completed in 2013. Aizawa Hospital (Nagano Pref.) (topic 5) plans to introduce the small-sized proton accelerator-gantry system (Sumitomo Heavy Ind., Ltd.) aiming the practice in 2013. Association for Nuclear Technology in Medicine (topic 6) reports the trends of current and future construction inside/outside Japan. Manufacturers comment their respective business: high-speed scanning irradiation system, next generation handling system of patient and particle beam therapy information system by Toshiba (topic 7); designation of the whole heavy ion beam therapy system (with NIRS), proton beam (as in topic 5) and system of BNCT (boron neutron-capture therapy) (Kyoto Univ.) by Sumitomo Heavy Ind., Ltd. (topic 8); and small-size proton therapeutic machine with 4D tracing capability for patient's movement (Hokkaido Univ.) and with spot-scanning irradiation technique by Hitachi (topic 9). (author)

Health physics considerations at a neutron therapy facility cyclotron

International Nuclear Information System (INIS)

Kleck, J.H.; Krueger, D.J.; Mc Laughlin, J.E.; Smathers, J.B.

1987-01-01

The U.C.L.A. Neutron Therapy Facility (NTF) is one of four such facilities in the United States currently involved in NCI sponsored trials of neutron therapy and reflects the present interest in the use of high energy neutron beams for treating certain types of human cancers. The NTF houses a CP-45 negative ion cyclotron which accelerates a 46 MeV proton beam for production of neutrons from a beryllium target. In addition to patient treatment, the NTF is involved in the production of positron emitting radioisotopes for diagnostic use in Positron Emission Tomography (PET). The activation of therapy treatment collimators, positron and neutron target systems, and a high and rapidly varying external radiation environment in a clinical setting have contributed to the need for a comprehensive radiation control program in which patient care is balanced with the maintenance of occupational exposures to ALARA levels

Distribution of exogenous porphyrins in vivo; implications for neutron capture therapy

International Nuclear Information System (INIS)

Fairchild, R.G.; Gabel, D.; Hillman, M.; Watts, K.

1982-01-01

Endogenous porphyrins (HpD) are already in clinical use for phototherapy, in which red light is used to stimulate a cytotoxic response in tumors. The evident success, at least with superficial cancers, gives biological evidence of selective concentrations of porphyrins in tumors adequate for therapy. The authors have investigated, in addition, the biodistribution of a synthetic porphyrin (tetraphenylporphinesulfonate, or TPPS) in seven different animal tumor models. Their data, as well as those of others, indicate abundant accumulations of TPPS in tumor. If boronated analogs behave in the same way, boron concentrations would be up to 10 times that needed for therapy. Utilization of such porphyrin analogs in the neutron capture therapy (NCT) procedure is similar in concept to phototherapy currently being used clinically, with the distinct advantage of deeper tissue penetration produced by the activating neutrons

Possible alternation of the blood-brain barrier by boron-neutron capture therapy

International Nuclear Information System (INIS)

Hatanaka, H.; Moritani, M.; Camillo, M.

1991-01-01

In the course of re-assessment of boron-neutron capture therapy (BNCT) for malignant brain tumors, fractionation of neutron irradiation has been proposed. The authors have used BNCT with a single fraction technique during the past 21 years and now decided to study some effects of fractionation. Twenty-two healthy mouse brains were irradiated with thermal neutrons after boron-10 injection (mercaptoundecahydrododecaborate). A second dose of boron-10 was administered and its uptake in the boron-neutron-capture-irradiated brains was determined. A tendency towards increased boron uptake in the moderately BNCT-treated brains was noticed, which may result in increased brain damage if fractionated neutron irradiation is used. (orig.)

A colorimetric determination of boron in biological sample for boron neutron capture therapy

International Nuclear Information System (INIS)

Camilo, M.A.P.; Tomac Junior, U.

1989-01-01

The boron neutron capture therapy (BNCT) has shown better prognosis in the treatment of gliomas and glioblastomas grade III and IV than other therapies. During the treatment of levels of Na 2 10 B 12 H 11 S H must be known in several compartments of the organism and with this purpose the method of colorimetric determination of boron using curcumin was established. This method is simples, reproducible and has adequate sensitivity for this control. (author). 7 refs, 3 figs, 1 tab

Ultrastructural changes in tumor cells following boron neutron capture therapy

International Nuclear Information System (INIS)

Barkla, D.H.; Brown, J.K.; Meriaty, H.; Allen, B.J.

1992-01-01

In a previous study the authors reported on morphological changes in two human melanoma cell lines treated with 10 B-phenylalanine(BPA) and Boron Neutron Capture Therapy(BNCT). The present study describes morphological changes in melanoma and glioma cell lines treated with boron-tetraphenyl porphyrin(BTPP) and BNCT. Porphyrin compounds are selectively taken up by tumor cells and have been used clinically in phototherapy treatment of cancer patients. Boronated porphyrins show good potential as therapeutic agents in BNCT treatment of human cancer patients

Physics of epi-thermal boron neutron capture therapy (epi-thermal BNCT).

Science.gov (United States)

Seki, Ryoichi; Wakisaka, Yushi; Morimoto, Nami; Takashina, Masaaki; Koizumi, Masahiko; Toki, Hiroshi; Fukuda, Mitsuhiro

2017-12-01

The physics of epi-thermal neutrons in the human body is discussed in the effort to clarify the nature of the unique radiologic properties of boron neutron capture therapy (BNCT). This discussion leads to the computational method of Monte Carlo simulation in BNCT. The method is discussed through two examples based on model phantoms. The physics is kept at an introductory level in the discussion in this tutorial review.

Local control of murine melanoma xenografts in nude mice by neutron capture therapy

International Nuclear Information System (INIS)

Allen, B.J.; Corderoy-Buck, S.; Moore, D.E.; Mishima, Y.; Ichihashi, M.

1992-01-01

In recent years considerable progress has been made in the development and implementation of neutron capture therapy (NCT) for the treatment of cancer. In particular, the boron analogue of the melanin precursor phenylalanine, i.e., DL-p-boronophenylalanine (BPA), has been used to demonstrate the regression and cure of Harding-Passey (HP) melanoma in syngeneic mice. However, 18 to 25% cures were obtained for neutron irradiations without boron, suggesting that the neutron dose alone plays an important role. Neutron capture therapy of B-16 melanoma xenografts in nude mice showed substantial tumor regression over 35 days, but the survival rate of NCT treated mice after 7 weeks was only 40-60%. In this paper the authors demonstrate the equivalence of the nude mouse model with a syngeneic model, using the same Harding-Passey murine melanoma line, and delineate the conditions required for maximum differential response between neutron irradiation with and without BPA administration, with complete local control as the end point

Carbon Capture and Sequestration from a Hydrogen Production Facility in an Oil Refinery

Energy Technology Data Exchange (ETDEWEB)

Engels, Cheryl; Williams, Bryan, Valluri, Kiranmal; Watwe, Ramchandra; Kumar, Ravi; Mehlman, Stewart

2010-06-21

The project proposed a commercial demonstration of advanced technologies that would capture and sequester CO2 emissions from an existing hydrogen production facility in an oil refinery into underground formations in combination with Enhanced Oil Recovery (EOR). The project is led by Praxair, Inc., with other project participants: BP Products North America Inc., Denbury Onshore, LLC (Denbury), and Gulf Coast Carbon Center (GCCC) at the Bureau of Economic Geology of The University of Texas at Austin. The project is located at the BP Refinery at Texas City, Texas. Praxair owns and operates a large hydrogen production facility within the refinery. As part of the project, Praxair would construct a CO2 capture and compression facility. The project aimed at demonstrating a novel vacuum pressure swing adsorption (VPSA) based technology to remove CO2 from the Steam Methane Reformers (SMR) process gas. The captured CO2 would be purified using refrigerated partial condensation separation (i.e., cold box). Denbury would purchase the CO2 from the project and inject the CO2 as part of its independent commercial EOR projects. The Gulf Coast Carbon Center at the Bureau of Economic Geology, a unit of University of Texas at Austin, would manage the research monitoring, verification and accounting (MVA) project for the sequestered CO2, in conjunction with Denbury. The sequestration and associated MVA activities would be carried out in the Hastings field at Brazoria County, TX. The project would exceed DOE?s target of capturing one million tons of CO2 per year (MTPY) by 2015. Phase 1 of the project (Project Definition) is being completed. The key objective of Phase 1 is to define the project in sufficient detail to enable an economic decision with regard to proceeding with Phase 2. This topical report summarizes the administrative, programmatic and technical accomplishments completed in Phase 1 of the project. It describes the work relative to project technical and design activities

Experimental neutron capture data of 58Ni from the CERN n_TOF facility

Directory of Open Access Journals (Sweden)

Žugec P.

2015-01-01

Full Text Available The neutron capture cross section of 58Ni was measured at the neutron time of flight facility n_TOF at CERN, from 27 meV to 400 keV neutron energy. Special care has been taken to identify all the possible sources of background, with the so-called neutron background obtained for the first time using high-precision GEANT4 simulations. The energy range up to 122 keV was treated as the resolved resonance region, where 51 resonances were identified and analyzed by a multilevel R-matrix code SAMMY. Above 122 keV the code SESH was used in analyzing the unresolved resonance region of the capture yield. Maxwellian averaged cross sections were calculated in the temperature range of kT = 5 – 100 keV, and their astrophysical implications were investigated.

Research on neutron capture therapy in the USSR

International Nuclear Information System (INIS)

Ryabukhin, Y.

1988-01-01

Research on neutron capture therapy in the USSR began in 1964. Towards 1975 prime knowledge in physics, pharmacology and radiobiology had been accumulated. It was realized that inherent to NCT is a variety of modalities as to the type and location of the tumor, the energy and source of neutrons, the nature and transportation of the nuclide-carrying agent (NCA), etc. Thus, it became likely that some modalities would turn out to be clinically feasible. At the end of the 70s, studies of boron derivatives began at the All-Union Oncological Research Center, Moscow. These studies were stimulated by the clinical trials in Japan. Still, neutron capturing nuclides (NCN) other than 10 b are regarded as promising. Research was aimed at clinical trials that could ensure sufficient safety, convenience and conclusiveness. Hence, new requirements emerged, such as the pre-clinical modeling of NCT in big animals and the monitoring of tumor response to each fraction of NCT. Usual requirements are also to be met, that is: tailoring neutron beams with an adequate intensity and energy, choosing NCNs and finding suitable NCAs, physical and radiobiological planning including adoption of tentative RBEs and time-fractionation regimen, selecting tumors as candidates for NCT, and developing techniques for monitoring NCNs in vivo

A colorimetric determination of boron in biological sample for boron neutron capture therapy (BNCT)

International Nuclear Information System (INIS)

Camillo, M.A.P.; Tomac Junior, U.

1990-01-01

The boron neutron capture therapy (BNCT) has shown better prognosis in the treatment of glyemas and gluoblastomas grade III and IV than other therapies. During the treatment the levels of Na 2 10 B 12 H 11 SH must be known in several compartiments of the organism and with this purpose the method of colorimetric determination of boron using curcumine was established. This method is simple, reprodutible and adequate sensitivity for this control. (author) [pt

Development of the JAERI computational dosimetry system (JCDS) for boron neutron capture therapy. Cooperative research

CERN Document Server

Kumada, H; Matsumura, A; Nakagawa, Y; Nose, T; Torii, Y; Uchiyama, J; Yamamoto, K; Yamamoto, T

2003-01-01

The Neutron Beam Facility at JRR-4 enables us to carry out boron neutron capture therapy with epithermal neutron beam. In order to make treatment plans for performing the epithermal neutron beam BNCT, it is necessary to estimate radiation doses in a patient's head in advance. The JAERI Computational Dosimetry System (JCDS), which can estimate distributions of radiation doses in a patient's head by simulating in order to support the treatment planning for epithermal neutron beam BNCT, was developed. JCDS is a software that creates a 3-dimentional head model of a patient by using CT and MRI images, and that generates a input data file automatically for calculation of neutron flux and gamma-ray dose distributions in the brain with the Monte Carlo code MCNP, and that displays these dose distributions on the head model for dosimetry by using the MCNP calculation results. JCDS has any advantages as follows; By using CT data and MRI data which are medical images, a detail three-dimensional model of patient's head is...

Power Burst Reactor Facility as an epithermal neutron source for brain cancer therapy

International Nuclear Information System (INIS)

Wheeler, F.J.

1986-01-01

The Power Burst Facility (PBF) reactor is considered for modification to provide an intense, clean source of intermediate-energy (epithermal) neutrons desirable for clinical studies of neutron capture therapy (NCT) for malignant tumors. The modifications include partial replacement of the reflector, installation of a neutron-moderating, shifting region, additional shielding, and penetration of the present concrete shield with a collimating (and optionally) filtering region. The studies have indicated that the reactor, after these modifications, will be safely operable at full power (28 MW) within the acceptable limits of the plant protection systems. The neutron beam exiting from the collimator port is predicted to be of sufficient intensity (approx.10 10 neutrons/cm 2 -s) to provide therapeutic doses in very short irradiation times. The beam would be relatively free of undesirable fast neutrons, thermal neutrons and gamma rays. The calculated neutron energy spectrum and associated gamma rays in the beam were provided as input in simulation studies that used a computer model of a patient with a brain tumor to determine predicted dose rates to the tumor and healthy tissue. The results of this conceptual study indicate an intense, clean beam of epithermal neutrons for NCT clinical trials is attainable in the PBF facility with properly engineered design modifications. 9 refs., 11 figs., 3 tabs

Boron compounds in neutron capture therapy of tumors

International Nuclear Information System (INIS)

Strouf, O.; Gregor, V.

1986-01-01

In the selective incorporation of a sufficient amount of a compound containing boron isotope 10 B in the tumor tissue for neutron capture therapy, high efficiency is achieved in tumor destruction while sparing the surrounding tissues. In the treatment of brain tumors, 4-carboxy phenylboric acid and the disodium salt of mercaptoundecahydrododecaborate were successfully tested. The use of the compounds minimizes radiation damage to the blood stream of the brain. In case of melanomas the L-DOPA-borate complex, boronophenylalanine and chlorpromazine preparations containing 10 B are used. In the treatment of cancer of the reproductive organs, boron derivatives of estradiol and testosterone have been proven. The immunobiological procedure, i.e., the use of antibodies with bound boron compounds, is being intensively studied. (M.D.)

The accelerator facility of the Heidelberg Ion-Beam Therapy Centre (HIT)

Science.gov (United States)

Peters, Andreas

The following sections are included: * Introduction * Beam parameters * General layout of the HIT facility * The accelerator chain in detail * Operational aspects of a particle therapy facility * 24/7 accelerator operation at 335 days per year * Safety and regulatory aspects * Status and perspectives * References

Verification of the computational dosimetry system in JAERI (JCDS) for boron neutron capture therapy

International Nuclear Information System (INIS)

Kumada, H; Yamamoto, K; Matsumura, A; Yamamoto, T; Nakagawa, Y; Nakai, K; Kageji, T

2004-01-01

Clinical trials for boron neutron capture therapy (BNCT) by using the medical irradiation facility installed in Japan Research Reactor No. 4 (JRR-4) at Japan Atomic Energy Research Institute (JAERI) have been performed since 1999. To carry out the BNCT procedure based on proper treatment planning and its precise implementation, the JAERI computational dosimetry system (JCDS) which is applicable to dose planning has been developed in JAERI. The aim of this study was to verify the performance of JCDS. The experimental data with a cylindrical water phantom were compared with the calculation results using JCDS. Data of measurements obtained from IOBNCT cases at JRR-4 were also compared with retrospective evaluation data with JCDS. In comparison with phantom experiments, the calculations and the measurements for thermal neutron flux and gamma-ray dose were in a good agreement, except at the surface of the phantom. Against the measurements of clinical cases, the discrepancy of JCDS's calculations was approximately 10%. These basic and clinical verifications demonstrated that JCDS has enough performance for the BNCT dosimetry. Further investigations are recommended for precise dose distribution and faster calculation environment

Proceedings of workshop on 'boron science and boron neutron capture therapy'

Energy Technology Data Exchange (ETDEWEB)

Kitaoka, Y. [ed.

1998-12-01

This volume contains the abstracts and programs of the 8th (1996), 9th (1997) and 10th (1998) of the workshop on 'the Boron Science and Boron Neutron Capture Therapy' and the recent progress reports especially subscribed. The 11 of the presented papers are indexed individually. (J.P.N.)

Boron neutron capture therapy of malignant brain tumors at the Brookhaven Medical Research Reactor

Energy Technology Data Exchange (ETDEWEB)

Joel, D.D.; Coderre, J.A.; Chanana, A.D. [Brookhaven National Lab., Upton, NY (United States). Medical Dept.

1996-12-31

Boron neutron capture therapy (BNCT) is a bimodal form of radiation therapy for cancer. The first component of this treatment is the preferential localization of the stable isotope {sup 10}B in tumor cells by targeting with boronated compounds. The tumor and surrounding tissue is then irradiated with a neutron beam resulting in thermal neutron/{sup 10}B reactions ({sup 10}B(n,{alpha}){sup 7}Li) resulting in the production of localized high LET radiation from alpha and {sup 7}Li particles. These products of the neutron capture reaction are very damaging to cells, but of short range so that the majority of the ionizing energy released is microscopically confined to the vicinity of the boron-containing compound. In principal it should be possible with BNCT to selectively destroy small nests or even single cancer cells located within normal tissue. It follows that the major improvements in this form of radiation therapy are going to come largely from the development of boron compounds with greater tumor selectivity, although there will certainly be advances made in neutron beam quality as well as the possible development of alternative sources of neutron beams, particularly accelerator-based epithermal neutron beams.

Boron neutron capture therapy of malignant brain tumors at the Brookhaven Medical Research Reactor

International Nuclear Information System (INIS)

Joel, D.D.; Coderre, J.A.; Chanana, A.D.

1996-01-01

Boron neutron capture therapy (BNCT) is a bimodal form of radiation therapy for cancer. The first component of this treatment is the preferential localization of the stable isotope 10 B in tumor cells by targeting with boronated compounds. The tumor and surrounding tissue is then irradiated with a neutron beam resulting in thermal neutron/ 10 B reactions ( 10 B(n,α) 7 Li) resulting in the production of localized high LET radiation from alpha and 7 Li particles. These products of the neutron capture reaction are very damaging to cells, but of short range so that the majority of the ionizing energy released is microscopically confined to the vicinity of the boron-containing compound. In principal it should be possible with BNCT to selectively destroy small nests or even single cancer cells located within normal tissue. It follows that the major improvements in this form of radiation therapy are going to come largely from the development of boron compounds with greater tumor selectivity, although there will certainly be advances made in neutron beam quality as well as the possible development of alternative sources of neutron beams, particularly accelerator-based epithermal neutron beams

Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT)

International Nuclear Information System (INIS)

Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, H.

2011-01-01

The purpose of this study was to compare the radiation dose between long-survivors and non-long-survivors in patients with glioblatoma (GBM) treated with boron neutron capture therapy (BNCT). Among 23 GBM patients treated with BNCT, there were five patients who survived more than three years after diagnosis. The physical and weighted dose of the minimum gross tumor volume (GTV) of long-survivors was much higher than that of non-long survivors with significant statistical differences.

Universal algorithm for diagnosis of biventricular capture in patients with cardiac resynchronization therapy.

Science.gov (United States)

Jastrzebski, Marek; Kukla, Piotr; Fijorek, Kamil; Czarnecka, Danuta

2014-08-01

An accurate and universal method for diagnosis of biventricular (BiV) capture using a standard 12-lead electrocardiogram (ECG) would be useful for assessment of cardiac resynchronization therapy (CRT) patients. Our objective was to develop and validate such an ECG method for BiV capture diagnosis that would be independent of pacing lead positions-a major confounder that significantly influences the morphologies of paced QRS complexes. On the basis of an evaluation of 789 ECGs of 443 patients with heart failure and various right ventricular (RV) and left ventricular (LV) lead positions, the following algorithm was constructed and validated. BiV capture was diagnosed if the QRS in lead I was predominantly negative and either V1 QRS was predominantly positive or V6 QRS was of negative onset and predominantly negative (step 1), or if QRS complex duration was capture. The algorithm showed good accuracy (93%), sensitivity (97%), and specificity (90%) for detection of loss of LV capture. The performance of the algorithm did not differ among apical, midseptal, and outflow tract RV lead positions and various LV lead positions. LV capture leaves diagnostic hallmarks in the fused BiV QRS related to different vectors of depolarization and more rapid depolarization of the ventricles. An accurate two-step ECG algorithm for BiV capture diagnosis was developed and validated. This algorithm is universally applicable to all CRT patients, regardless of the positions of the pacing leads. ©2014 Wiley Periodicals, Inc.

Geographic access to radiation therapy facilities and disparities of early-stage breast cancer treatment

Directory of Open Access Journals (Sweden)

Yan Lin

2018-05-01

Full Text Available Few studies of breast cancer treatment have focused on the Northern Plains of the United States, an area with a high mastectomy rate. This study examined the association between geographic access to radiation therapy facilities and receipt of breast cancer treatments among early-stage breast cancer patients in South Dakota. Based on 4,209 early-stage breast cancer patients diagnosed between 2001 and 2012 in South Dakota, the study measured geographic proximity to radiation therapy facilities using the shortest travel time for patients to the closest radiation therapy facility. Two-level logistic regression models were used to estimate for early stage cases i the odds of mastectomy versus breast conserving surgery (BCS; ii the odds of not receiving radiation therapy after BCS versus receiving follow-up radiation therapy. Covariates included race/ethnicity, age at diagnosis, tumour grade, tumour sequence, year of diagnosis, census tract-level poverty rate and urban/rural residence. The spatial scan statistic method was used to identify geographic areas with significantly higher likelihood of experiencing mastectomy. The study found that geographic accessibility to radiation therapy facilities was negatively associated with the likelihood of receiving mastectomy after adjustment for other covariates, but not associated with radiation therapy use among patients receiving BCS. Compared with patients travelling less than 30 minutes to a radiation therapy facility, patients travelling more than 90 minutes were about 1.5 times more likely to receive mastectomy (odds ratio, 1.51; 95% confidence interval, 1.08-2.11 and patients travelling more than 120 minutes were 1.7 times more likely to receive mastectomy (odds ratio, 1.70; 95% confidence interval, 1.19-2.42. The study also identified a statistically significant cluster of patients receiving mastectomy who were located in south-eastern South Dakota, after adjustment for other factors. Because

Proton therapy detector studies under the experience gained at the CATANA facility

International Nuclear Information System (INIS)

Cuttone, G.; Cirrone, G.A.P.; Di Rosa, F.; Lojacono, P.A.; Lo Nigro, S.; Marino, C.; Mongelli, V.; Patti, I.V.; Pittera, S.; Raffaele, L.; Russo, G.; Sabini, M.G.; Salamone, V.; Valastro, L.M.

2007-01-01

Proton therapy represents the most promising radiotherapy technique for external tumor treatments. At Laboratori Nazionali del Sud of the Istituto Nazionale di Fisica Nucleare (INFN-LNS), Catania (I), a proton therapy facility is active since March 2002 and 140 patients, mainly affected by choroidal and iris melanoma, have been successfully treated. Proton beams are characterized by higher dose gradients and linear energy transfer with respect to the conventional photon and electron beams, commonly used in medical centers for radiotherapy. In this paper, we report the experience gained in the characterization of different dosimetric systems, studied and/or developed during the last ten years in our proton therapy facility

Proton therapy detector studies under the experience gained at the CATANA facility

Energy Technology Data Exchange (ETDEWEB)

Cuttone, G.; Cirrone, G.A.P.; Di Rosa, F. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Lojacono, P.A. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Dipartimento di Fisica ed Astronomia, Universita degli Studi di Catania (Italy); Lo Nigro, S.; Marino, C. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Dipartimento di Fisica ed Astronomia, Universita degli Studi di Catania (Italy); Centro Siciliano di Fisica Nucleare e Struttura della Materia, Catania (Italy); Mongelli, V. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Dipartimento di Fisica ed Astronomia, Universita degli Studi di Catania (Italy); Patti, I.V. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Pittera, S. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Dipartimento di Fisica ed Astronomia, Universita degli Studi di Catania (Italy); Centro Siciliano di Fisica Nucleare e Struttura della Materia, Catania (Italy); Raffaele, L. [A.O.U. Policlinico, Universita degli Studi di Catania (Italy); Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Russo, G. [Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Dipartimento di Fisica ed Astronomia, Universita degli Studi di Catania (Italy); Sabini, M.G. [A.O. Cannizzaro, Catania (Italy); Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy); Salamone, V.; Valastro, L.M. [A.O.U. Policlinico, Universita degli Studi di Catania (Italy); Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali dei Sud, Catania (Italy)

2007-10-15

Proton therapy represents the most promising radiotherapy technique for external tumor treatments. At Laboratori Nazionali del Sud of the Istituto Nazionale di Fisica Nucleare (INFN-LNS), Catania (I), a proton therapy facility is active since March 2002 and 140 patients, mainly affected by choroidal and iris melanoma, have been successfully treated. Proton beams are characterized by higher dose gradients and linear energy transfer with respect to the conventional photon and electron beams, commonly used in medical centers for radiotherapy. In this paper, we report the experience gained in the characterization of different dosimetric systems, studied and/or developed during the last ten years in our proton therapy facility.

Proton therapy detector studies under the experience gained at the CATANA facility

Science.gov (United States)

Cuttone, G.; Cirrone, G. A. P.; Di Rosa, F.; Lojacono, P. A.; Lo Nigro, S.; Marino, C.; Mongelli, V.; Patti, I. V.; Pittera, S.; Raffaele, L.; Russo, G.; Sabini, M. G.; Salamone, V.; Valastro, L. M.

2007-10-01

Proton therapy represents the most promising radiotherapy technique for external tumor treatments. At Laboratori Nazionali del Sud of the Istituto Nazionale di Fisica Nucleare (INFN-LNS), Catania (I), a proton therapy facility is active since March 2002 and 140 patients, mainly affected by choroidal and iris melanoma, have been successfully treated. Proton beams are characterized by higher dose gradients and linear energy transfer with respect to the conventional photon and electron beams, commonly used in medical centers for radiotherapy.In this paper, we report the experience gained in the characterization of different dosimetric systems, studied and/or developed during the last ten years in our proton therapy facility.

Design of experiment existing parameter physics for supporting of Boron Neutron Capture Therapy (BNCT) method a t the piercing radial beam port of Kartini research reactor

International Nuclear Information System (INIS)

Indry Septiana Novitasari; Yosaphat Sumardi; Widarto

2014-01-01

The experiment existing parameters physics for supporting of in vivo and in vitro test facility of Boron Neutron Capture Therapy (BNCT) preliminary study at the piercing radial beam port has been done. The existing experiments is needed for determining that the parameter physics is fulfill the BNCT method requirement. To realize the existing experiment have been done by design analysis, methodology, calculation method and some procedure related with radiation safety analysis and environment. Preparation for existing experiment physics such as foil detector of Gold (Au) should be irradiated for 30 minute, irradiation instrument and procedure related with the experiment for radiation safety. (author)

Monte Carlo calculations on efficiency of boron neutron capture therapy for brain cancer

International Nuclear Information System (INIS)

Awadalla, Galaleldin Mohamed Suliman

2015-11-01

The search for ways to treat cancer has led to many different treatments, including surgery, chemotherapy, and radiation therapy. Among these treatments, boron neutron capture therapy (BNCT) has shown promising results. BNCT is a radiotherapy treatment modality that has been proposed to treat brain cancer. In this technique, cancerous cells are being injected with 1 0B and irradiated by thermal neutrons to increase the probability of 1 0B (n, a)7 L i reaction to occur. This reaction can potentially deliver a high radiation dose sufficient to kill cancer cells by concentrating boron in them. The short rang of 1 0B (n, a) 7 L i reaction limits the damage to only cancerous cells without affecting healthy tissues. The effectiveness and safety of radiotherapy are dependent on the radiation dose delivered to the tumor and healthy tissues. In this thesis, after reviewing the basics and working principles of boron neutron capture therapy (BNCT), monte Carlo simulations were carried out to model a thermal neutron source suitable for BNCT and to examine the performance of proposed model when used to irradiate a sample of boron containing both 1 0B and 1 1B isotopes. MCNP5 code was used to examine the modeled neutron source through different shielding materials. The results were presented, analyzed and discussed at the end of the work. (author)

Plastic scintillation dosimetry for radiation therapy: minimizing capture of Cerenkov radiation noise

International Nuclear Information System (INIS)

Beddar, A Sam; Suchowerska, Natalka; Law, Susan H

2004-01-01

Over the last decade, there has been an increased interest in scintillation dosimetry using small water-equivalent plastic scintillators, because of their favourable characteristics when compared with other more commonly used detector systems. Although plastic scintillators have been shown to have many desirable dosimetric properties, as yet there is no successful commercial detector system of this type available for routine clinical use in radiation oncology. The main factor preventing this new technology from realizing its full potential in commercial applications is the maximization of signal coupling efficiency and the minimization of noise capture. A principal constituent of noise is Cerenkov radiation. This study reports the calculated capture of Cerenkov radiation by an optical fibre in the special case where the radiation is generated by a relativistic particle on the fibre axis and the fibre axis is parallel to the Cerenkov cone. The fraction of radiation captured is calculated as a function of the fibre core refractive index and the refractive index difference between the core and the cladding of the fibre for relativistic particles. This is then used to deduce the relative intensity captured for a range of fibre core refractive indices and fibre core-cladding refractive index differences. It is shown that the core refractive index has little effect on the amount of radiation captured compared to the refractive index difference. The implications of this result for the design of radiation therapy plastic scintillation dosimeters are considered

The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

DEFF Research Database (Denmark)

Hampel, G.; Grunewald, C.; Schütz, C.

2011-01-01

The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed at Pavia (Italy) a few ...

Biomedical neutron research at the Californium User Facility for neutron science

International Nuclear Information System (INIS)

Martin, R.C.; Byrne, T.E.; Miller, L.F.

1997-01-01

The Californium User Facility for Neutron Science has been established at Oak Ridge National Laboratory (ORNL). The Californium User Facility (CUF) is a part of the larger Californium Facility, which fabricates and stores compact 252 Cf neutron sources for worldwide distribution. The CUF can provide a cost-effective option for research with 252 Cf sources. Three projects at the CUF that demonstrate the versatility of 252 Cf for biological and biomedical neutron-based research are described: future establishment of a 252 Cf-based neutron activation analysis system, ongoing work to produce miniature high-intensity, remotely afterloaded 252 Cf sources for tumor therapy, and a recent experiment that irradiated living human lung cancer cells impregnated with experimental boron compounds to test their effectiveness for boron neutron capture therapy

Animal-assisted interventions: A national survey of health and safety policies in hospitals, eldercare facilities, and therapy animal organizations.

Science.gov (United States)

Linder, Deborah E; Siebens, Hannah C; Mueller, Megan K; Gibbs, Debra M; Freeman, Lisa M

2017-08-01

Animal-assisted intervention (AAI) programs are increasing in popularity, but it is unknown to what extent therapy animal organizations that provide AAI and the hospitals and eldercare facilities they work with implement effective animal health and safety policies to ensure safety of both animals and humans. Our study objective was to survey hospitals, eldercare facilities, and therapy animal organizations on their AAI policies and procedures. A survey of United States hospitals, eldercare facilities, and therapy animal organizations was administered to assess existing health and safety policies related to AAI programs. Forty-five eldercare facilities, 45 hospitals, and 27 therapy animal organizations were surveyed. Health and safety policies varied widely and potentially compromised human and animal safety. For example, 70% of therapy animal organizations potentially put patients at risk by allowing therapy animals eating raw meat diets to visit facilities. In general, hospitals had stricter requirements than eldercare facilities. This information suggests that there are gaps between the policies of facilities and therapy animal organizations compared with recent guidelines for animal visitation in hospitals. Facilities with AAI programs need to review their policies to address recent AAI guidelines to ensure the safety of animals and humans involved. Copyright © 2017 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Development of inverse-planning system for neutron capture therapy

International Nuclear Information System (INIS)

Kumada, Hiroaki; Yamamoto, Kazuyoshi; Maruo, Takeshi

2006-01-01

To lead proper irradiation condition effectively, Japan Atomic Energy Agency (JAEA) is developing an inverse-planning system for neutron capture therapy (NCT-IPS) based on the JAEA computational dosimetry system (JCDS) for BNCT. The leading methodology of an optimum condition in the NCT-IPS has been applied spatial channel theory with adjoint flux solution of Botzman transport. By analyzing the results obtained from the adjoint flux calculations according to the theory, optimum incident point of the beam against the patient can be found, and neutron spectrum of the beam which can generate ideal distribution of neutron flux around tumor region can be determined. The conceptual design of the NCT-IPS was investigated, and prototype of NCT-IPS with JCDS is being developed. (author)

High-power liquid-lithium target prototype for accelerator-based boron neutron capture therapy.

Science.gov (United States)

Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Bisyakoev, M; Eliyahu, I; Feinberg, G; Hazenshprung, N; Kijel, D; Nagler, A; Silverman, I

2011-12-01

A prototype of a compact Liquid-Lithium Target (LiLiT), which will possibly constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals, was built. The LiLiT setup is presently being commissioned at Soreq Nuclear Research Center (SNRC). The liquid-lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power generated using a high-intensity proton beam (>10 kW), necessary for sufficient neutron flux. In off-line circulation tests, the liquid-lithium loop generated a stable lithium jet at high velocity, on a concave supporting wall; the concept will first be tested using a high-power electron beam impinging on the lithium jet. High intensity proton beam irradiation (1.91-2.5 MeV, 2-4 mA) will take place at Soreq Applied Research Accelerator Facility (SARAF) superconducting linear accelerator currently in construction at SNRC. Radiological risks due to the (7)Be produced in the reaction were studied and will be handled through a proper design, including a cold trap and appropriate shielding. A moderator/reflector assembly is planned according to a Monte Carlo simulation, to create a neutron spectrum and intensity maximally effective to the treatment and to reduce prompt gamma radiation dose risks. Copyright © 2011 Elsevier Ltd. All rights reserved.

Some thoughts on tolerance, dose, and fractionation in boron neutron capture therapy

International Nuclear Information System (INIS)

Gahbauer, R.; Goodman, J.; Blue, T.

1988-01-01

Unique to boron neutron capture therapy, the tolerance very strongly depends on the boron concentration in normal brain, skin and blood. If one first considers the ideal situation of a 2 KeV beam and a compound clearing from normal tissues and blood, the tolerance dose to epithermal beams relates to the maximum tolerated capture gamma dose and capture high LET dose, H (n,gamma)D and N(n,p) 14 C. The authors can relate this gamma and high LET dose to known clinical experience. Assuming gamma and high LET dose ratios as given by Fairchild and Bond, one may first choose a clearly safe high LET whole brain dose and calculate the unavoidably resulting gamma dose. To a first approximation 500 cGy of high LET dose results in 3,000 cGy gamma dose. One can speculate that this approximates the tolerance of whole brain to the 2 KeV beam with no contributing boron dose if the radiation is fractionated. It would clearly be beyond tolerance in a single fraction where most therapists would be uncomfortable to deliver even one third of the above doses

Response of the oral mucosa to porphyrin mediated boron neutron capture therapy

International Nuclear Information System (INIS)

Morris, G.M.

2003-01-01

Pre-clinical studies are now in progress to develop boron neutron capture therapy (BNCT) modalities for the treatment of head and neck carcinomas. BNCT is a bimodal therapy which involves the administration of a boron-10 enriched compound, that accumulates preferentially in tumours, prior to irradiation with low energy neutrons. These neutrons are captured by boron-10 atoms to produce a highly localised radiation exposure. More recently, it has been demonstrated that various boronated porphyrins can target a variety of tumours. Of the porphyrins evaluated to date, copper tetracarboranylphenyl porphyrin (CuTCPH) is a strong candidate for potential clinical evaluation. It has extremely high specificity for a variety of tumour models. Therapeutic efficacy of CuTCPH mediated BNCT has been demonstrated in pre-clinical studies using the murine EMT-6 carcinoma model. In the present investigation the response of the oral mucosa to CuTCPH mediated boron neutron capture (BNC) irradiation was assessed using a standard rat model (ventral tongue). Single exposure irradiation was carried out on the thermal neutron beam at the Brookhaven Medical Research Reactor, at 3 days after the final injection of the boronated porphyrin. The impact of CuTCPH mediated BNC irradiation on oral mucosa at therapeutically effective exposure times, assessed using the ventral tongue model, was minimal. This was primarily due to the fact that blood boron levels (from CuTCPH) were very low at the time of irradiation. Analysis of the dose-effect data for CuTCPH gave a compound biological effectiveness (CBE) factor of 2.5. It can be concluded that, although, the CBE factor (calculated using blood boron concentrations) was relatively high, CuTCPH mediated BNC irradiation should not cause significant damage at clinically relevant radiation doses. This is because blood boron levels would be very low at the time of irradiation

Final Report: 8th International Symposium on Neutron Capture Therapy (NCT) for Cancer, May 15, 1998 - May 15, 1999

International Nuclear Information System (INIS)

Hawthorne, M.F.

1999-01-01

The 8th International Symposium on Neutron Capture Therapy for Cancer (8th ISNCTC) was held in La Jolla, CA on Sept. 13-18, 1998. This biennial meeting of the International Society for Neutron Capture Therapy (ISNCT) was hosted by Society President M.F. Hawthorne (UCLA Dept. of Chemistry and Biochemistry). The Symposium brought together scientists (300 registrants from 21 countries) from diverse fields to report the latest developments in NCT. Topics of the 275 papers presented (30 plenary lectures, 81 oral presentations, and 164 posters) included the physics of neutron sources, chemistry of tumor-targeting agents, dosimetry, radiobiological studies, and clinical applications

Facile Synthesis of Magnetic Mesoporous Hollow Carbon Microspheres for Rapid Capture of Low-Concentration Peptides

OpenAIRE

Cheng, Gong; Zhou, Ming-Da; Zheng, Si-Yang

2014-01-01

Mesoporous and hollow carbon microspheres embedded with magnetic nanoparticles (denoted as MHM) were prepared via a facile self-sacrificial method for rapid capture of low-abundant peptides from complex biological samples. The morphology, structure, surface property, and magnetism were well-characterized. The hollow magnetic carbon microspheres have a saturation magnetization value of 130.2 emu g?1 at room temperature and a Brunauer?Emmett?Teller specific surface area of 48.8 m2 g?1 with an a...

Initiation of a phase-I trial of neutron capture therapy at the MIT research reactor

International Nuclear Information System (INIS)

Harling, O.K.; Bernard, J.A.; Yam, Chun-Shan

1995-01-01

The Massachusetts Institute of Technology (MIT), the New England Medical Center (NEMC), and Boston University Medical Center (BUMC) initiated a phase-1 trial of boron neutron capture therapy (BNCT) on September 6, 1994, at the 5-MW(thermal) MIT research reactor (MITR). A novel form of experimental cancer therapy, BNCT is being developed for certain types of highly malignant brain tumors such as glioblastoma and melanoma. The results of the phase-1 trials on patients with tumors in the legs or feet are described

Perspectives of boron-neutron capture therapy of malignant brain tumors

Science.gov (United States)

Kanygin, V. V.; Kichigin, A. I.; Krivoshapkin, A. L.; Taskaev, S. Yu.

2017-09-01

Boron neutron capture therapy (BNCT) is characterized by a selective effect directly on the cells of malignant tumors. The carried out research showed the perspective of the given kind of therapy concerning malignant tumors of the brain. However, the introduction of BNCT into clinical practice is hampered by the lack of a single protocol for the treatment of patients and the difficulty in using nuclear reactors to produce a neutron beam. This problem can be solved by using a compact accelerator as a source of neutrons, with the possibility of installation in a medical institution. Such a neutron accelerator for BNCT was developed at Budker Institute of Nuclear Physics, Novosibirsk. A neutron beam was obtained on this accelerator, which fully complies with the requirements of BNCT, as confirmed by studies on cell cultures and experiments with laboratory animals. The conducted experiments showed the relative safety of the method with the absence of negative effects on cell cultures and living organisms, and also confirmed the effectiveness of BNCT for malignant brain tumors.

Further development of thermal neutron capture therapy for metastatic and deeply-invasive human malignant melanoma

International Nuclear Information System (INIS)

Mishima, Yutaka

1995-03-01

This issue is the collection of the papers presented thermal neutron capture therapy for metastatic and deeply-invasive human malignant melanoma. Separate abstracts were prepared for 2 of the papers in this report. The remaining 32 papers were considered outside the subject scope of INIS. (J.P.N.)

Boron neutron capture therapy (BNCT) using fast neutrons: Effects in two human tumor cell lines

International Nuclear Information System (INIS)

Sauerwein, W.; Ziegler, W.; Szypniewski, H.; Streffer, C.

1990-01-01

The results demonstrate that the effect of fast neutrons on cell survival in cell culture can be enhanced by boron neutron capture reaction. Even with lower enhancement ratios, the concept of NCT assisted fast neutron therapy may successfully be applied for tumor treatment with the Essen cyclotron. (orig.)

Neutron capture prompt gamma-ray activation analysis at the NIST cold neutron research facility

Energy Technology Data Exchange (ETDEWEB)

Lindstrom, R M; Zeisler, R; Vincent, D H; Greenberg, R R; Stone, C A; Mackey, E A [National Inst. of Standards and Technology, Gaithersburg, MD (United States); Anderson, D L [Food and Drug Administration, Washington, DC (United States); Clark, D D [Cornell Univ., Ithaca, NY (United States)

1993-01-01

An instrument for neutron capture prompt gamma-ray activation analysis (PGAA) has been constructed as part of the Cold Neutron Research Facility at the 20 MW National Institute of Standards and Technology Research Reactor. The neutron fluence rate (thermal equivalent) is 1.5*10[sup 8] n*cm[sup -2]*s[sup -] [sup 1], with negligible fast neutrons and gamma-rays. With compact geometry and hydrogen-free construction, the sensitivity is sevenfold better than an existing thermal instrument. Hydrogen background is thirtyfold lower. (author) 17 refs.; 2 figs.

Biomedical neutron research at the Californium User Facility for Neutron Science

International Nuclear Information System (INIS)

Martin, R.C.; Byrne, T.E.; Miller, L.F.

1998-01-01

The Californium User Facility for Neutron Science has been established at Oak Ridge National Laboratory (ORNL). The Californium User Facility (CUF) is a part of the larger Californium Facility, which fabricates and stores compact 252 Cf neutron sources for worldwide distribution. The CUF can provide a cost-effective option for research with 252 Cf sources. Three projects at the CUF that demonstrate the versatility of 252 Cf for biological and biomedical neutron-based research are described: future establishment of a 252 Cf-based neutron activation analysis system, ongoing work to produce miniature high-intensity, remotely afterloaded 252 Cf sources for tumor therapy, and a recent experiment that irradiated living human lung cancer cells impregnated with experimental boron compounds to test their effectiveness for boron neutron capture therapy. (author)

Neutron field characterization and dosimetry at the TRIUMF proton therapy facility

International Nuclear Information System (INIS)

Mukherjee, B.

2002-01-01

Full text: In 1972 the 500 MeV H' Cyclotron of the TRIUMF (Tri University Meson Factory) located in Vancouver, Canada became operational. Beside Meson Physics, high-energy protons of various energy and beam current levels from the TRIUMF Cyclotron are used for scientific research and biomedical applications. Recently, a 500 MeV proton beam from the cyclotron was used as the booster beam for the radioactive ion beam facility, ISAC (Isotope Separator Accelerator) and a second beam as primary irradiation source for the Proton Irradiation Facility (PIF). The major commercial applications of the PIF are the provision of high-energy proton beams for radiation hardness testing of electronic components used in space applications (NASA) and proton therapy of ocular tumors (British Columbia Proton Therapy Facility). The PIF vault was constructed within the main accelerator hall of the TRIUMF using stacks of large concrete blocks. An intense field of fast neutrons is produced during the interaction of high-energy proton beam with target materials, such as, beam stops, collimators and beam energy degraders. The leakage of such neutrons due to insufficient radiological shielding or through the shielding discontinuities may constitute a major share of the personnel radiation exposure of the radiation workers. The neutron energy distribution and dose equivalent near a lead beam stopper bombarded with 116 MeV and 65 MeV collimated proton beams at the Ocular Tumor irradiation facility were evaluated using a Bonner-Sphere Spectrometer and a REM counter respectively. The results were utilized to investigate efficacy of the existing radiological shielding of the PIF. This paper highlights experimental methods to analyze the high-energy accelerator produced neutron beam and basic guideline for the radiological shielding designs of irradiation vault of Proton Therapy facilities

Design of an irradiation facility with thermal, epithermal and fast neutron beams

International Nuclear Information System (INIS)

Pfister, G.; Bernnat, W.; Seidel, R.; Schatz, A.K.; Wagner, F.M.; Waschkowski, W.; Schraube, H.

1992-01-01

The main features of a neutron irradiation facility to be installed at the planned research reactor FRM-II are presented. In addition to the operational possibilities of the existing facility at the reactor FRM-I, the new facility will produce quasi-monoenergetic neutron fields and a neutron beam in the keV region whose spectrum can be modified by application of suitable filters and scatterers. For this beam, which is well suited for boron capture therapy, calculated boron reaction rates inside a phantom and an experimental verification of the calculations at the existing facility are presented. (orig.) [de

A novel approach to the microdosimetry of neutron capture therapy. Part I. High-resolution quantitative autoradiography applied to microdosimetry in neutron capture therapy

International Nuclear Information System (INIS)

Solares, G.R.; Zamenhof, R.G.

1995-01-01

A novel approach to the microdosimetry of neutron capture therapy has been developed using high-resolution quantitative autoradiography (HRQAR) and two-dimensional Monte Carlo simulation. This approach has been applied using actual cell morophology (nuclear and cytoplasmic cell structures) and the measured microdistribution of boron-10 in a transplanted murine brain tumor (GL261) containing p-boronophenylalanine (BPA) as the boron compound. The 2D Monte Carlo transport code for the α and 7 Li charged particles from the 10 B(n,α) 7 Li reactions has been developed as a surrogate to a full 3D approach to calculate a variety of different microdosimetric parameters. The HRQAR method and the surrogate 2D Monte Carlo approach are described in detail and examples of their use are presented. 27 refs., 11 figs., 1 tab

Australian proton therapy facilities - status report

International Nuclear Information System (INIS)

Bleasel, S.; Jackson, M.

2000-01-01

may be funded by a combination of Private Enterprise and Government. This presentation describes the steps taken to date and the proposed 'road map' for the future. Physicists are invited to consider how they would use such a facility. In partnership with Mitsubishi and Toshiba, Hitachi built the rotating gantries for the proton facility at the National Cancer Centre in Kashiwa, Japan. Subsequently, they built the scientific/medical proton facility at Wakasa Bay in Japan. In March 2000 Hitachi will commission a facility at Tsukuba University Hospital dedicated to proton therapy and related basic research

Monte Carlo assessment of boron neutron capture therapy for the treatment of breast cancer

Directory of Open Access Journals (Sweden)

Mundy Daniel W.

2005-01-01

Full Text Available For a large number of women who are diagnosed with breast cancer every year the avail able treatment options are effective, though physically and mentally taxing. This work is a starting point of a study of the efficacy of boron neutron capture therapy as an alternative treatment for HER-2+ breast tumors. Using HER-2-specific monoclonal anti bodies coupled with a boron-rich oligomeric phosphate diester, it may be possible to deliver sufficient amounts of 10B to a tumor of the breast to al low for selective cell destruction via irradiation by thermal neutrons. A comprehensive computational model (MCNP for thermal neutron irradiation of the breast is described, as well as the results of calculations made using this model, in order to determine the optimum boron concentration within the tumor for an effective boron neutron capture therapy treatment, as compared with traditional X-ray radiotherapy. The results indicate that a boron concentration of 50-60 mg per gram of tumor tissue is optimal when considering treatment times, dose distributions and skin sparing. How ever these results are based upon best-guess assumptions that must be experimentally verified.

Dose Determination using alanine detectors in a Mixed Neutron and Gamma Field for Boron Neutron Capture Therapy of Liver Malignancies

DEFF Research Database (Denmark)

Schmitz, T.; Blaickner, M.; Ziegner, M.

2011-01-01

Introduction Boron Neutron Capture Therapy for liver malignancies is being investigated at the University of Mainz. One important aim is the set-up of a reliable dosimetry system. Alanine dosimeters have previously been applied for dosimetry of mixed radiation fields in antiproton therapy, and ma...

Nominal effective radiation doses delivered during clinical trials of boron neutron capture therapy

International Nuclear Information System (INIS)

Capala, J.; Diaz, A.Z.; Chanana, A.D.

1997-01-01

Boron neutron capture therapy (BNCT) is a binary system that, in theory, should selectively deliver lethal, high linear energy transfer (LET) radiation to tumor cells dispersed within normal tissues. It is based on the nuclear reaction 10-B(n, α)7-Li, which occurs when the stable nucleus of boron-10 captures a thermal neutron. Due to the relatively high cross-section of the 10-B nucleus for thermal neutron capture and short ranges of the products of this reaction, tumor cells in the volume exposed to thermal neutrons and containing sufficiently high concentration of 10-B would receive a much higher radiation dose than the normal cells contained within the exposed volume. Nevertheless, radiation dose deposited in normal tissue by gamma and fast neutron contamination of the neutron beam, as well as neutron capture in nitrogen, 14-N(n,p)14-C, hydrogen, 1-H(n,γ)2-H, and in boron present in blood and normal cells, limits the dose that can be delivered to tumor cells. It is, therefore, imperative for the success of the BNCT the dosed delivered to normal tissues be accurately determined in order to optimize the irradiation geometry and to limit the volume of normal tissue exposed to thermal neutrons. These are the major objectives of BNCT treatment planning

Determination of Thermal Neutron Capture Cross Sections Using Cold Neutron Beams at the Budapest PGAA-NIPS Facilities

International Nuclear Information System (INIS)

Belgya, T.

2006-01-01

A complete elemental gamma-ray library was measured with our guided thermal beam at the Budapest PGAA facility in the period of 1995-2000. Using this data library in an IAEA CRP on PGAA it was managed to re-normalize the ENSDF intensity data with the Budapest intensities. Based on this renormalization thermal neutron cross sections were deduced for several isotopes. Most of these calculations were done by Richard B. Firestone. The Budapest PGAA-NIPS facilities have been used for routine prompt gamma activation analysis with cold neutrons since the year of 2000. The advantage of the cold neutron beam is that the neutron guide has much higher neutron transmission. This resulted in a gain factor about 20 relative to our thermal guide. For the analytical works a precise comparator technique was developed that is routinely used to determine partial gamma-ray production cross sections. An additional development of our methodology was necessary to be worked out to determine thermal neutron capture cross sections based on the partial gamma-ray production cross sections. In this talk our methodology of radiative capture cross section determination will be presented, including our latest results on 129 I, 204,206,207 Pb and 209 Bi. Most of these works were done in cooperation with people from EU-JRC-IRMM, Geel, Belgium and CEA Cadarache, France. Many partial cross sections of short lived nuclei have been re-measured with our new chopper technique. The uncertainty calculations of the radiative capture cross section determination procedures will be also shown. (authors)

Utilizing horizontal reactors channels for neutron therapy

International Nuclear Information System (INIS)

Stankovsky, E.Yu.; Kurachenko, Yu.A.

2000-01-01

Two experimental heterogeneous reactors have been considered. The reactors may be applied in neutron capture therapy and in a conventional manner. The channel out of the core serves as the neutron source. At each of these facilities, both fast and epithermal neutron fluxes for BNCT research, human clinical trials, and characterized common computational techniques have been evaluated. (authors)

Two years of operating experience with the Seattle clinical neutron therapy facility

International Nuclear Information System (INIS)

Risler, R.; Brossard, S.; Eenmaa, J.; Kalet, I.; Wootton, P.

1987-01-01

After five years of planning, equipment acquisition, facility construction and beam testing the Seattle Clinical Neutron Therapy facility became operational in October 1984. In the past two years nearly 300 people have been treated in clinical trials. During this time 82 % of the planned treatment sessions were performed on schedule, 3 % had to be rescheduled for patient related reasons and 15 % because of equipment problems. The facility is at present running on a 5 days/week schedule: Three ten-hour treatment days, one maintenance day and one research day (radiobiology, therapy related physics). Short runs for short lived isotopes are done between patient treatments. The isocentric gantry, capable of 360 rotation is equipped with a variable collimator with 40 independent leaves. This collimation system allows the use of complex field shapes without the necessity of handling radioactive components like collimator inserts or blocks. It has turned out to be a very essential part for the efficient operation of the facility. Major causes for equipment downtime were associated with the control system, the beryllium target system, RF and magnet systems and the treatment gantry. (author)

Does Nursing Facility Use of Habilitation Therapy Improve Performance on Quality Measures?

Science.gov (United States)

Fitzler, Sandra; Raia, Paul; Buckley, Fredrick O; Wang, Mei

2016-12-01

The purpose of the project, Centers for Medicare & Medicaid Services (CMS) Innovation study, was to evaluate the impact on 12 quality measures including 10 Minimum Data Set (MDS) publicly reported measures and 2 nursing home process measures using habilitation therapy techniques and a behavior team to manage dementia-related behaviors. A prospective design was used to assess the changes in the measures. A total of 30 Massachusetts nursing homes participated in the project over a 12-month period. Project participation required the creation of an interdisciplinary behavior team, habilitation therapy training, facility visit by the program coordinator, attendance at bimonthly support and sharing calls, and monthly collection of process measure data. Participating facilities showed improvement in 9 of the 12 reported measures. Findings indicate potential quality improvement in having nursing homes learn habilitation therapy techniques and know how to use the interdisciplinary team to manage problem behaviors. © The Author(s) 2016.

Boron thermal/epithermal neutron capture therapy

International Nuclear Information System (INIS)

Fairchild, R.G.

1982-01-01

The development of various particle beams for radiotherapy represents an attempt to improve dose distribution, and to provide high LET radiations which are less sensitive to ambient physical and radiobiological factors such as oxygen tension, cell cycle, and dose rate. In general, a compromise is necessary as effective RBE is reduced in order to spread the dose distribution over the anticipated tumor volume. The approach of delivering stable non-toxic isotopes to tumor, and then activating these atoms subsequently via an external radiation beam has mator advantages; problems associated with high uptake of these isotopes in competing cell pools are obviated, and the general tumor volume can be included in the treatment field of the activating beam. As long as the normal tissues supporting tumor show a low uptake of the isotope to be activated, and as long as the range of the reaction products is short, dose will be restricted to tumor, with a consequent high therapeutic ratio. Neutron Capture Therapy (NCT) is generally carried out by activating boron-10 with low energy neutrons. The range of the high LET, low OER particles from the 10 B(n, α) 7 Li reaction is approx. 10μ, or one cell diameter, a situation that is optimal for cell killing. Significant advantages may be gained by using the NCT procedure in conjunction with improved tissue penetration provided with epithermal or filtered beams, and new compounds showing physiological binding to tumor

Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax

OpenAIRE

Wang, Peng; Zhen, Haining; Jiang, Xinbiao; Zhang, Wei; Cheng, Xin; Guo, Geng; Mao, Xinggang; Zhang, Xiang

2010-01-01

Abstract Background Boron neutron capture therapy (BNCT) is an alternative treatment modality for patients with glioma. The aim of this study was to determine whether induction of apoptosis contributes to the main therapeutic efficacy of BNCT and to compare the relative biological effect (RBE) of BNCT, γ-ray and reactor neutron irradiation. Methods The neutron beam was obtained from the Xi'an Pulsed Reactor (XAPR) and γ-rays were obtained from [60Co] γ source of the Fourth Military Medical Un...

New compounds for neutron capture therapy (NCT) and their significance

International Nuclear Information System (INIS)

Fairchild, R.G.; Bond, V.P.

1982-01-01

Clearly the most effective tumor therapy would be obtained by the selective targeting of cytotoxic agents to tumor cells. Although many biomolecules are known to be taken up in tumors, the targeting of cytotoxic agents to tumors is limited by the fact that other essential cell pools compete with equal or even greater effectiveness. The approach of delivering stable non-toxic isotopes to tumor, with activation by means of an external radiation beam, is advantageous for two reasons: (1) it obviates problems associated with high uptake of isotopes in normal tissues, as these cell pools can be excluded from the radiation field, and (2) the general tumor area can be included in the activating beam field; thus, the possibility exists that all microscopic tumor extensions can be irradiated. As long as range of reaction products is short, dose will be restricted to the tumor, with a resultant high therapeutic ratio. This method can be accomplished with either photon activation therapy (PAT) or Neutron Capture Therapy (NCT), the latter will be emphasized here. The range of the high LET, low OER particles from the 10 B(n,α) 7 Li reaction is approx. 10 μm, or one cell diameter; hence this reaction is optimal for cell killing. A number of biomolecules have been investigated as possible vehicles for transport of boron to tumors, including phenothiazines, thiouracils, porphyrins, nucleosides, and amino acids. Biodistributions of these compounds show selective concentration in tumor adequate for therapy. The biological halflives are in the order of days, allowing the possibility of fractionated or protracted irradiations. The radiobiological and physical implication of these parameters on NCT are discussed. The possibility of using an approximately-monoenergetic, scandium-filtered beam of about 2 keV, to reduce the dose from background radiations by about 85%, is also discussed

Boron-containing thioureas for neutron capture therapy

International Nuclear Information System (INIS)

Ketz, H.

1993-01-01

Melanin is produced in large amounts in malignant melanotic melanomas. Because thiourea compounds are covalently incorporated into melanin during its biosynthesis, the preparation of boronated thiourea-derivatives is of particular interest for the BNCT (Boron Neutron Capture Therapy). Accumulation of boron in tumors by means of boronated thiourea-derivatives may therefore provide levels of 10 B which are useful for BNCT. In BNCT the tumor containing the boron compound is irradiated with epithermal neutrons to generate He- and Li-nuclei from the 10 B which can then destroy the tumor cells. Because of the short ranges of these particles (approximately one cell diameter) the damage will be almost exclusively confined to the tumor leaving normal tissue unharmed. High accumulation of 2-mercapto-1-methylimidazole (methimazole) in melanotic melanomas has been described in the literature. Boronated derivatives of methimazole were therefore synthesized. Boron was in the form of a boronic acid, a nido-carbonate and a mercaptoundeca hydro-closo-dodecaborate (BSH). The synthesis of the boron cluster derivatives of methimazole (nido-carborate- and BSH-derivatives) with 9 resp. 12 boron atoms in the molecule were expected to achieve higher concentrations of boron in the tumor than in the case of the boronic acid compound with its single boron atom. (orig.) [de

Single photon image from PET with insertable collimator for boron neutron capture therapy

International Nuclear Information System (INIS)

Jung, Jooyoung; Suh, Tae Suk; Hong, Key Jo

2014-01-01

Boron neutron capture therapy (BNCT) is a radiation therapy technique for treating deep-seated brain tumors by irradiation with a thermal neutron in which boron-labelled low molecular weight compounds. Once completed, a single photon emission computed tomography (SPECT) scan is conducted to investigate for the region of therapy using an isotope exclusive to SPECT. In the case of an existing PET/SPECT combination system, at least two types of isotopes should be used for each scan with their purposes. Recently, researchers examined the effects of PET/SPECT dual modality on animal imaging systems. They reported that the PET/SPECT combination system was effective for simultaneous achievement of a single event and coincidence. The aim of our proposed system is to confirm the feasibility of extraction of two types of images from one PET module with an insertable collimator for brain tumor treatment during the BNCT. We attempted to acquire the PET and SPECT images simultaneously using only PET without an additional isotope. Single photon images were acquired using an insertable collimator on a PET detector

Improvement of JCDS, a computational dosimetry system in JAEA for neutron capture therapy

International Nuclear Information System (INIS)

Kumada, Hiroaki; Yamamoto, Kazuyoshi; Matsumura, Akira; Yamamoto, Tetsuya; Nakagawa, Yoshinobu; Kageji, Teruyoshi

2006-01-01

JCDS, a computational dosimetry system for neutron capture therapy, was developed by Japan Atomic Energy Agency. The system has been sophisticated to facilitate dose planning so far. In dosimetry with JCDS for BNCT clinical trials at JRR-4, several absorbed doses and the dose distributions are determined by a voxel model consisted of 2x2x2mm 3 voxel cells. By using the detailed voxel model, accuracy of the dosimetry can be improved. Clinical trials for melanoma and head-and-neck cancer as well as brain tumor were started using hot version of JCDS in 2005. JCDS is also being of improved so as to enable a JCDS application to dosimetry by PHITS as well as dosimetry by MCNP. By using PHITS, total doses of a patient by a combined modality therapy, for example a combination of BNCT and proton therapy, can be estimated consistently. Moreover, PET images can be adopted in combination with CT and MRI images as a farsighted approach. JCDS became able to identify target regions by using the PET values. (author)

A comparison of the COG and MCNP codes in computational neutron capture therapy modeling, Part II: gadolinium neutron capture therapy models and therapeutic effects.

Science.gov (United States)

Wangerin, K; Culbertson, C N; Jevremovic, T

2005-08-01

The goal of this study was to evaluate the COG Monte Carlo radiation transport code, developed and tested by Lawrence Livermore National Laboratory, for gadolinium neutron capture therapy (GdNCT) related modeling. The validity of COG NCT model has been established for this model, and here the calculation was extended to analyze the effect of various gadolinium concentrations on dose distribution and cell-kill effect of the GdNCT modality and to determine the optimum therapeutic conditions for treating brain cancers. The computational results were compared with the widely used MCNP code. The differences between the COG and MCNP predictions were generally small and suggest that the COG code can be applied to similar research problems in NCT. Results for this study also showed that a concentration of 100 ppm gadolinium in the tumor was most beneficial when using an epithermal neutron beam.

Neutron spectrum for neutron capture therapy in boron; Espectro de neutrones para terapia por captura de neutrones en boro

Energy Technology Data Exchange (ETDEWEB)

Medina C, D.; Soto B, T. G. [Universidad Autonoma de Zacatecas, Unidad Academica de Estudios Nucleares, Programa de Doctorado en Ciencias Basicas, 98068 Zacatecas, Zac. (Mexico); Baltazar R, A. [Universidad Autonoma de Zacatecas, Unidad Academica de Ingenieria Electrica, Programa de Doctorado en Ingenieria y Tecnologia Aplicada, 98068 Zacatecas, Zac. (Mexico); Vega C, H. R., E-mail: dmedina_c@hotmail.com [Universidad Autonoma de Zacatecas, Unidad Academica de Estudios Nucleares, Cipres No. 10, Fracc. La Penuela, 98068 Zacatecas, Zac. (Mexico)

2016-10-15

Glioblastoma multiforme is the most common and aggressive of brain tumors and is difficult to treat by surgery, chemotherapy or conventional radiation therapy. One treatment alternative is the Neutron Capture Therapy in Boron, which requires a beam modulated in neutron energy and a drug with {sup 10}B able to be fixed in the tumor. When the patients head is exposed to the neutron beam, they are captured by the {sup 10}B and produce a nucleus of {sup 7}Li and an alpha particle whose energy is deposited in the cancer cells causing it to be destroyed without damaging the normal tissue. One of the problems associated with this therapy is to have an epithermal neutrons flux of the order of 10{sup 9} n/cm{sup 2}-sec, whereby irradiation channels of a nuclear research reactor are used. In this work using Monte Carlo methods, the neutron spectra obtained in the radial irradiation channel of the TRIGA Mark III reactor are calculated when inserting filters whose position and thickness have been modified. From the arrangements studied, we found that the Fe-Cd-Al-Cd polyethylene filter yielded a ratio between thermal and epithermal neutron fluxes of 0.006 that exceeded the recommended value (<0.05), and the dose due to the capture gamma rays is lower than the dose obtained with the other arrangements studied. (Author)

The effect of facility-based antiretroviral therapy programs on outpatient services in Kenya and Uganda.

Science.gov (United States)

Wollum, Alexandra; Dansereau, Emily; Fullman, Nancy; Achan, Jane; Bannon, Kelsey A; Burstein, Roy; Conner, Ruben O; DeCenso, Brendan; Gasasira, Anne; Haakenstad, Annie; Hanlon, Michael; Ikilezi, Gloria; Kisia, Caroline; Levine, Aubrey J; Masters, Samuel H; Njuguna, Pamela; Okiro, Emelda A; Odeny, Thomas A; Allen Roberts, D; Gakidou, Emmanuela; Duber, Herbert C

2017-08-16

Considerable debate exists concerning the effects of antiretroviral therapy (ART) service scale-up on non-HIV services and overall health system performance in sub-Saharan Africa. In this study, we examined whether ART services affected trends in non-ART outpatient department (OPD) visits in Kenya and Uganda. Using a nationally representative sample of health facilities in Kenya and Uganda, we estimated the effect of ART programs on OPD visits from 2007 to 2012. We modeled the annual percent change in non-ART OPD visits using hierarchical mixed-effects linear regressions, controlling for a range of facility characteristics. We used four different constructs of ART services to capture the different ways in which the presence, growth, overall, and relative size of ART programs may affect non-ART OPD services. Our final sample included 321 health facilities (140 in Kenya and 181 in Uganda). On average, OPD and ART visits increased steadily in Kenya and Uganda between 2007 and 2012. For facilities where ART services were not offered, the average annual increase in OPD visits was 4·2% in Kenya and 13·5% in Uganda. Among facilities that provided ART services, we found average annual OPD volume increases of 7·2% in Kenya and 5·6% in Uganda, with simultaneous annual increases of 13·7% and 12·5% in ART volumes. We did not find a statistically significant relationship between annual changes in OPD services and the presence, growth, overall, or relative size of ART services. However, in a subgroup analysis, we found that Ugandan hospitals that offered ART services had statistically significantly less growth in OPD visits than Ugandan hospitals that did not provide ART services. Our findings suggest that ART services in Kenya and Uganda did not have a statistically significant deleterious effects on OPD services between 2007 and 2012, although subgroup analyses indicate variation by facility type. Our findings are encouraging, particularly given recent recommendations

Radiobiology of boron neutron capture therapy

International Nuclear Information System (INIS)

Bond, V.P.

1986-01-01

The author addresses the question of single session versus protracted therapy in the application of boron neutron therapy to tumors. As background he discusses the reasoning behind the current use of fractionated therapy with conventional low-LET radiations and difference which may obtain for neutron therapy. Several aspects of dose rates and dose levels are then addressed

Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

International Nuclear Information System (INIS)

Kreiner, A.J.; Castell, W.; Di Paolo, H.; Baldo, M.; Bergueiro, J.

2011-01-01

We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas.

Radiological protection considerations during the treatment of glioblastoma patients by boron neutron capture therapy at the high flux reactor in Petten, The Netherlands

International Nuclear Information System (INIS)

Moss, R.L.; Rassow, J.; Finke, E.; Sauerwein, W.; Stecher-Rasmussen, F.

2001-01-01

A clinical trial of Boron Neutron Capture Therapy (BNCT) for glioblastoma patients has been in progress at the High Flux Reactor (HFR) at Petten since October 1997. The JRC (as licence holder of the HFR) must ensure that radiological protection measures are provided. The BNCT trial is a truly European trial, whereby the treatment takes place at a facility in the Netherlands under the responsibility of clinicians from Germany and patients are treated from several European countries. Consequently, radiological protection measures satisfy both German and Dutch laws. To respect both laws, a BNCT radioprotection committee was formed under the chairmanship of an independent radioprotection expert, with members representing all disciplines in the trial. A special nuance of BNCT is that the radiation is provided by a mixed neutron/gamma beam. The radiation dose to the patient is thus a complex mix due to neutrons, gammas and neutron capture in boron, nitrogen and hydrogen, which, amongst others, need to be correctly calculated in non-commercial and validated treatment planning codes. Furthermore, due to neutron activation, measurements on the patient are taken regularly after treatment. Further investigations along these lines include dose determination using TLDs and boron distribution measurements using on-line gamma ray spectroscopy. (author)

A new target concept for proton accelerator driven boron neutron capture therapy applications

International Nuclear Information System (INIS)

Powell, J.R.; Ludewig, H.; Todosow, M.; Reich, M.

1998-01-01

A new target concept termed Discs Incorporating Sector Configured Orbiting Sources (DISCOS), is proposed for spallation applications, including BNCT (Boron Neutron Capture Therapy). In the BNCT application a proton beam impacts a sequence of ultra thin lithium DISCOS targets to generate neutrons by the 7 Li(p,n) 7 Be reaction. The proton beam loses only a few keV of its ∼MeV energy as it passes through a given target, and is re-accelerated to its initial energy, by a DC electric field between the targets

Carbon Capture and Sequestration (via Enhanced Oil Recovery) from a Hydrogen Production Facility in an Oil Refinery

Energy Technology Data Exchange (ETDEWEB)

Stewart Mehlman

2010-06-16

The project proposed a commercial demonstration of advanced technologies that would capture and sequester CO2 emissions from an existing hydrogen production facility in an oil refinery into underground formations in combination with Enhanced Oil Recovery (EOR). The project is led by Praxair, Inc., with other project participants: BP Products North America Inc., Denbury Onshore, LLC (Denbury), and Gulf Coast Carbon Center (GCCC) at the Bureau of Economic Geology of The University of Texas at Austin. The project is located at the BP Refinery at Texas City, Texas. Praxair owns and operates a large hydrogen production facility within the refinery. As part of the project, Praxair would construct a CO2 capture and compression facility. The project aimed at demonstrating a novel vacuum pressure swing adsorption (VPSA) based technology to remove CO2 from the Steam Methane Reformers (SMR) process gas. The captured CO2 would be purified using refrigerated partial condensation separation (i.e., cold box). Denbury would purchase the CO2 from the project and inject the CO2 as part of its independent commercial EOR projects. The Gulf Coast Carbon Center at the Bureau of Economic Geology, a unit of University of Texas at Austin, would manage the research monitoring, verification and accounting (MVA) project for the sequestered CO2, in conjunction with Denbury. The sequestration and associated MVA activities would be carried out in the Hastings field at Brazoria County, TX. The project would exceed DOE’s target of capturing one million tons of CO2 per year (MTPY) by 2015. Phase 1 of the project (Project Definition) is being completed. The key objective of Phase 1 is to define the project in sufficient detail to enable an economic decision with regard to proceeding with Phase 2. This topical report summarizes the administrative, programmatic and technical accomplishments completed in Phase 1 of the project. It describes the work relative to project technical and design activities

Proceedings of workshop on 'boron chemistry and boron neutron capture therapy'

International Nuclear Information System (INIS)

Kitaoka, Yoshinori

1993-09-01

This volume contains the proceedings of the 5th Workshop on 'the Boron Chemistry and Boron Neutron Capture Therapy' held on February 22 in 1993. The solubility of the boron carrier play an important role in the BNCT. New water-soluble p-boronophenylalanine derivatives are synthesized and their biological activities are investigated (Chap. 2 and 3). Some chemical problems on the BNCT were discussed, and the complex formation reaction of hydroxylboryl compounds were studied by the paper electrophoresis (Chap. 4). The results of the medical investigation on the BNCT using BSH compounds are shown in Chap. 5. Syntheses of o- and m-boronophenylalanine were done and their optical resolution was tried (Chap. 6). The complex formation reaction of p-boronophenylalanine (BPA) with L-DOPA and the oxidation reaction of the analogs are found in Chap. 7. The pka of BPA were determined by the isotachophoresis (Chap. 8). The chemical nature of dihydroxyboryl compounds were investigated by an infrared spectroscopy and electrophoresis (Chap. 9). New synthetic methods of BPA and p-boronophenylserine using ester of isocyanoacetic acid are described in Chap. 10. The induction of chromosomal aberations by neutron capture reaction are discussed from a point of the biological view. The a of the presented papers are indexed individually. (J.P.N.)

Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: A recursive partitioning analysis of BNCT patients

International Nuclear Information System (INIS)

Nakai, K.; Yamamoto, T.; Aiyama, H.; Takada, T.; Yoshida, F.; Kageji, T.; Kumada, H.; Isobe, T.; Endo, K.; Matsuda, M.; Tsurubuchi, T.; Shibata, Y.; Takano, S.; Mizumoto, M.; Tsuboi, K.; Matsumura, A.

2011-01-01

Eight patients to received Boron Neutron Capture Therapy (BNCT) were selected from 33 newly diagnosed glioblastoma patients (NCT(+) group). Serial 42 glioblastoma patients (NCT(−) group) were treated without BNCT. The median OS of the NCT(+) group and NCT (−) group were 24.4 months and 14.9 months. In the high risk patients (RPA class V), the median OS of the NCT(+) group tended to be better than that of NCT(−) group. 50% of BNCT patients were RPA class V. - Highlights: ► We treated 8 patients with boron neutron capture therapy (NCT) for glioblastoma. ► We compare the overall survival between NCT including series and without NCT series. ► The median overall survival of the NCT including series was 24.4 months. ► In the high risk patients, the median OS of NCT including series tended to be better.

Design study of a medical reactor for Boron Neutron Capture Therapy

International Nuclear Information System (INIS)

Sasaki, M.; Hirota, J.; Tamao, S.; Kanda, K.; Mishima, Y.

1992-01-01

A new design study of a medical reactor for Boron Neutron Capture Therapy (BNCT) has been carried out. The reactor is to be used exclusively for the treatment of malignant melanoma and other cancers as well as for the further biomedical research. Main specifications of the reactor are as follows; thermal power of 2 MW, water cooling by natural convection, semitight core of triangular lattice, UO 2 fuel rod of 9.5 mm diameter and no refueling in the reactor-life. Three horizontal and one vertical neutron beam hole are to be provided to deliver thermal and epithermal neutrons. N-γ coupling Sn transport calculations indicate that the patient treatment period will be about 30 minutes with minimal fast neutron and gamma contaminants. (author)

Boron neutron capture therapy for malignant brain tumor and future potential

International Nuclear Information System (INIS)

Nakagawa, Yoshinobu; Hatanaka, Hiroshi.

1994-01-01

This paper presents therapeutic experience with boron neutron capture therapy (BNCT) for malignant brain tumors. Nine patients who survived for 10 years or more as of 1986 are given in a table. A review of the 9 patients concluded that physical dose of 15 Gy is required. In addition, the following factors are defined to be the most important: (1) to determine tumor size and depth as accurately as possible, (2) to measure neutron doses in the deepest site of the tumor during irradiation, (3) to measure the content of boron within the tumor, and to deliver neutron beams as deeply as possible. Finally, the importance of knowing RBE of alpha particles for tumor cells of the human brain is emphasized. (N.K.)

Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy.

Science.gov (United States)

Kreiner, A J; Castell, W; Di Paolo, H; Baldo, M; Bergueiro, J; Burlon, A A; Cartelli, D; Vento, V Thatar; Kesque, J M; Erhardt, J; Ilardo, J C; Valda, A A; Debray, M E; Somacal, H R; Sandin, J C Suarez; Igarzabal, M; Huck, H; Estrada, L; Repetto, M; Obligado, M; Padulo, J; Minsky, D M; Herrera, M; Gonzalez, S J; Capoulat, M E

2011-12-01

We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the (7)Li(p,n)(7)Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas. Copyright © 2011 Elsevier Ltd. All rights reserved.

Preliminary investigations of Monte Carlo Simulations of neutron energy and LET spectra for fast neutron therapy facilities

International Nuclear Information System (INIS)

Kroc, T.K.

2009-01-01

No fast neutron therapy facility has been built with optimized beam quality based on a thorough understanding of the neutron spectrum and its resulting biological effectiveness. A study has been initiated to provide the information necessary for such an optimization. Monte Carlo studies will be used to simulate neutron energy spectra and LET spectra. These studies will be bench-marked with data taken at existing fast neutron therapy facilities. Results will also be compared with radiobiological studies to further support beam quality ptimization. These simulations, anchored by this data, will then be used to determine what parameters might be optimized to take full advantage of the unique LET properties of fast neutron beams. This paper will present preliminary work in generating energy and LET spectra for the Fermilab fast neutron therapy facility.

Measurement of the 241Am and the 243Am Neutron Capture Cross Sections at the n_TOF Facility at CERN

CERN Document Server

Mendoza, E; Guerrero, C; Altstadt, S; Andrzejewski, J; Audouin, L; Barbagallo, M; Bécares, V; Bečvář, F; Belloni, F; Berthoumieux, E; Billowes, J; Boccone, V; Bosnar, D; Brugger, M; Calviani, M; Calviño, F; Carrapiço, C; Cerutti, F; Chiaveri, E; Chin, M; Colonna, N; Cortés, G; Cortés-Giraldo, M A; Diakaki, M; Domingo-Pardo, C; Duran, I; Dressler, R; Dzysiuk, N; Eleftheriadis, C; Ferrari, A; Fraval, K; Ganesan, S; García, A R; Giubrone, G; Gómez-Hornillos, M B; Gonçalves, I F; González-Romero, E; Griesmayer, E; Gunsing, F; Gurusamy, P; Jenkins, D G; Jericha, E; Kadi, Y; Käppeler, F; Karadimos, D; Kivel, N; Koehler, P; Kokkoris, M; Korschinek, G; Krtička, M; Kroll, J; Langer, C; Lederer, C; Leeb, H; Leong, L S; Losito, R; Manousos, A; Marganiec, J; Martínez, T; Mastinu, P F; Mastromarco, M; Massimi, C; Meaze, M; Mengoni, A; Milazzo, P M; Mingrone, F; Mirea, M; Mondelaers, W; Paradela, C; Pavlik, A; Perkowski, J; Pignatari, M; Plompen, A; Praena, J; Quesada, J M; Rauscher, T; Reifarth, R; Riego, A; Roman, F; Rubbia, C; Sarmento, R; Schillebeeckx, P; Schmidt, S; Schumann, D; Tagliente, G; Tain, J L; Tarrío, D; Tassan-Got, L; Tsinganis, A; Valenta, S; Vannini, G; Variale, V; Vaz, P; Ventura, A; Versaci, R; Vermeulen, M J; Vlachoudis, V; Vlastou, R; Wallner, A; Ware, T; Weigand, M; Weiß, C; Wright, T J; Žugec, P

2014-01-01

The capture cross sections of Am-241 and Am-243 were measured at the n\\_TOF facility at CERN in the epithermal energy range with a BaF2 Total Absorption Calorimeter. A preliminary analysis of the Am-241 and a complete analysis of the Am-243 measurement, including the data reduction and the resonance analysis, have been performed.

Computational Dosimetry and Treatment Planning Considerations for Neutron Capture Therapy

International Nuclear Information System (INIS)

Nigg, David Waler

2003-01-01

Specialized treatment planning software systems are generally required for neutron capture therapy (NCT) research and clinical applications. The standard simplifying approximations that work well for treatment planning computations in the case of many other modalities are usually not appropriate for application to neutron transport. One generally must obtain an explicit three-dimensional numerical solution of the governing transport equation, with energy-dependent neutron scattering completely taken into account. Treatment planning systems that have been successfully introduced for NCT applications over the past 15 years rely on the Monte Carlo stochastic simulation method for the necessary computations, primarily because of the geometric complexity of human anatomy. However, historically, there has also been interest in the application of deterministic methods, and there have been some practical developments in this area. Most recently, interest has turned toward the creation of treatment planning software that is not limited to any specific therapy modality, with NCT as only one of several applications. A key issue with NCT treatment planning has to do with boron quantification, and whether improved information concerning the spatial biodistribution of boron can be effectively used to improve the treatment planning process. Validation and benchmarking of computations for NCT are also of current developmental interest. Various institutions have their own procedures, but standard validation models are not yet in wide use

Comparison of quality assurance for performance and safety characteristics of the facility for Boron Neutron Capture therapy in Petten/NL with medical electron accelerators

International Nuclear Information System (INIS)

Rassow, Juergen; Stecher-Rasmussen, Finn; Voorbraak, Wim; Moss, Ray; Vroegindeweij, Corine; Hideghety, Katalin; Sauerwein, Wolfgang

2001-01-01

Background and purpose: The European Council Directive on health protection 97/43/EURATOM requires radiotherapy quality assurance programmes for performance and safety characteristics including acceptance and repeated tests. For Boron Neutron Capture therapy (BNCT) at the High Flux Reactor (HFR) in Petten/NL such a programme has been developed on the basis of IEC publications for medical electron accelerators. Results: The fundamental differences of clinical dosimetry for medical electron accelerators and BNCT are presented and the order of magnitude of dose components and their stability and that of the main other influencing parameter 10 B concentration for BNCT patient treatments. A comparison is given for requirements for accelerators and BNCT units indicating items which are not transferable, equal or additional. Preliminary results of in vivo measurements done with a set of 55 Mn, 63 Cu and 197 Au activation foils for all single fields for the four fractions at all 15 treated patients show with <±4% up to now a worse reproducibility than the used dose monitoring systems (±1.5%) caused by influence of hair position on the foil-skull distance. Conclusions: Despite the more complex clinical dosimetry (because of four relevant dose components, partly of different linear energy transfer (LET)) BNCT can be regulated following the principles of quality assurance procedures for therapy with medical electron accelerators. The reproducibility of applied neutron fluence (proportional to absorbed doses) and the main safety aspects are equal for all teletherapy methods including BNCT

Slow-neutron capture therapy for malignant tumours: its history and recent development

International Nuclear Information System (INIS)

Hatanaka, H.

1975-01-01

Slow-neutron capture therapy was first suggested in 1936. The early clinical trials were performed at Brookhaven National Laboratory and Massachusetts Institute of Technology reactors. In the last series of treatments in 1960 and 1961, none of the 17 glioblastoma patients lived longer than a year and the clinical trial was discontinued, particularly because the was pathological evidence that normal tissue had been seriously damaged. Hatanaka, who worked first with Sweet between 1964 and 1967, continued intensive basic research and organized a collaborating team of chemists, physicists and physicians in Japan where he resumed treatment of brain tumour patients in 1968. The rationale of the revised therapy included: (1) use of promising compounds such as mercaptoundecahydrododecaborate, which has a high tumour binding property, (2) use of adrenocorticoid to minimize vascular damage, (3) intra-arterial infusion of boron to obtain a higher concentration in the tumour, (4) restriction of excessive neutron intensity, (5) and some technical improvements. New research techniques were also introduced, such as alpha autoradiography, electron microscopy, and immunotherapy. With the mercaptoundecahydrododecaborate compound an absolute concentration of 30 μg per gram of tumour is easily attainable, while the blood level of the isotope can be lowered to at least half of the tumour concentration. Normal dog brains were able to tolerate this therapy. Among the 15 patients so far treated, 13 were treated at the Hitachi Training Reactor. Patients, who had undergone repeated surgery as well as excessive irradiation before they came for the therapy, could not recover their full activities, but proved they could enjoy a significant prolongation of their lives. The only two fresh cases of glioblastoma responded so well to the therapy that one has been working as an engineer and the other as a farmer for 3 years without neurological deficits. Recent progress and future potentials of the

Job-Related Stress in Forensic Interviewers of Children with Use of Therapy Dogs Compared with Facility Dogs or No Dogs.

Science.gov (United States)

Walsh, Diane; Yamamoto, Mariko; Willits, Neil H; Hart, Lynette A

2018-01-01

Sexually abused children providing essential testimony regarding crimes in forensic interviews now sometimes are provided facility dogs or therapy dogs for comfort. Facility dogs are extensively trained to work with forensic interviewers; when using therapy dogs in interviews, volunteers are the dog handlers. Interviews can impact child welfare workers' mental health causing secondary traumatic stress (STS). To investigate this stress, first data were gathered on stress retrospectively for when interviewers initially started the job prior to working with a dog, and then currently, from forensic interviewers using a facility dog, a therapy or pet dog, or no dog. These retrospective and secondary traumatic stress scale (STSS) data compared job stress among interviewers of children using: a certified, workplace facility dog ( n  = 16), a volunteer's trained therapy dog or the interviewer's pet dog ( n  = 13/3), or no dog ( n  = 198). Retrospective scores of therapy dog and no dog interviewers' stress were highest for the first interviewing year 1 and then declined. Extremely or very stressful retrospective scores differed among the three groups in year 1 ( p  therapy dog group as compared with the facility dog group ( p  therapy dog users than no dog users ( p  dog users more consistently used dogs during interviews and conducted more interviews than therapy/pet dog users; both groups favored using dogs. Interviewers currently working with therapy dogs accompanied by their volunteers reported they had experienced heightened stress when they began their jobs; their high stress levels still persisted, indicating lower inherent coping skills and perhaps greater empathy among interviewers who later self-selected to work with therapy dogs. Results reveal extreme avoidant stress for interviewers witnessing children who are suffering and their differing coping approaches.

FiR 1 reactor in service for boron neutron capture therapy (BNCT) and isotope production

International Nuclear Information System (INIS)

Auterinen, I.; Salmenhaara, S.E.J. . Author

2004-01-01

The FiR 1 reactor, a 250 kW Triga reactor, has been in operation since 1962. The main purpose for the existence of the reactor is now the Boron Neutron Capture Therapy (BNCT), but FiR 1 has also an important national role in providing local enterprises and research institutions in the fields of industrial measurements, pharmaceuticals, electronics etc. with isotope production and activation analysis services. In the 1990's a BNCT treatment facility was built at the FiR 1 reactor located at Technical Research Centre of Finland. A special new neutron moderator material Fluental TM (Al+AlF3+Li) developed at VTT ensures the superior quality of the neutron beam. Also the treatment environment is of world top quality after a major renovation of the whole reactor building in 1997. Recently the lithiated polyethylene neutron shielding of the beam aperture was modified to ease the positioning of the patient close to the beam aperture. Increasing the reactor power to 500 kW would allow positioning of the patient further away from the beam aperture. Possibilities to accomplish a safety analysis for this is currently under considerations. Over thirty patients have been treated at FiR 1 since May 1999, when the license for patient treatment was granted to the responsible BNCT treatment organization, Boneca Corporation. Currently three clinical trial protocols for tumours in the brain as well as in the head and neck region are recruiting patients. (author)

Boron neutron capture therapy for advanced and/or recurrent cancers in the oral cavity

International Nuclear Information System (INIS)

Ariyoshi, Yasunori; Shimahara, Masashi; Kimura, Yoshihiro; Miyatake, Shin-ichi; Kuroiwa, Toshihiko; Nagata, Kenji; Sakurai, Yoshinori; Maruhashi, Akira; Ono, Koji

2006-01-01

This preliminary study of 5 patients with advanced and/or recurrent cancer in the oral cavity was performed to evaluate the effectiveness of Boron Neutron Capture Therapy (BNCT). The patients received therapy with the 10 B-carrier p-boronophenylalanine (BPA) with or without borocaptate sodium (BSH) and irradiation thereafter with epithermal neutrons. All underwent 18 F-BPA PET studies before receiving BNCT to determine the accumulation ratios of BPA in tumor and normal tissues. The tumor mass was decreased in size and at minimum a transient partial response was achieved in all cases, though rapid tumor re-growth was observed in 2. Although tentative clinical responses and improvements in quality of life were recognized, obliteration of the tumor was not obtained in any of the cases. Additional studies are required to determine the utility and indication of BNCT for oral cancer. (author)

Investigation of boron conjugated thiouracil derivates for neutron capture therapy of melanoma

International Nuclear Information System (INIS)

Corderoy-Buck, S.; Allen, B.J.; Wilson, J.G.; Tjarks, W.; Gabel, D.; Barkla, D.; Patwardhan, A.; Chandler, A.; Moore, D.E.

1990-01-01

Boron conjugated thiouracil derivatives were investigated as possible agents for boron neutron capture therapy (BNCT) of melanoma. Nude mice bearing human or murine melanoma xenografts were used for biodistribution studies following i.p. or i.t. (intratumoural) injection of these drugs. Boron content was analysed by inductively coupled plasma atomic emission spectrometry. Wide variation between tumour lines was observed with respect to accumulation of these drugs, but they appear to offer potential as melanoma affined boron carriers if solubility problems are overcome by liposome entrapment. Pre-treatment to stimulate melanogenesis may also prove a useful adjunct in achieving the therapeutic concentrations of boron necessary for successful BNCT. 25 refs., 4 tabs., 3 figs

Boron neutron capture therapy for oral precancer: proof of principle in an experimental animal model

Energy Technology Data Exchange (ETDEWEB)

A. Monti Hughes; ECC Pozzi; S. Thorp; M. A. Garabalino; R. O. Farias; S. J. Gonzalez; E. M. Heber; M. E. Itoiz; R. F. Aromando; A. J. Molinari; M. Miller; D. W. Nigg; P. Curotto; V. A. Trivillin; A. E. Schwint

2013-11-01

Field-cancerized tissue can give rise to second primary tumours, causing therapeutic failure. Boron neutron capture therapy (BNCT) is based on biological targeting and would serve to treat undetectable foci of malignant transformation. The aim of this study was to optimize BNCT for the integral treatment for oral cancer, with particular emphasis on the inhibitory effect on tumour development originating in precancerous conditions, and radiotoxicity of different BNCT protocols in a hamster cheek pouch oral precancer model.

Measurement of the radiative capture cross section of the s-process branching points 204Tl and 171Tm at the n_TOF facility (CERN)

Science.gov (United States)

Casanovas, A.; Domingo-Pardo, C.; Guerrero, C.; Lerendegui-Marco, J.; Calviño, F.; Tarifeño-Saldivia, A.; Dressler, R.; Heinitz, S.; Kivel, N.; Quesada, J. M.; Schumann, D.; Aberle, O.; Alcayne, V.; Andrzejewski, J.; Audouin, L.; Bécares, V.; Bacak, M.; Barbagallo, M.; Bečvář, F.; Bellia, G.; Berthoumieux, E.; Billowes, J.; Bosnar, D.; Brown, A.; Busso, M.; Caamaño, M.; Caballero-Ontanaya, L.; Calviani, M.; Cano-Ott, D.; Cerutti, F.; Chen, Y. H.; Chiaveri, E.; Colonna, N.; Cortés, G.; Cortés-Giraldo, M. A.; Cosentino, L.; Cristallo, S.; Damone, L. A.; Diakaki, M.; Dietz, M.; Dupont, E.; Durán, I.; Eleme, Z.; Fernández-Domínguez, B.; Ferrari, A.; Ferreira, P.; Finocchiaro, P.; Furman, V.; Göbel, K.; Gawlik, A.; Gilardoni, S.; Glodariu, T.; Gonçalves, I. F.; González-Romero, E.; Gunsing, F.; Heyse, J.; Jenkins, D. G.; Käppeler, F.; Kadi, Y.; Katabuchi, T.; Kimura, A.; Kokkoris, M.; Kopatch, Y.; Krtička, M.; Kurtulgil, D.; Ladarescu, I.; Lederer-Woods, C.; Meo, S. Lo; Lonsdale, S. J.; Macina, D.; Martínez, T.; Masi, A.; Massimi, C.; Mastinu, P.; Mastromarco, M.; Matteucci, F.; Maugeri, E. A.; Mazzone, A.; Mendoza, E.; Mengoni, A.; Michalopoulou, V.; Milazzo, P. M.; Mingrone, F.; Musumarra, A.; Negret, A.; Nolte, R.; Ogállar, F.; Oprea, A.; Patronis, N.; Pavlik, A.; Perkowski, J.; Persanti, L.; Porras, I.; Praena, J.; Radeck, D.; Ramos, D.; Rauscher, T.; Reifarth, R.; Rochman, D.; Sabaté-Gilarte, M.; Saxena, A.; Schillebeeckx, P.; Simone, S.; Smith, A. G.; Sosnin, N. V.; Stamatopoulos, A.; Tagliente, G.; Tain, J. L.; Talip, T.; Tassan-Got, L.; Tsinganis, A.; Ulrich, J.; Valenta, S.; Vannini, G.; Variale, V.; Vaz, P.; Ventura, A.; Vlachoudis, V.; Vlastou, R.; Wallner, A.; Woods, P. J.; Wright, T.; Žugec, P.; Köster, U.

2018-05-01

The neutron capture cross section of some unstable nuclei is especially relevant for s-process nucleosynthesis studies. This magnitude is crucial to determine the local abundance pattern, which can yield valuable information of the s-process stellar environment. In this work we describe the neutron capture (n,γ) measurement on two of these nuclei of interest, 204Tl and 171Tm, from target production to the final measurement, performed successfully at the n_TOF facility at CERN in 2014 and 2015. Preliminary results on the ongoing experimental data analysis will also be shown. These results include the first ever experimental observation of capture resonances for these two nuclei.

Multi-Family Pediatric Pain Group Therapy: Capturing Acceptance and Cultivating Change

Directory of Open Access Journals (Sweden)

Samantha E. Huestis

2017-12-01

Full Text Available Behavioral health interventions for pediatric chronic pain include cognitive-behavioral (CBT, acceptance and commitment (ACT, and family-based therapies, though literature regarding multi-family therapy (MFT is sparse. This investigation examined the utility and outcomes of the Courage to Act with Pain: Teens Identifying Values, Acceptance, and Treatment Effects (CAPTIVATE program, which included all three modalities (CBT, ACT, MFT for youth with chronic pain and their parents. Program utility, engagement, and satisfaction were evaluated via quantitative and qualitative feedback. Pain-specific psychological, behavioral, and interpersonal processes were examined along with outcomes related to disability, quality of life, pain interference, fatigue, anxiety, and depressive symptoms. Participants indicated that CAPTIVATE was constructive, engaging, and helpful for social and family systems. Clinical and statistical improvements with large effect sizes were captured for pain catastrophizing, acceptance, and protective parenting but not family functioning. Similar effects were found for functional disability, pain interference, fatigue, anxiety, and depression. Given the importance of targeting multiple systems in the management of pediatric chronic pain, preliminary findings suggest a potential new group-based treatment option for youth and families. Next steps involve evaluating the differential effect of the program over treatment as usual, as well as specific CBT, ACT, and MFT components and processes that may affect outcomes.

Clinical results of boron neutron capture therapy (BNCT) for glioblastoma

International Nuclear Information System (INIS)

Kageji, T.; Mizobuchi, Y.; Nagahiro, S.; Nakagawa, Y.; Kumada, H.

2011-01-01

The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment. - Highlights: ► In this study, we evaluate the clinical outcome of boron neutron capture therapy (BNCT) for malignant brain tumors. ► We have treated 23 glioblastoma (GBM) patients with BNCT without any additional chemotherapy. ► Clinical results of BNCT in patients with GBM are superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.

Clinical treatment planning for subjects undergoing boron neutron capture therapy at Harvard-MIT

International Nuclear Information System (INIS)

Zamenhof, R.G.; Palmer, M.R.; Buse, P.M.

2001-01-01

Treatment planning is a crucial component of the Harvard-MIT boron neutron capture therapy (BNCT) clinical trials. Treatment planning can be divided into five stages: (1) pre-planning, based on CT and MRI scans obtained when the subject arrives at the hospital and on assumed boron-10 distribution parameters; (2) subject set-up, or simulation, in the MITR-II medical therapy room to determine the boundary conditions for possible set-up configurations; (3) re-planning, following the subject simulation; (4) final localization of the subject in the medical therapy room for BNCT; and (5) final post facto recalculation of the doses delivered based on firm knowledge of the blood boron-10 concentration profiles and the neutron flux histories from precise online monitoring. The computer-assisted treatment planning is done using a specially written BNCT treatment planning code called MacNCTPLAN. The code uses the Los Alamos National Laboratory's Monte Carlo n-particle radiation transport code MCNPv.4b as the dose calculation engine and advanced anatomical model simulation based on an automatic evaluation of CT scan data. Results are displayed as isodose contours and dose-volume histograms, the latter correlated precisely with corresponding anatomical CT or MRI image planes. Examples of typical treatment planning scenarios will be presented. (author)

Job-Related Stress in Forensic Interviewers of Children with Use of Therapy Dogs Compared with Facility Dogs or No Dogs

Directory of Open Access Journals (Sweden)

Diane Walsh

2018-03-01

Full Text Available Sexually abused children providing essential testimony regarding crimes in forensic interviews now sometimes are provided facility dogs or therapy dogs for comfort. Facility dogs are extensively trained to work with forensic interviewers; when using therapy dogs in interviews, volunteers are the dog handlers. Interviews can impact child welfare workers’ mental health causing secondary traumatic stress (STS. To investigate this stress, first data were gathered on stress retrospectively for when interviewers initially started the job prior to working with a dog, and then currently, from forensic interviewers using a facility dog, a therapy or pet dog, or no dog. These retrospective and secondary traumatic stress scale (STSS data compared job stress among interviewers of children using: a certified, workplace facility dog (n = 16, a volunteer’s trained therapy dog or the interviewer’s pet dog (n = 13/3, or no dog (n = 198. Retrospective scores of therapy dog and no dog interviewers’ stress were highest for the first interviewing year 1 and then declined. Extremely or very stressful retrospective scores differed among the three groups in year 1 (p < 0.038, and were significantly elevated for the therapy dog group as compared with the facility dog group (p < 0.035. All interviewing groups had elevated STSS scores; when compared with other healthcare groups that have been studied, sub-scores were especially high for Avoidance: a psychological coping mechanism to avoid dealing with a stressor. STSS scores differed among groups (p < 0.016, primarily due to Avoidance sub-scores (p < 0.009, reflecting higher Avoidance scores for therapy dog users than no dog users (p < 0.009. Facility dog users more consistently used dogs during interviews and conducted more interviews than therapy/pet dog users; both groups favored using dogs. Interviewers currently working with therapy dogs accompanied by their volunteers reported

Biological dosimetry studies for boron neutron capture therapy at the RA-1 research reactor facility

International Nuclear Information System (INIS)

Trivillin, Veronica A.; Heber, Elisa M.; Itoiz, Maria E.; Schwint, Amanda E.; Castillo, Jorge

2004-01-01

Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminescent dosimeters to characterize the BNCT facility developed at the RA-1 research reactor operated by the National Atomic Energy Commission in Buenos Aires. Biological dosimetry was performed employing the hamster cheek pouch oral cancer model previously validated for BNCT studies by our group. Results indicate that the RA-1 neutron source produces useful dose rates for BNCT studies but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications. (author)

Synthesis and biological evaluation of boronated polyglycerol dendrimers as potential agent for neutron capture therapy

International Nuclear Information System (INIS)

Silva, Gerald S.; Camillo, Maria A.P.; Higa, Olga Z.; Pugliesi, Reynaldo; Fermamdes, Edson G.R.; Queiroz, Alvaro A.A. de

2005-01-01

In this work, the polyglycerol dendrimer (PGLD) generation 5 was used to obtain a boronated macromolecule for boron neutron capture therapy. The PGLD dendrimer was synthesized by the ring opening polymerization of deprotonated glycidol using polyglycerol as core functionality in a step-growth processes denominated divergent synthesis. The PGLD dendritic structure was confirmed by gel permeation chromatography, nuclear magnetic resonance ( 1 H-NMR, 13 C-NMR) and matrix assisted laser desorption/ionization techniques. The synthesized dendrimer presented low dispersion in molecular weights (M w /M n = 1.05) and a degree of branching of 0.82, which characterize the polymer dendritic structure. Quantitative neutron capture radiography was used to investigate the boron-10 enrichment of the polyglycerol dendrimer. The in vitro cytotoxicity to Chinese hamster ovary cells of 10 B-PGLD dendrimer indicate lower cytotoxicity, suggesting that the macromolecule is a biocompatible material. (author)

Research related to boron neutron capture therapy at The Ohio State University

International Nuclear Information System (INIS)

Barth, R.F.; Soloway, A.H.; Alam, F.

1986-01-01

Research in the area of boron neutron capture therapy (BNCT) at The Ohio State University is a highly multidisciplinary effort involving approximately twenty investigators in nine different departments. Major areas of interest include: (1) Boronation of monoclonal antibodies directed against tumor-associated antigens for the delivery of 10 B; (2) Synthesis of 10 B-containing derivatives of promazines and porphyrins that possess tumor-localizing properties; (3) Development of a rat model for the treatment of glioblastoma by BNCT; (4) Quantitation and microdistribution of 10 B in tissues by means of a solid state nuclear track detector. The ultimate goal of this research is to carry out the extensive preclinical studies that are required to bring BNCT to the point of a clinical trial. 13 references

Development of the JAERI computational dosimetry system (JCDS) for boron neutron capture therapy. Cooperative research

Energy Technology Data Exchange (ETDEWEB)

Kumada, Hiroaki; Yamamoto, Kazuyoshi; Torii, Yoshiya; Uchiyama, Junzo [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment; Matsumura, Akira; Yamamoto, Tetsuya; Nose, Tadao [Tsukuba Univ., Tsukuba, Ibaraki (Japan); Nakagawa, Yoshinobu [National Sanatorium Kagawa-Children' s Hospital, Kagawa (Japan); Kageji, Teruyoshi [Tokushima Univ., Tokushima (Japan)

2003-03-01

The Neutron Beam Facility at JRR-4 enables us to carry out boron neutron capture therapy with epithermal neutron beam. In order to make treatment plans for performing the epithermal neutron beam BNCT, it is necessary to estimate radiation doses in a patient's head in advance. The JAERI Computational Dosimetry System (JCDS), which can estimate distributions of radiation doses in a patient's head by simulating in order to support the treatment planning for epithermal neutron beam BNCT, was developed. JCDS is a software that creates a 3-dimentional head model of a patient by using CT and MRI images, and that generates a input data file automatically for calculation of neutron flux and gamma-ray dose distributions in the brain with the Monte Carlo code MCNP, and that displays these dose distributions on the head model for dosimetry by using the MCNP calculation results. JCDS has any advantages as follows; By using CT data and MRI data which are medical images, a detail three-dimensional model of patient's head is able to be made easily. The three-dimensional head image is editable to simulate the state of a head after its surgical processes such as skin flap opening and bone removal in the BNCT with craniotomy that are being performed in Japan. JCDS can provide information for the Patient Setting System which can support to set the patient to an actual irradiation position swiftly and accurately. This report describes basic design of JCDS and functions in several processing, calculation methods, characteristics and performance of JCDS. (author)

Automated rendezvous and capture development infrastructure

Science.gov (United States)

Bryan, Thomas C.; Roe, Fred; Coker, Cynthia

1992-01-01

The facilities at Marshall Space Flight Center and JSC to be utilized to develop and test an autonomous rendezvous and capture (ARC) system are described. This includes equipment and personnel facility capabilities to devise, develop, qualify, and integrate ARC elements and subsystems into flight programs. Attention is given to the use of a LEO test facility, the current concept and unique system elements of the ARC, and the options available to develop ARC technology.

Conceptual schematic for capture of biomethane released from hydroelectric power facilities.

Science.gov (United States)

Kikuchi, R; Amaral, P Bingre do

2008-09-01

Though dam-related biomethane was identified in the 1960s, its capture has not been sufficiently discussed. Captured biomethane could be burned to produce energy, and the burning of biomethane turns the carbon in it into CO(2) that is far less potent as a greenhouse gas; this paper therefore aims to technically discuss the capture/use of dam-related biomethane. A great amount of bubbles would be formed by the rapid drop in water pressure (i.e. cavitation) after turbine passage, so it is proposed to capture methane-bearing bubbles by means of a flow tube for adjusting residence time and hydrophilic screens for trapping these bubbles. The results from the performed calculation show that biomethane can be trapped in a yield of 60%.

Analysis of MCNP simulated gamma spectra of CdTe detectors for boron neutron capture therapy.

Science.gov (United States)

Winkler, Alexander; Koivunoro, Hanna; Savolainen, Sauli

2017-06-01

The next step in the boron neutron capture therapy (BNCT) is the real time imaging of the boron concentration in healthy and tumor tissue. Monte Carlo simulations are employed to predict the detector response required to realize single-photon emission computed tomography in BNCT, but have failed to correctly resemble measured data for cadmium telluride detectors. In this study we have tested the gamma production cross-section data tables of commonly used libraries in the Monte Carlo code MCNP in comparison to measurements. The cross section data table TENDL-2008-ACE is reproducing measured data best, whilst the commonly used ENDL92 and other studied libraries do not include correct tables for the gamma production from the cadmium neutron capture reaction that is occurring inside the detector. Furthermore, we have discussed the size of the annihilation peaks of spectra obtained by cadmium telluride and germanium detectors. Copyright © 2017 Elsevier Ltd. All rights reserved.

The TRIUMF radiative muon capture facility

International Nuclear Information System (INIS)

Wright, D.H.; Macdonald, J.A.; Poutissou, J.M.; Poutissou, R.; Ahmad, S.; Chen, C.Q.; Gorringe, T.P.; Hasinoff, M.D.; Sample, D.G.; Zhang, N.S.; Armstrong, D.S.; Blecher, M.; Serna-Angel, A.; Azuelos, G.; Bertl, W.; Henderson, R.S.; Robertson, B.C.; Taylor, G.

1992-01-01

Radiative muon capture (RMC) on hydrogen produces photons with a yield of ≅ 10 -8 per stopped muon. To measure RMC at TRIUMF we have constructed a lage-solid-angle photon pair-spectrometer which surrounds the liquid hydrogen target. The spectrometer consists of a cylindrical photon converter and a larget-volume cylindrical drift chamber to track the e + e - pairs. It is enclosed in a spectrometer magnet which produces a highly uniform axial magnetic field. The detector subsystems, the hardware trigger and the data acquisition system are described, chamber calibration and tracking techniques are presented, and the spectrometer performance and its Monte Carlo simulation are discussed. (orig.)

A beam optics study of the biomedical beam line at a proton therapy facility

International Nuclear Information System (INIS)

Yun, Chong Cheoul; Kim, Jong-Won

2007-01-01

A biomedical beam line has been designed for the experimental area of a proton therapy facility to deliver mm to sub-mm size beams in the energy range of 20-50 MeV using the TRANSPORT/TURTLE beam optics codes and a newly-written program. The proton therapy facility is equipped with a 230 MeV fixed-energy cyclotron and an energy selection system based on a degrader and slits, so that beam currents available for therapy decrease at lower energies in the therapeutic beam energy range of 70-230 MeV. The new beam line system is composed of an energy-degrader, two slits, and three quadrupole magnets. The minimum beam sizes achievable at the focal point are estimated for the two energies of 50 and 20 MeV. The focused FWHM beam size is approximately 0.3 mm with an expected beam current of 20 pA when the beam energy is reduced to 50 MeV from 100 MeV, and roughly 0.8 mm with a current of 10 pA for a 20 MeV beam

Superconducting ring magnets of the PIOTRON Pi-meson therapy facility at SIN

Energy Technology Data Exchange (ETDEWEB)

Maix, R K; Meyer, G; Roman, T; Horvath, I; Vecsey, G; Zellweger, J

1982-01-01

Negative Pi-mesons seem to be very promising for cancer therapy, because of their well defined penetration depth and their enhanced energy deposition in the absorption region. A prototype Pi-meson therapy facility, called PIOTRON, has been constructed at SIN, where also pion beams of sufficient intensity are available. The central part of this system are two ring magnets, consisting each of 60 superconducting flat coils, with the aid of which 60 pion beams can be guided around a heavy iron shield and focused on the patient. In this paper the fabrication and the initial operation of these magnets is discussed.

Neutron capture cross section measurement of $^{151}Sm$ at the CERN neutron Time of Flight Facility (nTOF)

CERN Document Server

Abbondanno, U; Alvarez-Velarde, F; Alvarez-Pol, H; Andriamonje, Samuel A; Andrzejewski, J; Badurek, G; Baumann, P; Becvar, F; Benlliure, J; Berthoumieux, E; Calviño, F; Cano-Ott, D; Capote, R; Cennini, P; Chepel, V; Chiaveri, Enrico; Colonna, N; Cortés, G; Cortina-Gil, D; Couture, A; Cox, J; Dababneh, S; Dahlfors, M; David, S; Dolfini, R; Domingo-Pardo, C; Durán, I; Embid-Segura, M; Ferrant, L; Ferrari, A; Ferreira-Marques, R; Frais-Kölbl, H; Furman, W; Gonçalves, I; Gallino, R; Gonzalez-Romero, E; Goverdovski, A; Gramegna, F; Griesmayer, E; Gunsing, F; Haas, B; Haight, R; Heil, M; Herrera-Martínez, A; Isaev, S; Jericha, E; Kappeler, F; Kadi, Y; Karadimos, D; Kerveno, M; Ketlerov, V; Köhler, P; Konovalov, V; Krticka, M; Lamboudis, C; Leeb, H; Lindote, A; Lopes, I; Lozano, M; Lukic, S; Marganiec, J; Marrone, S; Martinez-Val, J; Mastinu, P; Mengoni, A; Milazzo, P M; Molina-Coballes, A; Moreau, C; Mosconi, M; Neves, F; Oberhummer, Heinz; O'Brien, S; Pancin, J; Papaevangelou, T; Paradela, C; Pavlik, A; Pavlopoulos, P; Perlado, J M; Perrot, L; Pignatari, M; Plag, R; Plompen, A; Plukis, A; Poch, A; Policarpo, Armando; Pretel, C; Quesada, J; Raman, S; Rapp, W; Rauscher, T; Reifarth, R; Rosetti, M; Rubbia, Carlo; Rudolf, G; Rullhusen, P; Salgado, J; Soares, J C; Stéphan, C; Tagliente, G; Taín, J L; Tassan-Got, L; Tavora, L; Terlizzi, R; Vannini, G; Vaz, P; Ventura, A; Villamarín, D; Vincente, M C; Vlachoudis, V; Voss, F; Wendler, H; Wiescher, M; Wissha, K

2004-01-01

The measurement of **1**5**1Sm(n, gamma)**1**5**2Sm (samarium) cross section showed improved performance of the new spallation neutron facility. It covered a wide energy range with good resolution, high neutron flux, low backgrounds and a favourable duty factor. The samarium cross section was found to be of great importance for characterizing neutron capture nucleosynthesis in asymptotic giant stars. The combination of these features provided a promising basis for a broad experimental program directed towards application in astrophysics and advanced nuclear technologies. (Edited abstract)

Biological models in vivo for boron neutronic capture studies as tumors therapy

International Nuclear Information System (INIS)

Kreimann, Erica L.; Dagrosa, Maria A.; Schwint, Amanda E.; Itoiz, Maria E.; Pisarev, Mario A.; Farias, Silvia S.; Garavaglia, Ricardo N.; Batistoni, Daniel A.

1999-01-01

The use of experimental models for Boron Neutronic Capture studies as Tumors Therapy have as two main objectives: 1) To contribute to the basic knowledge of the biological mechanisms involved to increase the method therapeutical advantage, and 2) To explore the possible application of this therapeutic method to other pathologies. In this frame it was studied the carcinogenesis model of hamster cheek pouch, a type of human buccal cancer. Biodistribution studies of boron compound were performed in tumor, blood and in different precancerous and normal tissues as well as BNCT studies. Results validated this method for BNCT studies and show the capacity of the oral mucosa tumors of selectively concentrate the boron compound, showing a deleterious clear effect on the tumor after 24 hours with BNCT treatment. (author)

Boron neutron capture therapy induces cell cycle arrest and DNA fragmentation in murine melanoma cells

Energy Technology Data Exchange (ETDEWEB)

Faiao-Flores, F. [Biochemical and Biophysical Laboratory, Butantan Institute, 1500 Vital Brasil Avenue, Sao Paulo (Brazil)] [Faculty of Medicine, University of Sao Paulo, 455 Doutor Arnaldo Avenue, Sao Paulo (Brazil); Coelho, P.R.P. [Institute for Nuclear and Energy Research, 2242 Lineu Prestes Avenue, Sao Paulo (Brazil); Arruda-Neto, J. [Physics Institute, University of Sao Paulo, 187 Matao Street, Sao Paulo (Brazil)] [FESP, Sao Paulo Engineering School, 5520 Nove de Julho Avenue, Sao Paulo (Brazil); Maria, Durvanei A., E-mail: durvaneiaugusto@yahoo.br [Biochemical and Biophysical Laboratory, Butantan Institute, 1500 Vital Brasil Avenue, Sao Paulo (Brazil)

2011-12-15

The melanoma is a highly lethal skin tumor, with a high incidence. Boron Neutron Capture Therapy (BNCT) is a radiotherapy which combines Boron with thermal neutrons, constituting a binary system. B16F10 melanoma and L929 fibroblasts were treated with Boronophenylalanine and irradiated with thermal neutron flux. The electric potential of mitochondrial membrane, cyclin D1 and caspase-3 markers were analyzed. BNCT induced a cell death increase and cyclin D1 amount decreased only in B16F10 melanoma. Besides, there was not caspase-3 phosphorylation.

Ion chambers compliance results of Brazilian radiation therapy facilities.

Science.gov (United States)

Joana, G; Salata, C; Leal, P; Vasconcelos, R; Couto, N do; Teixeira, F C; Soares, A D; Santini, E S; Gonçalves, M

2018-03-01

The Brazilian Nuclear Energy Commission (cnen) has been making a constant effort to keep up to date with international standards and national needs to strengthen the status of radiological protection of the country. The guidelines related to radiation therapy facilities have been revised in the last five years in order to take into consideration the most relevant aspects of the growing technology as well as to mitigate the accidents or incidents observed in practice. Hence, clinical dosimeters have gained special importance in this matter. In the present work, we discuss the effectiveness of regulation and inspections to the enforcement of instrument calibration accuracy for the improvement of patient dosimetry and quality control. As a result, we observed that the number of calibrated instruments, mainly well chambers, is increasing each year. The same behavior is observed for instruments employed in technologically advanced radiation treatments such as intensity modulated radiotherapy, volumetric therapy and stereotatic radiosurgery. We ascribe this behavior to the new regulation.

Possible application of boron neutron capture therapy to canine osteosarcoma

International Nuclear Information System (INIS)

Takeuchi, Akira

1985-01-01

Possibility for successful treatment of canine osteosarcoma by boron neutron capture therapy (BNCT) was demonstrated based upon an uptake study of the boron compound and an experimental treatment by BNCT. In the up take study following intravenous administration of Na 2 B 12 H 11 SH, satisfactorily higher boron concentration with some variation between tumors is likely to be obtained 12 hours after the administration, together with significantly lower boron levels in blood and bone. Based upon these results, osteosarcoma of a mongrel dog was successfully treated by BNCT. The tumor received approximately 3800 rads with single neutron irradiation (approximately 1.4 x 10 13 n./cm 2 ) about 12 hours after intravenous infusion of Na 2 B 12 H 11 SH of 96 % enriched 10 B in the ratio of 50 mg 10 B/kg. Clinical and radiographical improvements were remarkable and no neoplastic cell was found in any part of the original neoplastic lesion and its surrounding tissue at the time of autopsy after 30 days. (author)

Irradiation system for neutron capture therapy using the small accelerator

International Nuclear Information System (INIS)

Kobayashi, Tooru; Hoshi, Masaharu

2002-01-01

Neutron capture therapy (NCT) is to kill tumor cells that previously incorporated the stable isotope which generates heavy charged particles with a short range and a high linear energy transfer (LET) on neutron irradiation. Boron-10 is ordinarily used as such an isotope. The tumor tissue is neutron-irradiated at craniotomy after preceding craniotomy for tumor extraction: therefore two surgeries are required for the present NCT in Japan. The reactions 10 B(n, αγ) 7 Li and 7 Li (p, n) 7 Be are thought preferential for patients and doctors if a convenient small accelerator, not the reactor used at present, is available in the hospital because only one craniotomy is sufficient. Authors' examinations of the system for NCT using the small accelerator involve irradiation conditions, desirable energy spectrum of neutron, characterization of thermal and epi-thermal neutrons, social, practical and technical comparison of the reactor and accelerator, and usefulness of the reaction 7 Li (p, n) 7 Be. The system devoted to the NCT is awaited in future. (K.H.)

Application of adjoint Monte Carlo to accelerate simulations of mono-directional beams in treatment planning for Boron Neutron Capture Therapy

NARCIS (Netherlands)

Nievaart, V.A.; Legrady, D.; Moss, R.L.; Kloosterman, J.L.; Van der Hagen, T.H.; Van Dam, H.

2007-01-01

This paper deals with the application of the adjoint transport theory in order to optimize Monte Carlo based radiotherapy treatment planning. The technique is applied to Boron Neutron Capture Therapy where most often mixed beams of neutrons and gammas are involved. In normal forward Monte Carlo

Job-Related Stress in Forensic Interviewers of Children with Use of Therapy Dogs Compared with Facility Dogs or No Dogs

Science.gov (United States)

Walsh, Diane; Yamamoto, Mariko; Willits, Neil H.; Hart, Lynette A.

2018-01-01

Sexually abused children providing essential testimony regarding crimes in forensic interviews now sometimes are provided facility dogs or therapy dogs for comfort. Facility dogs are extensively trained to work with forensic interviewers; when using therapy dogs in interviews, volunteers are the dog handlers. Interviews can impact child welfare workers’ mental health causing secondary traumatic stress (STS). To investigate this stress, first data were gathered on stress retrospectively for when interviewers initially started the job prior to working with a dog, and then currently, from forensic interviewers using a facility dog, a therapy or pet dog, or no dog. These retrospective and secondary traumatic stress scale (STSS) data compared job stress among interviewers of children using: a certified, workplace facility dog (n = 16), a volunteer’s trained therapy dog or the interviewer’s pet dog (n = 13/3), or no dog (n = 198). Retrospective scores of therapy dog and no dog interviewers’ stress were highest for the first interviewing year 1 and then declined. Extremely or very stressful retrospective scores differed among the three groups in year 1 (p pet dog users; both groups favored using dogs. Interviewers currently working with therapy dogs accompanied by their volunteers reported they had experienced heightened stress when they began their jobs; their high stress levels still persisted, indicating lower inherent coping skills and perhaps greater empathy among interviewers who later self-selected to work with therapy dogs. Results reveal extreme avoidant stress for interviewers witnessing children who are suffering and their differing coping approaches. PMID:29594160

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer

International Nuclear Information System (INIS)

Kankaanranta, Leena; Seppaelae, Tiina; Koivunoro, Hanna; Saarilahti, Kauko; Atula, Timo; Collan, Juhani; Salli, Eero; Kortesniemi, Mika; Uusi-Simola, Jouni; Maekitie, Antti; Seppaenen, Marko; Minn, Heikki; Kotiluoto, Petri; Auterinen, Iiro; Savolainen, Sauli; Kouri, Mauri; Joensuu, Heikki

2007-01-01

Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites

A shielding design for an accelerator-based neutron source for boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Hawk, A.E.; Blue, T.E. E-mail: blue.1@osu.edu; Woollard, J.E

2004-11-01

Research in boron neutron capture therapy (BNCT) at The Ohio State University Nuclear Engineering Department has been primarily focused on delivering a high quality neutron field for use in BNCT using an accelerator-based neutron source (ABNS). An ABNS for BNCT is composed of a proton accelerator, a high-energy beam transport system, a {sup 7}Li target, a target heat removal system (HRS), a moderator assembly, and a treatment room. The intent of this paper is to demonstrate the advantages of a shielded moderator assembly design, in terms of material requirements necessary to adequately protect radiation personnel located outside a treatment room for BNCT, over an unshielded moderator assembly design.

Analysis of touch used by occupational therapy practitioners in skilled nursing facilities.

Science.gov (United States)

Morris, Douglas; Henegar, J; Khanin, S; Oberle, G; Thacker, S

2014-09-01

Instrumental touch is identified as having purposeful physical contact in order to complete a task. Expressive touch is identified as warm, friendly physical contact and is not solely for performing a task. Expressive touch has been associated with improved client status, increased rapport and greater gains made during therapy. The purpose of the study was to observe the frequency of expressive and instrumental touch utilized by an occupational therapist during an occupational therapy session. Thirty-three occupational therapy professionals, including occupational therapists and occupational therapy assistants, employed at skilled nursing facilities in southwest Florida were observed. Data were collected on the Occupational Therapy Interaction Assessment. The results of the data analysis showed a positive relationship between the gender of the therapist and the frequency of expressive touch. The data also showed that a large majority of touches were instrumental touch and pertained to functional mobility. The results of the study can contribute to a better understanding of the holistic aspects of occupational therapy. By the use of more expressive touch, occupational therapy practitioners may have a positive, beneficial effect on both the client and the therapy process as a whole. Further research is needed to determine the effect an occupational therapy setting has on the frequency of instrumental and expressive touch. A larger sample size and a distinction between evaluation and treatment sessions would benefit future studies. Copyright © 2014 John Wiley & Sons, Ltd.

The effects of light therapy on depression and sleep disruption in older adults in a long-term care facility.

Science.gov (United States)

Wu, Mann-Chian; Sung, Huei-Chuan; Lee, Wen-Li; Smith, Graeme D

2015-10-01

This study aims to evaluate the effect of light therapy on depression and sleep disruption in older adults residing in a long-term care facility. Psychological morbidity is a problem commonly seen in older adults residing in long-term care facilities. Limited research has addressed the effect of light therapy on depression in this population. A quasi-experimental pretest and posttest design was used. Thirty-four participants in the experimental group received light therapy by sitting in front of a 10000-lux light box 30 min in the morning, three times a week for 4 weeks. Thirty-one participants in the control group received routine care without light therapy. Depression was measured by Geriatric Depression Scale-Short Form at baseline and week 4. After receiving 4 weeks of light therapy, the mean depression score in the experimental group decreased from 7.24 (SD3.42) at pretest to 5.91 (SD 3.40) at posttest, and had a significant reduction (t = 2.22, P = 0.03). However, there was no significant difference in depression score and sleep disruption between the experimental group and control group. Light therapy might have the potential to reduce depressive symptoms and sleep disruption and may be a viable intervention to improve mental health of older adults in the long-term care facilities. © 2014 Wiley Publishing Asia Pty Ltd.

The 3D tomographic image reconstruction software for prompt-gamma measurement of the boron neutron capture therapy

International Nuclear Information System (INIS)

Morozov, Boris; Auterinen, Iiro; Kotiluoto, Petri; Kortesniemi, Mika

2006-01-01

A tomographic imaging system based on the spatial distribution measurement of the neutron capture reaction during Boron Neutron Capture Therapy (BNCT) would be very useful for clinical purpose. Using gamma-detectors in a 2D-panel, boron neutron capture and hydrogen neutron capture gamma-rays emitted by the neutron irradiated region can be detected, and an image of the neutron capture events can be reconstructed. A 3D reconstruction software package has been written to support the development of a 3D prompt-gamma tomographic system. The package consists of three independent modules: phantom generation, reconstruction and evaluation modules. The reconstruction modules are based on algebraic approach of the iterative reconstruction algorithm (ART), and on the maximum likelihood estimation method (ML-EM). In addition to that, two subsets of the ART, the simultaneous iterative reconstruction technique (SIRT) and the component averaging algorithms (CAV) have been included to the package employing parallel codes for multiprocessor architecture. All implemented algorithms use two different field functions for the reconstruction of the region. One is traditional voxel function, another is, so called, blob function, smooth spherically symmetric generalized Kaiser-Bessel function. The generation module provides the phantom and projections with background by tracing the prompt gamma-rays for a given scanner geometry. The evaluation module makes statistical comparisons between the generated and reconstructed images, and provides figure-of-merit (FOM) values for the applied reconstruction algorithms. The package has been written in C language and tested under Linux and Windows platforms. The simple graphical user interface (GUI) is used for command execution and visualization purposed. (author)

Incentives for early adoption of carbon capture technology

International Nuclear Information System (INIS)

Comello, Stephen; Reichelstein, Stefan

2014-01-01

We analyze a policy proposal for regulating the next generation of baseload electricity generation facilities in the United States. The cornerstone of this regulation is a (hypothetical) EPA mandate for an emission standard of 80 kg of CO 2 per MWh of electricity generated. The mandate would go into effect at the end of 2027 for all power generating facilities that come into operation after 2017. Fossil-fuel power plants could meet the standard by capturing between 80 and 90% of their current CO 2 emissions. While the initial cost of complying with this standard is relatively high for first-of-a-kind facilities, learning effects are projected to reduce this cost substantially by the end of 2027, provided new facilities consistently adopt carbon capture technology in the intervening years. We identify a combination of investment- and production tax credits that provide the required incentives for new facilities to be willing to comply with the standard ahead of the mandate. Due to the anticipated learning effects, the incremental cost associated with the stricter emission limit is projected to about 1.2¢ per kWh of electricity in the long run. - Highlights: • Study the cost effects of a CO 2 emission standard for natural gas power plants. • The standard requires the deployment of carbon capture technology. • Future compliance costs are reduced through learning effects. • Identify tax incentives that induce early technology adoption. • Early adoption results in relatively modest electricity cost increases

Boron neutron capture therapy for malignant brain tumor in Japan

Energy Technology Data Exchange (ETDEWEB)

Nakagawa, Yoshinobu [National Kagawa Children`s Hospital, Takamatsu, Kagawa (Japan)

1998-03-01

Since 1968, we have treated 149 patients and performed boron-neutron capture therapy (BNCT) on 164 occasions using 5 reactors in Japan. There were 64 patients with glioblastoma, 39 patients with anaplastic astrocytoma and 17 patients with low grade astrocytoma (grade 1 or 2). There were 30 patients with other types of tumor. The overall response rate in the glioma patients was 64%. Seven patients (12%) of glioblastoma, 22 patients (56%) of anaplastic astrocytoma and 8 patients (62%) of low grade astrocytoma lived more than 2 years Median survival time of glioblastoma was 640 days. Median survival times of patients with anaplastic astrocytoma was 1811 days, and 1669 days in low grade astrocytoma. Six patients (5 glioblastoma and one anaplastic astrocytoma) died within 90 days after BNCT. Six patients lived more than 10 years. Histological grading, age of the patients, neutron fluence at the target point and target depth or size of the tumor were proved to be important factors. BNCT is an effective treatment for malignant brain tumors. We are now became able to radiate the tumor more correctly with a high enough dose of neutron beam even if we use thermal neutron beam. (author)

Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

Science.gov (United States)

Blue, Thomas E; Yanch, Jacquelyn C

2003-01-01

This paper reviews the development of low-energy light ion accelerator-based neutron sources (ABNSs) for the treatment of brain tumors through an intact scalp and skull using boron neutron capture therapy (BNCT). A major advantage of an ABNS for BNCT over reactor-based neutron sources is the potential for siting within a hospital. Consequently, light-ion accelerators that are injectors to larger machines in high-energy physics facilities are not considered. An ABNS for BNCT is composed of: (1) the accelerator hardware for producing a high current charged particle beam, (2) an appropriate neutron-producing target and target heat removal system (HRS), and (3) a moderator/reflector assembly to render the flux energy spectrum of neutrons produced in the target suitable for patient irradiation. As a consequence of the efforts of researchers throughout the world, progress has been made on the design, manufacture, and testing of these three major components. Although an ABNS facility has not yet been built that has optimally assembled these three components, the feasibility of clinically useful ABNSs has been clearly established. Both electrostatic and radio frequency linear accelerators of reasonable cost (approximately 1.5 M dollars) appear to be capable of producing charged particle beams, with combinations of accelerated particle energy (a few MeV) and beam currents (approximately 10 mA) that are suitable for a hospital-based ABNS for BNCT. The specific accelerator performance requirements depend upon the charged particle reaction by which neutrons are produced in the target and the clinical requirements for neutron field quality and intensity. The accelerator performance requirements are more demanding for beryllium than for lithium as a target. However, beryllium targets are more easily cooled. The accelerator performance requirements are also more demanding for greater neutron field quality and intensity. Target HRSs that are based on submerged-jet impingement and

Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine

International Nuclear Information System (INIS)

Coderre, J.A.; Greenberg, D.; Micca, P.L.; Joel, D.D.; Saraf, S.; Packer, S.

1990-01-01

During conventional radiotherapy, the dose that can be delivered to the tumor is limited by the tolerance of the surrounding normal tissue within the treatment volume. Boron Neutron Capture Therapy (BNCT) represents a promising modality for selective tumor irradiation. The key to effective BNCT is selective localization of 10 B in the tumor. We have shown that the synthetic amino acid p-boronophenylalanine (BPA) will selectively deliver boron to melanomas and other tumors such as gliosarcomas and mammary carcinomas. Systemically delivered BPA may have general utility as a boron delivery agent for BNCT. In this paper, BNCT with BPA is used in treatment of experimentally induced gliosarcoma in rats and nonpigmented melanoma in rabbits. The tissue distribution of boron is described, as is response to the BNCT. 6 refs., 4 figs., 1 tab

Hyper-thermal neutron irradiation field for neutron capture therapy

International Nuclear Information System (INIS)

Sakurai, Yoshinori; Kobayashi, Tooru; Kanda, Keiji

1994-01-01

The utilization of hyper-thermal neutrons, which have an energy spectrum of a Maxwell distribution higher than the room temperature of 300 K, has been studied in order to improve the thermal neutron flux distribution in a living body for a deep-seated tumor in neutron capture therapy (NCT). Simulation calculations using MCNP-V3 were carried out in order to investigate the characteristics of the hyper-thermal neutron irradiation field. From the results of simulation calculations, the following were confirmed: (i) The irradiation field of the hyper-thermal neutrons is feasible by using some scattering materials with high temperature, such as Be, BeO, C, SiC and ZrH 1.7 . Especially, ZrH 1.7 is thought to be the best material because of good characteristics of up-scattering for thermal neutrons. (ii) The ZrH 1.7 of 1200 K yields the hyper-thermal neutrons of a Maxwell-like distribution at about 2000 K and the treatable depth is about 1.5 cm larger comparing with the irradiation of the thermal neutrons of 300 K. (iii) The contamination by the secondary gamma-rays from the scattering materials can be sufficiently eliminated to the tolerance level for NCT through the bismuth layer, without the larger change of the energy spectrum of hyper-thermal neutrons. ((orig.))

Current status of accelerator-based boron neutron capture therapy

International Nuclear Information System (INIS)

Kreiner, A. J.; Bergueiro, J.; Di Paolo, H.; Castell, W.; Vento, V. Thatar; Cartelli, D.; Kesque, J.M.; Valda, A.A.; Ilardo, J.C.; Baldo, M.; Erhardt, J.; Debray, M.E.; Somacal, H.R.; Estrada, L.; Sandin, J.C. Suarez; Igarzabal, M.; Huck, H.; Padulo, J.; Minsky, D.M.

2011-01-01

The direct use of proton and heavy ion beams for radiotherapy is a well established cancer treatment modality, which is becoming increasingly widespread due to its clear advantages over conventional photon-based treatments. This strategy is suitable when the tumor is spatially well localized. Also the use of neutrons has a long tradition. Here Boron Neutron Capture Therapy (BNCT) stands out, though on a much smaller scale, being a second-generation promising alternative for tumors which are diffuse and infiltrating. On this sector, so far only nuclear reactors have been used as neutron sources. In this paper we describe the current situation worldwide as far as the use of accelerator-based neutron sources for BNCT is concerned (so-called Accelerator-Based (AB)-BNCT). In particular we discuss the present status of an ongoing project to develop a folded Tandem-ElectroStatic-Quadrupole (TESQ) accelerator at the Atomic Energy Commission of Argentina. The project goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams to perform BNCT for deep-seated tumors in less than an hour. (author)

Application of generalized perturbation theory to sensitivity analysis in boron neutron capture therapy

International Nuclear Information System (INIS)

Garcia, Vanessa S.; Silva, Fernando C.; Silva, Ademir X.; Alvarez, Gustavo B.

2011-01-01

Boron neutron capture therapy - BNCT - is a binary cancer treatment used in brain tumors. The tumor is loaded with a boron compound and subsequently irradiated by thermal neutrons. The therapy is based on the 10 B (n, α) 7 Li nuclear reaction, which emits two types of high-energy particles, α particle and the 7 Li nuclei. The total kinetic energy released in this nuclear reaction, when deposited in the tumor region, destroys the cancer cells. Since the success of the BNCT is linked to the different selectivity between the tumor and healthy tissue, it is necessary to carry out a sensitivity analysis to determinate the boron concentration. Computational simulations are very important in this context because they help in the treatment planning by calculating the lowest effective absorbed dose rate to reduce the damage to healthy tissue. The objective of this paper is to present a deterministic method based on generalized perturbation theory (GPT) to perform sensitivity analysis with respect to the 10 B concentration and to estimate the absorbed dose rate by patients undergoing this therapy. The advantage of the method is a significant reduction in computational time required to perform these calculations. To simulate the neutron flux in all brain regions, the method relies on a two-dimensional neutron transport equation whose spatial, angular and energy variables are discretized by the diamond difference method, the discrete ordinate method and multigroup formulation, respectively. The results obtained through GPT are consistent with those obtained using other methods, demonstrating the efficacy of the proposed method. (author)

Application of generalized perturbation theory to sensitivity analysis in boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Garcia, Vanessa S. [Universidade Federal Fluminense (EEIMVR/UFF-RJ), Volta Redonda, RJ (Brazil). Escola de Engenharia Industrial e Metalurgica. Programa de Pos-Graduacao em Modelagem Computacional em Ciencia e Tecnologia; Silva, Fernando C.; Silva, Ademir X., E-mail: fernando@con.ufrj.b, E-mail: ademir@con.ufrj.b [Coordenacao dos Programas de Pos-Graduacao de Engenharia (PEN/COPPE/UFRJ), Rio de Janeiro, RJ (Brazil). Programa de Engenharia Nuclear; Alvarez, Gustavo B. [Universidade Federal Fluminense (EEIMVR/UFF-RJ), Volta Redonda, RJ (Brazil). Escola de Engenharia Industrial e Metalurgica. Dept. de Ciencias Exatas

2011-07-01

Boron neutron capture therapy - BNCT - is a binary cancer treatment used in brain tumors. The tumor is loaded with a boron compound and subsequently irradiated by thermal neutrons. The therapy is based on the {sup 10}B (n, {alpha}) {sup 7}Li nuclear reaction, which emits two types of high-energy particles, {alpha} particle and the {sup 7}Li nuclei. The total kinetic energy released in this nuclear reaction, when deposited in the tumor region, destroys the cancer cells. Since the success of the BNCT is linked to the different selectivity between the tumor and healthy tissue, it is necessary to carry out a sensitivity analysis to determinate the boron concentration. Computational simulations are very important in this context because they help in the treatment planning by calculating the lowest effective absorbed dose rate to reduce the damage to healthy tissue. The objective of this paper is to present a deterministic method based on generalized perturbation theory (GPT) to perform sensitivity analysis with respect to the {sup 10}B concentration and to estimate the absorbed dose rate by patients undergoing this therapy. The advantage of the method is a significant reduction in computational time required to perform these calculations. To simulate the neutron flux in all brain regions, the method relies on a two-dimensional neutron transport equation whose spatial, angular and energy variables are discretized by the diamond difference method, the discrete ordinate method and multigroup formulation, respectively. The results obtained through GPT are consistent with those obtained using other methods, demonstrating the efficacy of the proposed method. (author)

Preliminary safety evaluation for a medical therapy reactor

International Nuclear Information System (INIS)

Jones, J.L.; Neuman, W.A.

1989-01-01

A conceptual design of a passively safe reactor facility for boron neutron capture therapy has been previously described. The medical therapy reactor (MTR) has a maximum power level of 10 MW(thermal) and utilizes 45 wt% uranium in UZrH, 20 wt% 235 U enriched hydride fuel matrix with 1 wt% erbium, which is a burnable poison and provides prompt negative reactivity feedback. The facility has five beam ports for patient treatment and advanced neutron beam research and is capable of 2,000 to 10,000 treatments per year, assuming single 8h/day, 5 day/week operation. The epithermal treatment flux from the beam ports is large, enabling single-session treatment of brain cancers of <10-min duration, with minimal fast neutron and gamma contaminants. The reactor core is designed with sufficient excess reactivity to yield a core lifetime equal to a facility lifetime of 30 yr. A preliminary safety evaluation was performed using the RELAP5 thermal-hydraulic code. The analysis addressed accidents in several major categories, including a pump coastdown, a loss of secondary heat sink, and a $0.5 step reactivity insertion

The uses of neutron capture γ-rays in environmental pollution measurements

International Nuclear Information System (INIS)

Abdel-Haleem, A.S.; Abdel-Samad, M.A.; Zaghloul, R.A.; Hassan, A.M.

1996-01-01

A neutron capture γ-ray spectroscopy facility using an isotopic neutron source, 252 Cf, has been installed and used for investigation of some environmental samples. The facility is designed and calibrated for measurement of the prompt γ-ray spectra due to thermal neutron capture. Qualitative analysis studies of some local environmental samples have been carried out using some developed analytical programs. The experimental results of the environmental pollutant analysis are discussed. (author)

Recent development of capture of CO2

CERN Document Server

Chavez, Rosa Hilda

2014-01-01

"Recent Technologies in the capture of CO2" provides a comprehensive summary on the latest technologies available to minimize the emission of CO2 from large point sources like fossil-fuel power plants or industrial facilities. This ebook also covers various techniques that could be developed to reduce the amount of CO2 released into the atmosphere. The contents of this book include chapters on oxy-fuel combustion in fluidized beds, gas separation membrane used in post-combustion capture, minimizing energy consumption in CO2 capture processes through process integration, characterization and application of structured packing for CO2 capture, calcium looping technology for CO2 capture and many more. Recent Technologies in capture of CO2 is a valuable resource for graduate students, process engineers and administrative staff looking for real-case analysis of pilot plants. This eBook brings together the research results and professional experiences of the most renowned work groups in the CO2 capture field...

Capture cavity II results at FNAL

Energy Technology Data Exchange (ETDEWEB)

Branlard, Julien; Chase, Brian; Cancelo, G.; Carcagno, R.; Edwards, H.; Fliller, R.; Hanna, B.; Harms, Elvan; Hocker, A.; Koeth, T.; Kucera, M.; /Fermilab

2007-06-01

As part of the research and development towards the International Linear Collider (ILC), several test facilities have been developed at Fermilab. This paper presents the latest Low Level RF (LLRF) results obtained with Capture Cavity II (CCII) at the ILC Test Accelerator (ILCTA) test facility. The main focus will be on controls and RF operations using the SIMCON based LLRF system developed in DESY [1]. Details about hardware upgrades and future work will be discussed.

Fast neutron capture cross section facility at Cadarache

International Nuclear Information System (INIS)

Le Rigoleur, C.; Arnaud, A.

1975-01-01

The total energy weighting technique has been applied to measure absolute fast neutron capture cross section at Cadarache. We use a non hydrogeneous liquid scintillator to detect the gamma from the cascade. The neutron flux is measured with a B 10 INa(Tl) detector or Li 6 glass scintillator of well known efficiency. Time of flight technique is used with on line digital computer data processing. (orig.) [de

Progress in study of a medical reactor for boron neutron capture therapy

International Nuclear Information System (INIS)

Sasaki, Makoto; Hirota, Jitsuya; Tamao, Shigeo; Kanda, Keiji; Mishima, Yutaka.

1993-01-01

A design study of a medical reactor for Boron Neutron Capture Therapy has made progress. Main specifications of the reactor are as follows; thermal power of 2 MW, water cooling by natural convection, semitight core of hexagonal lattice, UO 2 fuel rod of 9.5 mm diameter and no refueling in the reactor-life. Three horizontal and one vertical neutron beam holes are to be provided for simultaneous treatments by thermal and epithermal neutrons and for further biomedical research. The design objectives for the beam holes are to deliver the therapeutic doses in a modest time (30 to 60 min) with minimal fast neutron and gamma contaminants. The n-γ coupling Sn transport calculations have been carried out using n-21 and γ-9 group cross sections on 2-dim. practical models. The calculated results indicate that the design objectives will be achievable even if the thermal power of the reactor is reduced to 1 MW. (author)

Biodistribution, toxicity and efficacy of a boronated porphyrin for boron neutron capture therapy

International Nuclear Information System (INIS)

Miura, Michiko; Micca, P.; Fairchild, R.; Slatkin, D.; Gabel, D.

1992-01-01

Boron-containing porphyrins may be useful for boron neutron capture therapy (BNCT) in the treatment of brain tumors. Porphyrins have been shown to accumulate in tumor tissue and to be essentially excluded from normal brain. However, problems of toxicity may prevent some boron-containing porphyrins from being considered for BNCT. The authors have synthesized the boronated porphyrin 2,4-bis-vinyl-o-nidocarboranyl-deuteroporphyrin IX (VCDP). Preliminary studies in tumor-bearing mice showed considerable uptake of boron at a total dose of 150 μg/gbw with low mortality. They now report that a total dose to mice of ∼ 275 μg VCDP/gbw administered in multiple intraperitoneal (ip) injections can provide 40-50μg B per gram of tumor with acceptable toxicity. Toxicity experiments and a preliminary trial of BNCT in mice given such doses are also reported

Analytical applications of neutron capture gamma-rays

International Nuclear Information System (INIS)

Lindstrom, R.M.; Paul, R.L.; Anderson, D.L.; Paul, R.L.

1997-01-01

Field and industrial applications of neutron capture gamma-ray spectrometry with isotopic sources or neutron generators are economically important. Geochemical exploration in boreholes is done routinely with neutron probes. Coal and ores are assayed with analyzers adjacent to a conveyor belt in dozens of industrial facilities. The use of capture gamma rays for explosives detection has been described in the literature, both for scanning airline baggage and for characterizing obsolete munitions; a packaged system for the latter is available commercially. Generalizations are drawn from the history of the field, and predictions are made about the future usefulness of capture gamma rays. (author)

High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases

Energy Technology Data Exchange (ETDEWEB)

Halfon, S. [Soreq NRC, Yavne 81800 (Israel); Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel)], E-mail: halfon@phys.huji.ac.il; Paul, M. [Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel); Steinberg, D. [Biofilm Laboratory, Institute of Dental Sciences, Faculty of Dentistry, Hebrew University-Hadassah (Israel); Nagler, A.; Arenshtam, A.; Kijel, D. [Soreq NRC, Yavne 81800 (Israel); Polacheck, I. [Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center (Israel); Srebnik, M. [Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Hebrew University, Jerusalem 91120 (Israel)

2009-07-15

A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction {sup 7}Li(p,n){sup 7}Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.

Experimental neutron capture data of $^{58}$Ni from the CERN n_TOF facility

CERN Document Server

Žugec, P.; Colonna, N.; Bosnar, D.; Altstadt, S.; Andrzejewski, J.; Audouin, L.; Bécares, V.; Bečvář, F.; Belloni, F.; Berthoumieux, E.; Billowes, J.; Boccone, V.; Brugger, M.; Calviani, M.; Calviño, F.; Cano-Ott, D.; Carrapiço, C.; Cerutti, F.; Chiaveri, E.; Chin, M.; Cortés, G.; Cortés-Giraldo, M.A.; Diakaki, M.; Domingo-Pardo, C.; Duran, I.; Dzysiuk, N.; Eleftheriadis, C.; Ferrari, A.; Fraval, K.; Ganesan, S.; García, A.R.; Giubrone, G.; Gómez-Hornillos, M.B.; Gonçalves, I.F.; González-Romero, E.; Griesmayer, E.; Guerrero, C.; Gunsing, F.; Gurusamy, P.; Jenkins, D.G.; Jericha, E.; Kadi, Y.; Käppeler, F.; Karadimos, D.; Koehler, P.; Kokkoris, M.; Krtička, M.; Kroll, J.; Langer, C.; Lederer, C.; Leeb, H.; Leong, L.S.; Losito, R.; Manousos, A.; Marganiec, J.; Martìnez, T.; Massimi, C.; Mastinu, P.F.; Mastromarco, M.; Meaze, M.; Mendoza, E.; Mengoni, A.; Milazzo, P.M.; Mingrone, F.; Mirea, M.; Mondalaers, W.; Paradela, C.; Pavlik, A.; Perkowski, J.; Pignatari, M.; Plompen, A.; Praena, J.; Quesada, J.M.; Rauscher, T.; Reifarth, R.; Riego, A.; Roman, F.; Rubbia, C.; Sarmento, R.; Schillebeeckx, P.; Schmidt, S.; Tagliente, G.; Tain, J.L.; Tarrío, D.; Tassan-Got, L.; Tsinganis, A.; Valenta, S.; Vannini, G.; Variale, V.; Vaz, P.; Ventura, A.; Versaci, R.; Vermeulen, M.J.; Vlachoudis, V.; Vlastou, R.; Wallner, A.; Ware, T.; Weigand, M.; Weiß, C.; Wright, T.

2013-01-01

The $^{58}$Ni $(n,\\gamma)$ cross section has been measured at the neutron time of flight facility n_TOF at CERN, in the energy range from 27 meV up to 400 keV. In total, 51 resonances have been analyzed up to 122 keV. Maxwellian averaged cross sections (MACS) have been calculated for stellar temperatures of kT$=$5-100 keV with uncertainties of less than 6%, showing fair agreement with recent experimental and evaluated data up to kT = 50 keV. The MACS extracted in the present work at 30 keV is 34.2$\\pm$0.6$_\\mathrm{stat}\\pm$1.8$_\\mathrm{sys}$ mb, in agreement with latest results and evaluations, but 12% lower relative to the recent KADoNIS compilation of astrophysical cross sections. When included in models of the s-process nucleosynthesis in massive stars, this change results in a 60% increase of the abundance of $^{58}$Ni, with a negligible propagation on heavier isotopes. The reason is that, using both the old or the new MACS, 58Ni is efficiently depleted by neutron captures.

Boron neutron capture therapy as new treatment for clear cell sarcoma: Trial on different animal model

International Nuclear Information System (INIS)

Andoh, Tooru; Fujimoto, Takuya; Sudo, Tamotsu; Suzuki, Minoru; Sakurai, Yoshinori; Sakuma, Toshiko; Moritake, Hiroshi; Sugimoto, Tohru; Takeuchi, Tamotsu; Sonobe, Hiroshi; Epstein, Alan L.; Fukumori, Yoshinobu; Ono, Koji; Ichikawa, Hideki

2014-01-01

Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In our previous study, the tumor disappeared under boron neutron capture therapy (BNCT) on subcutaneously-transplanted CCS-bearing animals. In the present study, the tumor disappeared under this therapy on model mice intramuscularly implanted with three different human CCS cells. BNCT led to the suppression of tumor-growth in each of the different model mice, suggesting its potentiality as an alternative to, or integrative option for, the treatment of CCS. - Highlights: • BNCT with the use of L-BPA was applied for three human clear cell sarcoma (CCS) cell lines. • BNCT trial was performed on a newly established intramuscularly CCS-bearing animal model. • A significant decrease of the tumor-volume was seen by single BNCT with the use of L-BPA. • A multiple BNCT application would be required for controlling the growth of any residual tumors

The radiation biology of Boron Neutron Capture Therapy

International Nuclear Information System (INIS)

Coderre, J.A.

2003-01-01

Boron Neutron Capture Therapy (BNCT) produces a complex mixture of high and low-LET radiations in tissue. Using data on the biological effectiveness of these various dose components, derived primarily in small animals irradiated with thermal neutrons, it has been possible to express clinical BNCT doses in photon-equivalent units. The accuracy of these calculated doses in normal tissue and tumor will be reviewed. Clinical trials are underway at a number of centers. There are differences in the neutron beams at these centers, and differences in the details of the clinical protocols. Ideally, data from all centers using similar boron compounds and treatment protocols should be compared and combined, if appropriate, in a multi-institutional study in order to strengthen statistical analysis. An international dosimetry exchange is underway that will allow the physical doses from the various treatment centers to be quantitatively compared. As a first step towards the comparison of the clinical data, the normal brain tolerance data from the patients treated in the initial Brookhaven National Laboratory and the Harvard/MIT BNCT clinical trials have been compared. The data provide a good estimate of the normal brain tolerance for a somnolence syndrome endpoint, and provide guidance for setting normal brain tolerance limits in ongoing and future clinical trials. Escalation of the dose in BNCT can be accomplished by increasing the amount of the boron compound administered, increasing the duration of the neutron exposure, or both. The dose escalations that have been carried out to date at the various treatment centers will be compared and contrasted. Possible future clinical trials using BNCT in combination with other modalities will be discussed

Boron neutron capture therapy in cancer: past, present and future

Energy Technology Data Exchange (ETDEWEB)

Pisarev, Mario A.; Dagrosa, Maria Alejandra; Juvenal, Guilermo J. [National Atomic Energy Commission, Buenos Aires (Argentina). Div. of Nuclear Biochemistry; University of Buenos Aires (Argentina). School of Medicine. Dept. of Human Biochemistry

2007-07-15

Undifferentiated thyroid cancer (UTC) is a very aggressive tumor with no effective treatment, since it lacks iodine uptake and does not respond to radio or chemotherapy. The prognosis of these patients is bad, due to the rapid growth of the tumor and the early development of metastasis. Boron neutron capture therapy (BNCT) is based on the selective uptake of certain boron non-radioactive compounds by a tumor, and the subsequent irradiation of the area with an appropriate neutron beam. {sup 10}B is then activated to {sup 11}B, which will immediately decay releasing alpha particles and {sup 7}Li, of high linear energy transfer (LET) and limited reach. Clinical trials are being performed in patients with glioblastoma multiform and melanoma. We have explored its possible application to UTC. Our results demonstrated that a cell line of human UTC has a selective uptake of borophenylalanine (BPA) both in vitro and after transplantation to nude mice. Treatment of mice by BNCT led to a complete control of growth and cure of 100% of the animals. Moreover dogs with spontaneous UTC also have a selective uptake of BPA. At the present we are studying the biodistribution of BPA in patients with UTC before its application in humans. (author)

Dose prescription in boron neutron capture therapy

International Nuclear Information System (INIS)

Gupta, N.M.S.; Gahbauer, R.A.; Blue, T.E.; Wambersie, A.

1994-01-01

The purpose of this paper is to address some aspects of the many considerations that need to go into a dose prescription in boron neutron capture therapy (BNCT) for brain tumors; and to describe some methods to incorporate knowledge from animal studies and other experiments into the process of dose prescription. Previously, an algorithm to estimate the normal tissue tolerance to mixed high and low linear energy transfer radiations in BNCT was proposed. The authors have developed mathematical formulations and computational methods to represent this algorithm. Generalized models to fit the central axis dose rate components for an epithermal neutron field were also developed. These formulations and beam fitting models were programmed into spreadsheets to simulate two treatment techniques which are expected to be used in BNCT: a two-field bilateral scheme and a single-field treatment scheme. Parameters in these spreadsheets can be varied to represent the fractionation scheme used, the 10 B microdistribution in normal tissue, and the ratio of 10 B in tumor to normal tissue. Most of these factors have to be determined for a given neutron field and 10 B compound combination from large animal studies. The spreadsheets have been programmed to integrate all of the treatment-related information and calculate the location along the central axis where the normal tissue tolerance is exceeded first. This information is then used to compute the maximum treatment time allowable and the maximum tumor dose that may be delivered for a given BNCT treatment. The effect of different treatment variables on the treatment time and tumor dose has been shown to be very significant. It has also been shown that the location of D max shifts significantly, depending on some of the treatment variables-mainly the fractionation scheme used. These results further emphasize the fact that dose prescription in BNCT is very complicated and nonintuitive. 11 refs., 6 figs., 3 tabs

Collaborative Physical and Biological Dosimetry Studies for Neutron Capture Therapy at the RA-1 Research Reactor Facility

Energy Technology Data Exchange (ETDEWEB)

David W. Nigg; Amanda E. Schwint; John K. Hartwell; Elisa M. Heber; Veronica Trivillin; Jorge Castillo; Luis Wentzeis; Patrick Sloan; Charles A. Wemple

2004-10-01

Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminiscent dosimeters to characterize the BNCT irradiation facility developed at the RA-1 research reactor operated by the Argentine National Atomic Energy Commission in Buenos Aires. Some biological scoping irradiations have also been completed using a small-animal (hamster) oral mucosa tumor model. Results indicate that the RA-1 neutron source produces useful dose rates but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications.

Collaborative Physical and Biological Dosimetry Studies for Neutron Capture Therapy at the RA-1 Research Reactor Facility

Energy Technology Data Exchange (ETDEWEB)

Nigg, D.W.; Schwint, A.E.; Hartwell, J.K.; Heber, E.M.; Trivillin, V.; Castillo, J.; Wentzeis, L.; Sloan, P.; Wemple, C.A.

2004-10-04

Initial physical dosimetry measurements have been completed using activation spectrometry and thermoluminiscent dosimeters to characterize the BNCT irradiation facility developed at the RA-1 research reactor operated by the Argentine National Atomic Energy Commission in Buenos Aires. Some biological scoping irradiations have also been completed using a small-animal (hamster) oral mucosa tumor model. Results indicate that the RA-1 neutron source produces useful dose rates but that some improvements in the initial configuration will be needed to optimize the spectrum for thermal-neutron BNCT research applications.

Gadolinium neutron capture therapy for brain tumors. Biological aspects

International Nuclear Information System (INIS)

Takagaki, Masao; Oda, Yoshifumi; Matsumoto, Masato; Kikuchi, Haruhiko; Kobayashi, Tooru; Kanda, Keiji; Ujeno, Yowri.

1994-01-01

This study investigated the tumoricidal effect of gadolinium neutron capture therapy (Gd-NCT) in in vitro and in vivo systems using Gd-DTPA. In in vitro study, a certain amount of Gd-DTPA, yielding 5000 ppm Gd-n, was added to human glioma cells, T98G, upon which thermal neutrons were exposed. After irradiation, the cells were incubated and the colonies were counted 10 days later. In in vivo study, Fisher-344 rats with experimentally induced gliosarcoma cells (9L) were exposed to thermal neutrons at a fluence rate of 3E+9/s for 1 h immediately after iv injection of Gd-DTPA. Two weeks after irradiation, brain samples were histologically examined. Tumor clearance of Gd-DTPA was also determined. In vitro analysis showed that a 1% survival level was obtained at 3.75E+12 (n/cm 2 ) for the Gd (+) medium and 2.50E+13 (n/cm 2 ) for the Gd (-) medium. In in vivo analysis, the concentration of Gd in 9L-rat brain tumor after iv injection of 0.2 mg/kg Gd-DTPA was found to be less than 100 ppm, but Gd-NCT on 9L-rat brain tumor administered with a ten-fold dose showed a substantial killing effect on tumor without serious injury to the normal brain structure. The killing effect of Gd-NCT was confirmed in in vitro and in vivo systems. (N.K.)

Demonstration of a high-intensity neutron source based on a liquid-lithium target for Accelerator based Boron Neutron Capture Therapy.

Science.gov (United States)

Halfon, S; Arenshtam, A; Kijel, D; Paul, M; Weissman, L; Berkovits, D; Eliyahu, I; Feinberg, G; Kreisel, A; Mardor, I; Shimel, G; Shor, A; Silverman, I; Tessler, M

2015-12-01

A free surface liquid-lithium jet target is operating routinely at Soreq Applied Research Accelerator Facility (SARAF), bombarded with a ~1.91 MeV, ~1.2 mA continuous-wave narrow proton beam. The experiments demonstrate the liquid lithium target (LiLiT) capability to constitute an intense source of epithermal neutrons, for Accelerator based Boron Neutron Capture Therapy (BNCT). The target dissipates extremely high ion beam power densities (>3 kW/cm(2), >0.5 MW/cm(3)) for long periods of time, while maintaining stable conditions and localized residual activity. LiLiT generates ~3×10(10) n/s, which is more than one order of magnitude larger than conventional (7)Li(p,n)-based near threshold neutron sources. A shield and moderator assembly for BNCT, with LiLiT irradiated with protons at 1.91 MeV, was designed based on Monte Carlo (MCNP) simulations of BNCT-doses produced in a phantom. According to these simulations it was found that a ~15 mA near threshold proton current will apply the therapeutic doses in ~1h treatment duration. According to our present results, such high current beams can be dissipated in a liquid-lithium target, hence the target design is readily applicable for accelerator-based BNCT. Copyright © 2015 Elsevier Ltd. All rights reserved.

The Clatterbridge high-energy neutron therapy facility: specification and performance

International Nuclear Information System (INIS)

Bonnett, D.E.; Blake, S.W.; Shaw, J.E.; Bewley, D.K.

1988-01-01

A high energy neutron therapy facility has been installed at the Douglas Cyclotron Centre, Clatterbridge Hospital Merseyside, to extend M.R.C. clinical trials of fast neutrons. The neutron beam is produced by bombarding a beryllium target with 62 MeV protons. The target is isocentrically mounted with potential for 360 0 rotation, with a fully variable collimator, giving a range of rectilinear field sizes from 5 cm x 5 cm to 30 cm x 30 cm. Basic neutron beam data including output, field flatness, penumbra and depth-dose data have been measured. For a 10 cm x 10 cm field, 50% depth dose occurs at 16.2 cm in water and output is 1.63 cGy μ A -1 min -1 at maximum dose depth. Effectiveness of the target shielding and neutron-induced radioactivity in the treatment head were also measured. It is concluded that the equipment meets design specifications and fully satisfies criticisms of earlier neutron therapy equipment. A full radiation survey showed that radiation levels present no significant staff hazard. (UK)

The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

Energy Technology Data Exchange (ETDEWEB)

Hampel, G.; Grunewald, C.; Schutz, C.; Schmitz, T.; Kratz, J.V. [Nuclear Chemistry, University of Mainz, D-55099 Mainz (Germany); Brochhausen, C.; Kirkpatrick, J. [Department of Pathology, University of Mainz, D-55099 Mainz (Germany); Bortulussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Kudejova, P. [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Appelman, K.; Moss, R. [Joint Research Centre (JRC) of the European Commission, NL-1755 ZG Petten (Netherlands); Bassler, N. [University of Aarhus, Norde Ringade, DK-8000, Aarhus C (Denmark); Blaickner, M.; Ziegner, M. [Molecular Medicine, Health and Environment Department, AIT Austrian Institute of Technology GmbH (Austria); Sharpe, P.; Palmans, H. [National Physical Laboratory, Teddington TW11 0LW, Middlesex (United Kingdom); Otto, G. [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, D-55099 Mainz (Germany)

2011-07-01

The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed in Pavia (Italy) a few years ago, where patients with liver metastases were treated by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and the treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appears to be an appropriate dosimetry technique. (author)

Drug delivery system design and development for boron neutron capture therapy on cancer treatment

International Nuclear Information System (INIS)

Sherlock Huang, Lin-Chiang; Hsieh, Wen-Yuan; Chen, Jiun-Yu; Huang, Su-Chin; Chen, Jen-Kun; Hsu, Ming-Hua

2014-01-01

We have already synthesized a boron-containing polymeric micellar drug delivery system for boron neutron capture therapy (BNCT). The synthesized diblock copolymer, boron-terminated copolymers (Bpin-PLA-PEOz), consisted of biodegradable poly(D,L-lactide) (PLA) block and water-soluble polyelectrolyte poly(2-ethyl-2-oxazoline) (PEOz) block, and a cap of pinacol boronate ester (Bpin). In this study, we have demonstrated that synthesized Bpin-PLA-PEOz micelle has great potential to be boron drug delivery system with preliminary evaluation of biocompatibility and boron content. - Highlights: • Herein, we have synthesized boron-modified diblock copolymer. • Bpin-PLA-PEOz, which will be served as new boron containing vehicle for transporting the boron drug. • This boron containing Bpin-PLA-PEOz micelle was low toxicity can be applied to drug delivery

Optimization study for an epithermal neutron beam for boron neutron capture therapy at the University of Virginia Research Reactor

International Nuclear Information System (INIS)

Burns, T.D. Jr.

1995-05-01

The non-surgical brain cancer treatment modality, Boron Neutron Capture Therapy (BNCT), requires the use of an epithermal neutron beam. This purpose of this thesis was to design an epithermal neutron beam at the University of Virginia Research Reactor (UVAR) suitable for BNCT applications. A suitable epithermal neutron beam for BNCT must have minimal fast neutron and gamma radiation contamination, and yet retain an appreciable intensity. The low power of the UVAR core makes reaching a balance between beam quality and intensity a very challenging design endeavor. The MCNP monte carlo neutron transport code was used to develop an equivalent core radiation source, and to perform the subsequent neutron transport calculations necessary for beam model analysis and development. The code accuracy was validated by benchmarking output against experimental criticality measurements. An epithermal beam was designed for the UVAR, with performance characteristics comparable to beams at facilities with cores of higher power. The epithermal neutron intensity of this beam is 2.2 x 10 8 n/cm 2 · s. The fast neutron and gamma radiation KERMA factors are 10 x 10 -11 cGy·cm 2 /n epi and 20 x 10 -11 cGy·cm 2 /n epi , respectively, and the current-to-flux ratio is 0.85. This thesis has shown that the UVAR has the capability to provide BNCT treatments, however the performance characteristics of the final beam of this study were limited by the low core power

MCNP speed advances for boron neutron capture therapy

International Nuclear Information System (INIS)

Goorley, J.T.; McKinney, G.; Adams, K.; Estes, G.

1998-04-01

The Boron Neutron Capture Therapy (BNCT) treatment planning process of the Beth Israel Deaconess Medical Center-M.I.T team relies on MCNP to determine dose rates in the subject's head for various beam orientations. In this time consuming computational process, four or five potential beams are investigated. Of these, one or two final beams are selected and thoroughly evaluated. Recent advances greatly decreased the time needed to do these MCNP calculations. Two modifications to the new MCNP4B source code, lattice tally and tracking enhancements, reduced the wall-clock run times of a typical one million source neutrons run to one hour twenty five minutes on a 200 MHz Pentium Pro computer running Linux and using the GNU FORTRAN compiler. Previously these jobs used a special version of MCNP4AB created by Everett Redmond, which completed in two hours two minutes. In addition to this 30% speedup, the MCNP4B version was adapted for use with Parallel Virtual Machine (PVM) on personal computers running the Linux operating system. MCNP, using PVM, can be run on multiple computers simultaneously, offering a factor of speedup roughly the same as the number of computers used. With two 200 MHz Pentium Pro machines, the run time was reduced to forty five minutes, a 1.9 factor of improvement over the single Linux computer. While the time of a single run was greatly reduced, the advantages associated with PVM derive from using computational power not already used. Four possible beams, currently requiring four separate runs, could be run faster when each is individually run on a single machine under Windows NT, rather than using Linux and PVM to run one after another with each multiprocessed across four computers. It would be advantageous, however, to use PVM to distribute the final two beam orientations over four computers

BCI and FES Based Therapy for Stroke Rehabilitation Using VR Facilities

Directory of Open Access Journals (Sweden)

Robert Gabriel Lupu

2018-01-01

Full Text Available In recent years, the assistive technologies and stroke rehabilitation methods have been empowered by the use of virtual reality environments and the facilities offered by brain computer interface systems and functional electrical stimulators. In this paper, a therapy system for stroke rehabilitation based on these revolutionary techniques is presented. Using a virtual reality Oculus Rift device, the proposed system ushers the patient in a virtual scenario where a virtual therapist coordinates the exercises aimed at restoring brain function. The electrical stimulator helps the patient to perform rehabilitation exercises and the brain computer interface system and an electrooculography device are used to determine if the exercises are executed properly. Laboratory tests on healthy people led to system validation from technical point of view. The clinical tests are in progress, but the preliminary results of the clinical tests have highlighted the good satisfaction degree of patients, the quick accommodation with the proposed therapy, and rapid progress for each user rehabilitation.

Monte Carlo calculations of lung dose in ORNL phantom for boron neutron capture therapy

International Nuclear Information System (INIS)

Krstic, D.; Markovic, V.M.; Jovanovic, Z.; Milenkovic, B.; Nikezic, D.; Atanackovic, J.

2014-01-01

Monte Carlo simulations were performed to evaluate dose for possible treatment of cancers by boron neutron capture therapy (BNCT). The computational model of male Oak Ridge National Laboratory (ORNL) phantom was used to simulate tumours in the lung. Calculations have been performed by means of the MCNP5/X code. In this simulation, two opposite neutron beams were considered, in order to obtain uniform neutron flux distribution inside the lung. The obtained results indicate that the lung cancer could be treated by BNCT under the assumptions of calculations. The difference in evaluated dose in cancer and normal lung tissue suggests that BNCT could be applied for the treatment of cancers. The difference in exposure of cancer and healthy tissue can be observed, so the healthy tissue can be spared from damage. An absorbed dose ratio of metastatic tissue-to-the healthy tissue was ∼5. Absorbed dose to all other organs was low when compared with the lung dose. Absorbed dose depth distribution shows that BNC therapy can be very useful in the treatments for tumour. The ratio of the tumour absorbed dose and irradiated healthy tissue absorbed dose was also ∼5. It was seen that an elliptical neutron field was better irradiation choice. (authors)

Boron neutron capture therapy for recurrent head and neck malignancies

International Nuclear Information System (INIS)

Kato, Itsuro; Ono, Koji; Sakurai, Yoshinori

2006-01-01

To avoid severe impairment of oro-facial structures and functions, it is necessary to explore new treatments for recurrent head and neck malignancies (HNM). Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle. So far for 4 years and 3 months, we have treated with 37 times of BNCT for 21 patients (14 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and 3 sarcomas) with a recurrent and far advanced HNM since 2001. Results are (1) 10 B concentration of tumor/normal tissue ratio (T/N ratio) of FBPA-PET studies were SCC: 1.8-5.7, sarcoma: 2.5-4.0, parotid tumor: 2.5-3.7. (2) Therapeutic effects were CR: 6cases, PR: 11cases, PD: 3cases NE (not evaluated): 1case. Response rate was 81%. (3) Improvement of QOL such as a relief of severe pain, bleeding, and exudates at the local lesion, improvement of PS, disappearance of ulceration, covered with normal skin and preserved oral and maxillofacial functions and tissues. (4) Survival periods after BNCT were 1-51 months (mean: 9.8 months). 4-year survival rate was 39% by Kaplan-Meier analysis. (5) A few adverse-effects such as transient mucositis, alopecia were recognized. These results indicate that BNCT represents a new and promising treatment approach for advanced HNM. (author)

Boron neutron capture therapy for children with malignant brain tumor

International Nuclear Information System (INIS)

Nakagawa, Yoshinobu; Komatsu, Hisao; Kageji, Teruyoshi; Tsuji, Fumio; Matsumoto, Keizo; Kitamura, Katsuji; Hatanaka, Hiroshi; Minobe, Takashi.

1993-01-01

Among the 131 cases with brain tumors treated by boron-neutron capture therapy (BNCT), seventeen were children. Eight supratentorial tumors included five astrocytomas(grade 2-4), two primitive neuroectodermal tumors (PNET) and one rhabdomyosarcoma. Seven pontine tumors included one astrocytoma, one PNET and 5 unverified gliomas. Two cerebellar tumors (PNET and astrocytoma) were also treated. All pontine tumors showed remarkable decrease in size after BNCT. However, most of them showed regrowth of the tumors because the neutrons were insufficient due to the depth. Four cases with cerebral tumor died of remote cell dissemination, although they all responded to BNCT. One of them survived 7 years after repeated BNCTs. An 11 years old girl with a large astrocytoma in the right frontal lobe has lived more than 11 years and is now a draftswoman at a civil engineering company after graduating from a technical college. An 8 years old girl with an astrocytoma in the left occipital lobe has no recurrence of the tumor for 2 years and attends on elementary school without mental and physical problems. Two children (one year old girl and four years old boy) with cerebellar tumors have shown showed an excellent growth after BNCT and had no neurological deficits. Mental and physical development in patients treated by BNCT is usually better than that in patients treated by conventional radiotherapy. (author)

In vitro and in vivo studies in boron neutron capture therapy of malignant melanoma

International Nuclear Information System (INIS)

Allen, B.J.

1982-01-01

A multidisciplinary research project in boron neutron capture therapy of malignant melanoma is under consideration by the Australian Atomic Energy Commission. This paper reviews the biochemistry of melanoma and the properties of some melanoma-affined radiopharmaceuticals and their boron analogues. Human cell lines are being used for in vitro tests of uptake and incorporation of some of these compounds, and selected lines will then be implanted in nude mice for in vivo distribution studies. The fidelity of human melanoma xenografts in nude mice has been well studied, and results are reviewed in this paper. Boron concentration will be measured directly by plasma arc emission spectroscopy or liquid scintillation counting with 14 C-labelled boron analogues. Track-etch techniques will be used for the microscopic determination of boron in tumor sections. Neutron irradiation and radiobiology experiments are outlined

The BNCT facility at the HFR Petten: Quality assurance for reactor facilities in clinical trials

International Nuclear Information System (INIS)

Moss, R.; Watkins, P.; Vroegindeweij, C.; Stecher-Rasmussen, F.; Huiskamp, R.; Ravensberg, K.; Appelman, K.; Sauerwein, W.; Hideghety, K.; Gabel, D.

2001-01-01

The first clinical trial in Europe of Boron Neutron Capture Therapy (BNCT) for the treatment of glioblastoma was opened in July 1997. The trial is a Phase I study with the principal aim to establish the maximum tolerated radiation dose and the dose limiting toxicity under defined conditions. It is the first time that a clinical application could be realised on a completely multi-national scale. The treatment takes place at the High Flux Reactor (HFR) in Petten, the Netherlands, is operated by an international team of experts under the leadership of a German radiotherapist, and treats patients coming from different European countries. It has therefore been necessary to create a very specialised organisation and contractual structure with the support of administrations from different countries, who had to find and adapt solutions within existing laws that had never foreseen such a situation. Furthermore, the treatment does not take place in an hospital environment and even more so, the facility is at a nuclear research reactor. Hence, special efforts were made on quality assurance, in order that the set-up at the facility and the personnel involved complied, as closely as possible, with similar practices in conventional radiotherapy departments. (author)

Clinical trials of boron neutron capture therapy [in humans] [at Beth Israel Deaconess Medical Center][at Brookhaven National Laboratory

International Nuclear Information System (INIS)

Wallace, Christine

2001-01-01

Assessment of research records of Boron Neutron Capture Therapy was conducted at Brookhaven National Laboratory and Beth Israel Deaconess Medical Center using the Code of Federal Regulations, FDA Regulations and Good Clinical Practice Guidelines. Clinical data were collected FR-om subjects' research charts, and differences in conduct of studies at both centers were examined. Records maintained at Brookhaven National Laboratory were not in compliance with regulatory standards. Beth Israel's records followed federal regulations. Deficiencies discovered at both sites are discussed in the reports

The 236U neutron capture cross-section measured at the n_TOF CERN facility

Directory of Open Access Journals (Sweden)

Mastromarco M.

2017-01-01

Full Text Available The 236U isotope plays an important role in nuclear systems, both for future and currently operating ones. The actual knowledge of the capture reaction of this isotope is satisfactory in the thermal region, but it is considered insufficient for Fast Reactor and ADS applications. For this reason the 236U(n, γ reaction cross-section has been measured for the first time in the whole energy region from thermal energy up to 1 MeV at the n_TOF facility with two different detection systems: an array of C6D6 detectors, employing the total energy deposited method, and a FX1 total absorption calorimeter (TAC, made of 40 BaF2 crystals. The two n_TOF data sets agree with each other within the statistical uncertainty in the Resolved Resonance Region up to 800 eV, while sizable differences (up to ≃ 20% are found relative to the current evaluated data libraries. Moreover two new resonances have been found in the n_TOF data. In the Unresolved Resonance Region up to 200 keV, the n_TOF results show a reasonable agreement with previous measurements and evaluated data.

The Effect of Deep Brain Stimulation Therapy on Fear-Related Capture of Attention in Parkinson's Disease and Essential Tremor: A Comparison to Healthy Individuals.

Science.gov (United States)

Camalier, Corrie R; McHugo, Maureen; Zald, David H; Neimat, Joseph S

2018-01-01

In addition to motor symptoms, Parkinson's disease (PD) involves significant non-motor sequelae, including disruptions in cognitive and emotional processing. Fear recognition appears to be affected both by the course of the disease and by a common interventional therapy, deep brain stimulation of the subthalamic nucleus (STN-DBS). Here, we examined if these effects extend to other aspects of emotional processing, such as attentional capture by negative emotional stimuli. Performance on an emotional attentional blink (EAB) paradigm, a common paradigm used to study emotional capture of attention, was examined in a cohort of individuals with PD, both on and off STN-DBS therapy (n=20). To contrast effects of healthy aging and other movement disorder and DBS targets, we also examined performance in a healthy elderly (n=20) and young (n=18) sample on the same task, and a sample diagnosed with Essential Tremor (ET) undergoing therapeutic deep brain stimulation of the ventral-intermediate nucleus (VIM-DBS, n=18). All four groups showed a robust attentional capture of emotional stimuli, irrespective of aging processes, movement disorder diagnosis, or stimulation. PD patients on average had overall worse performance, but this decrement in performance was not related to the emotional capture of attention. PD patients exhibited a robust EAB, indicating that the ability of emotion to direct attention remains intact in PD. Congruent with other recent data, these findings suggest that fear recognition deficits in PD may instead reflect a highly specific problem in recognition, rather than a general deficit in emotional processing of fearful stimuli.

Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy

Directory of Open Access Journals (Sweden)

Schaffran T

2014-07-01

Full Text Available Tanja Schaffran,1 Nan Jiang,1 Markus Bergmann,2,3 Ekkehard Küstermann,4 Regine Süss,5 Rolf Schubert,5 Franz M Wagner,6 Doaa Awad,7 Detlef Gabel1,2,8 1Department of Chemistry, University of Bremen, 2Institute of Neuropathology, Klinikum Bremen-Mitte; 3Cooperative Center Medicine, University of Bremen, 4“In-vivo-MR” AG, FB2, University of Bremen, Bremen, 5Pharmaceutical Technology, University of Freiburg, Freiburg im Breisgau, 6Forschungsneutronenquelle Heinz Maier-Leibnitz (FRM II, Technische Unversitaet Muenchen, Garching, Germany; 7Department of Biochemistry, Alexandria University, Alexandria, Egypt; 8School of Engineering and Science, Jacobs University Bremen, Bremen, Germany Abstract: The potential of boron-containing lipids with three different structures, which were intended for use in boron neutron capture therapy, was investigated. All three types of boron lipids contained the anionic dodecaborate cluster as the headgroup. Their effects on two different tumor models in mice following intravenous injection were tested; for this, liposomes with boron lipid, distearoyl phosphatidylcholine, and cholesterol as helper lipids, and containing a polyethylene glycol lipid for steric protection, were administered intravenously into tumor-bearing mice (C3H mice for SCCVII squamous cell carcinoma and BALB/c mice for CT26/WT colon carcinoma. With the exception of one lipid (B-THF-14, the lipids were well tolerated, and no other animal was lost due to systemic toxicity. The lipid which led to death was not found to be much more toxic in cell culture than the other boron lipids. All of the lipids that were well tolerated showed hemorrhage in both tumor models within a few hours after administration. The hemorrhage could be seen by in vivo magnetic resonance and histology, and was found to occur within a few hours. The degree of hemorrhage depended on the amount of boron administered and on the tumor model. The observed unwanted effect of the lipids

Boron Neutron Capture Therapy at European research reactors - Status and perspectives

International Nuclear Information System (INIS)

Moss, R.L.

2004-01-01

Over the last decade. there has been a significant revival in the development of Boron Neutron Capture Therapy (BNCT) as a treatment modality for curing cancerous tumours, especially glioblastoma multiforme and subcutaneous malignant melanoma. In 1987 a European Collaboration on BNCT was formed, with the prime task to identify suitable research reactors in Europe where BNCT could be applied. Due to reasons discussed in this paper, the HFR Petten was chosen as the test-bed for demonstrating BNCT. Currently, the European Collaboration is approaching the start of clinical trials, using epithermal neutrons and borocaptate sodium (BSH) as the 10 B delivery agent. The treatment is planned to start in the first half of 1996. The paper here presents an overview on the principle of BNCT, the requirements imposed on a research reactor in order to be considered for BNCT, and the perspectives for other European materials testing reactors. A brief summary on the current status of the work at Petten is given, including: the design, construction and characterisation of the epithermal neutron beam: performance and results of the healthy tissue tolerance study; the development of a treatment planning programme based on the Monte Carlo code MCNP; the design of an irradiation room; and on the clinical trials themselves. (author)

Early effects of boron neutron capture therapy on rat glioma models

International Nuclear Information System (INIS)

Nakagawa, N.; Akai, F.; Fukawa, N.; Taneda, M.; Ono, K.; Suzuki, M.

2006-01-01

Early effects of boron neutron capture therapy on malignant gliomas are characterized by reduction of the enhanced area regression of the peritumoral edema radiologically. The aim of this study is to investigate the early histological changes of tumors and inflammatory cells after BNCT in the rat brain. The rats were treated with BNCT using boronophenyialanine (BPA) 7 days after implantation of C6 glioma cells. The tumors were assessed their sizes and configurations with magnetic resonance imaging, then killed 4 days after BNCT. The mean tumor volumes were 39mm 3 in BNCT-treated group, and 138 mm 3 in the control group. In the histological examination, tumors of the BNCT group showed less pleomorphic appearance with atypical nuclei and mitotic figures, compared with the control group. Necrosis and edematous changes in the neuropile were negligible. There existed remnant tumors adjacent to the lateral ventricle. The reactions of the inflammatory cells were examined with ED-1 of macrophage marker. ED-1 positive cells and their processes were reduced in the marginal area of tumor in the BNCT group. BNCT reduce the tumor progression by suppression of the proliferation. Inhibition of the activated macrophages may reduce peritumoral edema in early phase. (author)

Development of reference problems for neutron capture therapy treatment planning systems

International Nuclear Information System (INIS)

Albritton, J.R.; Kiger, W.S. III

2006-01-01

Currently, 5 different treatment planning systems (TPSs) are or have been used in clinical trials of Neutron Capture Therapy (NCT): MacNCTPlan, NCTPlan, BNCT Rtpe, SERA, and JCDS. This paper describes work performed to comprehensively test and compare 4 of these NCT treatment planning systems in order to facilitate the pooling of patient data from the different clinical sites for analysis of the clinical results as well as to provide an important quality assurance tool for existing and future TPSs. Two different phantoms were used to evaluate the planning systems: the modified Snyder head phantom and a large water-filled box, similar to that used in the International Dosimetry Exchange for NCT. The comparison of the resulting dose profile, isodose contours, and dose volume histograms to reference calculations performed with the Monte Carlo radiation transport code MCNP5 yielded many interesting differences. Each of the planning systems deviated from the reference calculations, with the newer systems (i.e., SERA and NCTPlan) most often yielding better agreement than their predecessors (i.e., BNCT Rtpe and MacNCTPlan). The combination of simple phantoms and sources with more complicated and realistic planning conditions has produced a well-rounded and useful suite of test problems for NCT treatment planning system analysis. (author)

Subtask 2.18 - Advancing CO₂ Capture Technology: Partnership for CO₂ Capture (PCO₂C) Phase III

Energy Technology Data Exchange (ETDEWEB)

Kay, John; Azenkeng, Alexander; Fiala, Nathan; Jensen, Melanie; Laumb, Jason; Leroux, Kerryanne; McCollor, Donald; Stanislowski, Joshua; Tolbert, Scott; Curran, Tyler

2016-03-31

Industries and utilities continue to investigate ways to decrease their carbon footprint. Carbon capture and storage (CCS) can enable existing power generation facilities to meet the current national CO₂ reduction goals. The Partnership for CO2 Capture Phase III focused on several important research areas in an effort to find ways to decrease the cost of capture across both precombustion and postcombustion platforms. Two flue gas pretreatment technologies for postcombustion capture, an SO₂ reduction scrubbing technology from Cansolv Technologies Inc. and the Tri-Mer filtration technology that combines particulate, NOx, and SO₂ control, were evaluated on the Energy & Environmental Research Center’s (EERC’s) pilot-scale test system. Pretreating the flue gas should enable more efficient, and therefore less expensive, CO₂ capture. Both technologies were found to be effective in pretreating flue gas prior to CO₂ capture. Two new postcombustion capture solvents were tested, one from the Korea Carbon Capture and Sequestration R&D Center (KCRC) and one from CO₂ Solutions Incorporated. Both of these solvents showed the ability to capture CO₂ while requiring less regeneration energy, which would reduce the cost of capture. Hydrogen separation membranes from Commonwealth Scientific and Industrial Research Organisation were evaluated through precombustion testing. They are composed of vanadium alloy, which is less expensive than the palladium alloys that are typically used. Their performance was comparable to that of other membranes that have been tested at the EERC. Aspen Plus® software was used to model the KCRC and CO₂ Solutions solvents and found that they would result in significantly improved overall plant performance. The modeling effort also showed that the parasitic steam load at partial capture of 45% is less than half that of 90% overall capture, indicating savings that

Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

International Nuclear Information System (INIS)

Capala, J.; Diaz, A.Z.; Chadha, M.

1997-01-01

The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains

Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

Energy Technology Data Exchange (ETDEWEB)

Capala, J. [Brookhaven National Lab., Upton, NY (United States); Diaz, A.Z.; Chadha, M. [Univ. Hospital, State Univ. of New York, NY (United States)] [and others

1997-12-31

The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains.

Study on high speed lithium jet for neutron source of boron neutron capture therapy (BNCT)

International Nuclear Information System (INIS)

Takahashi, Minoru; Kobayashi, Tooru; Zhang, Mingguang; Mak, Michael; Stefanica, Jiri; Dostal, Vaclav; Zhao Wei

2012-01-01

The feasibility study of a liquid lithium type proton beam target was performed for the neutron source of the boron neutron capture therapy (BNCT). As the candidates of the liquid lithium target, a thin sheet jet and a thin film flow on a concave wall were chosen, and a lithium flow experiment was conducted to investigate the hydrodynamic stability of the targets. The surfaces of the jets and film flows with a thickness of 0.5 mm and a width of 50 mm were observed by means of photography. It has been found that a stable sheet jet and a stable film flow on a concave wall can be formed up to certain velocities by using a straight nozzle and a curved nozzle with the concave wall, respectively. (author)

Boron neutron capture therapy: An interdisciplinary co-operation

International Nuclear Information System (INIS)

Sauerwein, W.; Hideghety, K.; Rassow, J.; Moss, R.L.; Stecher-Rasmussen, F.; Heimans, J.; Gabel, D.; Vries, M.J. de; Touw, D.J.

2001-01-01

The international (European) undertaking in BNCT in the Netherlands has required close scrutiny of the organisational structure required to establish BNCT facilities. The multidisciplinary co-operation and the tasks of the participants in the hospital (Radiation Oncologist, Medical Physicist, Pharmacist and other medical and paramedical staff) and those attached to the reactor) are described. The organisational structure and regulatory aspects required for the international functioning of the Petten treatment facility are provided for guidance to new projects in this field. (author)

Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer

International Nuclear Information System (INIS)

Lim, Diana; Quah, Daniel SC; Leech, Michelle; Marignol, Laure

2015-01-01

This review compares the safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of previously irradiated, inoperable locoregional recurrent HNC patients and compares BNCT against the standard treatment of platinum-based chemotherapy. Our analysis of published clinical trials highlights efficacy of BNCT associated with mild side effects. However, the use of BNCT should be explored in stratified randomised trials. - Highlights: • BNCT can prolong median overall survival. • BNCT can be associated with severe adverse effects. • BNCT may be comparable to chemotherapy-based regimens. • BNCT may be comparable to re-irradiation techniques regimens in patients with low performance status.

Factors affecting post-capture survivability of lobster Homarus americanus.

Science.gov (United States)

Basti, David; Bricknell, Ian; Hoyt, Ken; Chang, Ernest S; Halteman, William; Bouchard, Deborah

2010-06-11

Technological advances in gear and fishing practices have driven the global expansion of the American lobster live seafood market. These changes have had a positive effect on the lobster industry by increasing capture efficiency. However, it is unknown what effect these improved methods will have on the post-capture fitness and survival of lobsters. This project utilized a repeated measures design to compare the physiological changes that occur in lobsters over time as the result of differences in depth, hauling rate, and storage methodology. The results indicate that lobsters destined for long distance transport or temporary storage in pounds undergo physiological disturbance as part of the capture process. These changes are significant over time for total hemocyte counts, crustacean hyperglycemic hormone, L-lactate, ammonia, and glucose. Repeated measures multivariate analysis of variance (MANOVA) for glucose indicates a significant interaction between depth and storage methodology over time for non-survivors. A Gram-negative bacterium, Photobacterium indicum, was identified in pure culture from hemolymph samples of 100% of weak lobsters. Histopathology revealed the presence of Gram-negative bacteria throughout the tissues with evidence of antemortem edema and necrosis suggestive of septicemia. On the basis of these findings, we recommend to the lobster industry that if a reduction in depth and hauling rate is not economically feasible, fishermen should take particular care in handling lobsters and provide them with a recovery period in recirculating seawater prior to land transport. The ecological role of P. indicum is not fully defined at this time. However, it may be an emerging opportunistic pathogen of stressed lobsters. Judicious preemptive antibiotic therapy may be necessary to reduce mortality in susceptible lobsters destined for high-density holding facilities.

Recoil separators for radiative capture using radioactive ion beams. Recent advances and detection techniques

Energy Technology Data Exchange (ETDEWEB)

Ruiz, Chris [TRIUMF, Vancouver, BC (Canada); Greife, Uwe; Hager, Ulrike [Colorado School of Mines, Golden, CO (United States)

2014-06-15

Radiative capture reactions involving the fusion of hydrogen or helium are ubiquitous in the stellar history of the universe, and are some of the most important reactions in the processes that govern nucleosynthesis and energy generation in both static and explosive scenarios. However, radiative capture reactions pose some of the most difficult experimental challenges due to extremely small cross sections. With the advent of recoil separators and techniques in inverse kinematics, it is now possible to measure radiative capture reactions on very short-lived radioactive nuclei, and in the presence of high experimental backgrounds. In this paper we review the experimental needs for making measurements of astrophysical importance on radiative capture reactions. We also review some of the important historical advances in the field of recoil separators as well as describe current techniques and performance milestones, including descriptions of some of the separators most recently working at radioactive ion beam facilities, such as DRAGON at TRIUMF and the DRS at the Holifield Radioactive Ion Beam Facility. We will also summarize some of the scientific highlight measurements at the RIB facilities. (orig.)

A theoretical model for the production of Ac-225 for cancer therapy by neutron capture transmutation of Ra-226.

Science.gov (United States)

Melville, G; Melville, P

2013-02-01

Radium needles that were once implanted into tumours as a cancer treatment are now obsolete and constitute a radioactive waste problem, as their half-life is 1600 years. We are investigating the reduction of radium by transmutation by bombarding Ra-226 with high-energy neutrons from a neutron source to produce Ra-225 and hence Ac-225, which can be used as a generator to produce Bi-213 for use in 'Targeted Alpha Therapy' for cancer. This paper examines the possibility of producing Ac-225 by neutron capture using a theoretical model in which neutron energy is convoluted with the corresponding neutron cross sections of Ra-226. The total integrated yield can then be obtained. This study shows that an intense beam of high-energy neutrons could initiate neutron capture on Ra-226 to produce Ra-225 and hence practical amounts of Ac-225 and a useful reduction of Ra-226. Copyright © 2012 Elsevier Ltd. All rights reserved.

Molecular Medicine: Synthesis and In Vivo Detection of Agents for use in Boron Neutron Capture Therapy. Final Report

Energy Technology Data Exchange (ETDEWEB)

Kabalka, G. W.

2005-06-28

The primary objective of the project was the development of in vivo methods for the detection and evaluation of tumors in humans. The project was focused on utilizing positron emission tomography (PET) to monitor the distribution and pharamacokinetics of a current boron neutron capture therapy (BNCT) agent, p-boronophenylalanine (BPA) by labeling it with a fluorine-18, a positron emitting isotope. The PET data was then used to develop enhanced treatment planning protocols. The study also involved the synthesis of new tumor selective BNCTagents that could be labeled with radioactive nuclides for the in vivo detection of boron.

Molecular Medicine: Synthesis and In Vivo Detection of Agents for use in Boron Neutron Capture Therapy. Final Report

International Nuclear Information System (INIS)

Kabalka, G. W.

2005-01-01

The primary objective of the project was the development of in vivo methods for the detection and evaluation of tumors in humans. The project was focused on utilizing positron emission tomography (PET) to monitor the distribution and pharmacokinetics of a current boron neutron capture therapy (BNCT) agent, p-boronophenylalanine (BPA) by labeling it with a fluorine-18, a positron emitting isotope. The PET data was then used to develop enhanced treatment planning protocols. The study also involved the synthesis of new tumor selective BNCT agents that could be labeled with radioactive nuclides for the in vivo detection of boron

Development and in vitro testing of liposomal gadolinium-formulations for neutron capture therapy of glioblastoma multiforme

International Nuclear Information System (INIS)

Peters, Tanja

2013-01-01

For the improvement of current neutron capture therapy, several liposomal formulations of neutron capture agent gadolinium were developed and tested in a glioma cell model. Formulations were analyzed regarding physicochemical and biological parameters, such as size, zeta potential, uptake into cancer cells and performance under neutron irradiation. The neutron and photon dose derived from intracellular as well as extracellular Gd was calculated via Monte Carlo simulations and set in correlation with the reduction of cell survival after irradiation. To investigate the suitability of Gd as a radiosensitizer for photon radiation, cells were also irradiated with synchrotron radiation in addition to clinically used photons generated by linear accelerator. Irradiation with neutrons led to significantly lower survival for Gd-liposome-treated F98 and LN229 cells, compared to irradiated control cells and cells treated with non-liposomal Gd-DTPA. Correlation between Gd-content and -dose and respective cell survival displayed proportional relationship for most of the applied formulations. Photon irradiation experiments showed the proof-of-principle for the radiosensitizer approach, although the photon spectra currently used have to be optimized for higher efficiency of the radiosensitizer. In conclusion, the newly developed Gd-liposomes show great potential for the improvement of radiation treatment options for highly malignant glioblastoma.

Dosimetry and stability studies of the boron neutron capture therapy agent F-BPA-Fr using PET and MRI

Science.gov (United States)

Dyke, Jonathan Paul

The treatment of deep seated brain tumors such as glioblastoma Multiforme has been unsuccessful for many patients. Surgical debulking, chemotherapy and standard radiotherapy have met with limited success. Boron neutron capture therapy offers a binary mode brachytherapy based on the following capture reaction that may provide an innovative alternative to standard forms of treatment:10B + n /to/ 11B /to 7Li + 4He + 2.31 MeVBoron is chemically attached to a tumor binding compound creating a non-toxic neutron absorber. A dose of epithermal neutrons provides the catalyst to produce the lithium and alpha particles which destroy any tissue within a length of one cell diameter from the boron compound. This dissertation uses 19F-MRI and 18F-PET to provide answers to the localization and biodistribution questions that arise in such a treatment modality. Practical patient dosimetry and actual treatment planning using the PET data is also examined. Finally, theoretical work done in the areas of compartmental modelling dealing with pharmacokinetic uptake of the PET radiotracer and dose analysis in microdosimetry is also presented.

Boron neutron capture therapy of intracerebral rat gliosarcomas

International Nuclear Information System (INIS)

Joel, D.D.; Fairchild, R.G.; Laissue, J.A.; Saraf, S.K.; Kalef-Ezra, J.A.; Slatkin, D.N.

1990-01-01

The efficacy of boron neutron capture therapy (BNCT) for the treatment of intracerebrally implanted rat gliosarcomas was tested. Preferential accumulation of 10B in tumors was achieved by continuous infusion of the sulfhydryl borane dimer, Na4(10)B24H22S2, at a rate of 45-50 micrograms of 10B per g of body weight per day from day 11 to day 14 after tumor initiation (day 0). This infusion schedule resulted in average blood 10B concentrations of 35 micrograms/ml in a group of 12 gliosarcoma-bearing rats and 45 micrograms/ml in a group of 10 similar gliosarcoma-bearing rats treated by BNCT. Estimated tumor 10B levels in these two groups were 26 and 34 micrograms/g, respectively. On day 14, boron-treated and non-boron-treated rats were exposed to 5.0 or 7.5 MW.min of radiation from the Brookhaven Medical Research Reactor that yielded thermal neutron fluences of approximately 2.0 x 10(12) or approximately 3.0 x 10(12) n/cm2, respectively, in the tumors. Untreated rats had a median postinitiation survival time of 21 days. Reactor radiation alone increased median postinitiation survival time to 26 (5.0 MW.min) or 28 (7.5 MW.min) days. The 12 rats that received 5 MW.min of BNCT had a median postinitiation survival time of 60 days. Two of these animals survived greater than 15 months. In the 7.5 MW.min group, the median survival time is not calculable since 6 of the 10 animals remain alive greater than 10 months after BNCT. The estimated radiation doses to tumors in the two BNCT groups were 14.2 and 25.6 Gy equivalents, respectively. Similar gliosarcoma-bearing rats treated with 15.0 or 22.5 Gy of 250-kilovolt peak x-rays had median survival times of only 26 or 31 days, respectively, after tumor initiation

ESR-dosimetry in thermal and epithermal neutron fields for application in boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Schmitz, Tobias

2016-01-22

Dosimetry is essential for every form of radiotherapy. In Boron Neutron Capture Therapy (BNCT) mixed neutron and gamma fields have to be considered. Dose is deposited in different neutron interactions with elements in the penetrated tissue and by gamma particles, which are always part of a neutron field. The therapeutic dose in BNCT is deposited by densely ionising particles, originating from the fragmentation of the isotope boron-10 after capture of a thermal neutron. Despite being investigated for decades, dosimetry in neutron beams or fields for BNCT remains complex, due to the variety in type and energy of the secondary particles. Today usually ionisation chambers combined with metal foils are used. The applied techniques require extensive effort and are time consuming, while the resulting uncertainties remain high. Consequently, the investigation of more effective techniques or alternative dosimeters is an important field of research. In this work the possibilities of ESR-dosimeters in those fields have been investigated. Certain materials, such as alanine, generate stable radicals upon irradiation. Using Electron Spin Resonance (ESR) spectrometry the amount of radicals, which is proportional to absorbed dose, can be quantified. Different ESR detector materials have been irradiated in the thermal neutron field of the research reactor TRIGA research reactor in Mainz, Germany, with five setups, generating different secondary particle spectra. Further irradiations have been conducted in two epithermal neutron beams. The detector response, however, strongly depends on the dose depositing particle type and energy. It is hence necessary to accompany measurements by computational modelling and simulation. In this work the Monte Carlo code FLUKA was used to calculate absorbed doses and dose components. The relative effectiveness (RE), linking absorbed dose and detector response, has been calculated using amorphous track models. For the simulation, detailed models of

Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy.

Science.gov (United States)

Ciofani, Gianni; Raffa, Vittoria; Menciassi, Arianna; Cuschieri, Alfred

2008-11-25

Boron neutron capture therapy (BNCT) is increasingly being used in the treatment of several aggressive cancers, including cerebral glioblastoma multiforme. The main requirement for this therapy is selective targeting of tumor cells by sufficient quantities of (10)B atoms required for their capture/irradiation with low-energy thermal neutrons. The low content of boron targeting species in glioblastoma multiforme accounts for the difficulty in selective targeting of this very malignant cerebral tumor by this radiation modality. In the present study, we have used for the first time boron nitride nanotubes as carriers of boron atoms to overcome this problem and enhance the selective targeting and ablative efficacy of BNCT for these tumors. Following their dispersion in aqueous solution by noncovalent coating with biocompatible poly-l-lysine solutions, boron nitride nanotubes were functionalized with a fluorescent probe (quantum dots) to enable their tracking and with folic acid as selective tumor targeting ligand. Initial in vitro studies have confirmed substantive and selective uptake of these nanovectors by glioblastoma multiforme cells, an observation which confirms their potential clinical application for BNCT therapy for these malignant cerebral tumors.

Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy

Directory of Open Access Journals (Sweden)

Ciofani Gianni

2008-01-01

Full Text Available Abstract Boron neutron capture therapy (BNCT is increasingly being used in the treatment of several aggressive cancers, including cerebral glioblastoma multiforme. The main requirement for this therapy is selective targeting of tumor cells by sufficient quantities of10B atoms required for their capture/irradiation with low-energy thermal neutrons. The low content of boron targeting species in glioblastoma multiforme accounts for the difficulty in selective targeting of this very malignant cerebral tumor by this radiation modality. In the present study, we have used for the first time boron nitride nanotubes as carriers of boron atoms to overcome this problem and enhance the selective targeting and ablative efficacy of BNCT for these tumors. Following their dispersion in aqueous solution by noncovalent coating with biocompatible poly-l-lysine solutions, boron nitride nanotubes were functionalized with a fluorescent probe (quantum dots to enable their tracking and with folic acid as selective tumor targeting ligand. Initial in vitro studies have confirmed substantive and selective uptake of these nanovectors by glioblastoma multiforme cells, an observation which confirms their potential clinical application for BNCT therapy for these malignant cerebral tumors.

A study on the utilization of hyper-thermal neutrons for neutron capture therapy

International Nuclear Information System (INIS)

Sakurai, Yoshinori; Kobayashi, Tooru; Kanda, Keiji

1993-01-01

The utilization of hyper-thermal neutrons, which have an energy spectrum of a Maxwellian distribution of a higher temperature than the room temperature of 300 K, was studied in order to improve the thermal neutron flux distribution at the deeper part in a living body for neutron capture therapy. Simulation calculations were carried out using MCNP-V3 in order to confirm the characteristics of hyper-thermal neutrons, i.e., (1) depth dependence of neutron energy spectrum, and (2) depth distribution of the reaction rate in a water phantom for materials with 1/v neutron absorption. It is confirmed that the hyper-thermal neutron irradiation can improve the thermal neutron flux distribution in the deeper and wider area in a living body compared with the thermal neutron irradiation. Practically, by the incidence of the hyper-thermal neutrons with a 3000 K Maxwellian distribution, the thermal neutron flux at 5 cm depth can be given about four times larger than by the incidence of the thermal neutrons of 300 K. (author)

A sensitive DNA biosensor based on a facile sulfamide coupling reaction for capture probe immobilization

International Nuclear Information System (INIS)

Wang, Qingxiang; Ding, Yingtao; Gao, Feng; Jiang, Shulian; Zhang, Bin; Ni, Jiancong; Gao, Fei

2013-01-01

Graphical abstract: A novel DNA biosensor was fabricated through a facile sulfamide coupling reaction between probe DNA and the sulfonic dye of 1-amino-2-naphthol-4-sulfonic acid that electrodeposited on a glassy carbon electrode. -- Highlights: •A versatile sulfonic dye of ANS was electrodeposited on a GCE. •A DNA biosensor was fabricated based on a facile sulfamide coupling reaction. •High probe DNA density of 3.18 × 10 13 strands cm −2 was determined. •A wide linear range and a low detection limit were obtained. -- Abstract: A novel DNA biosensor was fabricated through a facile sulfamide coupling reaction. First, the versatile sulfonic dye molecule of 1-amino-2-naphthol-4-sulfonate (AN-SO 3 − ) was electrodeposited on the surface of a glassy carbon electrode (GCE) to form a steady and ordered AN-SO 3 − layer. Then the amino-terminated capture probe was covalently grafted to the surface of SO 3 − -AN deposited GCE through the sulfamide coupling reaction between the amino groups in the probe DNA and the sulfonic groups in the AN-SO 3 − . The step-by-step modification process was characterized by electrochemistry and attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy. Using Ru(NH 3 ) 6 3+ as probe, the probe density and the hybridization efficiency of the biosensor were determined to be 3.18 × 10 13 strands cm −2 and 86.5%, respectively. The hybridization performance of the biosensor was examined by differential pulse voltammetry using Co(phen) 3 3+/2+ (phen = 1,10-phenanthroline) as the indicator. The selectivity experiments showed that the biosensor presented distinguishable response after hybridization with the three-base mismatched, non-complementary and complementary sequences. Under the optimal conditions, the oxidation peak currents of Co(phen) 3 3+/2+ increased linearly with the logarithm values of the concentration of the complementary sequences in the range from 1.0 × 10 −13 M to 1.0 × 10 −8 M with

Study of the interaction of boron-containing amino acids for the neutron capture therapy with biologically interesting compounds by using 'three-spot zone electrophoresis'

International Nuclear Information System (INIS)

Kitaoka, Yoshinori; Kobayashi, Mitsue; Morimoto, Tsuguhiro; Kirihata, Mitsunori; Ichimoto, Itsuo.

1995-01-01

As the boron carriers for boron neutron capture therapy, p-borono phenylalanine (BPA) is the boron compound which has been clinically used together with sodium borocaptate. It was found by the electrophoresis behavior that the BPA interacted with organic carboxylic acids in its dissolved state. In this paper, the electrophoresis behavior of general amino acids as seen in three-spot zone electrophoresis and the peculiar interaction of the amino acids having dihydroxyboryl radical are described. Zone electrophoresis has been developed as separation means, and three-spot process excludes the errors due to accidental factors as far as possible. The behaviors of zone electrophoresis of ordinary neutral amino acids, orthoboric acid and p-BPA are reported. For utilizing the features of boron neutron capture therapy, it is necessary to develop the carrier which is singularly taken into cancer cells. There is not a good method for discriminating normal cells and cancer cells. As for the administration of BPA to patients, its solubility is insufficient, therefore, its fructose complex has been used. The research on the biochemical peculiarity of boron is important. (K.I.)

Monte Carlo treatment planning and high-resolution alpha-track autoradiography for neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Zamenhof, R.G.; Lin, K.; Ziegelmiller, D.; Clement, S.; Lui, C.; Harling, O.K.

Monte Carlo simulations of thermal neutron flux distributions in a mathematical head model have been compared to experimental measurements in a corresponding anthropomorphic gelatin-based head phantom irradiated by a thermal neutron beam as presently available at the MITR-II Research Reactor. Excellent agreement between Monte Carlo and experimental measurements has encouraged us to employ the Monte Carlo simulation technique to approach treatment planning problems in neutron capture therapy. We have also implemented a high-resolution alpha-track autoradiography technique originally developed in our laboratory at MIT. Initial autoradiograms produced by this technique meet our expectations in terms of the high resolution available and the ability to etch tracks without concommitant destruction of stained tissue. Our preliminary results with computer-aided track distribution analysis indicate that this approach is very promising in being able to quantify boron distributions in tissue at the subcellular level with a minimum amount of operator effort necessary.

Establishment of optimal thermal neutron capture therapy for 5 types of human malignant melanoma

International Nuclear Information System (INIS)

Mishima, Yutaka

1993-03-01

A series of boron neutron capture therapy (BNCT) studies has already germinated in 1972, with a view to establishing the BNCT particularly suited for the treatment of various types of malignant melanoma, and has been succeeded by research teams comprised of multi-disciplinary members. Twelve patients (7 men and 5 women, aged from 50 to 85 years) with malignant melanoma have been treated with BNCT; among them, six patients were completely cured, four had extremely reduced tumors, and two were still in the clinical process. The present Progress Report is a compilation of 39 research presentations for the recent two years. In this report, three patients are described. Of these, one patient had deep-seated lesions in right and left lymph nodes. These lesions were cured by the use of D 2 O that allowed neutron beams to reach them. Application of positron emission tomography to the diagnosis of melanoma is a highlight in this Report. (N.K.)

Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Ferrari, C. [Department of Surgery, Experimental Surgery Laboratory, University of Pavia, Piazza Botta, Pavia (Italy)], E-mail: ferraric@unipv.it; Zonta, C.; Cansolino, L.; Clerici, A.M.; Gaspari, A. [Department of Surgery, Experimental Surgery Laboratory, University of Pavia, Piazza Botta, Pavia (Italy); Altieri, S.; Bortolussi, S.; Stella, S. [Department of Nuclear and Theoretical Physics of University, Via Bassi, 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi, 6, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics of University, Via Bassi, 6, Pavia (Italy); Dionigi, P.; Zonta, A. [Department of Surgery, Experimental Surgery Laboratory, University of Pavia, Piazza Botta, Pavia (Italy)

2009-07-15

Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone. Current osteosarcoma treatments combine multiagent chemotherapy with extensive surgical resection, which in some cases makes necessary the amputation of the entire limb. Nevertheless its infiltrative growth leads to a high incidence of local and distant recurrences that reduce the percentage of cured patients to less than 60%. These poor data required to set up a new therapeutic approach aimed to restrict the surgical removal meanwhile performing a radical treatment. Boron neutron capture therapy (BNCT), a particular radiotherapy based on the nuclear capture and fission reactions by atoms of {sup 10}B, when irradiated with thermal neutrons, could be a valid alternative or integrative option in case of osteosarcoma management, thanks to its peculiarity in selectively destroying neoplastic cells without damaging normal tissues. Aim of the present work is to investigate the feasibility of employing BNCT to treat the limb osteosarcoma. Boronophenylalanine (BPA) is used to carry {sup 10}B inside the neoplastic cells. As a first step the endocellular BPA uptake is tested in vitro on the UMR-106 osteosarcoma cell line. The results show an adequate accumulation capability. For the in vivo experiments, an animal tumor model is developed in Sprague-Dawley rats by means of an intrafemoral injection of UMR-106 cells at the condyle site. The absolute amounts of boron loading and the tumor to normal tissue {sup 10}B ratio are evaluated 2 h after the i.v. administration of BPA. The boron uptake by the neoplastic tissue is almost twice the normal one. However, higher values of boron concentration in tumor are requested before upholding BNCT as a valid therapeutic option in the treatment of osteosarcoma.

GPU-based prompt gamma ray imaging from boron neutron capture therapy

International Nuclear Information System (INIS)

Yoon, Do-Kun; Jung, Joo-Young; Suk Suh, Tae; Jo Hong, Key; Sil Lee, Keum

2015-01-01

Purpose: The purpose of this research is to perform the fast reconstruction of a prompt gamma ray image using a graphics processing unit (GPU) computation from boron neutron capture therapy (BNCT) simulations. Methods: To evaluate the accuracy of the reconstructed image, a phantom including four boron uptake regions (BURs) was used in the simulation. After the Monte Carlo simulation of the BNCT, the modified ordered subset expectation maximization reconstruction algorithm using the GPU computation was used to reconstruct the images with fewer projections. The computation times for image reconstruction were compared between the GPU and the central processing unit (CPU). Also, the accuracy of the reconstructed image was evaluated by a receiver operating characteristic (ROC) curve analysis. Results: The image reconstruction time using the GPU was 196 times faster than the conventional reconstruction time using the CPU. For the four BURs, the area under curve values from the ROC curve were 0.6726 (A-region), 0.6890 (B-region), 0.7384 (C-region), and 0.8009 (D-region). Conclusions: The tomographic image using the prompt gamma ray event from the BNCT simulation was acquired using the GPU computation in order to perform a fast reconstruction during treatment. The authors verified the feasibility of the prompt gamma ray image reconstruction using the GPU computation for BNCT simulations

Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?

Science.gov (United States)

De Stasio, Gelsomina; Rajesh, Deepika; Casalbore, Patrizia; Daniels, Matthew J; Erhardt, Robert J; Frazer, Bradley H; Wiese, Lisa M; Richter, Katherine L; Sonderegger, Brandon R; Gilbert, Benjamin; Schaub, Sebastien; Cannara, Rachel J; Crawford, John F; Gilles, Mary K; Tyliszczak, Tolek; Fowler, John F; Larocca, Luigi M; Howard, Steven P; Mercanti, Delio; Mehta, Minesh P; Pallini, Roberto

2005-06-01

Gadolinium neutron capture therapy (GdNCT) is a potential treatment for malignant tumors based on two steps: (1) injection of a tumor-specific (157)Gd compound; (2) tumor irradiation with thermal neutrons. The GdNC reaction can induce cell death provided that Gd is proximate to DNA. Here, we studied the nuclear uptake of Gd by glioblastoma (GBM) tumor cells after treatment with two Gd compounds commonly used for magnetic resonance imaging, to evaluate their potential as GdNCT agents. Using synchrotron X-ray spectromicroscopy, we analyzed the Gd distribution at the subcellular level in: (1) human cultured GBM cells exposed to Gd-DTPA or Gd-DOTA for 0-72 hours; (2) intracerebrally implanted C6 glioma tumors in rats injected with one or two doses of Gd-DOTA, and (3) tumor samples from GBM patients injected with Gd-DTPA. In cell cultures, Gd-DTPA and Gd-DOTA were found in 84% and 56% of the cell nuclei, respectively. In rat tumors, Gd penetrated the nuclei of 47% and 85% of the tumor cells, after single and double injection of Gd-DOTA, respectively. In contrast, in human GBM tumors 6.1% of the cell nuclei contained Gd-DTPA. Efficacy of Gd-DTPA and Gd-DOTA as GdNCT agents is predicted to be low, due to the insufficient number of tumor cell nuclei incorporating Gd. Although multiple administration schedules in vivo might induce Gd penetration into more tumor cell nuclei, a search for new Gd compounds with higher nuclear affinity is warranted before planning GdNCT in animal models or clinical trials.

Measurement of the 241Am neutron capture cross section at the n_TOF facility at CERN

Directory of Open Access Journals (Sweden)

Mendoza E.

2017-01-01

Full Text Available New neutron cross section measurements of minor actinides have been performed recently in order to reduce the uncertainties in the evaluated data, which is important for the design of advanced nuclear reactors and, in particular, for determining their performance in the transmutation of nuclear waste. We have measured the 241Am(n,γ cross section at the n_TOF facility between 0.2 eV and 10 keV with a BaF2 Total Absorption Calorimeter, and the analysis of the measurement has been recently concluded. Our results are in reasonable agreement below 20 eV with the ones published by C. Lampoudis et al. in 2013, who reported a 22% larger capture cross section up to 110 eV compared to experimental and evaluated data published before. Our results also indicate that the 241Am(n,γ cross section is underestimated in the present evaluated libraries between 20 eV and 2 keV by 25%, on average, and up to 35% for certain evaluations and energy ranges.

Boron Neutron Capture Therapy (BCNT) for the Treatment of Liver Metastases: Biodistribution Studies of Boron Compounds in an Experimental Model

Energy Technology Data Exchange (ETDEWEB)

Marcela A. Garabalino; Andrea Monti Hughes; Ana J. Molinari; Elisa M. Heber; Emiliano C. C. Pozzi; Maria E. Itoiz; Veronica A. Trivillin; Amanda E. Schwint; Jorge E. Cardoso; Lucas L. Colombo; Susana Nievas; David W. Nigg; Romina F. Aromando

2011-03-01

Abstract We previously demonstrated the therapeutic efficacy of different boron neutron capture therapy (BNCT) protocols in an experimental model of oral cancer. BNCT is based on the selective accumulation of 10B carriers in a tumor followed by neutron irradiation. Within the context of exploring the potential therapeutic efficacy of BNCT for the treatment of liver metastases, the aim of the present study was to perform boron biodistribution studies in an experimental model of liver metastases in rats. Different boron compounds and administration conditions were assayed to determine which administration protocols would potentially be therapeutically useful in in vivo BNCT studies at the RA-3 nuclear reactor. A total of 70 BDIX rats were inoculated in the liver with syngeneic colon cancer cells DHD/K12/TRb to induce the development of subcapsular tumor nodules. Fourteen days post-inoculation, the animals were used for biodistribution studies. We evaluated a total of 11 administration protocols for the boron compounds boronophenylalanine (BPA) and GB-10 (Na210B10H10), alone or combined at different dose levels and employing different administration routes. Tumor, normal tissue, and blood samples were processed for boron measurement by atomic emission spectroscopy. Six protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue. Boron concentration values in tumor and normal tissues in the liver metastases model show it would be feasible to reach therapeutic BNCT doses in tumor without exceeding radiotolerance in normal tissue at the thermal neutron facility at RA-3.

Risk management of radiation therapy. Survey by north Japan radiation therapy oncology group

International Nuclear Information System (INIS)

Aoki, Masahiko; Abe, Yoshinao; Yamada, Shogo; Hareyama, Masato; Nakamura, Ryuji; Sugita, Tadashi; Miyano, Takashi

2004-01-01

A North Japan Radiation Oncology Group (NJRTOG) survey was carried out to disclose the risk management of radiation therapy. During April 2002, we sent questionnaires to radiation therapy facilities in northern Japan. There were 31 replies from 27 facilities. Many incidents and accidents were reported, including old cases. Although 60% of facilities had a risk management manual and/or risk manager, only 20% had risk management manuals for radiation therapy. Eighty five percent of radiation oncologists thought that incidents may be due to a lack of manpower. Ninety percent of radiation oncologists want to know the type of cases happened in other facilities. The risk management system is still insufficient for radiation therapy. We hope that our data will be a great help to develop risk management strategies for radiation therapy for all radiation oncologists in Japan. (author)

In-phantom dosimetry using the 13C(d,n)14N reaction for BNCT (boron neutron capture therapy)

International Nuclear Information System (INIS)

Burlon, Alejandro; Kreiner, Andres J.; White, S.; Blackburn, B.; Gierga, David; Yanch, Jacquelyn C.

2000-01-01

The use of the 13 C(d,n) 14 N reaction at E d =1.5 MeV for accelerator-based boron neutron capture therapy is investigated. The 13 C(d,n) 14 N reaction presents the advantages of carbon as a target material and its large cross section. The deuteron beam was produced by a tandem accelerator at MIT's Laboratory for Accelerator Beam Applications. The resulting neutron spectra were evaluated in terms of RBE-dose rates at different depths inside a water-filled brain phantom using a heavy water moderator and lead reflector assembly. All results were simulated using the code MCNP. (author)

Hadron Therapy: Past, Present and Perspectives

International Nuclear Information System (INIS)

Jones, D.T.L

1999-01-01

Fast neutron therapy began as long ago as 1938 and subsequently proton, alpha particle, heavy ion, pion and neutron capture therapy have been used. To date it is estimated that in excess of 45000 people have undergone some form of hadron therapy. In the future it is expected that fast neutron therapy will be used for selected tumour types for which neutron are known to show improved cure rates. The future trends in charged particle therapy will be driven by increasing commercialization. The future of neutron capture therapy will depend on current clinical trials with epithermal neutron beams and the development of new tumour-seeking drugs

The neutron therapy facility at the University of Pennsylvania-Fox Chase Cancer Center

International Nuclear Information System (INIS)

Bloch, P.; Chu, J.; Larsen, R.

1983-01-01

The fusion of deuterium and tritium nuclei results in the formation of a helium-4 nucleus and a 14 MEV neutron. This reaction readily takes place when deuterium and tritium ions are accelerated to potentials between 150-200 kV. These energy ions can be obtained in a moderate size accelerator. A DT neutron facility has been installed in the radiation therapy department of the University of Pennsylvania Hospital-Fox Chase Cancer Center. The system is being commissioned in a hospital setting to test the efficacy of fast neutron radiotherapy

Proton therapy

International Nuclear Information System (INIS)

Smith, Alfred R

2006-01-01

Proton therapy has become a subject of considerable interest in the radiation oncology community and it is expected that there will be a substantial growth in proton treatment facilities during the next decade. I was asked to write a historical review of proton therapy based on my personal experiences, which have all occurred in the United States, so therefore I have a somewhat parochial point of view. Space requirements did not permit me to mention all of the existing proton therapy facilities or the names of all of those who have contributed to proton therapy. (review)

Radiation field characterization of a BNCT research facility using Monte Carlo method - code MCNP-4B

International Nuclear Information System (INIS)

Hernandez, Antonio Carlos

2002-01-01

Boron Neutron Capture Therapy - BNCT - is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an Am Be neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these Becton studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluencyN T = 1,35x10 8 n/cm , a fast neutron dose of 5,86x10 -10 Gy/N T and a gamma ray dose of 8,30x10 -14 Gy/N T . (author)

Radiation field characterization of a BNCT research facility using Monte Carlo Method - Code MCNP-4B

International Nuclear Information System (INIS)

Hernandes, Antonio Carlos

2002-01-01

Boron Neutron Capture Therapy - BNCT- is a selective cancer treatment and arises as an alternative therapy to treat cancer when usual techniques - surgery, chemotherapy or radiotherapy - show no satisfactory results. The main proposal of this work is to project a facility to BNCT studies. This facility relies on the use of an AmBe neutron source and on a set of moderators, filters and shielding which will provide the best neutron/gamma beam characteristic for these BNCT studies, i.e., high intensity thermal and/or epithermal neutron fluxes and with the minimum feasible gamma rays and fast neutrons contaminants. A computational model of the experiment was used to obtain the radiation field in the sample irradiation position. The calculations have been performed with the MCNP 4B Monte Carlo Code and the results obtained can be regarded as satisfactory, i.e., a thermal neutron fluency Ν Τ = 1,35x10 8 n/cm 2 , a fast neutron dose of 5,86x -1 0 Gy/Ν Τ and a gamma ray dose of 8,30x -14 Gy/Ν Τ . (author)

The roles of the Q (q) wave in lead I and QRS frontal axis for diagnosing loss of left ventricular capture during cardiac resynchronization therapy.

Science.gov (United States)

Cao, Yuan-Yuan; Su, Yan-Gang; Bai, Jin; Wang, Wei; Wang, Jing-Feng; Qin, Sheng-Mei; Ge, Jun-Bo

2015-01-01

Loss of left ventricular (LV) capture may lead to deterioration of heart failure in patients with cardiac resynchronization therapy (CRT). Recognition of loss of LV capture in time is important in clinical practice. A total of 422 electrocardiograms were acquired and analyzed from 53 CRT patients at 8 different pacing settings (LV only, right ventricle [RV] only, biventricular [BV] pacing with LV preactivation of 60, 40, 20, and 0 milliseconds and RV preactivation of 20 and 40 milliseconds). A modified Ammann algorithm by adding a third step-presence of Q (q, or QS) wave-to the original 2-step Ammann algorithm and a QRS axis shift method were devised to identify the loss of LV capture. The accuracy of modified Ammann algorithm was significantly higher than that of Ammann algorithm (78.9% vs. 69.1%, P capture. The LV preactivation, or simultaneous BV activation and LV lead positioned in nonposterior or noninferior wall can increase the diagnostic power of the modified Ammann algorithm and QRS axis shift method. © 2014 Wiley Periodicals, Inc.

Boron-containing thioureas for neutron capture therapy. Borhaltige Thioharnstoffe fuer die Neutroneneinfangtherapie

Energy Technology Data Exchange (ETDEWEB)

Ketz, H.

1993-10-21

Melanin is produced in large amounts in malignant melanotic melanomas. Because thiourea compounds are covalently incorporated into melanin during its biosynthesis, the preparation of boronated thiourea-derivatives is of particular interest for the BNCT (Boron Neutron Capture Therapy). Accumulation of boron in tumors by means of boronated thiourea-derivatives may therefore provide levels of [sup 10]B which are useful for BNCT. In BNCT the tumor containing the boron compound is irradiated with epithermal neutrons to generate He- and Li-nuclei from the [sup 10]B which can then destroy the tumor cells. Because of the short ranges of these particles (approximately one cell diameter) the damage will be almost exclusively confined to the tumor leaving normal tissue unharmed. High accumulation of 2-mercapto-1-methylimidazole (methimazole) in melanotic melanomas has been described in the literature. Boronated derivatives of methimazole were therefore synthesized. Boron was in the form of a boronic acid, a nido-carbonate and a mercaptoundeca hydro-closo-dodecaborate (BSH). The synthesis of the boron cluster derivatives of methimazole (nido-carborate- and BSH-derivatives) with 9 resp. 12 boron atoms in the molecule were expected to achieve higher concentrations of boron in the tumor than in the case of the boronic acid compound with its single boron atom. (orig.)

Design of radiation shielding for the proton therapy facility at the National Cancer Center in Korea

International Nuclear Information System (INIS)

Kim, J. W.; Kwon, J. W.; Lee, J.

2005-01-01

The design of radiation shielding was evaluated for a proton therapy facility being established at the National Cancer Center in Korea. The proton beam energy from a 230 MeV cyclotron is varied for therapy using a graphite target. This energy variation process produces high radiation and thus thick shielding walls surround the region. The evaluation was first carried out using analytical expressions at selected locations. Further detailed evaluations have been performed using the Monte Carlo method. Dose equivalent values were calculated to be compared with analytical results. The analytical method generally yielded more conservative values. With consideration of adequate occupancy factors annual dose equivalent rates are kept -1 in all areas. Construction of the building is expected to be completed near the end of 2004 and the installation of therapy equipments will begin a few months later. (authors)

Beamlines of the biomedical imaging and therapy facility at the Canadian light source-Part 1

International Nuclear Information System (INIS)

Wysokinski, Tomasz W.; Chapman, Dean; Adams, Gregg; Renier, Michel; Suortti, Pekka; Thomlinson, William

2007-01-01

The BioMedical Imaging and Therapy (BMIT) Facility will provide synchrotron-specific imaging and therapy capabilities. This paper describes one of the BMIT beamlines: the bend magnet (BM) beamline 05B1-1. It plays a complementary role to the insertion device (ID) beamline 051D-2 and allows either monochromatic or filtered white beam to be used in the experimental hutch. The monochromatic spectral range will span 8-40 keV, and the beam is more than 200 mm wide in the experimental hutch for imaging studies of small and medium-size animals (up to sheep size). The experimental hutch will have a positioning system that will allow imaging (computed tomography and planar imaging) as well as radiation therapy applications with both filtered white and monochromatic X-ray beams and will handle subjects up to 120 kg. Several different focal plane detectors (cameras) will be available with resolutions ranging from 10 to 150 μm

PEMODELAN KOLIMATOR DI RADIAL BEAM PORT REAKTOR KARTINI UNTUK BORON NEUTRON CAPTURE THERAPY

Directory of Open Access Journals (Sweden)

Bemby Yulio Vallenry

2015-03-01

Full Text Available Salah satu metode terapi kanker adalah Boron Neutron Capture Therapy (BNCT. BNCT memanfaatkan tangkapan neutron oleh 10B yang terendapkan pada sel kanker. Keunggulan BNCT dibandingkan dengan terapi radiasi lainnya adalah tingkat selektivitas yang tinggi karena tingkatannya adalah sel. Pada penelitian ini dilakukan pemodelan kolimator di radial beamport reaktor Kartini sebagai dasar pemilihan material dan manufature kolimator sebagai sumber neutron untuk BNCT. Pemodelan ini dilakukan dengan simulasi menggunakan perangkat lunak Monte Carlo N-Particle versi 5 (MCNP 5. MCNP 5 adalah suatu paket program untuk memodelkan sekaligus menghitung masalah transpor partikel dengan mengikuti sejarah hidup neutron semenjak lahir, bertranspor pada bahan hingga akhirnya hilang karena mengalami reaksi penyerapan atau keluar dari sistem. Pemodelan ini menggunakan variasi material dan ukurannya agar menghasilkan nilai dari tiap parameter-parameter yang sesuai dengan rekomendasi I International Atomic Energy Agency (IAEA untuk BNCT, yaitu fluks neutron epitermal (Фepi > 9 n.cm-2.s-1, rasio antara laju dosis neutron cepat dan fluks neutron epitermal (Ḋf/Фepi 0,7. Berdasarkan hasil optimasi dari pemodelan ini, material dan ukuran penyusun kolimator yang didapatkan yaitu 0,75 cm Ni sebagai dinding kolimator, 22 cm Al sebagai moderator dan 4,5 cm Bi sebagai perisai gamma. Keluaran berkas radiasi yang dihasilkan dari pemodelan kolimator radial beamport yaitu Фepi = 5,25 x 106 n.cm-2s-1, Ḋf/Фepi =1,17 x 10-13 Gy.cm2.n-1, Ḋγ/Фepi = 1,70 x 10-12 Gy.cm2.n-1, Фth/Фepi = 1,51 dan J/Фepi = 0,731. Berdasarkan penelitian ini, hasil optimasi 5 parameter sebagai persyaratan kolimator untuk BNCT yang keluar dari radial beam port tidak sepenuhnya memenuhi kriteria yang direkomendasikan oleh IAEA sehingga perlu dilakukan penelitian lebih lanjut agar tercapainya persyaratan IAEA. Kata kunci: BNCT, radial beamport, MCNP 5, kolimator   One of the cancer therapy methods is

Applying the flow-capturing location-allocation model to an authentic network: Edmonton, Canada

NARCIS (Netherlands)

M.J. Hodgson (John); K.E. Rosing (Kenneth); A.L.G. Storrier (Leontien)

1996-01-01

textabstractTraditional location-allocation models aim to locate network facilities to optimally serve demand expressed as weights at nodes. For some types of facilities demand is not expressed at nodes, but as passing network traffic. The flow-capturing location-allocation model responds to this

Neutron Capture Reactions on Fe and Ni Isotopes for the Astrophysical s-process

Energy Technology Data Exchange (ETDEWEB)

Lederer, C., E-mail: claudia.lederer@ed.ac.uk [University of Vienna, Faculty of Physics, 1090 Vienna (Austria); Johann-Wolfgang-Goethe Universität, 60438 Frankfurt (Germany); Giubrone, G. [Instituto de Física Corpuscular, CSIC-Universidad de Valencia, 46071 Valencia (Spain); Massimi, C. [Dipartimento di Fisica, Università di Bologna, and Sezione INFN di Bologna, 40100 Bologna (Italy); Žugec, P. [Department of Physics, Faculty of Science, University of Zagreb, 10002 Zagreb (Croatia); Barbagallo, M.; Colonna, N. [Istituto Nazionale di Fisica Nucleare, 70125 Bari (Italy); Domingo-Pardo, C. [Instituto de Física Corpuscular, CSIC-Universidad de Valencia, 46071 Valencia (Spain); Guerrero, C. [European Organization for Nuclear Research (CERN), CH-1211 Geneva (Switzerland); Gunsing, F. [Commissariat à l' Énergie Atomique (CEA) Saclay – Irfu, 91191 Gif-sur-Yvette (France); Käppeler, F. [Karlsruhe Institute of Technology, Campus Nord, Institut für Kernphysik, 76021 Karlsruhe (Germany); Tain, J.L. [Instituto de Física Corpuscular, CSIC-Universidad de Valencia, 46071 Valencia (Spain); Altstadt, S. [Johann-Wolfgang-Goethe Universität, 60438 Frankfurt (Germany); Andrzejewski, J. [Uniwersytet Łódzki, 90131 Lodz (Poland); Audouin, L. [Centre National de la Recherche Scientifique/IN2P3 – IPN, 91406 Orsay (France); Bécares, V. [Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid (Spain); Bečvář, F. [Faculty of Mathematics and Physics, Charles University, CZ-180 00 Prague (Czech Republic); and others

2014-06-15

Neutron capture cross sections in the keV neutron energy region are the key nuclear physics input to study the astrophysical slow neutron capture process. In the past years, a series of neutron capture cross section measurements has been performed at the neutron time-of-flight facility n{sub T}OF at CERN focussing on the Fe/Ni mass region. Recent results and future developments in the neutron time-of-flight technique are discussed.

Carbon Dioxide Capture and Transportation Options in the Illinois Basin

Energy Technology Data Exchange (ETDEWEB)

M. Rostam-Abadi; S. S. Chen; Y. Lu

2004-09-30

This report describes carbon dioxide (CO{sub 2}) capture options from large stationary emission sources in the Illinois Basin, primarily focusing on coal-fired utility power plants. The CO{sub 2} emissions data were collected for utility power plants and industrial facilities over most of Illinois, southwestern Indiana, and western Kentucky. Coal-fired power plants are by far the largest CO{sub 2} emission sources in the Illinois Basin. The data revealed that sources within the Illinois Basin emit about 276 million tonnes of CO2 annually from 122 utility power plants and industrial facilities. Industrial facilities include 48 emission sources and contribute about 10% of total emissions. A process analysis study was conducted to review the suitability of various CO{sub 2} capture technologies for large stationary sources. The advantages and disadvantages of each class of technology were investigated. Based on these analyses, a suitable CO{sub 2} capture technology was assigned to each type of emission source in the Illinois Basin. Techno-economic studies were then conducted to evaluate the energy and economic performances of three coal-based power generation plants with CO{sub 2} capture facilities. The three plants considered were (1) pulverized coal (PC) + post combustion chemical absorption (monoethanolamine, or MEA), (2) integrated gasification combined cycle (IGCC) + pre-combustion physical absorption (Selexol), and (3) oxygen-enriched coal combustion plants. A conventional PC power plant without CO2 capture was also investigated as a baseline plant for comparison. Gross capacities of 266, 533, and 1,054 MW were investigated at each power plant. The economic study considered the burning of both Illinois No. 6 coal and Powder River Basin (PRB) coal. The cost estimation included the cost for compressing the CO{sub 2} stream to pipeline pressure. A process simulation software, CHEMCAD, was employed to perform steady-state simulations of power generation systems

Basic and clinical study of boron neutron capture therapy for malignant brain tumor

International Nuclear Information System (INIS)

Nose, Tadao; Matsumura, Akira; Nakai, Kei; Nakagawa, Kunio; Yoshii, Yoshihiko; Shibata, Yasushi; Yamamoto, Tetsuya; Hayakawa, Yoshinori; Yamada, Takashi

1998-01-01

Rat malignant cells (9L glioma cell) were exposed to neutron radiation after culturing with boron compounds; BSH and STA-BX909, and cell growing ability after the exposure was determined by colony forming assay. The effects of in vivo radiation were examined by measuring neutron flux levels in rat brain and skin aiming to use neutron radiation in clinical study. STA-BX909 was found to show a dose-dependent cell toxicity, which was higher than that of BSH. The radiation induced G2/M block in 9L-glioma cells and their cell cycles recovered thereafter in low-dose radiated cells, but high-dose radiated cells became aneuploidy. Furthermore, boron neutron capture therapy (BNCT) was applied in two patients, 41-year old woman with glioma grade 3 recurred and 45-year old man with glioblastoma multiforme. The former died from systemic deterioration due to ileus, but BNCT was made only one time although conventional radiotherapy is carried out for a relatively long period. Therefore, BNCT was thought to be beneficial from an aspect of 'quality of life' and the effects to repress a recurrence of cancer also seemed larger than the conventional one. (M.N.)

Basic and clinical study of boron neutron capture therapy for malignant brain tumor

Energy Technology Data Exchange (ETDEWEB)

Nose, Tadao; Matsumura, Akira; Nakai, Kei; Nakagawa, Kunio; Yoshii, Yoshihiko [Tsukuba Univ., Ibaraki (Japan). Inst. of Clinical Medicine; Shibata, Yasushi; Yamamoto, Tetsuya; Hayakawa, Yoshinori; Yamada, Takashi

1998-01-01

Rat malignant cells (9L glioma cell) were exposed to neutron radiation after culturing with boron compounds; BSH and STA-BX909, and cell growing ability after the exposure was determined by colony forming assay. The effects of in vivo radiation were examined by measuring neutron flux levels in rat brain and skin aiming to use neutron radiation in clinical study. STA-BX909 was found to show a dose-dependent cell toxicity, which was higher than that of BSH. The radiation induced G2/M block in 9L-glioma cells and their cell cycles recovered thereafter in low-dose radiated cells, but high-dose radiated cells became aneuploidy. Furthermore, boron neutron capture therapy (BNCT) was applied in two patients, 41-year old woman with glioma grade 3 recurred and 45-year old man with glioblastoma multiforme. The former died from systemic deterioration due to ileus, but BNCT was made only one time although conventional radiotherapy is carried out for a relatively long period. Therefore, BNCT was thought to be beneficial from an aspect of `quality of life` and the effects to repress a recurrence of cancer also seemed larger than the conventional one. (M.N.)

Basic study for development of new tumor specific agents for neutron capture therapy

International Nuclear Information System (INIS)

Matsumura, Akira; Nakagawa, Kunio; Yoshii, Yoshihiko; Nose, Tadao

1994-01-01

New tissue specific agents for neutron capture therapy was studied. Monoclonal labeled gadolinium-DTPA (Gd-MoAb) and porphyrin (ATN-10)-Gd-DTPA (Gd-ATN10) were studied as possible agents by using 9-L experimental brain tumor model. The tissue concentration were analyzed with magnetic resonance imaging (MRI) and inductively coupled plasma (ICP) analyzer. Gd-MoAb showed persistent retention in the tumor on MRI, but tissue gadolinium concentration was not detectable in the tumor by ICP analyzer, while there was high accumulation of Gd-MoAb in the liver. Gd-ATN10 showed prolonged and high accumulation in the tumor up to 48 hours on MRI. Gadolinium concentration reached up to 9 ppm in the tumor by 0.02 mmol/kg administration, but it disappeared within 6 hours after administration. This dissociation between MRI and ICP analysis was due to separation of ATN-10 and Gd-DTPA. As conclusions, the porphyrin compounds are potential agents for delivering gadolinium or boron specific to the tumor tissue, thus further improvement such as more stable conjugation between porphyrinfic to the tumor tissue, thus further improvement such as more stable conjugation between porphyrin and Gd-DTPA is needed. (author)

Research of accelerator-based neutron source for boron neutron capture therapy

International Nuclear Information System (INIS)

Li Changkai; Ma Yingjie; Tang Xiaobin; Xie Qin; Geng Changran; Chen Da

2013-01-01

Background: 7 Li (p, n) reaction of high neutron yield and low threshold energy has become one of the most important neutron generating reactions for Accelerator-based Boron Neutron Capture Therapy (BNCT). Purpose Focuses on neutron yield and spectrum characteristics of this kind of neutron generating reaction which serves as an accelerator-based neutron source and moderates the high energy neutron beams to meet BNCT requirements. Methods: The yield and energy spectrum of neutrons generated by accelerator-based 7 Li(p, n) reaction with incident proton energy from 1.9 MeV to 3.0 MeV are researched using the Monte Carlo code-MCNPX2.5.0. And the energy and angular distribution of differential neutron yield by 2.5-MeV incident proton are also given in this part. In the following part, the character of epithermal neutron beam generated by 2.5-MeV incident protons is moderated by a new-designed moderator. Results: Energy spectra of neutrons generated by accelerator-based 7 Li(p, n) reaction with incident proton energy from 1.9 MeV to 3.0 MeV are got through the simulation and calculation. The best moderator thickness is got through comparison. Conclusions: Neutron beam produced by accelerator-based 7 Li(p, n) reaction, with the bombarding beam of 10 mA and the energy of 2.5 MeV, can meet the requirement of BNCT well after being moderated. (authors)

An accelerator-based epithermal photoneutron source for boron neutron capture therapy

International Nuclear Information System (INIS)

Mitchell, H.E.

1996-04-01

Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 10 7 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF 3 composite and a stacked Al/Teflon design) at various incident electron energies

An accelerator-based epithermal photoneutron source for boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Mitchell, Hannah E. [Georgia Inst. of Technology, Atlanta, GA (United States)

1996-04-01

Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 10⁷ neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF₃ composite and a stacked Al/Teflon design) at various incident electron energies.

Fabrication of ATALANTE Dissolver Off-Gas Sorbent-Based Capture System

Energy Technology Data Exchange (ETDEWEB)

Walker, Jr., Joseph Franklin [Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States); Jubin, Robert Thomas [Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)

2015-04-30

A small sorbent-based capture system was designed that could be placed in the off-gas line from the fuel dissolver in the ATALANTE hot cells with minimal modifications to the ATALANTE dissolver off-gas system. Discussions with personnel from the ATALANTE facility provided guidance that was used for the design. All components for this system have been specified, procured, and received on site at Oak Ridge National Laboratory (ORNL), meeting the April 30, 2015, milestone for completing the fabrication of the ATALANTE dissolver off-gas capture system. This system will be tested at ORNL to verify operation and to ensure that all design requirements for ATALANTE are met. Modifications to the system will be made, as indicated by the testing, before the system is shipped to ATALANTE for installation in the hot cell facility.

Accelerator based-boron neutron capture therapy (BNCT)-clinical QA and QC

International Nuclear Information System (INIS)

Suzuki, Minoru; Tanaka, Hiroki; Sakurai, Yoshinori; Yong, Liu; Kashino, Genro; Kinashi, Yuko; Masunaga, Shinichiro; Ono, Koji; Maruhashi, Akira

2009-01-01

Alpha-particle and recoil Li atom yielded by the reaction ( 10 B, n), due to their high LET properties, efficiently and specifically kill the cancer cell that has incorporated the boron. Efficacy of this boron neutron capture therapy (BNCT) has been demonstrated mainly in the treatment of recurrent head/neck and malignant brain cancers in Kyoto University Research Reactor Institute (KUR). As the clinical trial of BNCT is to start from 2009 based on an accelerator (not on the Reactor), this paper describes the tentative outline of the standard operation procedure of BNCT for its quality assurance (QA) and quality control (QC) along the flow of its clinical practice. Personnel concerned in the practice involve the attending physician, multiple physicians in charge of BNCT, medical physicists, nurses and reactor stuff. The flow order of the actual BNCT is as follows: Pre-therapeutic evaluation mainly including informed consent and confirmation of the prescription; Therapeutic planning including setting of therapy volume, and of irradiation axes followed by meeting for stuffs' agreement, decision of irradiating field in the irradiation room leading to final decision of the axis, CT for the planning, decision of the final therapeutic plan according to Japan Atomic Energy Agency-Computational Dosimetry System (JCDS) and meeting of all related personnel for the final confirmation of therapeutic plan; and BNCT including the transport of patient to KUR, dripping of boronophenylalanine, setting up of the patient on the machine, blood sampling for pharmacokinetics, boron level measurement for decision of irradiating time, switch on/off of the accelerator, confirmation of patient's movement in the irradiated field after the neutron irradiation, blood sampling for confirmation of the boron level, and patient's leave from the room. The QA/QC check is principally to be conducted with the two-person rule. The purpose of the clinical trial is to establish the usefulness of BNCT

Design of hyper-thermal neutron irradiation fields for neutron capture therapy in KUR-heavy water neutron irradiation facility. Mounting of hyper-thermal neutron converter in therapeutic collimator

International Nuclear Information System (INIS)

Sakurai, Y.; Kobayashi, T.

2001-01-01

Neutron capture therapy (NCP) using thermal neutron needs to improve of depth dose distribution in a living body. Epi-thermal neutron following moderation of fast neutron is usually used for improving of the depth dose distribution. The moderation method of fast neutron, however, gets mixed some of high energy neutron which give some of serious effects to a living body, and involves the difficulty for collimation of thermal neutron to the diseased part. Hyper-thermal neutrons, which are in an energy range of 0.1-3 eV at high temperature side of thermal neutron, are under consideration for application to the NCP. The hyper-thermal neutrons can be produced by up-scattering of thermal neutron in a high temperature material. Fast neutron components in collimator for the NCP reduce on application of the up-scattering method. Graphite at high temperature (>1000k) is used as a hyper-thermal neutron converter. The hyper-thermal neutron converter is planted to mount on therapeutic collimator which is located at the nearest side of patient for the NCP. Total neutron flux, ratio of hyper-thermal neutron to total neutron, and ratio of gamma-ray dose to neutron flux are calculated as a function of thickness of the graphite converter using monte carlo code MCNP-V4B. (M. Suetake)

IMPROVED COMPUTATIONAL CHARACTERIZATION OF THE THERMAL NEUTRON SOURCE FOR NEUTRON CAPTURE THERAPY RESEARCH AT THE UNIVERSITY OF MISSOURI

Energy Technology Data Exchange (ETDEWEB)

Stuart R. Slattery; David W. Nigg; John D. Brockman; M. Frederick Hawthorne

2010-05-01

Parameter studies, design calculations and initial neutronic performance measurements have been completed for a new thermal neutron beamline to be used for neutron capture therapy cell and small-animal radiobiology studies at the University of Missouri Research Reactor. The beamline features the use of single-crystal silicon and bismuth sections for neutron filtering and for reduction of incident gamma radiation. The computational models used for the final beam design and performance evaluation are based on coupled discrete-ordinates and Monte Carlo techniques that permit detailed modeling of the neutron transmission properties of the filtering crystals with very few approximations. This is essential for detailed dosimetric studies required for the anticipated research program.

Boron Neutron Capture Therapy activity of diffused tumors at TRIGA Mark II in Pavia

Energy Technology Data Exchange (ETDEWEB)

Bortolussi, S.; Stella, S.; De Bari, A.; Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy)]|[National Institute of Nuclear Physics (INFN), Pavia (Italy); Bruschi, P.; Bakeine, J.G. [Department of Nuclear and Theoretical Physics, University of Pavia, Pavia (Italy); Clerici, A.; Ferrari, C.; Zonta, C.; Zonta, A. [Department of Surgery, University of Pavia, Pavia (Italy); Nano, R. [Department of Animal Biology, University of Pavia, Pavia (Italy)

2008-10-29

The Boron neutron Capture Therapy research in Pavia has a long tradition: it begun more than 20 years ago at the TRIGA Mark II reactor of the University. A technique for the treatment of the hepatic metastases was developed, consisting in explanting the liver treated with {sup 10}B, irradiating it in the thermal column of the reactor, and re-implanting the organ in the patient. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research will be presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. (authors)

Boron Neutron Capture Therapy activity of diffused tumors at TRIGA Mark II in Pavia

International Nuclear Information System (INIS)

Bortolussi, S.; Stella, S.; De Bari, A.; Altieri, S.; Bruschi, P.; Bakeine, J.G.; Clerici, A.; Ferrari, C.; Zonta, C.; Zonta, A.; Nano, R.

2008-01-01

The Boron neutron Capture Therapy research in Pavia has a long tradition: it begun more than 20 years ago at the TRIGA Mark II reactor of the University. A technique for the treatment of the hepatic metastases was developed, consisting in explanting the liver treated with 10 B, irradiating it in the thermal column of the reactor, and re-implanting the organ in the patient. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research will be presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,α) spectroscopy and neutron autoradiography. (authors)

Boron Neutron Capture Therapy at the TRIGA Mark II of Pavia, Italy - The BNCT of the diffuse tumours

Energy Technology Data Exchange (ETDEWEB)

Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Gadan, M.A. [University of Pavia (Italy); INFN - National Institute for Nuclear Physics, of Pavia (Italy)

2008-10-29

The selectivity based on the B distribution rather than on the irradiation field makes Boron neutron Capture Therapy (BNCT) a valid option for the treatment of the disseminated tumours. As the range of the high LET particles is shorter than a cell diameter, the normal cells around the tumour are not damaged by the reactions occurring in the tumoral cells. PAVIA 2001: first treatment of multiple hepatic metastases from colon ca by BNCT and auto-transplantation technique: TAOrMINA project. The liver was extracted after BPA infusion, irradiated in the Thermal Column of the Pavia TRIGA Mark II reactor, and re-implanted in the patient. Two patients were treated, demonstrating the feasibility of the therapy and the efficacy in destroying the tumoral nodules sparing the healthy tissues. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research are presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. The dose distribution in the thorax are simulated using MCNP and the anthropomorphic model ADAM. To have a good thermal flux distribution inside the lung epithermal neutrons must be used, which thermalize crossing the first tissue layers. Thermal neutrons do not penetrate and the obtained uniformity is poor. In the future, the construction of a PGNAA facility using a horizontal channel of the TRIGA Mark II is planned. With this method the B concentration can be measured also in liquid samples (blood, urine) and

Cell cycle dependence of boron uptake in various boron compounds used for neutron capture therapy

International Nuclear Information System (INIS)

Yoshida, F.; Matsumura, A.; Shibata, Y.; Yamamoto, T.; Nose, T.; Okumura, M.

2000-01-01

In neutron capture therapy, it is important that the tumor take boron in selectively. Furthermore, it is ideal when the uptake is equal in each tumor cell. Some indirect proof of differences in boron uptake among neoplastic cell cycles has been documented. However, no investigation has yet measured boron uptake directly. Using flow cytometry, in the present study cells were sorted by G0/G1 phase and G2/M phase, and the boron concentration of each fraction was measured with inductively coupled plasma-atomic emission spectroscopy (ICP-AES). The results were that BSH (sodiumborocaptate) and BPA (p-boronophenylalanine) had higher rates of boron uptake in the G2/M group than in the G0/G1 group. However, in BPA the difference was more prominent, which revealed a 2.2-3.3 times higher uptake of boron in the G2/M group than in the G0/G1 group. (author)

Boron microquantification in oral mucosa and skin following administration of a neutron capture therapy agent

International Nuclear Information System (INIS)

Kiger, S.W. III; Micca, P.L.; Morris, G.M.; Coderre, J.A.

2002-01-01

Clinical trials of boron neutron capture therapy (BNCT) for intracranial tumours using boronphenylalanine-fructose undertaken at Harvard-MIT and Brookhaven National Laboratory have observed acute normal tissue reactions in the skin and oral mucosa. Because the range of the 10 B(n,a) 7 Li reaction products is very short, 10-14 μm combined, knowledge of the 10B microdistribution in tissue is critical for understanding the microdosimetry and radiobiology of BNCT. This paper reports measurements of the microdistribution of 10 B in an animal model, rat skin and tongue, using high resolution quantitative autoradiography (HRQAR), a neutron-induced track etch autoradiographic technique. The steep spatial gradient and high absolute value relative to blood of the 10 B concentration observed in some strata of the rat tongue epithelium and skin are important for properly evaluating the radiobiology and the biological effectiveness factors for normal tissue reactions such as oral mucositis, which are generally assessed using the blood boron concentration rather than the tissue boron concentration. (author)

Two-step rapid sulfur capture. Final report

Energy Technology Data Exchange (ETDEWEB)

NONE

1994-04-01

The primary goal of this program was to test the technical and economic feasibility of a novel dry sorbent injection process called the Two-Step Rapid Sulfur Capture process for several advanced coal utilization systems. The Two-Step Rapid Sulfur Capture process consists of limestone activation in a high temperature auxiliary burner for short times followed by sorbent quenching in a lower temperature sulfur containing coal combustion gas. The Two-Step Rapid Sulfur Capture process is based on the Non-Equilibrium Sulfur Capture process developed by the Energy Technology Office of Textron Defense Systems (ETO/TDS). Based on the Non-Equilibrium Sulfur Capture studies the range of conditions for optimum sorbent activation were thought to be: activation temperature > 2,200 K for activation times in the range of 10--30 ms. Therefore, the aim of the Two-Step process is to create a very active sorbent (under conditions similar to the bomb reactor) and complete the sulfur reaction under thermodynamically favorable conditions. A flow facility was designed and assembled to simulate the temperature, time, stoichiometry, and sulfur gas concentration prevalent in the advanced coal utilization systems such as gasifiers, fluidized bed combustors, mixed-metal oxide desulfurization systems, diesel engines, and gas turbines.

Radiation Transport Simulation for Boron Neutron Capture Therapy (BNCT)

Energy Technology Data Exchange (ETDEWEB)

Ziegner, M.; Blaickner, M. [AIT Austrian Institute of Technology GmbH, Health and Environment Department, Molecular Medicine, Muthgasse 11, 1190 Wien (Austria); Ziegner, M.; Khan, R.; Boeck, H. [Vienna University of Technology, Institute of Atomic and Subatomic Physics, Stadionallee 2, 1020 Wien (Austria); Bortolussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Schmitz, T.; Hampel, G. [Nuclear Chemistry, University of Mainz, Fritz Strassmann Weg 2, 55099 Mainz (Germany)

2011-07-01

This work is part of a larger project initiated by the University of Mainz and aiming to use the university's TRIGA reactor to develop a treatment for liver metastases based on Boron Neutron Capture Therapy (BNCT). Diffuse distribution of cancerous cells within the organ makes complete resection difficult and the vicinity to radiosensitive organs impedes external irradiation. Therefore the method of 'autotransplantation', first established at the University of Pavia, is used. The liver is taken out of the body, irradiated in the thermal column of the reactor, therewith purged of metastases and then reimplanted. A highly precise dosimetry system is to be developed by means of measurements at the University of Mainz and computational calculations at the AIT. The stochastic MCNP-5 Monte Carlo-Code, developed by Los Alamos Laboratories, is applied. To verify the calculations of the flux and the absorbed dose in matter a number of measurements are performed irradiating different phantoms and liver sections in a 20cm x 20cm beam tube, which was created by removing graphite blocks from the thermal column of the reactor. The detector material consists of L- {alpha} -alanine pellets which are thought to be the most suitable because of their good tissue equivalence, small size and their wide response range. Another experiment focuses on the determination of the relative biological effectiveness (RBE-factor) of the neutron and photon dose for liver cells. Therefore cell culture plates with the cell medium enriched with {sup 157}Gd and {sup 10}B at different concentrations are irradiated. With regard to the alanine pellets MCNP-5 calculations give stable results. Nevertheless the absorbed dose is underestimated compared to the measurements, a phenomenon already observed in previous works. The cell culture calculations showed the enormous impact of the added isotopes with high thermal neutron cross sections, especially {sup 157}Gd, on the absorbed dose

Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models

International Nuclear Information System (INIS)

Andoh, T.; Fujimoto, T.; Sudo, T.; Fujita, I.; Imabori, M.; Moritake, H.; Sugimoto, T.; Sakuma, Y.; Takeuchi, T.; Kawabata, S.; Kirihata, M.; Akisue, T.; Yayama, K.; Kurosaka, M.; Miyatake, S.; Fukumori, Y.; Ichikawa, H.

2011-01-01

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake L-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10 B (45–74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg).

Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models

Energy Technology Data Exchange (ETDEWEB)

Andoh, T. [Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan); Fujimoto, T. [Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-0021 (Japan); Sudo, T. [Section of Translational Research, Hyogo Cancer Center, Akashi 673-0021 (Japan); Fujita, I.; Imabori, M. [Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-0021 (Japan); Moritake, H. [Department of Pediatrics, Miyazaki University, Kiyotake 889-1692 (Japan); Sugimoto, T. [Department of Pediatrics, Saiseikai Shigaken Hospital, Ritto 520-3046 (Japan); Sakuma, Y. [Department of Pathology, Hyogo Cancer Center, Akashi 673-0021 (Japan); Takeuchi, T. [Department of Pathology, Kochi University, Nangoku 783-8505 (Japan); Kawabata, S. [Department of Neurosurgery, Osaka Medical College, Osaka 569-8686 (Japan); Kirihata, M. [Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Sakai 599-8531 (Japan); Akisue, T. [Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017 (Japan); Yayama, K. [Laboratory of Cardiovascular Pharmacology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan); Kurosaka, M. [Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017 (Japan); Miyatake, S. [Department of Neurosurgery, Osaka Medical College, Osaka 569-8686 (Japan); Fukumori, Y. [Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan); Ichikawa, H., E-mail: ichikawa@pharm.kobegakuin.ac.jp [Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan)

2011-12-15

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake L-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of {sup 10}B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg).

Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies

Energy Technology Data Exchange (ETDEWEB)

Kato, Itsuro [Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka (Japan)], E-mail: katoitsu@dent.osaka-u.ac.jp; Fujita, Yusei [Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka (Japan); Maruhashi, Akira [Radiation Oncology Research Laboratory, Research Reactor Institut, Kyoto University, Osaka (Japan); Kumada, Hiroaki [Japan Atomic Energy Agency, Tokai Research and Development Center, Ibaraki (Japan); Ohmae, Masatoshi [Department of Oral and Maxillofacial Surgery, Izimisano Municipal Hospital, Rinku General Hospital, Izumisano, Osaka (Japan); Kirihata, Mitsunori [Graduate School of Environment and Life Science, Osaka prefectural University, Osaka (Japan); Imahori, Yoshio [Department of Neurosurgery, Kyoto Prefectural University, Kyoto (Japan); CEO of Cancer Intelligence Care Systems, Inc., Tokyo (Japan); Suzuki, Minoru [Radiation Oncology Research Laboratory, Research Reactor Institut, Kyoto University, Osaka (Japan); Sakrai, Yoshinori [Graduate School of Medicine, Sapporo Medical University of Medicine, Hokkaido (Japan); Sumi, Tetsuro; Iwai, Soichi; Nakazawa, Mitsuhiro [Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka (Japan); Murata, Isao; Miyamaru, Hiroyuki [Division of Electrical, Electronic and Information Engineering, Graduate School of Engineering, Osaka University (Japan); Ono, Koji [Radiation Oncology Research Laboratory, Research Reactor Institut, Kyoto University, Osaka (Japan)

2009-07-15

It is necessary to explore new treatments for recurrent head and neck malignancies (HNM) to avoid severe impairment of oro-facial structures and functions. Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle. We have treated with BNCT 42 times for 26 patients (19 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and 3 sarcomas) with a recurrent and far advanced HNM since 2001. Results of (1) {sup 10}B concentration of tumor/normal tissue ratios (T/N ratio) of FBPA-PET studies were SCC: 1.8-5.7, sarcoma: 2.5-4.0, parotid tumor: 2.5-3.7. (2) Therapeutic effects were CR: 12 cases, PR: 10 cases, PD: 3 cases NE (not evaluated): 1 case. Response rate was 85%. (3) Improvement of QOL such as a relief of severe pain, bleeding, and exudates at the local lesion, improvement of PS, disappearance of ulceration, covered with normal skin and preserved oral and maxillofacial functions and tissues. (4) Survival periods after BNCT were 1-72 months (mean: 13.6 months). Six-year survival rate was 24% by Kaplan-Meier analysis. (5) Adverse-events were transient mucositis and alopecia in most of the cases; three osteomyelitis and one brain necrosis were recognized. These results indicate that BNCT represents a new and promising treatment approach for advanced HNM.

Medical set-up of boron neutron capture therapy (BNCT) for malignant glioma at the Japan research reactor (JRR)-4

International Nuclear Information System (INIS)

Yamamoto, T.; Matsumura, A.; Nose, T.; Shibata, Y.; Nakai, K.; Sakurai, F.; Kishi, T.; Kumada, H.; Yamamoto, K.; Torii, Y.

2001-01-01

The University of Tsukuba project for boron neutron capture therapy (BNCT) was initiated at the Japan Atomic Energy Research Institute (JAERI) in 1992. The clinical study for BNCT began at the Japan Research Reactor (JRR)-2 of the JAERI in November 1995. By the end of 1998, a new medical irradiation facility had been installed in JRR-4 of that included a new medical treatment room and patient-monitoring area adjacent to the irradiation room. The medical treatment room was built to reflect a hospital-type operation room that includes an operating table with a carbon head frame, anesthesia apparatus with several cardiopulmonary monitors, etc. Following craniotomy in the treatment room, a patient under anesthesia is transported into the irradiation room for BNCT. The boron concentration in tissue is measured with prompt gamma ray analysis (PGA) and simultaneously by inductively coupled plasma atomic emission spectroscopy (ICP-AES) methods. For the immediate pre- and post-BNCT care, a collaborating neurosurgical department of the University of Tsukuba was prepared in the vicinity of the JAERI. The long term follow-up is done at the University of Tsukuba Hospital. Epithermal neutron beam also became available at the new JRR-4. By changing the thickness and/or the configuration of heavy water, a cadmium plate, and a graphite reflector, the JRR-4 provides a variety of neutron beams, including three typical beams (Epithermal mode and Thermal modes I and II). Intraoperative BNCT using the thermal beam is planned to study at the beginning of the clinical trial. The ongoing development of the JAERI Computational Dosimetry System (JCDS) and radiobiological studies have focused in the application of the epithermal beam for BNCT. After obtaining these basic data, we are planning to use the epithermal beam for intraoperative BNCT. (author)

Facility transition instruction

International Nuclear Information System (INIS)

Morton, M.R.

1997-01-01

The Bechtel Hanford, Inc. facility transition instruction was initiated in response to the need for a common, streamlined process for facility transitions and to capture the knowledge and experience that has accumulated over the last few years. The instruction serves as an educational resource and defines the process for transitioning facilities to long-term surveillance and maintenance (S and M). Generally, these facilities do not have identified operations missions and must be transitioned from operational status to a safe and stable configuration for long-term S and M. The instruction can be applied to a wide range of facilities--from process canyon complexes like the Plutonium Uranium Extraction Facility or B Plant, to stand-alone, lower hazard facilities like the 242B/BL facility. The facility transition process is implemented (under the direction of the US Department of Energy, Richland Operations Office [RL] Assistant Manager-Environmental) by Bechtel Hanford, Inc. management, with input and interaction with the appropriate RL division and Hanford site contractors as noted in the instruction. The application of the steps identified herein and the early participation of all organizations involved are expected to provide a cost-effective, safe, and smooth transition from operational status to deactivation and S and M for a wide range of Hanford Site facilities

Measurement of the tissue to A-150 tissue equivalent plastic kerma ratio at two p(66)Be neutron therapy facilities

International Nuclear Information System (INIS)

Langen, K M; Binns, P J; Schreuder, A N; Lennox, A J; Deluca, P M Jr.

2003-01-01

The ICRU tissue to A-150 tissue equivalent plastic kerma ratio is needed for neutron therapy dosimetry. The current ICRU protocol for neutron dosimetry recommends using a common conversion factor of 0.95 at all high-energy neutron therapy facilities. In an effort to determine facility specific ICRU tissue to A-150 plastic kerma ratios, an experimental approach was pursued. Four low pressure proportional counters that differed in wall materials (i.e. A-150, carbon, zirconium and zirconium-oxide) were used as dosimeters and integral kerma ratios were determined directly in the clinical beam. Measurements were performed at two p(66)Be facilities: iThemba LABS near Cape Town and Fermilab near Chicago. At the iThemba facility the clinical neutron beam is routinely filtered by a flattening and hardening filter combination. The influence of beam filtration on the kerma ratio was evaluated. Using two recent gas-to-wall dose conversion factor (r m,g value) evaluations a mean ICRU tissue to A-150 plastic kerma ratio of 0.93 ± 0.05 was determined for the clinical beam at iThemba LABS. The respective value for the Fermilab beam is 0.95 ± 0.05. The experimentally determined ICRU tissue to A-150 plastic kerma ratios for the two clinical beams are in agreement with theoretical evaluations. Beam filtration reduces the kerma ratio by 3 ± 2%

Towards gadolinium neutron capture therapy

International Nuclear Information System (INIS)

Stalpers, L.; Kuipers, S.; Vroegindeweij, C.; Stecher-Rasmussen, F.; Slotman, B.

2000-01-01

As glioblastoma multiforme has macroscopic areas with poor vascularisation, and thereby poor uptake of an NCT-agent, the long-range γ-rays from GdNCT might enhance dose deposition compared to BNCT and to conformal photon therapy. Multicellular spheroids from a human glioblastoma cell line (Gli-6) were irradiated with conventional X-rays, with neutrons only (from the NRG Argonaut Reactor, LFR), and with neutrons (from the LFR) + 157 Gd-DTPA (240 ppm 157 Gd). Preliminary results demonstrate that after neutron irradiation in the presence of 157 Gd, the spheroids showed growth arrest. By 3D treatment planning calculations on MRI's from patients with brain tumours, dose volume histograms (DVH) for GdNCT were compared to DVH for conventional conformal radiotherapy. The calculations indicate that GdNCT on patients with large, deep-seated tumours yields better tumour/brain dose distribution than conformal radiotherapy. (author)

Research and design of pulsed switching power supply for deep tumor therapy facility with heavy ions accelerator in Lanzhou

International Nuclear Information System (INIS)

Shi Chunfeng; Zhao Jiang; Yan Hongbin; Wu Fengjun; Gao Daqing

2012-01-01

The pulsed switching power supply was developed for deep tumor therapy facility with heavy ions in cooler-storage-ring of the heavy ions research facility in Lanzhou (HIRFL-CSR). The control principle of the dual closed-loop scheme was described and the open-loop Bode diagrams were given. The results of simulation and prototype experiment show that the current error gets much smaller than that of the single closed-loop pulsed switching power supply. Moreover, the simulation and test results were analyzed, and the circuit configuration and dual closed-loop strategy selected are practicable. (authors)

Intracellular targeting of mercaptoundecahydrododecaborate (BSH) to malignant glioma by transferrin-PEG liposomes for boron neutron capture therapy (BNCT)

International Nuclear Information System (INIS)

Doi, Atsushi; Miyatake, Shin-ichi; Iida, Kyouko

2006-01-01

Malignant glioma is one of the most difficult tumor to control with usual therapies. In our institute, we select boron neutron capture therapy (BNCT) as an adjuvant radiation therapy after surgical resection. This therapy requires the selective delivery of high concentration of 10 B to malignant tumor tissue. In this study, we focused on a tumor-targeting 10 B delivery system (BDS) for BNCT that uses transferrin-conjugated polyethylene-glycol liposome encapsulating BSH (TF-PEG liposome-BSH) and compared 10 B uptake of the tumor among BSH, PEG liposome-BSH and TF-PEG liposome-BSH. In vitro, we analyzed 10 B concentration of the cultured human U87Δ glioma cells incubated in medium containing 20 μg 10 B/ml derived from each BDS by inductively coupled plasma atomic emission spectrometry (ICP-AES). In vivo, human U87Δ glioma-bearing nude mice were administered with each BDS (35mg 10 B/kg) intravenously. We analyzed 10 B concentration of tumor, normal brain and blood by ICP-AES. The TF-PEG liposome-BSH showed higher absolute concentration more than the other BDS. Moreover, TF-PEG liposome-BSH decreased 10 B concentration in blood and normal tissue while it maintained high 10 B concentration in tumor tissue for a couple of days. This showed the TF-PEG liposome-BSH caused the selective delivery of high concentration of 10 B to malignant tumor tissue. The TF-PEG liposome-BSH is more potent BDS for BNCT to obtain absolute high 10 B concentration and good contrast between tumor and normal tissue than BSH and PEG liposome-BSH. (author)

DCDS: A Real-time Data Capture and Personalized Decision Support System for Heart Failure Patients in Skilled Nursing Facilities.

Science.gov (United States)

Zhu, Wei; Luo, Lingyun; Jain, Tarun; Boxer, Rebecca S; Cui, Licong; Zhang, Guo-Qiang

2016-01-01

Heart disease is the leading cause of death in the United States. Heart failure disease management can improve health outcomes for elderly community dwelling patients with heart failure. This paper describes DCDS, a real-time data capture and personalized decision support system for a Randomized Controlled Trial Investigating the Effect of a Heart Failure Disease Management Program (HF-DMP) in Skilled Nursing Facilities (SNF). SNF is a study funded by the NIH National Heart, Lung, and Blood Institute (NHLBI). The HF-DMP involves proactive weekly monitoring, evaluation, and management, following National HF Guidelines. DCDS collects a wide variety of data including 7 elements considered standard of care for patients with heart failure: documentation of left ventricular function, tracking of weight and symptoms, medication titration, discharge instructions, 7 day follow up appointment post SNF discharge and patient education. We present the design and implementation of DCDS and describe our preliminary testing results.

Carbon capture and storage-Investment strategies for the future?

International Nuclear Information System (INIS)

Rammerstorfer, Margarethe; Eisl, Roland

2011-01-01

The following article deals with real options modeling for investing into carbon capture and storage technologies. Herein, we derive two separate models. The first model incorporates a constant convenience yield and dividend for the investment project. In the second model, the convenience yield is allowed to follow a mean reverting process which seems to be more realistic, but also increases the model's complexity. Both frameworks are to be solved numerically. Therefore, we calibrate our model with respect to empirical data and provide insights into the models' sensitivity toward the chosen parameter values. We found that given the recently observable prices for carbon dioxide, an investment into C O2-storage facilities is not profitable. - Highlights: → Real options modeling for investing into carbon capture and storage technologies. → Given the recently observable prices for carbon dioxide, an investment into CO 2 -storage facilities is not profitable. → Investment decision is mainly affected by risk free rate and volatility.

Radiation protection metrology at a high-energy neutron therapy facility

International Nuclear Information System (INIS)

Bonnett, D.E.; Sherwin, A.G.; More, B.R.

1991-01-01

A radiation protection survey has been carried out at a high-energy neutron therapy facility using a combination of different detectors and counters. Included in the survey were measurements with a tissue equivalent proportional counter (TEPC), a rem meter, a large volume ionisation chamber (LVI) and a Geiger counter. Dose equivalent rates, normalised to a proton beam current of 25 μA, of between 1 μSv.h -1 and 0.7 Sv.h -1 were recorded depending on the location. In general the results confirm the tendency of the rem meter to over-read in fields consisting mainly of low energy neutrons and illustrate the advantages of the diagnostic and gamma discriminating properties of the TEPC. The LVI-Geiger system was found to be the least favourable combination of dosemeters, substantially under-reading and being unable to estimate the neutron dose rate at levels below about 32 μGy.h -1 . (author)

Intraoperative boron neutron capture therapy for malignant gliomas. First clinical results of Tsukuba phase I/II trial using JAERI mixed thermal-epithermal beam

International Nuclear Information System (INIS)

Matsumura, A.; Yamamoto, T.; Shibata, Y.

2000-01-01

Since October 1999, a clinical trial of intraoperative boron neutron capture therapy (IOBNCT) is in progress at JRR-4 (Japan Research Reactor-4) in Japan Atomic Energy Research Institute (JAERI) using mixed thermal-epithermal beam (thermal neutron beam I: TNB-I). Compared to pure thermal beam (thermal neutron beam II: TNB-II), TNB-I has an improved neutron delivery into the deep region than TNB-II. The clinical protocol and the preliminary results will be discussed. (author)

Enhanced therapeutic effect on murine melanoma and angiosarcoma cells by boron neutron capture therapy using a boronated metalloporphyrin

International Nuclear Information System (INIS)

Yamada, Yoshihiko; Ichihashi, Masamitsu; Kahl, S.B.; Toda, Ken-ichi.

1994-01-01

We have already achieved successful treatment of several human patients with malignant melanoma by boron neutron capture therapy (BNCT) using 10 B 1 -paraboronophenylalanine ( 10 B 1 -BPA·HCl). In this study we used a new compound, a manganese boronated protoporphyrin (Mn- 10 BOPP), and compared it to 10 B 1 -BPA·HCl with respect to uptake in murine melanoma and angiosarcoma cells as well as to their cell killing effect. 10 B uptake was measured in a new method, and the new compound was much more incorporated into both cells than 10 B 1 -BPA·HCl. Furthermore, melanoma and angiosarcoma cells preincubated with the new compound were 15 to 20 times more efficiently killed by BNCT than cells preincubated with 10 B 1 -BPA·HCl. (author)

{sup 1}H and {sup 10}B NMR and MRI investigation of boron- and gadolinium-boron compounds in boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Bonora, M., E-mail: marco.bonora@unipv.it [Physics Department ' A. Volta' , University of Pavia, Via Bassi 6, 27100 Pavia (Italy)] [CNISM Unit (Italy); Corti, M.; Borsa, F. [Physics Department ' A. Volta' , University of Pavia, Via Bassi 6, 27100 Pavia (Italy)] [CNISM Unit (Italy); Bortolussi, S.; Protti, N.; Santoro, D.; Stella, S.; Altieri, S. [Nuclear and Theoretical Physics Department, University of Pavia, Via Bassi 6, 27100 Pavia (Italy)] [INFN Pavia (Italy); Zonta, C.; Clerici, A.M.; Cansolino, L.; Ferrari, C.; Dionigi, P. [Surgical Sciences Department, Experimental Surgery Laboratory, University of Pavia, Pavia (Italy); Porta, A.; Zanoni, G.; Vidari, G. [Organic Chemistry Department, University of Pavia, Via Taramelli 10, 27100 Pavia (Italy)

2011-12-15

{sup 10}B molecular compounds suitable for Boron Neutron Capture Therapy (BNCT) are tagged with a Gd(III) paramagnetic ion. The newly synthesized molecule, Gd-BPA, is investigated as contrast agent in Magnetic Resonance Imaging (MRI) with the final aim of mapping the boron distribution in tissues. Preliminary Nuclear Magnetic Resonance (NMR) measurements, which include {sup 1}H and {sup 10}B relaxometry in animal tissues, proton relaxivity of the paramagnetic Gd-BPA molecule in water and its absorption in tumoral living cells, are reported.

Beam neutron energy optimization for boron neutron capture therapy using monte Carlo method

International Nuclear Information System (INIS)

Pazirandeh, A.; Shekarian, E.

2006-01-01

In last two decades the optimal neutron energy for the treatment of deep seated tumors in boron neutron capture therapy in view of neutron physics and chemical compounds of boron carrier has been under thorough study. Although neutron absorption cross section of boron is high (3836b), the treatment of deep seated tumors such as glioblastoma multiform requires beam of neutrons of higher energy that can penetrate deeply into the brain and thermalized in the proximity of the tumor. Dosage from recoil proton associated with fast neutrons however poses some constraints on maximum neutron energy that can be used in the treatment. For this reason neutrons in the epithermal energy range of 10eV-10keV are generally to be the most appropriate. The simulation carried out by Monte Carlo methods using MCBNCT and MCNP4C codes along with the cross section library in 290 groups extracted from ENDF/B6 main library. The ptimal neutron energy for deep seated tumors depends on the sue and depth of tumor. Our estimated optimized energy for the tumor of 5cm wide and 1-2cm thick stands at 5cm depth is in the range of 3-5keV

Overview of research and therapy facilities for radiobiological experimental work in particle therapy. Report from the European Particle Therapy Network radiobiology group.

Science.gov (United States)

Dosanjh, Manjit; Jones, Bleddyn; Pawelke, Jörg; Pruschy, Martin; Sørensen, Brita Singers

2018-04-24

Particle therapy (PT) as cancer treatment, using protons or heavier ions, can provide a more favorable dose distribution compared to X-rays. While the physical characteristics of particle radiation have been the aim of intense research, less focus has been placed on the actual biological responses arising from particle irradiation. One of the biggest challenges for proton radiobiology is the RBE, with an increasing concern that the clinically-applied generic RBE-value of 1.1 is an approximation, as RBE is a complex quantity, depending on both biological and physical parameters, such as dose, LET, cellular and tissue radiobiological characteristics, as well as the endpoints being studied. Most of the available RBE data derive from in vitro experiments, with very limited in vivo data available, especially in late-reacting tissues, which provide the main constraints and influence the quality of life endpoints in radiotherapy. There is a need for systematic, large-scale studies to thoroughly establish the biology of particle radiation in a number of different experimental models in order to refine biophysical mathematical models that can potentially be used to guide PT. The overall objective of the European Particle Therapy Network (EPTN) WP6 is to form a network of research and therapy facilities in order to coordinate and standardize the radiobiological experiments, to obtain more accurate predictive parameters than in the past. Coordinated research is required in order to obtain the most appropriate experimental data. The aim in this paper is to describe the available radiobiology infrastructure of the centers involved in EPTN WP6. Copyright © 2018 Elsevier B.V. All rights reserved.

About neutron capture therapy method development at WWR-SM reactor in institute of Nuclear Physics of Uzbekistan Academy of Sciences

International Nuclear Information System (INIS)

Abdullaeva, G.A.; Baytelesov, S.A.; Dosimbaev, A.A.; Koblik, Yu.N.; Gritsay, O.O.

2006-01-01

Full text: Neutron capture therapy (NCT) is developing method of swellings treatment, on which specialists set one's serious hopes, as at its realization the practical possibilities of the effect on any swellings open. The essence of method is simple and lies in the fact that to the swelling enter preparation containing boron or gadolinium, which one have a large capture cross-section of the thermal and slow neutrons. Then the swelling is irradiated once with the slow (epithermal) neutron beam with fluency about 10 9 neutrons /sm 2 s for a short time and single. As a result of thermal neutrons capture by the boron (or gadolinium) nuclei secondary radiation which affecting swelling cells is emitted. NCT of oncologic diseases makes the specific demands to physical parameters of neutron beams. Now research reactors are often used for NCT. However, research reactor WWR-SM (INP, Uzbekistan AS, Tashkent) doesn't provide with the epithermal neutron beams and to develop this technique the reactor, first of all, needs for obtaining the epithermal neutron beams with energy spectrum in range from 1 eV up to 10 keV and with intensity ∼ 10 9 neutron /sm 2 s. Practically it is connected with upgrade of at least one of existed reactor channels, namely with equipping with the special equipment (filters), forming from the reactor spectrum the beam of necessary energy neutrons. It requires realization of preliminary model calculations, including calculations of capture cross-sections, of filters types and their geometrical parameters on the basis of optimal selected materials. Such calculations, as a rule, are carried out on the basis of Monte-Carlo method and designed software for calculation of nuclear reactor physical and technical characteristics [1]. In this work the calculation results of devices variants and problems discussion, related with possibility of WWR-SM reactor using for NCT are presented. (author)

Medical cyclotron facilities

International Nuclear Information System (INIS)

1984-09-01

This report examines the separate proposals from the Austin Hospital and the Australian Atomic Energy Commission for a medical cyclotron facility. The proponents have argued that a cyclotron facility would benefit Australia in areas of patient care, availability and export of radioisotopes, and medical research. Positron emission tomography (PET) and neutron beam therapy are also examined

Research and design of scanning power supply for deep tumor therapy facility with heavy ions accelerator in Lanzhou

International Nuclear Information System (INIS)

Huang Yuzhen; Liu Yuntao; Chen Youxin; Gao Daqing; Zhang Shu; Gao Yalin

2009-01-01

This paper describes the technique targets and operation principle of the scanning power supply for the deep tumor therapy facility with heavy ions in Cooler-Storage-Ring of the Heavy Ion Research Facility in Lanzhou (HIRFL-CSR). To ensure the specified accuracy of the current, the hysteresis loop control strategy was adopted, and tracking error was constrained in the specified tolerance. One prototype was designed and installed. And the simulation results and test results were listed in the paper. The results show that all the targets can meet the design requirements, and that the circuit configuration and hysteresis loop control strategy selected are practicable. (authors)

Biodistribution of nanoparticles of hydrophobic gadopentetic-acid derivative prepared with a planetary ball mill for neutron-capture therapy of cancer

International Nuclear Information System (INIS)

Nabeta, Chika; Ichikawa, Hideki; Fukumori, Yoshinobu

2006-01-01

Nanoparticles of hydrophobic gadopentetic-acid derivatives (Gd-nanoGR) were prepared with a wet ball-milling process for gadolinium neutron-capture therapy. Ball-milling of solid mass of gadopentetic acid distearylamide with soybean lecithin as a dispersant in the presence of water and subsequent sonication at 70degC resulted in the Gd-nanoGR with the particle size of 63 nm. Biodistribution study using melanoma-bearing hamsters demonstrated that the i.v. injection of the Gd-nanoGR made a higher gadolinium accumulation in tumor (109 μg Gd/g wet tumor at 6h after administration), when compared with the gadolinium-loaded micellar-like nanoparticles previously reported. (author)

Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.

Science.gov (United States)

Andoh, T; Fujimoto, T; Sudo, T; Fujita, I; Imabori, M; Moritake, H; Sugimoto, T; Sakuma, Y; Takeuchi, T; Kawabata, S; Kirihata, M; Akisue, T; Yayama, K; Kurosaka, M; Miyatake, S; Fukumori, Y; Ichikawa, H

2011-12-01

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of (10)B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg). Copyright © 2011 Elsevier Ltd. All rights reserved.

Boronated monoclonal antibody 225.28S for potential use in neutron capture therapy of malignant melanoma

International Nuclear Information System (INIS)

Tamat, S.R.; Moore, D.E.; Patwardhan, A.; Hersey, P.

1989-01-01

The concept of conjugating boron cluster compounds to monoclonal antibodies has been examined by several groups of research workers in boron neutron capture therapy (BNCT). The procedures reported to date for boronation of monoclonal antibodies resulted in either an inadequate level of boron incorporation, the precipitation of the conjugates, or a loss of immunological activity. The present report describes the conjugation of dicesium-mercapto-undecahydrododecaborate (Cs2B12H11SH) to 225.28S monoclonal antibody directed against high molecular weight melanoma-associated antigens (HMW-MAA), using poly-L-ornithine as a bridge to increase the carrying capacity of the antibody and to minimize change in the conformational structure of antibody. The method produces a boron content of 1,300 to 1,700 B atoms per molecule 225.28S while retaining the immunoreactivity. Characterization in terms of the homogeneity of the conjugation of the boron-monoclonal antibody conjugates has been studied by gel electrophoresis and ion-exchange HPLC

Hybrid Calcium Phosphate-Polymeric Micelles Incorporating Gadolinium Chelates for Imaging-Guided Gadolinium Neutron Capture Tumor Therapy.

Science.gov (United States)

Mi, Peng; Dewi, Novriana; Yanagie, Hironobu; Kokuryo, Daisuke; Suzuki, Minoru; Sakurai, Yoshinori; Li, Yanmin; Aoki, Ichio; Ono, Koji; Takahashi, Hiroyuki; Cabral, Horacio; Nishiyama, Nobuhiro; Kataoka, Kazunori

2015-06-23

Gadolinium (Gd) chelates-loaded nanocarriers have high potential for achieving magnetic resonance imaging (MRI)-guided Gd neutron capture therapy (GdNCT) of tumors. Herein, we developed calcium phosphate micelles hybridized with PEG-polyanion block copolymers, and incorporated with the clinical MRI contrast agent Gd-diethylenetriaminepentaacetic acid (Gd-DTPA/CaP). The Gd-DTPA/CaP were nontoxic to cancer cells at the concentration of 100 μM based on Gd-DTPA, while over 50% of the cancer cells were killed by thermal neutron irradiation at this concentration. Moreover, the Gd-DTPA/CaP showed a dramatically increased accumulation of Gd-DTPA in tumors, leading to the selective contrast enhancement of tumor tissues for precise tumor location by MRI. The enhanced tumor-to-blood distribution ratio of Gd-DTPA/CaP resulted in the effective suppression of tumor growth without loss of body weight, indicating the potential of Gd-DTPA/CaP for safe cancer treatment.

Synthesis of o-carboranylmethyl ethers of steroids as potential target substrates for boron neutron capture therapy

International Nuclear Information System (INIS)

Schneiderova, L.; Gruener, B.; Strouf, O.; Kimlova, I.

1992-01-01

o-carboranylmethyl ethers of steroids were synthesized by insertion of steroidal 2-propynyloxy derivatives into 6,9-bis(acetonitrile)decarborane. This reaction provided compounds with an estrane and androstane skeleton, potentially useful in boron neutron capture therapy of hormone-sensitive forms of cancer: 17β-o-carboranylmethyl ether of estradiol IXb (yield 14%) and 3β- and 17β-carboranylmethyl ethers of androstenediol Vb and VIIb (yield 12% and 13%, respectively). Jones oxidation gave the carboranyl derivative of androsten-17-one VIb in 75% yield. As shown by a study of insertion of 3β-(2-propynyloxy)cholest-5-ene (IVa), the low yields of the insertion reaction cannot be increased by change in the reaction conditions. The relative binding affinity of compound IXb to the estrogen receptor from rat uterine and human breast tumor cytosol was 3.0 and 0.29%, respectively, of that of estradiol. (author) 2 figs., 2 tabs., 20 refs

Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis

Directory of Open Access Journals (Sweden)

Ana M.C. Barradas

2013-12-01

Full Text Available Circulating Tumor Cells (CTC are rare cells originated from tumors that travel into the blood stream, extravasate to different organs of which only a small fraction will develop into metastasis. The presence of CTC enumerated with the CellSearch system is associated with a relative short survival and their continued presence after the first cycles of therapy indicates a futile therapy in patients with metastatic carcinomas. Detailed characterization of CTC holds the promise to enable the choice of the optimal therapy for the individual patients during the course of the disease. The phenotype, physical and biological properties are however not well understood making it difficult to assess the merit of recent technological advancements to improve upon the capture of CTC or to evaluate their metastatic potential. Here we will discuss the recent advances in the classification of CTC captured by the CellSearch system, the implications of their features and numbers. Latest capture platforms are reviewed and placed in the light of technology improvements needed to detect CTC. Physical properties, phenotype, viability and proliferative potential and means to assess their proliferation and metastatic capacity will be summarized and placed in the context of the latest CTC capture platforms.

A technique to prepare boronated B72.3 monoclonal antibody for boron neutron capture therapy

International Nuclear Information System (INIS)

Ranadive, G.N.; Rosenzweig, H.S.; Epperly, M.W.

1993-01-01

B72.3 monoclonal antibody has been successfully boronated using mercaptoundecahydro-closo-dodecaborate (boron cage compound). The reagent was incorporated by first reacting the lysine residues of the antibody with m-maleimidobenzoyl succinimide ester (MBS), followed by Michael addition to the maleimido group by the mercapto boron cage compound to form a physiologically stable thioether linkage. Boron content of the antibody was determined by atomic absorption spectroscopy. For biodistribution studies, boronated antibody was radioiodinated with iodogen. 125 I-labeled and boronated B72.3 monoclonal antibody demonstrated clear tumor localization when administered via tail vein injections to athymic nude mice bearing LS174-T tumor xenografts. Boronated antibody was calculated to deliver 10 6 boron atoms per tumor cell. Although this falls short of the specific boron content originally proposed as necessary for boron neutron capture therapy (BNCT), recent calculations suggest that far fewer atoms of 10 B per tumor cell would be necessary to effect successful BNCT when the boron is targeted to the tumor cell membrane. (author)

Alanine and TLD coupled detectors for fast neutron dose measurements in neutron capture therapy (NCT)

Energy Technology Data Exchange (ETDEWEB)

Cecilia, A.; Baccaro, S.; Cemmi, A. [ENEA-FIS-ION, Casaccia RC, Via Anguillarese 301, 00060 Santa Maria di Galeria, Rome (Italy); Colli, V.; Gambarini, G. [Dept. of Physics of the Univ., INFN, Via Celoria 16, 20133 Milan (Italy); Rosi, G. [ENEA-FIS-ION, Casaccia RC, Via Anguillarese 301, 00060 Santa Maria di Galeria, Rome (Italy); Scolari, L. [Dept. of Physics of the Univ., INFN, Via Celoria 16, 20133 Milan (Italy)

2004-07-01

A method was investigated to measure gamma and fast neutron doses in phantoms exposed to an epithermal neutron beam designed for neutron capture therapy (NCT). The gamma dose component was measured by TLD-300 [CaF{sub 2}:Tm] and the fast neutron dose, mainly due to elastic scattering with hydrogen nuclei, was measured by alanine dosemeters [CH{sub 3}CH(NH{sub 2})COOH]. The gamma and fast neutron doses deposited in alanine dosemeters are very near to those released in tissue, because of the alanine tissue equivalence. Couples of TLD-300 and alanine dosemeters were irradiated in phantoms positioned in the epithermal column of the Tapiro reactor (ENEA-Casaccia RC). The dosemeter response depends on the linear energy transfer (LET) of radiation, hence the precision and reliability of the fast neutron dose values obtained with the proposed method have been investigated. Results showed that the combination of alanine and TLD detectors is a promising method to separate gamma dose and fast neutron dose in NCT. (authors)

What happens to patients on antiretroviral therapy who transfer out to another facility?

Directory of Open Access Journals (Sweden)

Joseph Kwong-Leung Yu

Full Text Available BACKGROUND: Long term retention of patients on antiretroviral therapy (ART in Africa's rapidly expanding programmes is said to be 60% at 2 years. Many reports from African ART programmes make little mention of patients who are transferred out to another facility, yet Malawi's national figures show a transfer out of 9%. There is no published information about what happens to patients who transfer-out, but this is important because if they transfer-in and stay alive in these other facilities then national retention figures will be better than previously reported. METHODOLOGY/PRINCIPAL FINDINGS: Of all patients started on ART over a three year period in Mzuzu Central Hospital, North Region, Malawi, those who transferred out were identified from the ART register and master cards. Clinic staff attempted to trace these patients to determine whether they had transferred in to a new ART facility and their outcome status. There were 805 patients (19% of the total cohort who transferred out, of whom 737 (92% were traced as having transferred in to a new ART facility, with a median time of 1.3 months between transferring-out and transferring-in. Survival probability was superior and deaths were lower in the transfer-out patients compared with those who did not transfer. CONCLUSION/SIGNIFICANCE: In Mzuzu Central Hospital, patients who transfer-out constitute a large proportion of patients not retained on ART at their original clinic of registration. Good documentation of transfer-outs and transfer-ins are needed to keep track of national outcomes. Furthermore, the current practice of regarding transfer-outs as being double counted in national cohorts and subtracting this number from the total national registrations to get the number of new patients started on ART is correct.

Analysis of metastasis of melanoma-bearing hamsters in thermal neutron capture therapy

International Nuclear Information System (INIS)

Ueda, Masataka; Mishima, Yutaka; Ichihashi, Masamitsu

1985-01-01

Melanoma-bearing hamsters were divided into three groups: the MG I was treated with both 10 B 1 -para-boronophenylalanine.HCl ( 10 B 1 -BPA) and neutron capture therapy (NCT); the MG II was treated with NCT alone; and the control group (MG III). The most satisfactory effect on regression was seen in the MG I. When the opposite site to the transplanted tumor site was exposed to thermal neutrons, no enhanced effect on metastasis was seen. Tumor cells of MG I and MG II were transplanted subcutaneously 24 hr after NCT into normal hamsters (MG It and MG IIt), and their growth and metastasis abilities were examined. MG It cells possessed neither growth nor metastasis ability; while MG IIt cells showed normal growth and metastasis abilities. Lethal effects on tumor cells seemed to occur in the MG I at 24 hr after NCT, suggesting no effects of NCT on the metastasis ability of tumor cells. Metastasis was seen in 2 of 8 animals in the MG III; however, inhibitory effects on tumor cells were the same as those in the other groups MG I and MG II. When the cells were exposed to 100 rad and 300 rad of gamma rays to assess effects of gamma rays during NCT, neither tumor growth nor lung metastasis was affected. When the tumor was excised with 5 mm margin, relapse occurred in a high incidence. There was no difference in lung metastasis between NCT and gamma irradiation. (Namekawa, K.)

Gadolinium as an element for neutron capture therapy

International Nuclear Information System (INIS)

Brugger, R.M.; Liu, H.B.; Laster, B.H.; Gordon, C.R.; Greenberg, D.D.; Warkentien, L.S.

1992-01-01

At BNL, preparations are being made to test in vitro compounds containing Gd and compare their response to the response of GD-DTPA to determine if one or several compounds can be located that enter the cells and enhance the Auger effect. Two similar rotators with positions for cell vials that have been constructed for these tests. The first rotator is made of only paraffin which simulates healthy tissue and provides control curves. The second rotator has 135 ppM of Gd-157 in the paraffin to simulate a Gd loaded tumor. Cells are irradiated in vials in the paraffin rotator and in the Gd-paraffin rotator at the epithermal beam of the Brookhaven Medical Research Reactor (BMRR). This produces an irradiation similar to what a patient would receive In an actual treatment. A combination of irradiations are made with both rotators; with no Gd compound or IdUrd In the cell media, with only Gd compound in the cell media and with both Gd compound and IdUrd in the cell media. The first set shows the effects of gamma rays from the H(n,gamma) reaction and the prompt gamma rays from capture of neutrons by Gd. The second set shows if there is any effect of Gd being in the cell media or inside the cells, i.e., an Auger effect. The third set shows the effect of enhancement by the IdUrd produced by the gamma rays from neutrons captured by either H or Gd. The fourth set combines all of the reactions and enhancements. Preliminary calculations and physical measurements of the doses that the cells will receive In these rotators have been made

Proposal of cancer therapy system without rotating gantry

International Nuclear Information System (INIS)

Kodaira, Masanobu

2002-01-01

Beam therapy is one of useful methods for cancer therapy. Many results in National Institute of Radiological Sciences (NIRS) show many abilities of beam therapy for cancer therapy. In Japan, several beam therapy facilities are constructed or under construction. If its construction budget becomes to be smaller, beam therapy may be used as the general cancer therapy. But in the present beam therapy facilities, the budget of its construction is very large. One of the reasons of big budget is the construction of the big buildings equipped with thick shielding walls. Most of space of the facilities with thick shielding walls is devoted to the treatment equipments such as rotating gantries and beam transport lines. This proposal is that using oblique beam line and rotating treatment bed, multi-portal irradiation is realized without rotating gantry. At the same time, we designed adequate beam lines to minimize the total facilities. (author)

Atmospheric Radiation Measurement's Data Management Facility captures metadata and uses visualization tools to assist in routine data management.

Science.gov (United States)

Keck, N. N.; Macduff, M.; Martin, T.

2017-12-01

The Atmospheric Radiation Measurement's (ARM) Data Management Facility (DMF) plays a critical support role in processing and curating data generated by the Department of Energy's ARM Program. Data are collected near real time from hundreds of observational instruments spread out all over the globe. Data are then ingested hourly to provide time series data in NetCDF (network Common Data Format) and includes standardized metadata. Based on automated processes and a variety of user reviews the data may need to be reprocessed. Final data sets are then stored and accessed by users through the ARM Archive. Over the course of 20 years, a suite of data visualization tools have been developed to facilitate the operational processes to manage and maintain the more than 18,000 real time events, that move 1.3 TB of data each day through the various stages of the DMF's data system. This poster will present the resources and methodology used to capture metadata and the tools that assist in routine data management and discoverability.

Measurement and analysis of the $^{243}$Am neutron capture cross section at the n_TOF facility at CERN

CERN Document Server

Mendoza, E; Guerrero, C; Berthoumieux, E; Abbondanno, U; Aerts, G; Alvarez-Velarde, F; Andriamonje, S; Andrzejewski, J; Assimakopoulos, P; Audouin, L; Badurek, G; Balibrea, J; Baumann, P; Becvar, F; Belloni, F; Calvino, F; Calviani, M; Capote, R; Carrapico, C; Carrillo de Albornoz, A; Cennini, P; Chepel, V; Chiaveri, E; Colonna, N; Cortes, G; Couture, A; Cox, J; Dahlfors, M; David, S; Dillmann, I; Dolfini, R; Domingo-Pardo, C; Dridi, W; Duran, I; Eleftheriadis, C; Ferrant†, L; Ferrari, A; Ferreira-Marques, R; Fitzpatrick, L; Frais-Koelbl, H; Fujii, K; Furman, W; Goncalves, I; Gonz alez-Romero, E; Goverdovski, A; Gramegna, F; Griesmayer, E; Gunsing, F; Haas, B; Haight, R; Heil, M; Herrera-Martinez, A; Igashira, M; Isaev, S; Jericha, E; Kappeler, F; Kadi, Y; Karadimos, D; Karamanis, D; Ketlerov, V; Kerveno, M; Koehler, P; Konovalov, V; Kossionides, E; Krticka, M; Lampoudis, C; Leeb, H; Lindote, A; Lopes, I; Lossito, R; Lozano, M; Lukic, S; Marganiec, J; Marques, L; Marrone, S; Martınez, T; Massimi, C; Mastinu, P; Mengoni, A; Milazzo, P M; Moreau, C; Mosconi, M; Neves, F; Oberhummer, H; O’Brien, S; Oshima, M; Pancin, J; Papachristodoulou, C; Papadopoulos, C; Paradela, C; Patronis, N; Pavlik, A; Pavlopoulos, P; Perrot, L; Pigni, M T; Plag, R; Plompen, A; Plukis, A; Poch, A; Praena, J; Pretel, C; Quesada, J; Rauscher, T; Reifarth, R; Rosetti, M; Rubbia, C; Rudolf, G; Rullhusen, P; Salgado, J; Santos, C; Sarchiapone, L; Savvidis, I; Stephan, C; Tagliente, G; Tain, J L; Tassan-Got, L; Tavora, L; Terlizzi, R; Vannini, G; Vaz, P; Ventura, A; Villamarin, D; Vicente, M C; Vlachoudis, V; Vlastou, R; Voss, F; Walter, S; Wendler, H; Wiescher, M; Wisshak, K

2014-01-01

Background:The design of new nuclear reactors and transmutation devices requires to reduce the present neutron cross section uncertainties of minor actinides. Purpose: Reduce the $^{243}$Am(n,$\\gamma$) cross section uncertainty. Method: The $^{243}$Am(n,$\\gamma$) cross section has been measured at the n_TOF facility at CERN with a BaF$_{2}$ Total Absorption Calorimeter, in the energy range between 0.7 eV and 2.5 keV. Results: The $^{243}$Am(n,$\\gamma$) cross section has been successfully measured in the mentioned energy range. The resolved resonance region has been extended from 250 eV up to 400 eV. In the unresolved resonance region our results are compatible with one of the two incompatible capture data sets available below 2.5 keV. The data available in EXFOR and in the literature has been used to perform a simple analysis above 2.5 keV. Conclusions: The results of this measurement contribute to reduce the $^{243}$Am(n,$\\gamma$) cross section uncertainty and suggest that this cross section is underestimate...

CO2 capture takes its industrial turn

International Nuclear Information System (INIS)

Remoue, A.; Lutzky, A.

2009-01-01

The CO 2 capture and sequestration is entering the industrial era. The technologies are ready, the regulation is progressively put into action, the financing of demonstration facilities is unfreezing and companies are on the starting line from Canada to China, including the USA and Europe. The market takeoff is expected for 2015 but the competition is already hard between equipment manufacturers who wish to develop proprietary technologies. (J.S.)

Astrophysics at nTOF facility

International Nuclear Information System (INIS)

Tagliente, G.; Colonna, N.; Maronne, S.; Terlizzi, R.; Abondanno, U.; Fujii, K.; Milazzo, P.M.; Moreau, C.; Belloni, F.; Aerts, G.; Berthoumieux, E.; Andriamonje, S.; Dridi, W.; Gunsing, F.; Pancin, J.; Perrot, L.; Alvarez, H.; Duran, I.; Paradela, C.; Alvarez-Velarde, F.; Cano-Ott, D.; Embid-Segura, M.; Guerrero, C.; Martinez, T.; Villamarin, D.; Vincente, M.C.; Gonzalez-Romero, E.; Andrzejewski, J.; Marganiec, J.; Assimakopoulos, P.; Karamanis, D.; Audouin, L.; Dillman, I.; Heil, M.; Kappeler, F.; Mosconi, M.; Plag, R.; Voss, F.; Walter, S.; Wissak, K.; Badurek, G.; Jericha, E.; Leeb, H.; Oberhummer, H.; Pigni, M.T.; Baumann, P.; David, S.; Kerveno, M.; Rudolf, G.; Lukic, S.; Becvar, F.; Krticka, M.; Bisterzo, S.; Ferrant, L.; Gallino, R.; Calvino, F.; Poch, A.; Pretel, C.; Calviani, M.; Gramegna, F.; Mastinu, P.; Capote, R.; Mengoni, A.; Capote, R.; Lozano, M.; Quesada, J.; Carrapico, C.; Salgado, J.; Santos, C.; Tavora, L.; Vaz, P.; Cennini, P.; Chiaveri, E.; Dahlfors, M.; Kadi, Y.; Sarchiapone, L.; Vlachoudis, V.; Wendler, H.; Chepel, V.; Ferreira-Marques, R.; Goncalves, I.; Lindote, A.; Lopes, I.; Neves, F.; Couture, A.; Cox, J.; O'Brien, S.; Wiescher, M.; Dominga-Pardo, C.; Tain, J.L.; Eleftheriadis, C.; Lamboudis, C.; Savvidis, I.; Stephan, C.; Tassan-Got, L.; Furman, W.; Haas, B.; Haight, R.; Reifarth, R.; Igashira, M.; Koehler, P.; Massimi, C.; Vannini, G.; Papadopoulos, C.; Pavlik, A.; Pavlopoulos, P.; Plomen, A.; Rullhusen, P.; Rauscher, T.; Rubbia, C.; Ventura, A.

2009-01-01

The neutron time of flight (n T OF) facility at CERN is a neutron spallation source, its white neutron energy spectrum ranges from thermal to several GeV, covering the full energy range of interest for nuclear astrophysics, in particular for measurements of the neutron capture cross-section required in s-process nucleosynthesis. This contribution gives an overview on the astrophysical program made at n T OF facility, the results and the implications will be considered.

Boron-neutron capture therapy for incurable cancer and inoperable brain tumors

International Nuclear Information System (INIS)

Hatanaka, Hiroshi

1993-01-01

Recent advances in cancer diagnosis and treatment have not yet improved the survival rate of patients with cancers of the brain, liver, etc. In these organs, an extirpation of the organ, which can be done for stomach, breast, cervix, lung, etc. is not allowed, and this fact is the cause of poor therapeutic results. Boron-neutron capture therapy (BNCT) utilizes the nuclear reaction which will take place between the boron-10 (loaded in the cancer cells artificially) and the thermal neutrons (delivered by reactors). The secondary radiations, helium and lithium hit the cancer cell itself and cause the death of the cancer cell while sparing the surrounding normal cells. BNCT is now being tried also by Oda of Kyoto University (9 cases) and by Nakagawa of Tokushima University (7 cases). It has been tried by Mishima (Kobe University) on 12 skin melanoma patients, proving satisfactory local control of the melanomas. Mercaptoundecahydrododecaborate (BHS) and boronophenylalanine (BPA) have been tried for brain tumors and for melanoma. For cancers of the liver and abdominal viscerae, antibody to the tumor specific antigen has been considered a good carrier of boron-10. Surgeons Takahashi, Fujii, Fujii, Yanagie, and Sekiguchi and immunologist Nariuchi of Tokyo University have been involved in the research and have obtained encouraging results in animals. Hatanaka has been proving good effect of BNCT upon giant cerebral arteriovenous malformation (AVM) and skull base meningioma. These diseases, although pathologically benign, have posed difficult problems in neurosurgery. It will be exciting good news to the patients. In conclusion, BNCT appears to be a good means to treat difficult lesions in the brain and other organs which defy sophisticated modern therapeutic means. (author)

Application of HVJ envelope system to boron neutron capture therapy (BNCT)

International Nuclear Information System (INIS)

Nakai, Kei; Kurooka, Masaaki; Kaneda, Yasufumi; Yamamoto, Tetsuya; Matsumura, Akira; Asano, Tomoyuki

2006-01-01

Boron Neutron Capture Therapy (BNCT) has been used clinically for the treatment of malignant tumors. Two drugs, p-boronophenylalanine (BPA) and sulfhydral borane (BSH), have been used as boron delivery agents. These drugs seem to be taken up preferentially in solid tumors, but it is uncertain whether therapeutic quantities of boron atoms are taken up by micro-invasive or distant tumor cells. High accumulation and high selective delivery of boron into tumor tissues are the most important requirements to achieve efficient BNCT for malignant tumor. The HVJ envelope (HVJ-E) vector system is a novel fusion-mediated gene delivery system based on inactivated hemagglutinating virus of Japan (HVJ; Sendai virus). Although we developed this vector system for gene transfer, it can also deliver proteins, synthetic oligonucleotides, and drugs. HVJ-liposome, which is liposome fused with HVJ-E, has higher boron trapping efficiency than HVJ-E alone. We report the boron delivery into cultured cells with HVJ-liposome systems. The cellular 10 B concentration after 60 min incubation with HVJ-E containing BSH was 24.9 μg/g cell pellet for BHK-21 cells (baby hamster kidney cells) and 19.4 μg/g cell pellet for SCC VII cells (murine squamous cell carcinoma). These concentrations are higher than that of 60 min incubated cells with BSH containing (100μg 10 B/ml) medium. These results indicate the HVJ-E fused with tumor cell membrane and rapidly delivered boron agents, and that the HVJ-E-mediated delivery system could be applicable to BNCT. Plans are underway to begin neutron radiation experiments in vivo and in vitro. (author)

POD evaluation for joint angles from inertial and optical motion capturing system

International Nuclear Information System (INIS)

Shimizu, Kai; Kobayashi, Futoshi; Nakamoto, Hiroyuki; Kojima, Fumio

2016-01-01

It has been recognized that advances in preventive maintenance can improve the sustainment of systems, facilities, and infrastructure. Robot technologies have also received attention for maintenance applications. In order to operate delicate tasks, multi-fingered robot hands have been proposed in cases where human capability is deficient. This paper deals with motion capturing systems for controlling the hand/arm robot remotely. Several types of motion capturing systems have been developed so far. However, it is difficult for individual motion capturing systems to measure precise joint angles of a human arm. Therefore, in this paper, we integrate the inertial motion capturing system with the optical motion capturing system to capture a human arm posture. By evaluating the reliability of each motion capturing system, the integration is carried out. The probability of detection (POD) is applied to evaluate and compare the reliability of datasets measured by each motion capturing system. POD is one of the widely used statistical techniques to determine reliability. We apply the â analysis to determine the POD(a) function from the data set. Based on the POD evaluation, two motion capturing systems are integrated. (author)

Considerations for boron neutron capture therapy studies; Consideracoes sobre o estudo da BNCT (terapia de captura neutronica por boro)

Energy Technology Data Exchange (ETDEWEB)

Faria Gaspar, P de

1994-12-31

Radiotherapy is indispensable as a mean to eradicate deeply or infiltrating tumor tissue that can not be removed surgically. Therefore, it is not selective and may also kill the surrounding health tissue. The principle of BNCT (Boron Neutron Capture Therapy) consist in targeting a tumor selectively with a boron-10 compound. This nuclide has a large capture cross section for thermal neutrons and the nuclear reaction and the delivered energy in locus will selective the tumor. Since its initial proposal in 1963 BNCT has made much progress, however it is not used in a routine treatment. In this work it was approached some complex procedures, as the obtention of selective boron compounds, the adequate set up of neutron beams, the biodistribution, the in vivo and in vitro studies, and also human patients treatments. This work provide fundamentals about BNCT to professional of different areas of knowledge since it comprises multidisciplinary study. It includes appendixes for the ones not related to the field for a better comprehension of the many aspects involved. It is also presented a glossary containing technical and basic aspects involved. It is also presented a glossary containing technical and basic terms referred in the work. (author). 174 refs, 1 fig, 12 apps.

Neutron Capture and Transmission Measurements and Resonance Parameter Analysis of Samarium

International Nuclear Information System (INIS)

Leinweber, G.; Burke, J.A.; Knox, H.D.; Drindak, N.J.; Mesh, D.W.; Haines, W.T.; Ballad, R.V.; Block, R.C.; Slovacek, R.E.; Werner, C.J.; Trbovich, M.J.; Barry, D.P.; Sato, T.

2001-01-01

The purpose of the present work is to accurately measure the neutron cross sections of samarium. The most significant isotope is 149 Sm, which has a large neutron absorption cross section at thermal energies and is a 235 U fission product with a 1% yield. Its cross sections are thus of concern to reactor neutronics. Neutron capture and transmission measurements were performed by the time-of-flight technique at the Rensselaer Polytechnic institute (RPI) LINAC facility using metallic and liquid Sm samples. The capture measurements were made at the 25 meter flight station with a multiplicity-type capture detector, and the transmission total cross-section measurements were performed at 15- and 25-meter flight stations with 6 Li glass scintillation detectors. Resonance parameters were determined by a combined analysis of six experiments (three capture and three transmission) using the multi-level R-matrix Bayesian code SAMMY version M2. The significant features of this work are as follows. Dilute samples of samarium nitrate in deuterated water (D 2 O) were prepared to measure the strong resonances at 0.1 and 8 eV without saturation. Disk-shaped spectroscopic quartz cells were obtained with parallel inner surfaces to provide a uniform thickness of solution. The diluent feature of the SAMMY program was used to analyze these data. The SAMMY program also includes multiple scattering corrections to capture yield data and resolution functions specific to the RPI facility. Resonance parameters for all stable isotopes of samarium were deduced for all resonances up to 30 eV. Thermal capture cross-section and capture resonance integral calculations were made using the resultant resonance parameters and were compared to results obtained using resonance parameters from ENDF/B-VI updated through release 3. Extending the definition of the capture resonance integral to include the strong 0.1 eV resonance in 149 Sm, present measurements agree within estimated uncertainties with En

Hadron therapy at the end of the 20th century

International Nuclear Information System (INIS)

Prokes, K.; Lokajicek, M.

1998-01-01

An overview of radiotherapy methods (brachytherapy, external irradiation with X-rays, betatrons, linear accelerators, hadron therapy, neutron capture therapy) is given, including their description and basic ways of application. Improved results can be achieved through precise dosimetry, diagnostic preparation, mathematical 3D modelling, procedure simulation and conformal therapy (adaptation of the radiation field to the shape of the target volume and preparation of compensation filters). The use of accelerated protons or ions also contributes to a substantial improvement. Neutron capture therapy is a promising method; the problem of suitable chemical compounds carrying boron 10, to be captured by the neoplasm tissue, and the problem of a suitable source of thermal neutrons are being addressed. (M.D.)

Monte Carlo calculations of thermal neutron capture in gadolinium: a comparison of GEANT4 and MCNP with measurements.

Science.gov (United States)

Enger, Shirin A; Munck af Rosenschöld, Per; Rezaei, Arash; Lundqvist, Hans

2006-02-01

GEANT4 is a Monte Carlo code originally implemented for high-energy physics applications and is well known for particle transport at high energies. The capacity of GEANT4 to simulate neutron transport in the thermal energy region is not equally well known. The aim of this article is to compare MCNP, a code commonly used in low energy neutron transport calculations and GEANT4 with experimental results and select the suitable code for gadolinium neutron capture applications. To account for the thermal neutron scattering from chemically bound atoms [S(alpha,beta)] in biological materials a comparison of thermal neutron fluence in tissue-like poly(methylmethacrylate) phantom is made with MCNP4B, GEANT4 6.0 patch1, and measurements from the neutron capture therapy (NCT) facility at the Studsvik, Sweden. The fluence measurements agreed with MCNP calculated results considering S(alpha,beta). The location of the thermal neutron peak calculated with MCNP without S(alpha,beta) and GEANT4 is shifted by about 0.5 cm towards a shallower depth and is 25%-30% lower in amplitude. Dose distribution from the gadolinium neutron capture reaction is then simulated by MCNP and compared with measured data. The simulations made by MCNP agree well with experimental results. As long as thermal neutron scattering from chemically bound atoms are not included in GEANT4 it is not suitable for NCT applications.

Towards boron neutron capture therapy: the formulation and preliminary in vitro evaluation of liposomal vehicles for the therapeutic delivery of the dequalinium salt of bis-nido-carborane.

Science.gov (United States)

Theodoropoulos, Dimitrios; Rova, Aikaterini; Smith, James R; Barbu, Eugen; Calabrese, Gianpiero; Vizirianakis, Ioannis S; Tsibouklis, John; Fatouros, Dimitrios G

2013-11-15

Liposomes of phosphatidylcholine or of dimyristoylphosphatidylcholine that incorporate bis-nido-carborane dequalinium salt are stable in physiologically relevant media and have in vitro toxicity profiles that appear to be compatible with potential therapeutic applications. These features render the structures suitable candidate boron-delivery vehicles for evaluation in the boron neutron capture therapy of cancer. Copyright © 2013 Elsevier Ltd. All rights reserved.

Boron neutron capture therapy induces cell cycle arrest and cell apoptosis of glioma stem/progenitor cells in vitro

International Nuclear Information System (INIS)

Sun, Ting; Zhang, Zizhu; Li, Bin; Chen, Guilin; Xie, Xueshun; Wei, Yongxin; Wu, Jie; Zhou, Youxin; Du, Ziwei

2013-01-01

Glioma stem cells in the quiescent state are resistant to clinical radiation therapy. An almost inevitable glioma recurrence is due to the persistence of these cells. The high linear energy transfer associated with boron neutron capture therapy (BNCT) could kill quiescent and proliferative cells. The present study aimed to evaluate the effects of BNCT on glioma stem/progenitor cells in vitro. The damage induced by BNCT was assessed using cell cycle progression, apoptotic cell ratio and apoptosis-associated proteins expression. The surviving fraction and cell viability of glioma stem/progenitor cells were decreased compared with differentiated glioma cells using the same boronophenylalanine pretreatment and the same dose of neutron flux. BNCT induced cell cycle arrest in the G2/M phase and cell apoptosis via the mitochondrial pathway, with changes in the expression of associated proteins. Glioma stem/progenitor cells, which are resistant to current clinical radiotherapy, could be effectively killed by BNCT in vitro via cell cycle arrest and apoptosis using a prolonged neutron irradiation, although radiosensitivity of glioma stem/progenitor cells was decreased compared with differentiated glioma cells when using the same dose of thermal neutron exposure and boronophenylalanine pretreatment. Thus, BNCT could offer an appreciable therapeutic advantage to prevent tumor recurrence, and may become a promising treatment in recurrent glioma

Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats

International Nuclear Information System (INIS)

Trivillin, V.A.; Garabalino, M.A.; Colombo, L.L.

2013-01-01

Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases in BDIX rats Introduction: Boron Neutron Capture Therapy (BNCT) is based on selective tumor uptake of boron compounds, followed by neutron irradiation. BNCT was proposed for the treatment of unresectable, diffuse lung metastases. The aim of the present study was to perform BNCT studies in an experimental model of lung metastases. Materials and Methods: 3 x 106/0.5 ml colon carcinoma cells (DHD/K12/TRb) were injected iv in syngeneic BDIX rats. Three weeks post-inoculation, rats with diffuse lung metastases were used for in vivo BNCT studies in the RA-3 Nuclear Reactor. Based on previous biodistribution studies and computational dosimetry with Monte Carlo simulation, 2 doses were prescribed, i.e. 4 Gy and 8 Gy minimum absorbed dose to tumor. The animals were assigned to 5 experimental groups (n= 4 to 8) at each dose level: T0 (euthanized pre-treatment), BPA-BNCT, Comb-BNCT (BPA+GB-10), Beam only (background dose) and Sham (same manipulation, no treatment). Boron concentration was measured in a blood sample taken pre-irradiation to verify that the value was in the range established in previous biodistribution studies. The animals were followed clinically for 2 weeks after neutron irradiation and then euthanized to assess the response of tumor and normal lung, macroscopically and histologically. To date we have evaluated the end-point weight of lung (normal lung + metastases) and % lung weight/body weight as an indicator of tumor growth. Results: The statistical analysis (ANOVA) of % lung weight/body weight showed statistically significant differences (p<0.05) between groups T0 (0.79 ± 0.38) and Sham (1.87 ± 0.91). No statistically significant differences were observed between the Beam only groups (at both dose levels) and Sham. Similar and statistically significant tumor control was induced in the groups BPA-BNCT Low dose (LD) (0.56 ± 0.11), BPA-BNCT High dose (HD) (0.80 ± 0.16), Comb

Evaluation of moderator assemblies for use in an accelerator-based neutron source for boron neutron capture therapy

International Nuclear Information System (INIS)

Woollard, J.E.; Blue, T.E.; Gupta, N.; Gahbauer, R.A.

1998-01-01

The neutron fields produced by several moderator assemblies were evaluated using both in-phantom and in-air neutron field assessment parameters. The parameters were used to determine the best moderator assembly, from among those evaluated, for use in the accelerator-based neutron source for boron neutron capture therapy. For a 10-mA proton beam current and the specified treatment parameters, a moderator assembly consisting of a BeO moderator and a Li 2 CO 3 reflector was found to be the best moderator assembly whether the comparison was based on in-phantom or in-air neutron field assessment parameters. However, the parameters were discordant regarding the moderator thickness. The in-phantom neutron field assessment parameters predict 20 cm of BeO as the best moderator thickness, whereas the in-air neutron field assessment parameters predict 25 cm of BeO as the best moderator thickness

Proton beam characterization in the experimental room of the Trento Proton Therapy facility

Science.gov (United States)

Tommasino, F.; Rovituso, M.; Fabiano, S.; Piffer, S.; Manea, C.; Lorentini, S.; Lanzone, S.; Wang, Z.; Pasini, M.; Burger, W. J.; La Tessa, C.; Scifoni, E.; Schwarz, M.; Durante, M.

2017-10-01

As proton therapy is becoming an established treatment methodology for cancer patients, the number of proton centres is gradually growing worldwide. The economical effort for building these facilities is motivated by the clinical aspects, but might be also supported by the potential relevance for the research community. Experiments with high-energy protons are needed not only for medical physics applications, but represent also an essential part of activities dedicated to detector development, space research, radiation hardness tests, as well as of fundamental research in nuclear and particle physics. Here we present the characterization of the beam line installed in the experimental room of the Trento Proton Therapy Centre (Italy). Measurements of beam spot size and envelope, range verification and proton flux were performed in the energy range between 70 and 228 MeV. Methods for reducing the proton flux from typical treatments values of 106-109 particles/s down to 101-105 particles/s were also investigated. These data confirm that a proton beam produced in a clinical centre build by a commercial company can be exploited for a broad spectrum of experimental activities. The results presented here will be used as a reference for future experiments.

Optimal timing of neutron irradiation for boron neutron capture therapy after intravenous infusion of sodium borocaptate in patients with glioblastoma

International Nuclear Information System (INIS)

Kageji, Teruyoshi; Nagahiro, Shinji; Kitamura, Katsushi; Nakagawa, Yoshinobu; Hatanaka, Hiroshi; Haritz, Dietrich; Grochulla, Frank; Haselsberger, Klaus; Gabel, Detlef

2001-01-01

Purpose: A cooperative study in Europe and Japan was conducted to determine the pharmacokinetics and boron uptake of sodium borocaptate (BSH: Na 2 B 12 H 11 SH), which has been introduced clinically as a boron carrier for boron neutron capture therapy in patients with glioblastoma. Methods and Materials: Data from 56 patients with glioblastoma who received BSH intravenous infusion were retrospectively reviewed. The pharmacokinetics were evaluated in 50 patients, and boron uptake was investigated in 47 patients. Patients received BSH doses between 12 and 100 mg/kg of body weight. For the evaluation, the infused boron dose was scaled linearly to 100 mg/kg BSH. Results: In BSH pharmacokinetics, the average value for total body clearance, distribution volume of steady state, and mean residence time was 3.6±1.5 L/h, 223.3±160.7 L, and 68.0±52.5 h, respectively. The average values of the boron concentration in tumor adjusted to 100 mg/kg BSH, the boron concentration in blood adjusted to 100 mg/kg BSH, and the tumor/blood boron concentration ratio were 37.1±35.8 ppm, 35.2±41.8 ppm, and 1.53±1.43, respectively. A good correlation was found between the logarithmic value of T adj and the interval from BSH infusion to tumor tissue sampling. About 12-19 h after infusion, the actual values for T adj and tumor/blood boron concentration ratio were 46.2±36.0 ppm and 1.70±1.06, respectively. The dose ratio between tumor and healthy tissue peaked in the same interval. Conclusion: For boron neutron capture therapy using BSH administered by intravenous infusion, this work confirms that neutron irradiation is optimal around 12-19 h after the infusion is started

Neutron shielding calculations in a proton therapy facility based on Monte Carlo simulations and analytical models: Criterion for selecting the method of choice

International Nuclear Information System (INIS)

Titt, U.; Newhauser, W. D.

2005-01-01

Proton therapy facilities are shielded to limit the amount of secondary radiation to which patients, occupational workers and members of the general public are exposed. The most commonly applied shielding design methods for proton therapy facilities comprise semi-empirical and analytical methods to estimate the neutron dose equivalent. This study compares the results of these methods with a detailed simulation of a proton therapy facility by using the Monte Carlo technique. A comparison of neutron dose equivalent values predicted by the various methods reveals the superior accuracy of the Monte Carlo predictions in locations where the calculations converge. However, the reliability of the overall shielding design increases if simulation results, for which solutions have not converged, e.g. owing to too few particle histories, can be excluded, and deterministic models are being used at these locations. Criteria to accept or reject Monte Carlo calculations in such complex structures are not well understood. An optimum rejection criterion would allow all converging solutions of Monte Carlo simulation to be taken into account, and reject all solutions with uncertainties larger than the design safety margins. In this study, the optimum rejection criterion of 10% was found. The mean ratio was 26, 62% of all receptor locations showed a ratio between 0.9 and 10, and 92% were between 1 and 100. (authors)

Investigation of current status in Europe and USA on boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

NONE

2000-11-01

This report describes on the spot investigation results of current status of medical irradiation in Europe and USA at Feb. 1999. In HFR (Netherlands), the phase 1 study with the Joint Research Centre (JRC) of the EU had been already finished in those days, at the same time, an improvement of medical irradiation field of VTT(Finland) had been finishing and then clinical trial research had been about to start. On the other hand, phase 1 studies by two groups of BNL (Brook heaven National Laboratory) and MIT (Nuclear Engineering of Massachusetts Institute of Technology) in US were now in almost final stage, and they would start on phase 2 study. Either reactors of MIT and BNL were in modification to increase neutron flux, especially that employing fission converter into the irradiation facility and installation of irradiation room were carrying out in the former. In Europe and USA, the accelerator-based BNCT planes are now in progress vigorously, and will have reality. A reform of dynamitron accelerator at University of Birmingham was progressed, and the clinical treatment would be started from September 2000. The accelerator group at MIT has a small type of tandem accelerator, and they were performing basic experiment for BNCS (Boron Neutron Capture Synovectomy) with this accelerator. The concept design for an accelerator and a moderator had been finished at Lawrence Berkeley National Laboratory and University of Berkeley. (author)

Neutron capture studies of {sup 206}Pb at a cold neutron beam

Energy Technology Data Exchange (ETDEWEB)

Schillebeeckx, P.; Kopecky, S.; Quetel, C.R.; Tresl, I.; Wynants, R. [Institute for Reference Materials and Measurements, European Commission, Joint Research Centre, Geel (Belgium); Belgya, T.; Szentmiklosi, L. [Institute for Energy Security and Environmental Safety, Centre for Energy Research, Budapest (Hungary); Borella, A. [Institute for Reference Materials and Measurements, European Commission, Joint Research Centre, Geel (Belgium); SCK CEN, Mol (Belgium); Mengoni, A. [Nuclear Data Section, International Atomic Energy Agency (IAEA), Wagramerstrasse 5, PO Box 100, Vienna (Austria); Agenzia Nazionale per le Nuove Tecnologie, l' Energia e lo Sviluppo Economico Sostenibile (ENEA), Bologna (Italy)

2013-11-15

Gamma-ray transitions following neutron capture in {sup 206}Pb have been studied at the cold neutron beam facility of the Budapest Neutron Centre using a metallic sample enriched in {sup 206}Pb and a natural lead nitrate powder pellet. The measurements were performed using a coaxial HPGe detector with Compton suppression. The observed {gamma} -rays have been incorporated into a decay scheme for neutron capture in {sup 206}Pb. Partial capture cross sections for {sup 206}Pb(n, {gamma}) at thermal energy have been derived relative to the cross section for the 1884 keV transition after neutron capture in {sup 14}N. From the average crossing sum a total thermal neutron capture cross section of 29{sup +2}{sub -1} mb was derived for the {sup 206}Pb(n, {gamma}) reaction. The thermal neutron capture cross section for {sup 206}Pb has been compared with contributions due to both direct capture and distant unbound s-wave resonances. From the same measurements a thermal neutron-induced capture cross section of (649 {+-} 14) mb was determined for the {sup 207}Pb(n, {gamma}) reaction. (orig.)

Ultra-fast electron capture by electrosterically-stabilized gold nanoparticles.

Science.gov (United States)

Ghandi, Khashayar; Findlater, Alexander D; Mahimwalla, Zahid; MacNeil, Connor S; Awoonor-Williams, Ernest; Zahariev, Federico; Gordon, Mark S

2015-07-21

Ultra-fast pre-solvated electron capture has been observed for aqueous solutions of room-temperature ionic liquid (RTIL) surface-stabilized gold nanoparticles (AuNPs; ∼9 nm). The extraordinarily large inverse temperature dependent rate constants (k(e)∼ 5 × 10(14) M(-1) s(-1)) measured for the capture of electrons in solution suggest electron capture by the AuNP surface that is on the timescale of, and therefore in competition with, electron solvation and electron-cation recombination reactions. The observed electron transfer rates challenge the conventional notion that radiation induced biological damage would be enhanced in the presence of AuNPs. On the contrary, AuNPs stabilized by non-covalently bonded ligands demonstrate the potential to quench radiation-induced electrons, indicating potential applications in fields ranging from radiation therapy to heterogeneous catalysis.

Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS.

Science.gov (United States)

Andoh, Tooru; Fujimoto, Takuya; Suzuki, Minoru; Sudo, Tamotsu; Sakurai, Yoshinori; Tanaka, Hiroki; Fujita, Ikuo; Fukase, Naomasa; Moritake, Hiroshi; Sugimoto, Tohru; Sakuma, Toshiko; Sasai, Hiroshi; Kawamoto, Teruya; Kirihata, Mitsunori; Fukumori, Yoshinobu; Akisue, Toshihiro; Ono, Koji; Ichikawa, Hideki

2015-12-01

Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In the present study, we established a lung metastasis animal model of CCS and investigated the therapeutic effect of boron neutron capture therapy (BNCT) using p-borono-L-phenylalanine (L-BPA). Biodistribution data revealed tumor-selective accumulation of (10)B. Unlike conventional gamma-ray irradiation, BNCT significantly suppressed tumor growth without damaging normal tissues, suggesting that it may be a potential new therapeutic option to treat CCS lung metastases. Copyright © 2015 Elsevier Ltd. All rights reserved.

The Proton Beams for the New Time-of-Flight Neutron Facility at the CERN-PS

CERN Document Server

Cappi, R; Métral, G

2000-01-01

The experimental determination of neutron cross sections in fission and capture reactions as a function of the neutron energy is of primary importance in nuclear physics. Recent developments at CERN and elsewhere have shown that many fields of research and development, such as the design of Accelerator-Driven Systems (ADS) for nuclear waste incineration, nuclear astrophysics, fundamental nuclear physics, dosimetry for radiological protection and therapy, would benefit from a better knowledge of neutron cross sections. A neutron facility at the CERN-PS has been proposed with the aim of carrying out a systematic and high resolution study of neutron cross sections through Time-Of-Flight (n-TOF) measurement. The facility requires a high intensity proton beam (about 0.7x1013 particles/bunch) distributed in a short bunch (about 25 ns total length) to produce the neutrons by means of a spallation process in a lead target. To achieve these characteristics, a number of complex beam gymnastics have to be performed. All...

Investigation of dose distribution in mixed neutron-gamma field of boron neutron capture therapy using N isopropylacrylamide gel

Energy Technology Data Exchange (ETDEWEB)

Bavarmegin, Elham; Sadremomtaz, Alireza [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Khalafi, Hossein; Kasesaz, Yaser [Dept. of Physics, University of Guilan, Rasht (Iran, Islamic Republic of); Khajeali, Azim [Medical Education Research Center, Tabriz (Iran, Islamic Republic of)

2017-02-15

Gel dosimeters have unique advantages in comparison with other dosimeters. Until now, these gels have been used in different radiotherapy techniques as a reliable dosimetric tool. Because dose distribution measurement is an important factor for appropriate treatment planning in different radiotherapy techniques, in this study, we evaluated the ability of the N-isopropylacrylamide (NIPAM) polymer gel to record the dose distribution resulting from the mixed neutron-gamma field of boron neutron capture therapy (BNCT). In this regard, a head phantom containing NIPAM gel was irradiated using the Tehran Research Reactor BNCT beam line, and then by a magnetic resonance scanner. Eventually, the R2 maps were obtained in different slices of the phantom by analyzing T2-weighted images. The results show that NIPAM gel has a suitable potential for recording three-dimensional dose distribution in mixed neutron-gamma field dosimetry.

Comparison of doses delivered in clinical trials of neutron capture therapy in the USA

International Nuclear Information System (INIS)

Albritton, J.R.; Binns, P.J.; Riley, K.J.; Coderre, J.A.; Harling, O.K.; Kiger, W.S. III

2006-01-01

A combined 81 brain tumor patients have been treated in dose escalation trials of Neutron Capture Therapy (NCT) at Harvard-MIT and Brookhaven National Laboratory (BNL). Pooling the clinical outcomes from these trials will permit evaluation with more statistical rigor. However, differences in physical and computational dosimetry between the institutions make direct comparison of the clinical dosimetry difficult. This paper describes work performed to normalize the BNL clinical dosimetry to that of Harvard-MIT for combined dose response analysis. This normalization involved analysis of MIT measurements and calculations using the BNL treatment planning system (TPS), BNCT - Rtpe, for two different phantoms. The BNL TPS was calibrated to dose measurements made by MIT at the BMRR in the BNL calibration phantom, a Lucite cube, and then validated by MIT dose measurements at the BMMR in an ellipsoidal water phantom. Treatment plans for all BNL patients were recomputed using the newly determined TPS calibration, yielding reductions in reported mean brain doses of 19% on average in the initial 15 patients and 31% in the latter 38 patients. These reductions in reported doses have clinically significant implications for those relying on reported BNL doses as a basis for initial dose selection in clinical studies. (author)

Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy

International Nuclear Information System (INIS)

Fujimoto, T.; Ichikawa, H.; Akisue, T.; Fujita, I.; Kishimoto, K.; Hara, H.; Imabori, M.; Kawamitsu, H.; Sharma, P.; Brown, S.C.; Moudgil, B.M.; Fujii, M.; Yamamoto, T.; Kurosaka, M.; Fukumori, Y.

2009-01-01

Neutron-capture therapy with gadolinium (Gd-NCT) has therapeutic potential, especially that gadolinium is generally used as a contrast medium in magnetic resonance imaging (MRI). The accumulation of gadolinium in a human sarcoma cell line, malignant fibrosis histiocytoma (MFH) Nara-H, was visualized by the MRI system. The commercially available MRI contrast medium Gd-DTPA (Magnevist, dimeglumine gadopentetate aqueous solution) and the biodegradable and highly gadopentetic acid (Gd-DTPA)-loaded chitosan nanoparticles (Gd-nanoCPs) were prepared as MRI contrast agents. The MFH cells were cultured and collected into three falcon tubes that were set into the 3-tesra MRI system to acquire signal intensities from each pellet by the spin echo method, and the longitudinal relaxation time (T1) was calculated. The amount of Gd in the sample was measured by inductively coupled plasma atomic emission spectrography (ICP-AES). The accumulation of gadolinium in cells treated with Gd-nanoCPs was larger than that in cells treated with Gd-DTPA. In contrast, and compared with the control, Gd-DTPA was more effective than Gd-nanoCPs in reducing T1, suggesting that the larger accumulation exerted the adverse effect of lowering the enhancement of MRI. Further studies are warranted to gain insight into the therapeutic potential of Gd-NCT.

Potential of para-boronophenylalaninol as a boron carrier in boron neutron capture therapy, referring to that of its enantiomers

International Nuclear Information System (INIS)

Masunaga, S.; Sakurai, Y.; Ono, K.; Suziki, M.; Nagata, K.; Takagaki, M.; Nagasawa, H.

2003-01-01

We evaluated the potential of a newly developed 10 B-containing alpha-amino alcohol of para-boronophenylalanine- 10 B (BPA), para-boronophenylalaninol (BPAol), as a boron carrier in boron neutron capture therapy. C57BL mice bearing EL4 tumors and C3H/He mice bearing SCC VII tumors received 5-bromo-2'-deoxyuridine (BrdU) continuously via implanted mini-osmotic pumps to label all proliferating (P) cells. After oral administration of L-BPA or D-BPA, or intraperitoneal injection of L-BPAol or D-BPAol, the tumors were irradiated with reactor thermal neutron beams. For the combination with mild temperature hyperthermia (MTH) and/or tirapazamine (TPZ), the tumors were heated at 40 degrees centigrade for 30 minutes right before neutron exposure, and/or TPZ was intraperitoneally injected 30 minutes before irradiation. The tumors were then excised, minced and trypsinized. The tumor cell suspensions thus obtained were incubated with cytochalasin-B (a cytokinesis blocker), and the micronucleus (MN) frequency in cells without BrdU labeling ( = quiescent (Q) cells) was determined using immunofluorescence staining for BrdU. Meanwhile, 6 hours after irradiation, tumor cell suspensions obtained in the same manner were used for determining the apoptosis frequency in Q cells. The apoptosis and MN frequency in total (P + Q) tumor cells were determined from the tumors that were not pretreated with BrdU. Without TPZ or MTH, L- and D-BPAol increased both frequencies markedly, especially for total cells. Although not significantly, L-BPA and D-BPAol increased both frequencies slightly more remarkably than D-BPA and L-BPAol, respectively. On combined treatment with both MTH and TPZ, the sensitivity difference between total and Q cells was markedly reduced. MTH increased the 10 B uptake of all 10 B-carriers into both tumor cells to some degree. Both L- and D-BPAol have potential as 10 B-carriers in neutron capture therapy, especially when combined with both MTH and TPZ

Client/server approach to image capturing

Science.gov (United States)

Tuijn, Chris; Stokes, Earle

1998-01-01

The diversity of the digital image capturing devices on the market today is quite astonishing and ranges from low-cost CCD scanners to digital cameras (for both action and stand-still scenes), mid-end CCD scanners for desktop publishing and pre- press applications and high-end CCD flatbed scanners and drum- scanners with photo multiplier technology. Each device and market segment has its own specific needs which explains the diversity of the associated scanner applications. What all those applications have in common is the need to communicate with a particular device to import the digital images; after the import, additional image processing might be needed as well as color management operations. Although the specific requirements for all of these applications might differ considerably, a number of image capturing and color management facilities as well as other services are needed which can be shared. In this paper, we propose a client/server architecture for scanning and image editing applications which can be used as a common component for all these applications. One of the principal components of the scan server is the input capturing module. The specification of the input jobs is based on a generic input device model. Through this model we make abstraction of the specific scanner parameters and define the scan job definitions by a number of absolute parameters. As a result, scan job definitions will be less dependent on a particular scanner and have a more universal meaning. In this context, we also elaborate on the interaction of the generic parameters and the color characterization (i.e., the ICC profile). Other topics that are covered are the scheduling and parallel processing capabilities of the server, the image processing facilities, the interaction with the ICC engine, the communication facilities (both in-memory and over the network) and the different client architectures (stand-alone applications, TWAIN servers, plug-ins, OLE or Apple-event driven

Accelerator-Based Boron Neutron Capture Therapy and the Development of a Dedicated Tandem-Electrostatic-Quadrupole

International Nuclear Information System (INIS)

Kreiner, A. J.; Di Paolo, H.; Burlon, A. A.; Valda, A. A.; Debray, M. E.; Somacal, H. R.; Minsky, D. M.; Kesque, J. M.; Giboudot, Y.; Levinas, P.; Fraiman, M.; Romeo, V.

2007-01-01

There is a generalized perception that the availability of suitable particle accelerators installed in hospitals, as neutron sources, may be crucial for the advancement of Boron Neutron Capture Therapy (BNCT). Progress on an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based (AB)-BNCT is described here. The project goal is a machine capable of delivering 30 mA of 2.5 MeV protons to be used in conjunction with a neutron production target based on the 7 Li(p,n) 7 Be reaction slightly beyond its resonance at 2.25 MeV. A folded tandem, with 1.25 MV terminal voltage, combined with an ESQ chain is being designed and constructed. A 30 mA proton beam of 2.5 MeV are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the 7 Li(p,n) 7 Be reaction, to perform BNCT treatment for deep-seated tumors in less than an hour. The first design and construction of an ESQ module is discussed and its electrostatic fields are investigated theoretically and experimentally. Also new beam transport calculations through the accelerator are presented

Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

Energy Technology Data Exchange (ETDEWEB)

Bakeine, G.J. [Department of Clinical Medicine and Neurology, Cattinara Hospital, University of Trieste (Italy)], E-mail: jamesbakeine1@yahoo.com; Di Salvo, M. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bortolussi, S.; Stella, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bertolotti, A.; Nano, R. [Department of Animal Biology University of Pavia, Piazza Botta, Pavia (Italy); Clerici, A.; Ferrari, C.; Zonta, C. [Department of Surgery University of Pavia, Piazza Botta, Pavia (Italy); Marchetti, A. [Scientific Research Office, Fondazione San Matteo University Policlinic, Pavia (Italy); Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy)

2009-07-15

In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

International Nuclear Information System (INIS)

Bakeine, G.J.; Di Salvo, M.; Bortolussi, S.; Stella, S.; Bruschi, P.; Bertolotti, A.; Nano, R.; Clerici, A.; Ferrari, C.; Zonta, C.; Marchetti, A.; Altieri, S.

2009-01-01

In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer

International Nuclear Information System (INIS)

Suzuki, Minoru; Kato, Ituro; Aihara, Teruhito

2014-01-01

We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records. Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10–12 Gy-eq to the skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range, 0.7–40.8). A total of 87 BNCT procedures were performed. The overall response rate was 58% within 6 months after BNCT. The median survival time was 10.1 months from the time of BNCT. The 1- and 2-year overall survival (OS) rates were 43.1% and 24.2%, respectively. The major acute Grade 3 or 4 toxicities were hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stomatitis (9.7%) and pain (9.7%), all of which were manageable. Three patients died of treatment-related toxicity. Three patients experienced carotid artery hemorrhage, two of whom had coexistent infection of the carotid artery. This study confirmed the feasibility of our dose-estimation method and that controlled trials are warranted. (author)

Search for neutrinoless double-electron capture of 156Dy

Science.gov (United States)

Finch, S. W.; Tornow, W.

2015-12-01

Background: Multiple large collaborations are currently searching for neutrinoless double-β decay, with the ultimate goal of differentiating the Majorana-Dirac nature of the neutrino. Purpose: Investigate the feasibility of resonant neutrinoless double-electron capture, an experimental alternative to neutrinoless double-β decay. Method: Two clover germanium detectors were operated underground in coincidence to search for the de-excitation γ rays of 156Gd following the neutrinoless double-electron capture of 156Dy. 231.95 d of data were collected at the Kimballton underground research facility with a 231.57 mg enriched 156Dy sample. Results: No counts were seen above background and half-life limits are set at O (1016-1018) yr for the various decay modes of 156Dy. Conclusion: Low background spectra were efficiently collected in the search for neutrinoless double-electron capture of 156Dy, although the low natural abundance and associated lack of large quantities of enriched samples hinders the experimental reach.

New measurement of neutron capture resonances of 209Bi

CERN Document Server

Domingo-Pardo, C.; Aerts, G.; Alvarez-Pol, H.; Alvarez-Velarde, F.; Andriamonje, S.; Andrzejewski, J.; Assimakopoulos, P.; Audouin, L.; Badurek, G.; Baumann, P.; Becvar, F.; Berthoumieux, E.; Calvino, F.; Cano-Ott, D.; Capote, R.; Carrillode Albornoz, A.; Cennini, P.; Chepel, V.; Chiaveri, E.; Colonna, N.; Cortes, G.; Couture, A.; Cox, J.; Dahlfors, M.; David, S.; Dillman, I.; Dolfini, R.; Dridi, W.; Duran, I.; Eleftheriadis, C.; Embid-Segura, M.; Ferrant, L.; Ferrari, A.; Ferreira-Marques, R.; Fitzpatrick, L.; Frais-Koelbl, H.; Fujii, K.; Furman, W.; Gallino, R.; Goncalves, I.; Gonzalez-Romero, E.; Goverdovski, A.; Gramegna, F.; Griesmayer, E.; Guerrero, C.; Gunsing, F.; Haas, B.; Haight, R.; Heil, M.; Herrera-Martinez, A.; Igashira, M.; Isaev, S.; Jericha, E.; Kadi, Y.; Kappeler, F.; Karamanis, D.; Karadimos, D.; Kerveno, M.; Ketlerov, V.; Koehler, P.; Konovalov, V.; Kossionides, E.; Krticka, M.; Lamboudis, C.; Leeb, H.; Lindote, A.; Lopes, I.; Lozano, M.; Lukic, S.; Marganiec, J.; Marques, L.; Marrone, S.; Mastinu, P.; Mengoni, A.; Milazzo, P.M.; Moreau, C.; Mosconi, M.; Neves, F.; Oberhummer, H.; Oshima, M.; O'Brien, S.; Pancin, J.; Papachristodoulou, C.; Papadopoulos, C.; Paradela, C.; Patronis, N.; Pavlik, A.; Pavlopoulos, P.; Perrot, L.; Plag, R.; Plompen, A.; Plukis, A.; Poch, A.; Pretel, C.; Quesada, J.; Rauscher, T.; Reifarth, R.; Rosetti, M.; Rubbia, C.; Rudolf, G.; Rullhusen, P.; Salgado, J.; Sarchiapone, L.; Savvidis, I.; Stephan, C.; Tagliente, G.; Tain, J.L.; Tassan-Got, L.; Tavora, L.; Terlizzi, R.; Vannini, G.; Vaz, P.; Ventura, Alberto; Villamarin, D.; Vincente, M.C.; Vlachoudis, V.; Vlastou, R.; Voss, F.; Walter, S.; Wendler, H.; Wiescher, M.; Wisshak, K.

2006-01-01

The neutron capture cross section of Bi209 has been measured at the CERN n TOF facility by employing the pulse-height-weighting technique. Improvements over previous measurements are mainly because of an optimized detection system, which led to a practically negligible neutron sensitivity. Additional experimental sources of systematic error, such as the electronic threshold in the detectors, summing of gamma-rays, internal electron conversion, and the isomeric state in bismuth, have been taken into account. Gamma-ray absorption effects inside the sample have been corrected by employing a nonpolynomial weighting function. Because Bi209 is the last stable isotope in the reaction path of the stellar s-process, the Maxwellian averaged capture cross section is important for the recycling of the reaction flow by alpha-decays. In the relevant stellar range of thermal energies between kT=5 and 8 keV our new capture rate is about 16% higher than the presently accepted value used for nucleosynthesis calculations. At th...

Potential occupational risk of amines in carbon capture for power generation.

Science.gov (United States)

Gentry, P Robinan; House-Knight, Tamara; Harris, Angela; Greene, Tracy; Campleman, Sharan

2014-08-01

While CO2 capture and storage (CCS) technology has been well studied in terms of its efficacy and cost of implementation, there is limited available data concerning the potential for occupational exposure to amines, mixtures of amines, or degradation of by-products from the CCS process. This paper is a critical review of the available data concerning the potential effects of amines and CCS-degradation by-products. A comprehensive review of the occupational health and safety issues associated with exposure to amines and amine by-products at CCS facilities was performed, along with a review of the regulatory status and guidelines of amines, by-products, and CCS process vapor mixtures. There are no specific guidelines or regulations regarding permissible levels of exposure via air for amines and degradation products that could form atmospheric oxidation of amines released from post-combustion CO2 capture plants. While there has been a worldwide effort to develop legal and regulatory frameworks for CCS, none are directly related to occupational exposures. By-products of alkanolamine degradation may pose the most significant health hazard to workers in CCS facilities, with several aldehydes, amides, nitramines, and nitrosamines classified as either known or potential/possible human carcinogens. The absence of large-scale CCS facilities; absence and unreliability of reported data in the literature from pilot facilities; and proprietary amine blends make it difficult to estimate potential amine exposures and predict formation and exposure to degradation products.

Boron neutron capture therapy (BNCT) for high-grade gliomas of the brain: a cautionary note

International Nuclear Information System (INIS)

Laramore, George E.; Spence, Alexander M.

1996-01-01

Purpose/Objective: Boron neutron capture therapy (BNCT) is a method of treating high-grade gliomas of the brain that involves incorporating 10 B into the tumor using appropriate pharmacological agents and then irradiating the tumor with thermal or epithermal neutron beams. To date, over 120 patients have been treated in this manner by Japanese investigators using a thermal neutron beam from a nuclear reactor. Favorable reports on outcome have motivated considerable current research in BNCT. The purpose of this study is to provide an independent analysis of the Japanese data by identifying the subset of patients from the United States who received this treatment in Japan and comparing their outcomes relative to a matched cohort who received conventional therapy in various Radiation Therapy Oncology Group (RTOG) studies. Methods and Materials: The principal referral sources of patients to Japan for BNCT were identified and the names of patients sent for treatment obtained. The treating physicians in Japan were also contacted to see if additional patients from the United States had been treated. Either the patients or their next of kin were contacted, and permission was obtained to retrieve medical records including tumor pathology for central review. Prognostic variables according to an analysis of the RTOG brain tumor database by Curran et al. were determined from these records and used to construct a matched cohort of patients treated conventionally. Results: A total of 14 patients were identified who had traveled to Japan for BNCT treatment between July, 1987 and June, 1994. In the case of one patient (deceased), it was not possible to contact the next of kin. Material was obtained on the other 13 patients and review of the pathology indicated that 1 patient had a central nervous system lymphoma rather than a high-grade glioma. Survival data was analyzed for the other 12 patients on an actuarial basis, and this showed no difference compared to survival data for a

Synovectomy by Neutron capture

International Nuclear Information System (INIS)

Vega C, H.R.; Torres M, C.

1998-01-01

The Synovectomy by Neutron capture has as purpose the treatment of the rheumatoid arthritis, illness which at present does not have a definitive curing. This therapy requires a neutron source for irradiating the articulation affected. The energy spectra and the intensity of these neutrons are fundamental since these neutrons induce nuclear reactions of capture with Boron-10 inside the articulation and the freely energy of these reactions is transferred at the productive tissue of synovial liquid, annihilating it. In this work it is presented the neutron spectra results obtained with moderator packings of spherical geometry which contains in its center a Pu 239 Be source. The calculations were realized through Monte Carlo method. The moderators assayed were light water, heavy water base and the both combination of them. The spectra obtained, the average energy, the neutron total number by neutron emitted by source, the thermal neutron percentage and the dose equivalent allow us to suggest that the moderator packing more adequate is what has a light water thickness 0.5 cm (radius 2 cm) and 24.5 cm heavy water (radius 26.5 cm). (Author)

The European Carbon dioxide Capture and Storage Laboratory Infrastructure (ECCSEL

Directory of Open Access Journals (Sweden)

Sverre Quale

2016-10-01

Full Text Available The transition to a non-emitting energy mix for power generation will take decades. This transition will need to be sustainable, e.g. economically affordable. Fossil fuels which are abundant have an important role to play in this respect, provided that Carbon Capture and Storage (CCS is progressively implemented. CCS is the only way to reduce emissions from energy intensive industries.Thus, the need for upgraded and new CCS research facilities is widely recognised among stakeholders across Europe, as emphasised by the Zero Emissions Platform (ZEP [1] and the European Energy Research Alliance on CCS (EERA-CCS [2].The European Carbon Dioxide Capture and Storage Laboratory Infrastructure, ECCSEL, provides funders, operators and researchers with significant benefits by offering access to world-class research facilities that, in many cases, are unlikely for a single nation to support in isolation. This implies creation of synergy and the avoidance of duplication as well as streamlining of funding for research facilities.ECCSEL offers open access to its advanced laboratories for talented scientists and visiting researchers to conduct cutting-edge research.In the planning of ECCSEL, gap analyses were performed and CCS technologies have been reviewed to underpin and envisage the future experimental setup; 1 Making use of readily available facilities, 2 Modifying existing facilities, and 3 Planning and building entirely new advanced facilities.The investments required for the first ten years (2015–2025 are expected to be in the range of €80–120 million. These investments show the current level of ambition, as proposed during the preparatory phase (2011–2014.Entering the implementation phase in 2015, 9 European countries signed Letter of Intent (LoI to join a ECCSEL legal entity: France, United Kingdom, Netherlands, Italy, Spain, Poland, Greece, Norway and Switzerland (active observer. As the EU ERIC-regulation [3] would offer the most

Application of drug delivery system to boron neutron capture therapy for cancer.

Science.gov (United States)

Yanagië, Hironobu; Ogata, Aya; Sugiyama, Hirotaka; Eriguchi, Masazumi; Takamoto, Shinichi; Takahashi, Hiroyuki

2008-04-01

Tumor cell destruction in boron neutron capture therapy (BNCT) is due to the nuclear reaction between (10)B and thermal neutrons ((10)B + (1)n --> (7)Li + (4)He (alpha) + 2.31 MeV (93.7 %)/2.79 MeV (6.3 %)). The resulting lithium ions and alphaparticles are high linear energy transfer (LET) particles which give a high biological effect. Their short range in tissue (5 - 9 mum) restricts radiation damage to those cells in which boron atoms are located at the time of neutron irradiation. BNCT has been applied clinically for the treatment of malignant brain tumors, malignant melanoma, head and neck cancer and hepatoma. Sodium mercaptoundecahydro-dodecaborate (Na(2)(10)B(12)H(11)SH: BSH) and borono-phenylalanine ((10)BPA) are currently being used in clinical treatments. These low molecule compounds are easily cleared from cancer cells and blood, so high accumulation and selective delivery of boron compounds into tumor tissues and cancer cells are most important to achieve effective BNCT and to avoid damage to adjacent healthy cells. In order to achieve the selective delivery of boron atoms to cancer cells, a drug delivery system (DDS) is an attractive intelligent technology for targeting and controlled release of drugs. We performed literature searches related to boron delivery systems in vitro and in vivo. We describe several DDS technologies for boron delivery to cancer tissues and cancer cells from the past to current status. We are convinced that it will be possible to use liposomes, monoclonal antibodies and WOW emulsions as boron delivery systems for BNCT clinically in accordance with the preparation of good commercial product (GCP) grade materials.

Estimating the number of HIV-infected injection drug users in Bangkok: a capture--recapture method.

Science.gov (United States)

Mastro, T D; Kitayaporn, D; Weniger, B G; Vanichseni, S; Laosunthorn, V; Uneklabh, T; Uneklabh, C; Choopanya, K; Limpakarnjanarat, K

1994-07-01

The purpose of the study was to estimate the number of injection drug users infected with the human immunodeficiency virus (HIV) in Bangkok to allow planning for health services for this population. A two-sample capture-recapture method was used. The first capture listed all persons on methadone treatment for opiate addiction from April 17 through May 17, 1991, at 18 facilities in Bangkok. The second capture involved urine testing of persons held at 72 Bangkok police stations from June 3 through September 30, 1991. Persons whose urine tests were positive for opiate metabolites or methadone were included on the second list. The first capture comprised 4064 persons and the recapture 1540 persons. There were 171 persons included on both lists, yielding an estimate of 36,600 opiate users in Bangkok. Existing data indicate that 89% of opiate users in Bangkok inject drugs and that about one third are infected with HIV, yielding an estimate of approximately 12,000 HIV-infected injection drug users in Bangkok in 1991. During the 1990s the number of cases of acquired immunodeficiency syndrome (AIDS) and other HIV-related diseases, including tuberculosis, in the population of HIV-infected injection drug users in Bangkok will increase dramatically, placing new demands on existing health care facilities. The capture-recapture method may be useful in estimating difficult-to-count populations, including injection drug users.

Standard services for the capture, processing, and distribution of packetized telemetry data

Science.gov (United States)

Stallings, William H.

1989-01-01

Standard functional services for the capture, processing, and distribution of packetized data are discussed with particular reference to the future implementation of packet processing systems, such as those for the Space Station Freedom. The major functions are listed under the following major categories: input processing, packet processing, and output processing. A functional block diagram of a packet data processing facility is presented, showing the distribution of the various processing functions as well as the primary data flow through the facility.

Assessing the economic feasibility of flexible integrated gasification Co-generation facilities

NARCIS (Netherlands)

Meerman, J.C.; Ramírez Ramírez, C.A.; Turkenburg, W.C.; Faaij, A.P.C.

2011-01-01

This paper evaluated the economic effects of introducing flexibility to state-of-the-art integrated gasification co-generation (IGCG) facilities equipped with CO2 capture. In a previous paper the technical and energetic performances of these flexible IG-CG facilities were evaluated. This paper

Studsvik thermal neutron facility

International Nuclear Information System (INIS)

Pettersson, O.A.; Larsson, B.; Grusell, E.; Svensson, P.

1992-01-01

The Studsvik thermal neutron facility at the R2-0 reactor originally designed for neutron capture radiography has been modified to permit irradiation of living cells and animals. A hole was drilled in the concrete shielding to provide a cylindrical channel with diameter of 25.3 cm. A shielding water tank serves as an entry holder for cells and animals. The advantage of this modification is that cells and animals can be irradiated at a constant thermal neutron fluence rate of approximately 10 9 n cm -2 s -1 (at 100 kW) without stopping and restarting the reactor. Topographic analysis of boron done by neutron capture autoradiography (NCR) can be irradiated under the same conditions as previously

Design of neutron beams at the Argonne Continuous Wave Linac (ACWL) for boron neutron capture therapy and neutron radiography

International Nuclear Information System (INIS)

Zhou, X.L.; McMichael, G.E.

1994-01-01

Neutron beams are designed for capture therapy based on p-Li and p-Sc reactions using the Argonne Continuous Wave Linac (ACWL). The p-Li beam will provide a 2.5 x 10 9 n/cm 2 s epithermal flux with 7 x 10 5 γ/cm 2 s contamination. On a human brain phantom, this beam allows an advantage depth (AD) of 10 cm, an advantage depth dose rate (ADDR) of 78 cGy/min and an advantage ratio (AR) of 3.2. The p-Sc beam offers 5.9 x 10 7 n/cm 2 s and a dose performance of AD = 8 cm and AR = 3.5, suggesting the potential of near-threshold (p,n) reactions such as the p-Li reaction at E p = 1.92 MeV. A thermal radiography beam could also be obtained from ACWL

Spatial interaction models facility location using game theory

CERN Document Server

D'Amato, Egidio; Pardalos, Panos

2017-01-01

Facility location theory develops the idea of locating one or more facilities by optimizing suitable criteria such as minimizing transportation cost, or capturing the largest market share. The contributions in this book focus an approach to facility location theory through game theoretical tools highlighting situations where a location decision is faced by several decision makers and leading to a game theoretical framework in non-cooperative and cooperative methods. Models and methods regarding the facility location via game theory are explored and applications are illustrated through economics, engineering, and physics. Mathematicians, engineers, economists and computer scientists working in theory, applications and computational aspects of facility location problems using game theory will find this book useful.

Heavy ion facility for radiation therapy

International Nuclear Information System (INIS)

Leemann, C.; Alonso, J.; Clark, D.; Grunder, H.; Hoyer, E.; Lou, K.; Staples, J.; Voelker, F.

1977-03-01

The accelerator requirements of particle radiation therapy are reviewed and a preliminary design of a heavy ion synchrotron for hospital installation is presented. Beam delivery systems and multi-treatment room arrangements are outlined

Association Between Facility-Level Utilization of Non-pharmacologic Chronic Pain Treatment and Subsequent Initiation of Long-Term Opioid Therapy.

Science.gov (United States)

Carey, Evan P; Nolan, Charlotte; Kerns, Robert D; Ho, P Michael; Frank, Joseph W

2018-05-01

Expert guidelines recommend non-pharmacologic treatments and non-opioid medications for chronic pain and recommend against initiating long-term opioid therapy (LTOT). We examined whether veterans with incident chronic pain receiving care at facilities with greater utilization of non-pharmacologic treatments and non-opioid medications are less likely to initiate LTOT. Retrospective cohort study PARTICIPANTS: Veterans receiving primary care from a Veterans Health Administration facility with incident chronic pain between 1/1/2010 and 12/31/2015 based on either of 2 criteria: (1) persistent moderate-to-severe patient-reported pain and (2) diagnoses "likely to represent" chronic pain. The independent variable was facility-level utilization of pain-related treatment modalities (non-pharmacologic, non-opioid medications, LTOT) in the prior calendar year. The dependent variable was patient-level initiation of LTOT (≥ 90 days within 365 days) in the subsequent year, adjusting for patient characteristics. Among 1,094,569 veterans with incident chronic pain from 2010 to 2015, there was wide facility-level variation in utilization of 10 pain-related treatment modalities, including initiation of LTOT (median, 16%; range, 5-32%). Veterans receiving care at facilities with greater utilization of non-pharmacologic treatments were less likely to initiate LTOT in the year following incident chronic pain. Conversely, veterans receiving care at facilities with greater non-opioid and opioid medication utilization were more likely to initiate LTOT; this association was strongest for past year facility-level LTOT initiation (adjusted rate ratio, 2.10; 95% confidence interval, 2.06-2.15, top vs. bottom quartile of facility-level LTOT initiation in prior calendar year). Facility-level utilization patterns of non-pharmacologic, non-opioid, and opioid treatments for chronic pain are associated with subsequent patient-level initiation of LTOT among veterans with incident chronic pain

Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome

International Nuclear Information System (INIS)

Kageji, Teruyoshi; Nagahiro, Shinji; Matsuzaki, Kazuhito; Mizobuchi, Yoshifumi; Toi, Hiroyuki; Nakagawa, Yoshinobu; Kumada, Hiroaki

2006-01-01

Purpose: To clarify the correlation between the radiation dose and clinical outcome of sodium borocaptate-based intraoperative boron neutron capture therapy in patients with malignant glioma. Methods and Materials: The first protocol (P1998, n = 8) prescribed a maximal gross tumor volume (GTV) dose of 15 Gy. In 2001, a dose-escalated protocol was introduced (P2001, n 11), which prescribed a maximal vascular volume dose of 15 Gy or, alternatively, a clinical target volume (CTV) dose of 18 Gy. Results: The GTV and CTV doses in P2001 were 1.1-1.3 times greater than those in P1998. The maximal vascular volume dose of those with acute radiation injury was 15.8 Gy. The mean GTV and CTV dose in long-term survivors with glioblastoma was 26.4 and 16.5 Gy, respectively. A statistically significant correlation between the GTV dose and median survival time was found. In the 11 glioblastoma patients in P2001, the median survival time was 19.5 months and 1- and 2-year survival rate was 60.6% and 37.9%, respectively. Conclusion: Dose escalation contributed to the improvement in clinical outcome. To avoid radiation injury, the maximal vascular volume dose should be <12 Gy. For long-term survival in patients with glioblastoma after boron neutron capture therapy, the optimal mean dose of the GTV and CTV was 26 and 16 Gy, respectively

Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

Energy Technology Data Exchange (ETDEWEB)

Ackermann, A.L. (ed.)

1990-10-01

This bulletin discusses activities during this reporting period in the areas of: supporting technology development; large animal model studies; melanoma project; human studies; stability, pharmacology, and toxicology of drugs; and PBF technical support. (FL)

New carbon-carbon linked amphiphilic carboranyl-porphyrins as boron neutron capture agents

International Nuclear Information System (INIS)

Vicente, M.G.H.; Wickramasinghe, A.; Shetty, S.J.; Smith, K.M.

2000-01-01

Novel amphiphilic carboranyl-porphyrins have been synthesized for Boron Neutron Capture Therapy (BNCT). These compounds have carbon-carbon bonds between the carborane residues and the porphyrin meso-phenyl groups, and contain 28-31% boron by weight . (author)

TU-FG-BRB-07: GPU-Based Prompt Gamma Ray Imaging From Boron Neutron Capture Therapy

Energy Technology Data Exchange (ETDEWEB)

Kim, S; Suh, T; Yoon, D; Jung, J; Shin, H; Kim, M [The catholic university of Korea, Seoul (Korea, Republic of)

2016-06-15

Purpose: The purpose of this research is to perform the fast reconstruction of a prompt gamma ray image using a graphics processing unit (GPU) computation from boron neutron capture therapy (BNCT) simulations. Methods: To evaluate the accuracy of the reconstructed image, a phantom including four boron uptake regions (BURs) was used in the simulation. After the Monte Carlo simulation of the BNCT, the modified ordered subset expectation maximization reconstruction algorithm using the GPU computation was used to reconstruct the images with fewer projections. The computation times for image reconstruction were compared between the GPU and the central processing unit (CPU). Also, the accuracy of the reconstructed image was evaluated by a receiver operating characteristic (ROC) curve analysis. Results: The image reconstruction time using the GPU was 196 times faster than the conventional reconstruction time using the CPU. For the four BURs, the area under curve values from the ROC curve were 0.6726 (A-region), 0.6890 (B-region), 0.7384 (C-region), and 0.8009 (D-region). Conclusion: The tomographic image using the prompt gamma ray event from the BNCT simulation was acquired using the GPU computation in order to perform a fast reconstruction during treatment. The authors verified the feasibility of the prompt gamma ray reconstruction using the GPU computation for BNCT simulations.

Seed irradiation facilities at TRIGA Mark II reactor

International Nuclear Information System (INIS)

Najzer, M.

1972-01-01

Fast neutrons and gamma-rays with their high and low LET respectively are excellent complementary tools for investigation of the effect of different types of mutations. TRIGA Irradiation Facility and Thermal Column Irradiation Facility were designed and installed for the first time in the TRIGA tank and thermal column respectively. The basic idea of design was the use of depleted uranium as gamma-ray and thermal neutron shield and simultaneously as thermal to fast neutron converter. Low LET radiation, due to direct and thermal neutron capture gamma-rays, is strongly attenuated while fast neutron flux is increased. GIF is made of a cadmium tube inserted in a graphite block. It is located in the central thermal column channel. The basic idea is to convert thermal neutrons to gamma-rays by capture in the cadmium

Design of small-animal thermal neutron irradiation facility at the Brookhaven Medical Research Reactor

International Nuclear Information System (INIS)

Liu, H.B.

1996-01-01

The broad beam facility (BBF) at the Brookhaven Medical Research Reactor (BMRR) can provide a thermal neutron beam with flux intensity and quality comparable to the beam currently used for research on neutron capture therapy using cell-culture and small-animal irradiations. Monte Carlo computations were made, first, to compare with the dosimetric measurements at the existing BBF and, second, to calculate the neutron and gamma fluxes and doses expected at the proposed BBF. Multiple cell cultures or small animals could be irradiated simultaneously at the so-modified BBF under conditions similar to or better than those individual animals irradiated at the existing thermal neutron irradiation Facility (TNIF) of the BMRR. The flux intensity of the collimated thermal neutron beam at the proposed BBF would be 1.7 x 10 10 n/cm 2 ·s at 3-MW reactor power, the same as at the TNIF. However, the proposed collimated beam would have much lower gamma (0.89 x 10 -11 cGy·cm 2 /n th ) and fast neutron (0.58 x 10 -11 cGy·cm 2 /n th ) contaminations, 64 and 19% of those at the TNIF, respectively. The feasibility of remodeling the facility is discussed

Validation and Comparison of the Therapeutic Efficacy of Boron Neutron Capture Therapy Mediated By Boron-Rich Liposomes in Multiple Murine Tumor Models

Directory of Open Access Journals (Sweden)

Charles A Maitz

2017-08-01

Full Text Available Boron neutron capture therapy (BNCT was performed at the University of Missouri Research Reactor in mice bearing CT26 colon carcinoma flank tumors and the results were compared with previously performed studies with mice bearing EMT6 breast cancer flank tumors. Mice were implanted with CT26 tumors subcutaneously in the caudal flank and were given two separate tail vein injections of unilamellar liposomes composed of cholesterol, 1,2-distearoyl-sn-glycer-3-phosphocholine, and K[nido-7-CH3(CH215–7,8-C2B9H11] in the lipid bilayer and encapsulated Na3[1-(2`-B10H9-2-NH3B10H8] within the liposomal core. Mice were irradiated 30 hours after the second injection in a thermal neutron beam for various lengths of time. The tumor size was monitored daily for 72 days. Despite relatively lower tumor boron concentrations, as compared to EMT6 tumors, a 45 minute neutron irradiation BNCT resulted in complete resolution of the tumors in 50% of treated mice, 50% of which never recurred. Median time to tumor volume tripling was 38 days in BNCT treated mice, 17 days in neutron-irradiated mice given no boron compounds, and 4 days in untreated controls. Tumor response in mice with CT26 colon carcinoma was markedly more pronounced than in previous reports of mice with EMT6 tumors, a difference which increased with dose. The slope of the dose response curve of CT26 colon carcinoma tumors is 1.05 times tumor growth delay per Gy compared to 0.09 times tumor growth delay per Gy for EMT6 tumors, indicating that inherent radiosensitivity of tumors plays a role in boron neutron capture therapy and should be considered in the development of clinical applications of BNCT in animals and man.

Neutron dose equivalent next to the target shield of a neutron therapy facility using an LET counter

International Nuclear Information System (INIS)

Stinchcomb, T.G.; Kuchnir, F.T.

1981-01-01

The use of a spherical tissue-equivalent proportional counter for measurements of the lineal energy (y) and derivations of the linear energy transfer (LET) for fast neutrons has the advantage of giving distributions of dose and dose equivalent as functions of either LET or y. A measurement next to the target shielding of the neutron therapy facility at the University of Chicago Hospitals and Clinics (UCHC) is described, and the data processing is outlined. The distributions are presented and compared to those from measurements in the neutron beam. The average quality factors are presented

Monitoring of blood-10B concentration for boron neutron capture therapy using prompt gamma-ray analysis

International Nuclear Information System (INIS)

Raaijmakers, C.P.J.; Konijnenberg, M.W.; Dewit, L.; Mijnheer, B.J.; Haritz, D.; Huiskamp, R.; Philipp, K.; Siefert, A.; Stecher-Rasmussen, F.

1995-01-01

The aim of the present study was to monitor the blood- 10 B concentration of laboratory dogs receiving boron neutron capture therapy, in order to obtain optimal agreement between prescribed and actual dose. A prompt gamma-ray analysis system was developed for this purpose at the High Flux Reactor in Petten. The technique was compared with inductively coupled plasma-atomic emission spectrometry and showed good agreement. A substantial variation in 10 B clearance pattern after administration of borocaptate sodium was found between the different dogs. Consequently, the irradiation commencement was adjusted to the individually determined boron elimination curve. Mean blood- 10 B concentratios during irradiation of 25.8±2.2 μg/g (1 SD, n=18) and 49.3±5.3 μg/g (1 SD, n=17) were obtained for intended concentrations of 25 μg/g and 50 μg/g, respectively. These variations are a factor of two smaller than irradiations performed at a uniform post-infusion irradiation starting time. Such a careful bolld- 10 B monitoring procedure is a prerequisite for accurately obtaining such steep dose-response curves as observed during the dog study. (orig.)

Feasibility of the utilization of BNCT in the fast neutron therapy beam at Fermilab

International Nuclear Information System (INIS)

Langen, Katja; Lennox, Arlene J.; Kroc, Thomas K.; DeLuca, Paul M. Jr.

2000-01-01

The Neutron Therapy Facility at Fermilab has treated cancer patients since 1976. Since then more than 2,300 patients have been treated and a wealth of clinical information accumulated. The therapeutic neutron beam at Fermilab is produced by bombarding a beryllium target with 66 MeV protons. The resulting continuous neutron spectrum ranges from thermal to 66 MeV in neutron energy. It is clear that this spectrum is not well suited for the treatment of tumors with boron neutron capture therapy (BNCT) only However, since this spectrum contains thermal and epithermal components the authors are investigating whether BNCT can be used in this beam to boost the tumor dose. There are clinical scenarios in which a selective tumor dose boost of 10 - 15% could be clinically significant. For these cases the principal treatment would still be fast neutron therapy but a tumor boost could be used either to deliver a higher dose to the tumor tissue or to reduce the dose to the normal healthy tissue while maintaining the absorbed dose level in the tumor tissue

The impact of the prospective payment system for skilled nursing facilities on therapy service provision: a transaction cost approach.

Science.gov (United States)

Zinn, Jacqueline S; Mor, Vincent; Intrator, Orna; Feng, Zhanlian; Angelelli, Joseph; Davis, Jullet A

2003-12-01

To examine skilled nursing facilities (SNFs) "make-or-buy" decisions with respect to rehabilitation therapy service provision in the 1990s, both before and after implementation of Medicare's Prospective Payment System (PPS) for SNFs. Longitudinal On-line Survey Certification and Reporting (OSCAR) data (1992-2001) on a sample of 10,241 freestanding urban SNFs. We estimated a longitudinal multinomial logistic regression model derived from transaction cost economic theory to predict the probability of the outcome in each of four service provision categories (all employed staff, all contract, mixed, and no services provided). Transaction frequency, uncertainty, and complexity result in greater control over therapy services through employment as opposed to outside contracting. For-profit status and chain affiliation were associated with greater control over therapy services. Following PPS, nursing homes acted to limit transaction costs by either exiting the rehabilitation market or exerting greater control over therapy services by managing rehabilitation services in-house. The financial incentives associated with changes in reimbursement methodology have implications that extend beyond the boundaries of the health care industry segment directly affected. Unintended quality and access consequences need to be carefully monitored by the Medicare program.

Borophene as a Promising Material for Charge-Modulated Switchable CO2 Capture.

Science.gov (United States)

Tan, Xin; Tahini, Hassan A; Smith, Sean C

2017-06-14

Ideal carbon dioxide (CO 2 ) capture materials for practical applications should bind CO 2 molecules neither too weakly to limit good loading kinetics nor too strongly to limit facile release. Although charge-modulated switchable CO 2 capture has been proposed to be a controllable, highly selective, and reversible CO 2 capture strategy, the development of a practical gas-adsorbent material remains a great challenge. In this study, by means of density functional theory (DFT) calculations, we have examined the possibility of conductive borophene nanosheets as promising sorbent materials for charge-modulated switchable CO 2 capture. Our results reveal that the binding strength of CO 2 molecules on negatively charged borophene can be significantly enhanced by injecting extra electrons into the adsorbent. At saturation CO 2 capture coverage, the negatively charged borophene achieves CO 2 capture capacities up to 6.73 × 10 14 cm -2 . In contrast to the other CO 2 capture methods, the CO 2 capture/release processes on negatively charged borophene are reversible with fast kinetics and can be easily controlled via switching on/off the charges carried by borophene nanosheets. Moreover, these negatively charged borophene nanosheets are highly selective for separating CO 2 from mixtures with CH 4 , H 2 , and/or N 2 . This theoretical exploration will provide helpful guidance for identifying experimentally feasible, controllable, highly selective, and high-capacity CO 2 capture materials with ideal thermodynamics and reversibility.

Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion.

Science.gov (United States)

Yanagie, Hironobu; Higashi, Syushi; Seguchi, Koji; Ikushima, Ichiro; Fujihara, Mituteru; Nonaka, Yasumasa; Oyama, Kazuyuki; Maruyama, Syoji; Hatae, Ryo; Suzuki, Minoru; Masunaga, Shin-ichiro; Kinashi, Tomoko; Sakurai, Yoshinori; Tanaka, Hiroki; Kondo, Natsuko; Narabayashi, Masaru; Kajiyama, Tetsuya; Maruhashi, Akira; Ono, Koji; Nakajima, Jun; Ono, Minoru; Takahashi, Hiroyuki; Eriguchi, Masazumi

2014-06-01

A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC. Copyright © 2014 Elsevier Ltd. All rights reserved.

Proton Radiation Therapy in the Hospital Environment: Conception, Development, and Operation of the Initial Hospital-Based Facility

Science.gov (United States)

Slater, James M.; Slater, Jerry D.; Wroe, Andrew J.

The world's first hospital-based proton treatment center opened at Loma Linda University Medical Center in 1990, following two decades of development. Patients' needs were the driving force behind its conception, development, and execution; the primary needs were delivery of effective conformal doses of ionizing radiation and avoidance of normal tissue to the maximum extent possible. The facility includes a proton synchrotron and delivery system developed in collaboration with physicists and engineers at Fermi National Accelerator Laboratory and from other high-energy-physics laboratories worldwide. The system, operated and maintained by Loma Linda personnel, was designed to be safe, reliable, flexible in utilization, efficient in use, and upgradeable to meet demands of changing patient needs and advances in technology. Since the facility opened, nearly 14,000 adults and children have been treated for a wide range of cancers and other diseases. Ongoing research is expanding the applications of proton therapy, while reducing costs.

MOSFET dosimetry of the radiation therapy microbeams at the European synchrotron radiation facility

International Nuclear Information System (INIS)

Rozenfeld, A.; Lerch, M.

2002-01-01

Full text: We have developed an innovative on-line MOSFET readout system for use in the quality assurance of radiation treatment beams. Recently the system has found application in areas where excellent spatial resolution is also a requirement in the quality assurance process, for example IMRT, and microbeam radiation therapy. The excellent spatial resolution is achieved by using a quadruple RADFET TM chip in 'edge on' mode. In developing this approach we have found that the system can be utilised to determine any error in the beam profile measurements due to misalignment of RADFET with respect to the radiation beam or microbeam. Using this approach will ensure that the excellent spatial resolution of the RADFET used in 'edge-on' mode is fully utilised. In this work we report on dosimetry measurements performed at the microbeam radiation therapy beamline located at the European Synchrotron Radiation Facility. The synchrotron planar array microbeam with size 10-30 μm and pitch ∼200 μm has found an important application in microbeam radiation therapy (MRT) of brain tumours in infants for whom other kinds of radiotherapy are inadequate and/or unsafe. The radiation damage from an array of parallel microbeams correlates strongly with the range of peak-valley dose ratios (PVDR), ie, the range of the ratio of the absorbed dose to tissue directly in line with the mid-plane of the microbeam to that in the mid-plane between adjacent microbeams. Novel physical dosimetry of the microbeams using the online MOSFET reader system will be presented. Comparison of the experimental results with both GaF film measurements and Monte Carlo computer-simulated dosimetry are described here for selected points in the peak and valley regions of a microbeam-irradiated tissue phantom

[A clinical trial of neutron capture therapy for brain tumors

International Nuclear Information System (INIS)

Zamenhof, R.G.

1989-01-01

This report describes accomplishments by this laboratory concerning development of high-resolution alpha-autoradiography design of an optimized epithermal neutron beam dosimetry and treatment planning Using Monte Carlo techniques development of a prompt-gamma 10 B analysis facility

Facile integration of multiple magnetite nanoparticles for theranostics combining efficient MRI and thermal therapy

Science.gov (United States)

Huang, Guoming; Zhu, Xianglong; Li, Hui; Wang, Lirong; Chi, Xiaoqin; Chen, Jiahe; Wang, Xiaomin; Chen, Zhong; Gao, Jinhao

2015-01-01

Multifunctional nanostructures with both diagnostic and therapeutic capabilities have attracted considerable attention in biomedical research because they can offer great advantages in disease management and prognosis. In this work, a facile way to transfer the hydrophobic iron oxide (IO) nanoparticles into aqueous media by employing carboxylic graphene oxide (GO-COOH) as the transferring agent has been reported. In this one-step process, IO nanoparticles adhere to GO-COOH and form water-dispersible clusters via hydrophobic interactions between the hydrophobic ligands of IO nanoparticles and the basal plane of GO-COOH. The multiple IO nanoparticles on GO-COOH sheets (IO/GO-COOH) present a significant increase in T2 contrast enhancement. Moreover, the IO/GO-COOH nanoclusters also display a high photothermal conversion efficiency and can effectively inhibit tumor growth through the photothermal effects. It is envisioned that such IO/GO-COOH nanocomposites combining efficient MRI and photothermal therapy hold great promise in theranostic applications.Multifunctional nanostructures with both diagnostic and therapeutic capabilities have attracted considerable attention in biomedical research because they can offer great advantages in disease management and prognosis. In this work, a facile way to transfer the hydrophobic iron oxide (IO) nanoparticles into aqueous media by employing carboxylic graphene oxide (GO-COOH) as the transferring agent has been reported. In this one-step process, IO nanoparticles adhere to GO-COOH and form water-dispersible clusters via hydrophobic interactions between the hydrophobic ligands of IO nanoparticles and the basal plane of GO-COOH. The multiple IO nanoparticles on GO-COOH sheets (IO/GO-COOH) present a significant increase in T2 contrast enhancement. Moreover, the IO/GO-COOH nanoclusters also display a high photothermal conversion efficiency and can effectively inhibit tumor growth through the photothermal effects. It is envisioned

Development of local radiation therapy

Energy Technology Data Exchange (ETDEWEB)

Lee, Seung Hoon; Lim, Sang Moo; Choi, Chang Woon; Chai, Jong Su; Kim, Eun Hee; Kim, Mi Sook; Yoo, Seong Yul; Cho, Chul Koo; Lee, Yong Sik; Lee, Hyun Moo

1999-04-01

The major limitations of radiation therapy for cancer are the low effectiveness of low LET and inevitable normal tissue damage. Boron Neutron Capture Therapy (BNCT) is a form of potent radiation therapy using Boron-10 having a high propensityof capturing theraml neutrons from nuclear reactor and reacting with a prompt nuclear reaction. Photodynamic therapy is a similiar treatment of modality to BNCT using tumor-seeking photosenistizer and LASER beam. If Boron-10 and photosensitizers are introduced selectively into tumor cells, it is theoretically possible to destroy the tumor and to spare the surrounding normal tissue. Therefore, BNCT and PDT will be new potent treatment modalities in the next century. In this project, we performed PDT in the patients with bladder cancers, oropharyngeal cancer, and skin cancers. Also we developed I-BPA, new porphyrin compounds, methods for estimation of radiobiological effect of neutron beam, and superficial animal brain tumor model. Furthermore, we prepared preclinical procedures for clinical application of BNCT, such as the macro- and microscopic dosimetry, obtaining thermal neutron flux from device used for fast neutron production in KCCH have been performed.

Development of local radiation therapy

International Nuclear Information System (INIS)

Lee, Seung Hoon; Lim, Sang Moo; Choi, Chang Woon; Chai, Jong Su; Kim, Eun Hee; Kim, Mi Sook; Yoo, Seong Yul; Cho, Chul Koo; Lee, Yong Sik; Lee, Hyun Moo

1999-04-01

The major limitations of radiation therapy for cancer are the low effectiveness of low LET and inevitable normal tissue damage. Boron Neutron Capture Therapy (BNCT) is a form of potent radiation therapy using Boron-10 having a high propensityof capturing theraml neutrons from nuclear reactor and reacting with a prompt nuclear reaction. Photodynamic therapy is a similiar treatment of modality to BNCT using tumor-seeking photosenistizer and LASER beam. If Boron-10 and photosensitizers are introduced selectively into tumor cells, it is theoretically possible to destroy the tumor and to spare the surrounding normal tissue. Therefore, BNCT and PDT will be new potent treatment modalities in the next century. In this project, we performed PDT in the patients with bladder cancers, oropharyngeal cancer, and skin cancers. Also we developed I-BPA, new porphyrin compounds, methods for estimation of radiobiological effect of neutron beam, and superficial animal brain tumor model. Furthermore, we prepared preclinical procedures for clinical application of BNCT, such as the macro- and microscopic dosimetry, obtaining thermal neutron flux from device used for fast neutron production in KCCH have been performed

Highly efficient capture of iodine by Cu/MIL-101

Science.gov (United States)

Qi, Bingbing; Liu, Ying; Zheng, Tao; Gao, Qianhong; Yan, Xuewu; Jiao, Yan; Yang, Yi

2018-02-01

In order to improve the uptake capacity of MIL-101 for iodine, Cu nanoparticles doped MIL-101 were successfully synthesized through a facile method. The obtained Cu/MIL-101 was characterized by SEM, XRD, EDS, TEM, IR, TGA and BET to examine the chemical and thermal stabilities. The capture experiments for the adsorbents showed that the capture capacity of Cu/MIL-101 for volatile iodine is 342 wt%, which is higher than that of pure MIL-101. An I2 uptake of 342 wt% is the highest value reported among metal-organic frameworks. Furthermore, Cu/MIL-101 has a cycle ratio of 95% after three cycles and exhibits a better cyclicity than pure MIL-101. Meanwhile, Cu/MIL-101 shows an excellent reversible adsorption of iodine in solution.

Utilization of RP-10 reactor for neutron therapy

International Nuclear Information System (INIS)

Paucar, R.; Nieto, M.; Parreno, F.; Vela, M.; Pozo, Z.

1997-01-01

In the Nuclear Energy Peruvian Institute, IPEN, a research area has established of Neutron Radiotherapy, know as NCT. This research joins the physics of particles (Neutrons and photons) and Medical Physics, and this one is an applied investigation where in considering the construction of a treatment hall in Huarangal (Peru) Reactor's irradiation facility, it can treat patients with brain tumors. In Neutron Therapy (NCT), it tries to use neutrons to destroy tumor cells where other therapeutic techniques are not effective. This process consist on to incise a neutrons beam of adequate characteristics over the tumor area of the patient. The neutrons used are of thermal energy and therefore irradiations are developed in experimental reactors. For this one, it is used horizontal channels prepared suitably. Before the irradiation, it is injected to the patient a substance which is absorbed by tumoral tissue. The substance components will be B-10, nuclide with an absorption cross section high to thermal neutrons (3837 b). The B-10 irradiate with thermal neutrons produce alpha particles of short reach (10 μm. on soft tissue) and with LET values (lineal energy transference) very high. The result is a cell preferential destruction which have absorbed the substance and it's next neighbors, like the cell size is 10 μm. This process as know as Boron Neutron Capture Therapy (BNCT). This work describes Peruvian RP-10 reactor and recently efforts to assess the design and feasibility of the medical neutron irradiation facility for NCT. (author). 22 refs., 6 tabs

Boron neutron capture therapy. Synthesis of boronated amines- and DNA intercalating agents for potential use in cancer therapy

International Nuclear Information System (INIS)

Ghaneolhosseini, H.

1998-01-01

Boron Neutron Capture Therapy is a binary cancer treatment modality, involving the delivery of a suitable boron compound to tumour cells followed by irradiation of the tumour by thermal neutrons. Boronated agents can selectively be delivered to tumour cells either directly with tumour-specific boron compounds, or by use of targeting strategies. However, the efficacy of this method would increase if the boron agents are localised in the cell nucleus rather than in the cell cytoplasm when neutron irradiation takes place. With these considerations in mind, some boronated DNA intercalating/interacting agents such as phenanthridine- acridine- spermidine- and naphthalimide derivatives were synthesised. Aminoalkyl-o-carboranes were synthesised in order to be used both for coupling to macromolecules and also for halogenation of their corresponding nido-derivatives. The amino groups were introduced using the Gabriel reagent N, N-dibenzyl iminodicarboxylate to provide 1-(aminomethyl)- and 1-(2-aminoethyl)-o-carboranes. The first attempt to achieve the possibility to accumulate a higher concentration of boron atoms in the cell nucleus was to synthesize carboranyl phenanthridinium analogues by reacting a p- or o-carboranyl moiety with phenanthridine, a chromophore with a planar aromatic ring system as DNA intercalator. Boronated acridine-spermidine, boronated diacridine, and boronated dispermidine were obtained in order to increase water solubility to avoid the interaction of these agents with non-DNA sides of the cell, especially membranes; and to enhance the feasibility of a higher DNA-binding constant and also decrease the DNA-drug dissociation rate. Finally, the synthesis of a boronated naphthalimide derivative was carried out by nucleophilic reaction of a primary aminoalkyl-p-carborane with naphthalic anhydride. Biological evaluations on DNA-binding, toxicity, and cellular binding with carboranyl phenanthridinium analogues, boronated acridine- and spermidine are described

SU-E-J-100: Reconstruction of Prompt Gamma Ray Three Dimensional SPECT Image From Boron Neutron Capture Therapy(BNCT)

Energy Technology Data Exchange (ETDEWEB)

Yoon, D; Jung, J; Suh, T [The Catholic University of Korea, College of medicine, Department of biomedical engineering (Korea, Republic of)

2014-06-01

Purpose: Purpose of paper is to confirm the feasibility of acquisition of three dimensional single photon emission computed tomography (SPECT) image from boron neutron capture therapy (BNCT) using Monte Carlo simulation. Methods: In case of simulation, the pixelated SPECT detector, collimator and phantom were simulated using Monte Carlo n particle extended (MCNPX) simulation tool. A thermal neutron source (<1 eV) was used to react with the boron uptake region (BUR) in the phantom. Each geometry had a spherical pattern, and three different BURs (A, B and C region, density: 2.08 g/cm3) were located in the middle of the brain phantom. The data from 128 projections for each sorting process were used to achieve image reconstruction. The ordered subset expectation maximization (OSEM) reconstruction algorithm was used to obtain a tomographic image with eight subsets and five iterations. The receiver operating characteristic (ROC) curve analysis was used to evaluate the geometric accuracy of reconstructed image. Results: The OSEM image was compared with the original phantom pattern image. The area under the curve (AUC) was calculated as the gross area under each ROC curve. The three calculated AUC values were 0.738 (A region), 0.623 (B region), and 0.817 (C region). The differences between length of centers of two boron regions and distance of maximum count points were 0.3 cm, 1.6 cm and 1.4 cm. Conclusion: The possibility of extracting a 3D BNCT SPECT image was confirmed using the Monte Carlo simulation and OSEM algorithm. The prospects for obtaining an actual BNCT SPECT image were estimated from the quality of the simulated image and the simulation conditions. When multiple tumor region should be treated using the BNCT, a reasonable model to determine how many useful images can be obtained from the SPECT could be provided to the BNCT facilities. This research was supported by the Leading Foreign Research Institute Recruitment Program through the National Research

Australian national proton facility

International Nuclear Information System (INIS)

Jackson, M.

2000-01-01

Full text: Proton therapy has been in use since 1954 and over 25,000 patients have been treated worldwide. Until recently most patients were treated at physics research facilities and apart from the Harvard Cyclotron Laboratory and some low energy machines for eye treatment, only small numbers of patients were treated in each centre and conditions were less than optimal. Limited beam time and lack of support facilities restricted the type of patient treated and conventional fractionation could not be used. The initial clinical experience was mainly with small tumours and other lesions close to critical organs. Large numbers of eye tumours have also been treated. Protons have a well-defined role in these situations and are now being used in the treatment of more common cancers. Since the development of hospital-based facilities, such as the one in Loma Linda in California, over 2,500 patients with prostate cancer have been treated using a simple technique which gives results at least as good as radical surgery, external beam radiotherapy or brachytherapy. Importantly, the incidence of severe complications is very low. There are encouraging results in many disease sites including lung, liver, soft tissue sarcomas and oesophagus. As proton therapy becomes more widely available, randomised trials comparing it with conventional radiotherapy or intensity modulated radiotherapy (IMRT) will be possible. In most situations the use of protons will enable a higher dose to be given safely but in situations where local control rates are already satisfactory, protons are expected to produce less complications than conventional treatment. The initial costs of a proton facility are high but the recurrent costs are similar to other forms of high technology radiotherapy. Simple treatment techniques with only a few fields are usually possible and proton therapy avoids the high integral doses associated with IMRT. This reduction in the low dose volume is likely to be particularly

Usability Briefing - a process model for healthcare facilities

DEFF Research Database (Denmark)

Fronczek-Munter, Aneta

2014-01-01

Background: In complex buildings with many types of users it can be difficult to satisfy the numerous, often contradictory requirements. Research in usability mostly focuses on evaluating products or facilities with users, after they were built. This paper is part of a PhD project “Usability...... with various users/stakeholders, using creative boundary objects at workshops.  Practical Implications: The research results have relevance to researchers, client organisations, facility managers and architects planning new complex facilities.  Research limitations: The proposed model is theoretical and needs...... briefing for hospitals”, where methods for capturing user needs and experiences at hospital facilities are investigated in order to feed into design processes and satisfy the users’ needs and maximise the effectiveness of facilities. Purpose: This paper introduces the concept of usability briefing...

Dosimetric analysis of BNCT - Boron Neutron Capture Therapy - coupled to 252Cf brachytherapy

International Nuclear Information System (INIS)

Brandao, Samia F.; Campos, Tarcisio P.R.

2009-01-01

The incidence of brain tumors is increasing in world population; however, the treatments employed in this type of tumor have a high rate of failure and in some cases have been considered palliative, depending on histology and staging of tumor. Its necessary to achieve the control tumor dose without the spread irradiation cause damage in the brain, affecting patient neurological function. Stereotactic radiosurgery is a technique that achieves this; nevertheless, other techniques that can be used on the brain tumor control must be developed, in order to guarantee lower dose on health surroundings tissues other techniques must be developing. The 252 Cf brachytherapy applied to brain tumors has already been suggested, showing promising results in comparison to photon source, since the active source is placed into the tumor, providing greater dose deposition, while more distant regions are spared. BNCT - Boron Neutron Capture Therapy - is another technique that is in developing to brain tumors control, showing theoretical superiority on the rules of conventional treatments, due to a selective irradiation of neoplasics cells, after the patient receives a borate compound infusion and be subjected to a epithermal neutrons beam. This work presents dosimetric studies of the coupling techniques: BNCT with 252 Cf brachytherapy, conducted through computer simulation in MCNP5 code, using a precise and well discretized voxel model of human head, which was incorporated a representative Glioblastoma Multiform tumor. The dosimetric results from MCNP5 code were exported to SISCODES program, which generated isodose curves representing absorbed dose rate in the brain. Isodose curves, neutron fluency, and dose components from BNCT and 252 Cf brachytherapy are presented in this paper. (author)

Reactor-moderated intermediate-energy neutron beams for neutron-capture therapy

International Nuclear Information System (INIS)

Less, T.J.

1987-01-01

One approach to producing an intermediate energy beam is moderating fission neutrons escaping from a reactor core. The objective of this research is to evaluate materials that might produce an intermediate beam for NCT via moderation of fission neutrons. A second objective is to use the more promising moderator material in a preliminary design of an NCT facility at a research reactor. The evaluations showed that several materials or combinations of materials could produce a moderator source for an intermediate beam for NCT. The best neutron spectrum for use in NCT is produced by Al 2 O 3 , but mixtures of Al metal and D 2 O are also attractive. Using the best moderator materials, results were applied to the design of an NCT moderator at the Georgia Institute of Technology Research Reactor's bio-medical facility. The amount of photon shielding and thermal neutron absorber were optimized with respect to the desired photon dose rate and intermediate neutron flux at the patient position

The present status of the n-TOF facility at CERN

International Nuclear Information System (INIS)

Igashira, Masayuki

2005-01-01

The main aim of the n - TOF facility at CERN is to provide precise neutron cross-section data relevant to the R and D of accelerator driven systems, nuclear astrophysics, etc. It is composed of a spallation neutron source, a 187.5-m flight path, a variety of detectors, a data acquisition system, etc. A 20 GeV proton synchrotron is employed together with a lead target for the spallation neutron source. The measurement of capture and fission cross sections started in 2002 and had been performed until the mid of November in 2004. The capture and fission measurements were performed for 28 and 7 isotopes, respectively. The brief history, present status, and future plan of the n - TOF facility are reported. (author)

Induction of chromosomal aberrations by neutron capture reactions

International Nuclear Information System (INIS)

Ikushima, Takaji

1993-01-01

Boron neutron capture reaction (B-NCR) has been practiced in the treatment of malignancies of the central nervous system and melanoma using a thermal neutron beam from the KUR. Because of the very large neutron absorption cross-section and high kinetic energy released, gadolinium (Gd-157) has been expected to be an another promising element for neutron capture therapy. The dose-response relationship was determined for the induction of chromosomal aberrations by neutron capture reactions by B-10 and Gd-157 in cultured mammalian cells. The cells were exposed to thermal neutron beam with and without B-10 enriched (97 atom %) boric acid or Gd-DTPA, and chromosome-type aberrations were analysed in the first metaphases following irradiation. The frequency of dicentrics and rings increased linearly with neutron fluence either in the presence or absence of B-10 boric acid, while the yield of chromosomal aberrations induced by Gd-NCR increased in a linear quadratic fashion as a function of dose as in γ-rayed cells. Survival curves for the cells exposed to thermal neutrons showed no shoulder irrespective of the loading of B-10, but Gd-NCR produced the survival curve with a small shoulder. The differential chromosomal response to B-NCR and Gd-NCR might reflect the difference in radiation quality generated from the two types of thermal neutron capture reaction. (J.P.N.)

Radiation therapy sources, equipment and installations

International Nuclear Information System (INIS)

2011-03-01

The safety code for Telegamma Therapy Equipment and Installations, (AERB/SC/MED-1) and safety code for Brachytherapy Sources, Equipment and Installations, (AERB/SC/MED-3) were issued by AERB in 1986 and 1988 respectively. These codes specified mandatory requirements for radiation therapy facilities, covering the entire spectrum of operations ranging from the setting up of a facility to its ultimate decommissioning, including procedures to be followed during emergency situations. The codes also stipulated requirements of personnel and their responsibilities. With the advent of new techniques and equipment such as 3D-conformal radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, treatment planning system, stereotactic radiosurgery, stereotactic radiotherapy, portal imaging, integrated brachytherapy and endovascular brachytherapy during the last two decades, AERB desires that these codes be revised and merged into a single code titled Radiation Therapy Sources, Equipment, and Installations

Analysis of rehabilitation activities within skilled nursing and inpatient rehabilitation facilities after hip replacement for acute hip fracture.

Science.gov (United States)

Munin, Michael C; Putman, Koen; Hsieh, Ching-Hui; Smout, Randall J; Tian, Wenqiang; DeJong, Gerben; Horn, Susan D

2010-07-01

To characterize rehabilitation services in two types of postacute facilities in patients who underwent hip replacement following a hip fracture. Multisite prospective observational cohort from 6 freestanding skilled nursing facilities and 11 inpatient rehabilitation facilities. Patients (n = 218) with hip fracture who had either hemiarthroplasty or total hip arthroplasty followed by rehabilitation at skilled nursing facilities or inpatient rehabilitation facilities were enrolled. Using a point-of-care methodology, we recorded data from actual physical therapy and occupational therapy sessions completed including functional outcomes during the postacute admission. Onset time from surgical repair to rehabilitation admission was not significantly different between sites. Average skilled nursing facilities length of stay was 24.7 +/- 13.6 days, whereas inpatient rehabilitation facilities was 13.0 +/- 5.7 days (P inpatient rehabilitation facilities. For weekdays only, these data changed to 1.6 in skilled nursing facilities and 2.6 hrs per patient in inpatient rehabilitation facilities (P inpatient rehabilitation facilities accrued more time for gait training and exercise in physical therapy, which was found to be 48% and 40% greater, respectively, through day 8. In occupational therapy, patients of inpatient rehabilitation facilities had more time allocated to lower body dressing and transfers. Significant differences in rehabilitation activities were observed, and intensity was notably different within the first 8 therapy days even though baseline demographics and medical complexity were comparable across facility types. Our data suggest that after more complex hip replacement surgery, hip fracture patients can tolerate more intensive therapy earlier within the rehabilitation program.

A large animal model for boron neutron capture therapy

International Nuclear Information System (INIS)

Gavin, P.R.; Kraft, S.L.; DeHaan, C.E.; Moore, M.P.; Griebenow, M.L.

1992-01-01

An epithermal neutron beam is needed to treat relatively deep seated tumors. The scattering characteristics of neutrons in this energy range dictate that in vivo experiments be conducted in a large animal to prevent unacceptable total body irradiation. The canine species has proven an excellent model to evaluate the various problems of boron neutron capture utilizing an epithermal neutron beam. This paper discusses three major components of the authors study: (1) the pharmacokinetics of borocaptate sodium (NA 2 B 12 H 11 SH or BSH) in dogs with spontaneously occurring brain tumors, (2) the radiation tolerance of normal tissues in the dog using an epithermal beam alone and in combination with borocaptate sodium, and (3) initial treatment of dogs with spontaneously occurring brain tumors utilizing borocaptate sodium and an epithermal neutron beam

Performance of simulated flexible integrated gasification polygeneration facilities. Part A: A technical-energetic assessment

NARCIS (Netherlands)

Meerman, J.C.; Ramírez Ramírez, C.A.; Turkenburg, W.C.; Faaij, A.P.C.

2011-01-01

This article investigates technical possibilities and performances of flexible integrated gasification polygeneration (IG-PG) facilities equipped with CO2 capture for the near future. These facilities can produce electricity during peak hours, while switching to the production of chemicals during

Proton Therapy at the Paul Scherrer Institute

International Nuclear Information System (INIS)

1996-03-01

The brochure deals with the following topics: radiation therapy and its significance, proton therapy - worldwide and at PSI, advantages of the protons, the new proton therapy facility at PSI, therapy at PSI using the spot-scan technique. figs., tabs., refs

User's manual of a supporting system for treatment planning in boron neutron capture therapy. JAERI computational dosimetry system

CERN Document Server

Kumada, H

2002-01-01

A boron neutron capture therapy (BNCT) with epithermal neutron beam is expected to treat effectively for malignant tumor that is located deeply in the brain. It is indispensable to estimate preliminarily the irradiation dose in the brain of a patient in order to perform the epithermal neutron beam BNCT. Thus, the JAERI Computational Dosimetry System (JCDS), which can calculate the dose distributions in the brain, has been developed. JCDS is a software that creates a 3-dimensional head model of a patient by using CT and MRI images and that generates a input data file automatically for calculation neutron flux and gamma-ray dose distribution in the brain by the Monte Carlo code: MCNP, and that displays the dose distribution on the head model for dosimetry by using the MCNP calculation results. JCDS has any advantages as follows; By treating CT data and MRI data which are medical images, a detail three-dimensional model of patient's head is able to be made easily. The three-dimensional head image is editable to ...

Joint Assessment of ETRR-2 Research Reactor Operations Program, Capabilities, and Facilities

International Nuclear Information System (INIS)

Bissani, M; O'Kelly, D S

2006-01-01

A joint assessment meeting was conducted at the Egyptian Atomic Energy Agency (EAEA) followed by a tour of Egyptian Second Research Reactor (ETRR-2) on March 22 and 23, 2006. The purpose of the visit was to evaluate the capabilities of the new research reactor and its operations under Action Sheet 4 between the U.S. DOE and the EAEA, ''Research Reactor Operation'', and Action Sheet 6, ''Technical assistance in The Production of Radioisotopes''. Preliminary Recommendations of the joint assessment are as follows: (1) ETRR-2 utilization should be increased by encouraging frequent and sustained operations. This can be accomplished in part by (a) Improving the supply-chain management for fresh reactor fuel and alleviating the perception that the existing fuel inventory should be conserved due to unreliable fuel supply; and (b) Promulgating a policy for sample irradiation priority that encourages the use of the reactor and does not leave the decision of when to operate entirely at the discretion of reactor operations staff. (2) Each experimental facility in operation or built for a single purpose should be reevaluated to focus on those that most meet the goals of the EAEA strategic business plan. Temporary or long-term elimination of some experimental programs might be necessary to provide more focused utilization. There may be instances of emerging reactor applications for which no experimental facility is yet designed or envisioned. In some cases, an experimental facility may have a more beneficial use than the purpose for which it was originally designed. For example, (a) An effective Boron Neutron Capture Therapy (BNCT) program requires nearby high quality medical facilities. These facilities are not available and are unlikely to be constructed near the Inshas site. Further, the BNCT facility is not correctly designed for advanced research and therapy programs using epithermal neutrons. (b) The ETRR-2 is frequently operated to provide color-enhanced gemstones but is

Joint Assessment of ETRR-2 Research Reactor Operations Program, Capabilities, and Facilities

Energy Technology Data Exchange (ETDEWEB)

Bissani, M; O' Kelly, D S

2006-05-08

A joint assessment meeting was conducted at the Egyptian Atomic Energy Agency (EAEA) followed by a tour of Egyptian Second Research Reactor (ETRR-2) on March 22 and 23, 2006. The purpose of the visit was to evaluate the capabilities of the new research reactor and its operations under Action Sheet 4 between the U.S. DOE and the EAEA, ''Research Reactor Operation'', and Action Sheet 6, ''Technical assistance in The Production of Radioisotopes''. Preliminary Recommendations of the joint assessment are as follows: (1) ETRR-2 utilization should be increased by encouraging frequent and sustained operations. This can be accomplished in part by (a) Improving the supply-chain management for fresh reactor fuel and alleviating the perception that the existing fuel inventory should be conserved due to unreliable fuel supply; and (b) Promulgating a policy for sample irradiation priority that encourages the use of the reactor and does not leave the decision of when to operate entirely at the discretion of reactor operations staff. (2) Each experimental facility in operation or built for a single purpose should be reevaluated to focus on those that most meet the goals of the EAEA strategic business plan. Temporary or long-term elimination of some experimental programs might be necessary to provide more focused utilization. There may be instances of emerging reactor applications for which no experimental facility is yet designed or envisioned. In some cases, an experimental facility may have a more beneficial use than the purpose for which it was originally designed. For example, (a) An effective Boron Neutron Capture Therapy (BNCT) program requires nearby high quality medical facilities. These facilities are not available and are unlikely to be constructed near the Inshas site. Further, the BNCT facility is not correctly designed for advanced research and therapy programs using epithermal neutrons. (b) The ETRR-2 is frequently operated to

Particle therapy for noncancer diseases

Energy Technology Data Exchange (ETDEWEB)

Bert, Christoph; Engenhart-Cabillic, Rita; Durante, Marco [GSI Helmholtzzentrum fuer Schwerionenforschung, Biophysics Department, Planckstrasse 1, 64291 Darmstadt (Germany); Philipps-University Marburg, Center for Radiology, Department of Radiation Therapy, Baldinger Strasse, 35043 Marburg (Germany); GSI Helmholtzzentrum fuer Schwerionenforschung, Biophysics Department, Planckstrasse 1, 64291 Darmstadt (Germany); Technische Universitaet Darmstadt, Institut fuer Festkoerperphysik, Hochschulstrasse 3, 64289 Darmstadt (Germany) and Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe University, Ruth-Moufang-Str. 1, 60438 Frankfurt am Main (Germany)

2012-04-15

Radiation therapy using high-energy charged particles is generally acknowledged as a powerful new technique in cancer treatment. However, particle therapy in oncology is still controversial, specifically because it is unclear whether the putative clinical advantages justify the high additional costs. However, particle therapy can find important applications in the management of noncancer diseases, especially in radiosurgery. Extension to other diseases and targets (both cranial and extracranial) may widen the applications of the technique and decrease the cost/benefit ratio of the accelerator facilities. Future challenges in this field include the use of different particles and energies, motion management in particle body radiotherapy and extension to new targets currently treated by catheter ablation (atrial fibrillation and renal denervation) or stereotactic radiation therapy (trigeminal neuralgia, epilepsy, and macular degeneration). Particle body radiosurgery could be a future key application of accelerator-based particle therapy facilities in 10 years from today.

Performance specifications for proton medical facility

Energy Technology Data Exchange (ETDEWEB)

Chu, W.T.; Staples, J.W.; Ludewigt, B.A.; Renner, T.R.; Singh, R.P.; Nyman, M.A.; Collier, J.M.; Daftari, I.K.; Petti, P.L.; Alonso, J.R. [Lawrence Berkeley Lab., CA (United States); Kubo, H.; Verhey, L.J. [University of California Davis Medical Center, Sacramento, CA (United States). Cancer Center]|[California Univ., San Francisco, CA (United States). School of Medicine; Castro, J.R. [Lawrence Berkeley Lab., CA (United States)]|[University of California Davis Medical Center, Sacramento, CA (United States). Cancer Center]|[California Univ., San Francisco, CA (United States). School of Medicine

1993-03-01

Performance specifications of technical components of a modern proton radiotherapy facility are presented. The technical items specified include: the accelerator; the beam transport system including rotating gantry; the treatment beamline systems including beam scattering, beam scanning, and dosimetric instrumentation; and an integrated treatment and accelerator control system. Also included are treatment ancillary facilities such as diagnostic tools, patient positioning and alignment devices, and treatment planning systems. The facility specified will accommodate beam scanning enabling the three-dimensional conformal therapy deliver .

Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire.

Science.gov (United States)

Weber, Damien C; Abrunhosa-Branquinho, André; Bolsi, Alessandra; Kacperek, Andrzej; Dendale, Rémi; Geismar, Dirk; Bachtiary, Barbara; Hall, Annika; Heufelder, Jens; Herfarth, Klaus; Debus, Jürgen; Amichetti, Maurizio; Krause, Mechthild; Orecchia, Roberto; Vondracek, Vladimir; Thariat, Juliette; Kajdrowicz, Tomasz; Nilsson, Kristina; Grau, Cai

2017-08-01

We performed a survey using the modified EORTC Facility questionnaire (pFQ) to evaluate the human, technical and organizational resources of particle centers in Europe. The modified pFQ consisted of 235 questions distributed in 11 sections accessible on line on an EORTC server. Fifteen centers from 8 countries completed the pFQ between May 2015 and December 2015. The average number of patients treated per year and per particle center was 221 (range, 40-557). The majority (66.7%) of centers had pencil beam or raster scanning capability. Four (27%) centers were dedicated to eye treatment only. An increase in the patients-health professional FTE ratio was observed for eye tumor only centers when compared to other centers. All centers treated routinely chordomas/chondrosarcomas, brain tumors and sarcomas but rarely breast cancer. The majority of centers treated pediatric cases with particles. Only a minority of the queried institutions treated non-static targets. As the number of particle centers coming online will increase, the experience with this treatment modality will rise in Europe. Children can currently be treated in these facilities in a majority of cases. The majority of these centers provide state of the art particle beam therapy. Copyright © 2017 Elsevier B.V. All rights reserved.

[A clinical trial of neutron capture therapy for brain tumors

International Nuclear Information System (INIS)

Zamenhof, R.G.

1990-01-01

This document briefly describes recent advances in the author's laboratory. Topics described include neutron beam design, high- resolution autoradiography, boronated phenylalanine (BPA) distribution and survival studies in glioma bearing mice, computer- aided treatment planning, prompt gamma boron 10 analysis facility at MITI-II, non-rodent BPA toxicity studies, and preparations for clinical studies

Planning guide for radiologic installations. fascicle 1 -- radiation therapy installations

International Nuclear Information System (INIS)

Tuddenham, W.J.

1976-01-01

Five articles dealing with the development and operation of radiation therapy facilities present recommendations for the design of various types of radiation therapy facilities, including the university center, the free-standing private oncology center, and the community hospital radiation therapy department. Different concepts of department design are represented. In one article, the planning room is conceived to be the central feature of a facility; in another article, radiation therapy is designed around examination rooms. Shielding requirements are also discussed, as are the advantages and space and licensing requirements of various types of equipment. There is a need for planning appropriate computer facilities in conjunction with other equipment plans, and a critique of one radiation therapy unit is provided. The concept of a regional network for the delivery of radiation therapy services is then explored. The volume contains extensive illustrations in the form of floor plans, drawings, figures, and tables. Many of the articles include a bibliography. This is the first in a series of publications on radiation department design which will be useful to architects, engineers, and hospital planners

Bevalac Radiotherapy Facility

International Nuclear Information System (INIS)

Alonso, J.R.; Howard, J.; Criswell, T.

1979-03-01

Patient Treatment Room at the Bevalac is now in full operation. In the design of this facility, emphasis has been placed on creating an atmosphere appropriate to a clinical facility; the usual features of an irradiation cave have been hidden behind carpets, curtains and paint. Patient positioning is done with a Philips Ram-style couch, with additional fixtures to accommodate a patient in the seated or standing, as well as the supine, position. Dosimetry apparatus, collimators, ion chambers and the beam flattening system used to produce the highly uniform 20 cm diameter therapy field are described

Bevalac Radiotherapy Facility

Energy Technology Data Exchange (ETDEWEB)

Alonso, J.R.; Howard, J.; Criswell, T.

1979-03-01

Patient Treatment Room at the Bevalac is now in full operation. In the design of this facility, emphasis has been placed on creating an atmosphere appropriate to a clinical facility; the usual features of an irradiation cave have been hidden behind carpets, curtains and paint. Patient positioning is done with a Philips Ram-style couch, with additional fixtures to accommodate a patient in the seated or standing, as well as the supine, position. Dosimetry apparatus, collimators, ion chambers and the beam flattening system used to produce the highly uniform 20 cm diameter therapy field are described.

Isobaric analog impurities from neutron capture and transmission by magnesium

International Nuclear Information System (INIS)

Weigmann, H.; Macklin, R.L.; Harvey, J.A.

1976-01-01

Resonance neutron interactions with the stable isotopes of magnesium were measured at the Oak Ridge Electron Linear Accelerator time-of-flight facility. The transmission of a natural metal sample (78.7% 24 Mg) was measured at 200 m, and capture by natural metal and by enriched isotope samples was measured at 40 m. Twenty-six resonances in 24 Mg + n up to 1.8 MeV were fitted with Breit--Wigner multilevel parameters. The data were sufficient to assign spin and parity to 19 of these. The capture data were analyzed for resonances up to 850 keV for 24 Mg + n, 265 keV for 25 Mg + n (17 + resonances), and 440 keV for 26 Mg + n (4 resonances). Average capture at stellar interior temperatures was calculated. The 24 Mg + n data serve to assess the isospin impurities in three isobaric analog states. Three other states exhibit reduced neutron widths, each several percent of the Wigner limit, which may be understood in terms of simple shell model configurations

Radiation safety in X-ray facilities

International Nuclear Information System (INIS)

2001-09-01

The guide specifies the radiation safety requirements for structural shielding and other safety arrangements used in X-ray facilities in medical and veterinary X-ray activities and in industry, research and education. The guide is also applicable to premises in which X-ray equipment intended for radiation therapy and operating at a voltage of less than 25 kV is used. The guide applies to new X-ray facilities in which X-ray equipment that has been used elsewhere is transferred. The radiation safety requirements for radiation therapy X-ray devices operating at a voltage exceeding 25 kV, and for the premices in which such devices are used, are set out in Guide ST 2.2

Radiation safety in X-ray facilities

Energy Technology Data Exchange (ETDEWEB)

NONE

2001-09-01

The guide specifies the radiation safety requirements for structural shielding and other safety arrangements used in X-ray facilities in medical and veterinary X-ray activities and in industry, research and education. The guide is also applicable to premises in which X-ray equipment intended for radiation therapy and operating at a voltage of less than 25 kV is used. The guide applies to new X-ray facilities in which X-ray equipment that has been used elsewhere is transferred. The radiation safety requirements for radiation therapy X-ray devices operating at a voltage exceeding 25 kV, and for the premices in which such devices are used, are set out in Guide ST 2.2.

Noise pollution and detaining captured persons at sea.

Science.gov (United States)

Nixon, S; Milner, R

2014-01-01

During the course of military operations, the UK Armed Forces may have to capture and detain individuals. International law sets down a framework for the minimum basic standards that are applicable in these circumstances, and it is the responsibility of the UK Armed Forces to understand and implement these. This case review looks at a specific example of this issue related to noise pollution and appropriate detention facilities during anti-piracy operations, and how a flexible approach combined with good understanding of the regulations ensured compliance with these basic standards.

Recent Results In Nuclear Astrophysics At The n_TOF Facility At CERN

CERN Document Server

Tagliente, Giuseppe; Andrzejewski, J; Audouin, L; Bacak, M; Balibrea, J; Barbagallo, M; Bečvář, F; Berthoumieux, E; Billowes, J; Bosnar, D; Brown, A; Caamaño, M; Calviño, F; Calviani, M; Cano-Ott, D; Cardella, R; Casanovas, A; Cerutti, F; Chen, Y H; Chiaveri, E; Colonna, N; Cortés, G; Cortés-Giraldo, M A; Cosentino; Damone, L A; Diakaki, M; Domingo-Pardo, C; Dressler, L R; Dupont, E; Durán, I; Fernández-Domínguez, B; Ferrari, A; Ferreira, P; Finocchiaro, P; Furman, V; Göbel, K; García, A R; Gawlik, A; Gilardoni, S; Glodariu, T; Gonçalves, I F; González, E; Griesmayer, E; Guerrero, C; Gunsing, F; Harada, H; Heinitz, S; Heyse, J; Jenkins, D G; Jericha, E; Käppeler, F; Kadi, Y; Kalamara, A; Kavrigin, P; Kimura, A; Kivel, N; Kokkoris, M; Krtička, M; Kurtulgil, D; Leal-Cidoncha, E; Lederer, C; Lerendegui-Marco, J; Leeb, H; Lo Meo, S; Lonsdale, S J; Macina, D; Marganiec, J; Martínez, T; Masi, A; Massimi, C; Mastinu, P; Mastromarco, M; Maugeri, E A; Mazzone, A; Mendoza, E; Mengoni, A; Mingrone, F; Milazzo, P M; Musumarra, A; Negret, A; Nolte, R; Oprea, A; Patronis, N; Pavlik, A; Perkowski, J; Porras, I; Praena, J; Quesada, J M; Radeck, D; Rauscher, T; Reifarth, R; Rubbia, C; Ryan, J A; Sabaté-Gilarte, M; Saxena, A; Schillebeeckx, P; Schumann, D; Sedyshev, P; Smith, A G; Sosnin, N V; Stamatopoulos, A; Tain, J L; Tarifeño-Saldivia, A; Valenta, S; Vannini, G; Variale, V; Vaz, P; Ventura, A; Vlachoudis, V; Vlastou, R; Wallner, A; Warren, S; Woods, P J; Żugec, P Č

2017-01-01

The neutron time of flight (n_TOF) facility at CERN is a spallation source characterized by a white neutron spectrum. The innovative features of the facility, in the two experimental areas, (20 m and 185 m), allow for an accurate determination of the neutron cross section for radioactive samples or for isotopes with small neutron capture cross section, of interest for Nuclear Astrophysics. The recent results obtained at n_TOF facility are presented.

Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women

International Nuclear Information System (INIS)

Punglia, Rinaa S.; Weeks, Jane C.; Neville, Bridget A.; Earle, Craig C.

2006-01-01

Purpose: We sought to study the effect of distance to the nearest radiation treatment facility on the use of postmastectomy radiation therapy (PMRT) in elderly women. Methods and Materials: Using data from the linked Surveillance, Epidemiology, and End Results-Medicare (SEER-Medicare) database, we analyzed 19,787 women with Stage I or II breast cancer who received mastectomy as definitive surgery during 1991 to 1999. Multivariable logistic regression was used to investigate the association of distance with receipt of PMRT after adjusting for clinical and sociodemographic factors. Results: Overall 2,075 patients (10.5%) treated with mastectomy received PMRT. In addition to cancer and patient characteristics, in our primary analysis, increasing distance to the nearest radiation treatment facility was independently associated with a decreased likelihood of receiving PMRT (OR 0.996 per additional mile, p = 0.01). Secondary analyses revealed that the decline in PMRT use appeared at distances of more than 25 miles and was statistically significant for those patients living more than 75 miles from the nearest radiation facility (odds of receiving PMRT of 0.58 [95% CI 0.34-0.99] vs. living within 25 miles of such a facility). The effect of distance on PMRT appeared to be more pronounced with increasing patient age (>75 years). Variation in the effect of distance on radiation use between regions of the country and nodal status was also identified. Conclusions: Oncologists must be cognizant of the potential barrier to quality care that is posed by travel distance, especially for elderly patients; and policy makers should consider this fact in resource allocation decisions about radiation treatment centers

A critical assessment of boron target compounds for boron neutron capture therapy.

Science.gov (United States)

Hawthorne, M Frederick; Lee, Mark W

2003-01-01

Boron neutron capture therapy (BNCT) has undergone dramatic developments since its inception by Locher in 1936 and the development of nuclear energy during World War II. The ensuing Cold War spawned the entirely new field of polyhedral borane chemistry, rapid advances in nuclear reactor technology and a corresponding increase in the number to reactors potentially available for BNCT. This effort has been largely oriented toward the eradication of glioblastoma multiforme (GBM) and melanoma with reduced interest in other types of malignancies. The design and synthesis of boron-10 target compounds needed for BNCT was not channeled to those types of compounds specifically required for GBM or melanoma. Consequently, a number of potentially useful boron agents are known which have not been biologically evaluated beyond a cursory examination and only three boron-10 enriched target species are approved for human use following their Investigational New Drug classification by the US Food and Drug Administration; BSH, BPA and GB-10. All ongoing clinical trials with GBM and melanoma are necessarily conducted with one of these three species and most often with BPA. The further development of BNCT is presently stalled by the absence of strong support for advanced compound evaluation and compound discovery driven by recent advances in biology and chemistry. A rigorous demonstration of BNCT efficacy surpassing that of currently available protocols has yet to be achieved. This article discusses the past history of compound development, contemporary problems such as compound classification and those problems which impede future advances. The latter include means for biological evaluation of new (and existing) boron target candidates at all stages of their development and the large-scale synthesis of boron target species for clinical trials and beyond. The future of BNCT is bright if latitude is given to the choice of clinical disease to be treated and if a recognized study

Dose distribution and clinical response of glioblastoma treated with boron neutron capture therapy

Energy Technology Data Exchange (ETDEWEB)

Matsuda, M. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)], E-mail: mhide-m@gk9.so-net.ne.jp; Yamamoto, T. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Kumada, H. [Japan Atomic Energy Agency, Shirakatashirane 2-4, Tokai (Japan); Nakai, K.; Shirakawa, M.; Tsurubuchi, T.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)

2009-07-15

The dose distribution and failure pattern after treatment with the external beam boron neutron capture therapy (BNCT) protocol were retrospectively analyzed. BSH (5 g/body) and BPA (250 mg/kg) based BNCT was performed in eight patients with newly diagnosed glioblastoma. The gross tumor volume (GTV) and clinical target volume (CTV)-1 were defined as the residual gadolinium-enhancing volume. CTV-2 and CTV-3 were defined as GTV plus a margin of 2 and 3 cm, respectively. As additional photon irradiation, a total X-ray dose of 30 Gy was given to the T2 high intensity area on MRI. Five of the eight patients were alive at analysis for a mean follow-up time of 20.3 months. The post-operative median survival time of the eight patients was 27.9 months (95% CI=21.0-34.8). The minimum tumor dose of GTV, CTV-2, and CTV-3 averaged 29.8{+-}9.9, 15.1{+-}5.4, and 12.4{+-}2.9 Gy, respectively. The minimum tumor non-boron dose of GTV, CTV-2, and CTV-3 averaged 2.0{+-}0.5, 1.3{+-}0.3, and 1.1{+-}0.2 Gy, respectively. The maximum normal brain dose, skin dose, and average brain dose were 11.4{+-}1.5, 9.6{+-}1.4, and 3.1{+-}0.4 Gy, respectively. The mean minimum dose at the failure site in cases of in-field recurrence (IR) and out-field recurrence (OR) was 26.3{+-}16.7 and 14.9 GyEq, respectively. The calculated doses at the failure site were at least equal to the tumor control doses which were previously reported. We speculate that the failure pattern was related to an inadequate distribution of boron-10. Further improvement of the microdistribution of boron compounds is expected, and may improve the tumor control by BNCT.

High energy resolution measurement of the sup 238 U neutron capture yield from 1 to 100 keV

Energy Technology Data Exchange (ETDEWEB)

Macklin, R.L. (Tennessee Univ., Knoxville, TN (United States). Dept. of Nuclear Engineering); Perez, R.B. (Tennessee Univ., Knoxville, TN (United States). Dept. of Nuclear Engineering Oak Ridge National Lab., TN (United States)); De Saussure, G.; Ingle, R.W. (Oak Ridge National Lab., TN (United States))

1991-01-01

The purpose of this work is the precise determination of the {sup 238}U neutron capture yield (i.e. the probability of neutron capture) as a function of neutron energy with the highest available neutron energy resolution. The motivation for this undertaking arises from the central role played by the {sup 238}U neutron capture process in the neutron balance of both thermal reactors and fast breeder reactors. The present measurement was performed using the Oak Ridge Electron Linear Accelerator (ORELA) facility. The pulsed beam of neutrons from the ORELA facility is collimated on a sample of {sup 238}U. The neutron capture rate in the sample is measured, as a function of neutron time-of-flight (TOF) by detecting the {gamma}-rays from the {sup 238}U(n, {gamma}){sup 239}U reaction with a large {gamma}-ray detector surrounding the {sup 238}U sample. At each energy, the capture yield is proportional to the observed capture rate divided by the measured intensity of the neutron beam. The constant of proportionality (the normalization constant) is obtained from the ratio of theoretical to experimentally measured areas under small {sup 238}U resonances where the resonance parameters have been determined from high-resolution {sup 238}U transmission measurements. The cross section for the reaction {sup 238}U(n,{gamma}){sup 239}U can be derived from the measured capture yield if one applies appropriate corrections for multiple scattering and resonance self-shielding. Some 200 {sup 238}U neutron resonances in the energy range from 250 eV to 10 keV have been observed which had not been detected in previous measurements. (author).

Development of Checklist for Self-Assessment of Regulatory Capture in Nuclear Safety Regulation

International Nuclear Information System (INIS)

Choi, K. S.; Lee, Y. E.; Chang, H. S.; Jung, S. J.

2011-01-01

Regulatory body performs its mission on behalf of the general public. As for nuclear industries, the public delegates the authority to the regulatory body for monitoring the safety in nuclear facilities and for ensuring that it is maintained in the socially and globally acceptable level. However, when the situation that a regulatory body behaves in the interests of industries happens, not working primarily for protecting public health and safety on behalf of the public, it is charged that regulatory body acts as an encouragement for industries which produce negative externalities such as radiation risk or radiation hazards. In this case, the regulatory body is called as 'Captured' or it is called that 'Regulatory Capture' happened. Regulatory capture is important as it may cause regulatory failure, one form of government failure, which is very serious phenomenon: severe nuclear accident at Fukushima nuclear power plants recently occurred in March, 2011. This paper aims to introduce the concept of regulatory capture into nuclear industry field through the literature survey, and suggest the sample checklist developed for self-assessment on the degree of regulatory capture within regulatory body

Functionalized metal organic frameworks for effective capture of radioactive organic iodides

KAUST Repository

Li, Baiyan

2017-06-27

Highly efficient capture of radioactive organic iodides (ROIs) from off-gas mixtures remains a substantial challenge for nuclear waste treatment. Current materials utilized for ROI sequestration suffer from low capacity, high cost (e.g. use of noble metals), and poor recyclability. Recently, we have developed a new strategy to tackle this challenge by functionalizing MOF materials with tertiary amines to create molecular traps for the effective capture and removal of ROIs (e.g. radioactive methyl iodide) from nuclear wastes. To further enhance the uptake capacity and performance of CH3I capture by ROI molecular traps, herein, we carry out a systematic study to investigate the effect of different amine molecules on ROI capture. The results demonstrate a record-high CH3I saturation uptake capacity of 80% for MIL-101-Cr-DMEDA at 150 °C, which is 5.3 times that of Ag0@MOR (15 wt%), a leading adsorbent material for capturing ROIs during nuclear fuel reprocessing. Furthermore, the CH3I decontamination factors (DFs) for MIL-101-Cr-DMEDA are as high as 5000 under simulated reprocessing conditions, largely exceeding that of facility regulatory requirements (DF = 3000). In addition, MIL-101-Cr-DMEDA can be recycled without loss of capacity, illustrating yet another advantage compared to known industrial adsorbents, which are typically of a

Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

International Nuclear Information System (INIS)

Nigg, David W.

2012-01-01

Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K(nido-7-CH3(CH2)15-7,8-C2B9H11) in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K(nido-7-CH3(CH2)15-7,8-C2B9H11) in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 (ae-B20H17NH3), administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential

Energy Technology Data Exchange (ETDEWEB)

David W. Nigg

2012-05-01

Boron neutron capture therapy (BNCT) combines selective accumulation of 10B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na3 [ae-B20H17NH3], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 {+-} 16.1 ppm at 48 h and to 43.9 {+-} 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.

Neutron capture measurements on 62Ni, 63Ni and 197Au and their relevance for stellar nucleosynthesis

CERN Document Server

Lederer, Claudia

Neutron capture reactions in stars are responsible for forming about 99% of the elemental abundances heavier than Fe. Two processes contribute about equally to the overall abundance pattern: the slow neutron capture process (s process) where neutron densities are small and therefore radioactive decay is generally faster than subsequent neutron capture on radionuclides, and the rapid neutron capture process (r process) which takes place in environments of high neutron densities, driving the reaction path towards the neutron rich side. The key nuclear physics input for s process studies are stellar neutron capture cross sections, called MACS (Maxwellian-averaged cross section). In the course of this work, dierent reactions relevant to s process nucleosynthesis have been studied. To improve and check existing information, neutron capture cross sections of most stable Fe and Ni isotopes were measured via the time-of-flight technique at the n TOF facility at CERN. This campaign was triggered by a work of Sneden et...

Power Systems Development Facility

International Nuclear Information System (INIS)

1993-06-01

The objective of the PSDF would be to provide a modular facility which would support the development of advanced, pilot-scale, coal-based power systems and hot gas clean-up components. These pilot-scale components would be designed to be large enough so that the results can be related and projected to commercial systems. The facility would use a modular approach to enhance the flexibility and capability for testing; consequently, overall capital and operating costs when compared with stand-alone facilities would be reduced by sharing resources common to different modules. The facility would identify and resolve technical barrier, as well as-provide a structure for long-term testing and performance assessment. It is also intended that the facility would evaluate the operational and performance characteristics of the advanced power systems with both bituminous and subbituminous coals. Five technology-based experimental modules are proposed for the PSDF: (1) an advanced gasifier module, (2) a fuel cell test module, (3) a PFBC module, (4) a combustion gas turbine module, and (5) a module comprised of five hot gas cleanup particulate control devices. The final module, the PCD, would capture coal-derived ash and particles from both the PFBC and advanced gasifier gas streams to provide for overall particulate emission control, as well as to protect the combustion turbine and the fuel cell

Environmental assessment of amine-based carbon capture Scenario modelling with life cycle assessment (LCA)

Energy Technology Data Exchange (ETDEWEB)

Brekke, Andreas; Askham, Cecilia; Modahl, Ingunn Saur; Vold, Bjoern Ivar; Johnsen, Fredrik Moltu

2012-07-01

This report contains a first attempt at introducing the environmental impacts associated with amines and derivatives in a life cycle assessment (LCA) of gas power production with carbon capture and comparing these with other environmental impacts associated with the production system. The report aims to identify data gaps and methodological challenges connected both to modelling toxicity of amines and derivatives and weighting of environmental impacts. A scenario based modelling exercise was performed on a theoretical gas power plant with carbon capture, where emission levels of nitrosamines were varied between zero (gas power without CCS) to a worst case level (outside the probable range of actual carbon capture facilities). Because of extensive research and development in the areas of solvents and emissions from carbon capture facilities in the latter years, data used in the exercise may be outdated and results should therefore not be taken at face value.The results from the exercise showed: According to UseTox, emissions of nitrosamines are less important than emissions of formaldehyde with regard to toxicity related to operation of (i.e. both inputs to and outputs from) a carbon capture facility. If characterisation factors for emissions of metals are included, these outweigh all other toxic emissions in the study. None of the most recent weighting methods in LCA include characterisation factors for nitrosamines, and these are therefore not part of the environmental ranking.These results shows that the EDecIDe project has an important role to play in developing LCA methodology useful for assessing the environmental performance of amine based carbon capture in particular and CCS in general. The EDecIDe project will examine the toxicity models used in LCA in more detail, specifically UseTox. The applicability of the LCA compartment models and site specificity issues for a Norwegian/Arctic situation will be explored. This applies to the environmental compartments

Evolution of a beam dynamics model for the transport line in a proton therapy facility

Science.gov (United States)

Rizzoglio, V.; Adelmann, A.; Baumgarten, C.; Frey, M.; Gerbershagen, A.; Meer, D.; Schippers, J. M.

2017-12-01

During the conceptual design of an accelerator or beamline, first-order beam dynamics models are essential for studying beam properties. However, they can only produce approximate results. During commissioning, these approximate results are compared to measurements, which will rarely coincide if the model does not include the relevant physics. It is therefore essential that this linear model is extended to include higher-order effects. In this paper, the effects of particle-matter interaction have been included in the model of the transport lines in the proton therapy facility at the Paul Scherrer Institut (PSI) in Switzerland. The first-order models of these beamlines provide an approximated estimation of beam size, energy loss and transmission. To improve the performance of the facility, a more precise model was required and has been developed with opal (Object Oriented Parallel Accelerator Library), a multiparticle open source beam dynamics code. In opal, the Monte Carlo simulations of Coulomb scattering and energy loss are performed seamless with the particle tracking. Beside the linear optics, the influence of the passive elements (e.g., degrader, collimators, scattering foils, and air gaps) on the beam emittance and energy spread can be analyzed in the new model. This allows for a significantly improved precision in the prediction of beam transmission and beam properties. The accuracy of the opal model has been confirmed by numerous measurements.

Inhibition of tumor growth in a glioma model treated with boron neutron capture therapy

International Nuclear Information System (INIS)

Goodman, J.H.; McGregor, J.M.; Clendenon, N.R.; Gahbauer, R.A.; Barth, R.F.; Soloway, A.H.; Fairchild, R.G.

1990-01-01

This investigation attempts to determine whether increased survival time seen when the F98 glioma model is treated with boron neutron capture therapy (BNCT) is a result of inhibition of tumor growth caused by radiation-induced alterations in endothelial cells and normal tissue components. This indirect effect of radiation has been called the tumor bed effect. A series of tumor-bearing rats was studied, using a standardized investigational BNCT protocol consisting of 50 mg/kg of Na2B12H11SH injected intravenously 14 to 17 hours before neutron irradiation at 4 x 10(12) n/cm2. Ten rats, serving as controls, received no treatment either before or after tumor implantation. A second group of 10 rats was treated with BNCT 4 days before tumor implantation; these animals received no further treatment. The remaining group of 10 rats received no pretreatment but was treated with BNCT 10 days after implantation. Histological and ultrastructural analyses were performed in 2 animals from each group 17 days after implantation. Survival times of the untreated control animals (mean, 25.8 days) did not differ statistically from the survival times of the rats in the pretreated group (mean, 25.5 days). The rats treated with BNCT after implantation survived significantly longer (P less than 0.02; mean, 33.2 days) than the controls and the preirradiated animals. Tumor size indices calculated from measurements taken at the time of death were similar in all groups. These results indicate that, with this tumor model, BNCT does not cause a tumor bed effect in cerebral tissue. The therapeutic gains observed with BNCT result from direct effects on tumor cells or on the peritumoral neovascularity

Meeting the challenge of homogenous boron targeting of heterogeneous tumors for effective boron neutron capture therapy (BNCT)

International Nuclear Information System (INIS)

Heber, Elisa M.; Trivillin, Veronica A.; Itoiz, Maria E.; Rebagliati, J. Raul; Batistoni, Daniel; Kreimann, Erica L.; Schwint, Amanda E.; Nigg, David W.; Gonzalez, Beatriz N.

2006-01-01

BNCT is a tumor cell targeted radiation therapy. Inadequately boron targeted tumor populations jeopardize tumor control. Meeting the to date unresolved challenge of homogeneous targeting of heterogeneous tumors with effective boron carriers would contribute to therapeutic efficacy. The aim of the present study was to evaluate the degree of variation in boron content delivered by boronophenylalanine (BPA), GB-10 (Na 2 10 B 10 H 10 ) and the combined administration of (BPA+GB-10) in different portions of tumor, precancerous tissue around tumor and normal pouch tissue in the hamster cheek pouch oral cancer model. Boron content was evaluated by ICP-AES. The degree of homogeneity in boron targeting was assessed in terms of the coefficient of variation ([S.D./Mean]x100) of boron values. Statistical analysis of the results was performed by one-way ANOVA and the least significant difference test. GB-10 and GB-10 plus BPA achieved respectively a statistically significant 1.8-fold and 3.3-fold increase in targeting homogeneity over BPA. The combined boron compound administration protocol contributes to homogeneous targeting of heterogeneous tumors and would increase therapeutic efficacy of BNCT by exposing all tumor populations to neutron capture reactions in boron. (author)

Implementation of co-trimoxazole preventive therapy policy for malaria in HIV-infected pregnant women in the public health facilities in Tanzania.

Science.gov (United States)

Kamuhabwa, Appolinary Ar; Gordian, Richard; Mutagonda, Ritah F

2016-01-01

In 2011, Tanzania adopted a policy for provision of daily co-trimoxazole prophylaxis to HIV-infected pregnant women for prevention of malaria and other opportunistic infections. As per the policy, HIV-infected pregnant women should not be given sulfadoxine-pyrimethamine (SP) for intermittent preventive therapy. The challenges associated with this policy change and the extent to which the new policy for prevention of malaria in pregnant women coinfected with HIV was implemented need to be assessed. To assess the implementation of malaria-preventive therapy policy among HIV-infected pregnant women in the public health facilities in Dar es Salaam, Tanzania. The study was conducted in Kinondoni Municipality, Dar es Salaam, Tanzania, from January 2015 to July 2015. Three hundred and fifty-three HIV-infected pregnant women who were attending antenatal clinics (ANCs) and using co-trimoxazole for prevention of malaria were interviewed. Twenty-six health care workers working at the ANCs were also interviewed regarding provision of co-trimoxazole prophylaxis to pregnant women. A knowledge scale was used to grade the level of knowledge of health care providers. Focus group discussions were also conducted with 18 health care workers to assess the level of implementation of the policy and the challenges encountered. Twenty-three (6.5%) pregnant women with known HIV serostatus were using co-trimoxazole for prevention of opportunistic infections even before they became pregnant. Out of the 353 HIV-infected pregnant women, eight (2.5%) were coadministered with both SP and co-trimoxazole. Sixty (16.7%) pregnant women had poor adherence to co-trimoxazole prophylaxis. Out of the 26 interviewed health care providers, 20 had high level of knowledge regarding malaria-preventive therapy in HIV-infected pregnant women. Lack of adequate supply of co-trimoxazole in health facilities and inadequate training of health care providers were among the factors causing poor implementation of co

Enhancement of mercury capture by the simultaneous addition of hydrogen bromide (HBr) and fly ashes in a slipstream facility.

Science.gov (United States)

Cao, Yan; Wang, Quan-Hai; Li, Jun; Cheng, Jen-Chieh; Chan, Chia-Chun; Cohron, Marten; Pan, Wei-Ping

2009-04-15

Low halogen content in tested Powder River Basin (PRB) coals and low loss of ignition content (LOI) in PRB-derived fly ash were likely responsible for higher elemental mercury content (averaging about 75%) in the flue gas and also lower mercury capture efficiency by electrostatic precipitator (ESP) and wet-FGD. To develop a cost-effective approach to mercury capture in a full-scale coal-fired utility boiler burning PRB coal, experiments were conducted adding hydrogen bromide (HBr) or simultaneously adding HBr and selected fly ashes in a slipstream reactor (0.152 x 0.152 m) under real flue gas conditions. The residence time of the flue gas inside the reactorwas about 1.4 s. The average temperature of the slipstream reactor was controlled at about 155 degrees C. Tests were organized into two phases. In Phase 1, only HBr was added to the slipstream reactor, and in Phase 2, HBr and selected fly ash were added simultaneously. HBr injection was effective (>90%) for mercury oxidation at a low temperature (155 degrees C) with an HBr addition concentration of about 4 ppm in the flue gas. Additionally, injected HBr enhanced mercury capture by PRB fly ash in the low-temperature range. The mercury capture efficiency, attesting conditions of the slipstream reactor, reached about 50% at an HBr injection concentration of 4 ppm in the flue gas. Compared to only the addition of HBr, simultaneously adding bituminous-derived fly ash in a minimum amount (30 lb/MMacf), together with HBr injection at 4 ppm, could increase mercury capture efficiency by 30%. Injection of lignite-derived fly ash at 30 lb/MMacf could achieve even higher mercury removal efficiency (an additional 35% mercury capture efficiency compared to HBr addition alone).

A parameter study to determine the optimal source neutron energy in boron neutron capture therapy of brain tumours

Energy Technology Data Exchange (ETDEWEB)

Nievaart, V A [Reactor Physics Department, Delft University of Technology, Mekelweg 15, 2629JB Delft (Netherlands); Moss, R L [Joint Research Centre of the European Commission, Postbus 2, 1755ZG Petten (Netherlands); Kloosterman, J L [Reactor Physics Department, Delft University of Technology, Mekelweg 15, 2629JB Delft (Netherlands); Hagen, T H J J van der [Reactor Physics Department, Delft University of Technology, Mekelweg 15, 2629JB Delft (Netherlands); Dam, H van [Reactor Physics Department, Delft University of Technology, Mekelweg 15, 2629JB Delft (Netherlands)

2004-09-21

The values of the parameters used in boron neutron capture therapy (BNCT) to calculate a given dose to human tissue vary with patients due to different physical, biological and/or medical circumstances. Parameters include the tissue dimensions, the {sup 10}B concentration and the relative biological effectiveness (RBE) factors for the different dose components associated with BNCT. Because there is still no worldwide agreement on RBE values, more often than not, average values for these parameters are used. It turns out that the RBE-problem can be circumvented by taking into account all imaginable parameter values. Approaching this quest from another angle: the outcome will also provide the parameters (and values) which influence the optimal source neutron energy. For brain tumours it turns out that the {sup 10}B concentration, the RBE factors for {sup 10}B as well as fast neutrons, together with the dose limit set for healthy tissue, affect the optimal BNCT source neutron energy. By using source neutrons of a few keV together with neutrons of a few eV, it ensures that, under all imaginable circumstances, a maximum of alpha (and lithium) particles can be delivered in the tumour.

A medical facility proposal to use the SSC linac

International Nuclear Information System (INIS)

Funk, L.W.

1994-01-01

A consortium organized by the Texas National Research Laboratory Commission under a Department of Energy grant proposes to build and operate a Regional Medical Technology Center to function as a combined medical radioisotope production complex and proton cancer therapy facility using the Linear Accelerator (Linac) assets of the Superconducting Super Collider (SSC). The radioisotope production complex will serve as a domestic source of radioisotopes critically needed by the U.S. pharmaceutical industry and nuclear medicine facilities throughout North America. Presently, more than 70 percent of radioisotopes used in U.S. nuclear medicine procedures are produced outside the country. The Center's state-of-the-art proton cancer therapy facility will serve the Central United States, providing advanced capabilities and augmenting facilities in California and Massachusetts. Long-term, it is anticipated that the RMTC also will stimulate nuclear medicine research, advance medical diagnostic technologies, and generate new industrial applications for linear accelerator technology

Quality of antiretroviral therapy in public health facilities in Nigeria and perceptions of end users.

Science.gov (United States)

Chiegil, Robert J; Zungu, Lindiwe I; Jooste, Karien

2014-04-01

This paper describes perceptions of the end users on quality of antiretroviral therapy (ART) in public health facilities in Nigeria. Health care services in Nigeria face challenges of meeting end users' requirements and expectations for quality ART service provision. A qualitative design was followed. Unstructured focus group discussions were conducted with end users (n = 64) in six locations across the six geopolitical zones of Nigeria. The findings indicate that end users were satisfied with uninterrupted antiretroviral drug supplies, courtesy treatment, volunteerism of support group members and quality counselling services. End users expect effective collaboration between healthcare providers and support group members, to enhance the quality of life of people living with HIV. A best practice guideline for the provision of end user focused ART service provision was developed for nurse managers. © 2013 John Wiley & Sons Ltd.

Performance Criteria for Capture and/or Immobilization Technologies

Energy Technology Data Exchange (ETDEWEB)

Jubin, R. T. [Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States); Bruffey, S. H. [Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States); Strachan, D. M. [Strata-G, LLC, Knoxville, TN (United States); Soelberg, N. R. [Idaho National Lab. (INL), Idaho Falls, ID (United States); Spencer, B. B. [Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States); Riley, B. J. [Pacific Northwest National Lab. (PNNL), Richland, WA (United States)

2016-02-01

The capture and subsequent immobilization of the four volatile radionuclides (³H, ¹⁴C, ⁸⁵Kr, and ¹²⁹I) from the off-gas streams of a used nuclear fuel reprocessing facility has been a topic of substantial research interest for the US DOE and international colleagues. Regulations set forth by the US EPA direct that some or all of these radionuclides (based upon fuel burnup, fuel type, cooling time, etc.) will require removal, to some extent, from the plant effluent streams prior to discharge to the environment. Upon removal, the radionuclide, as well as any associated sorbent, is destined for waste. Research of separation and capture methodologies has included a wide range of technologies including liquid caustic scrubbing systems, solid adsorbents, and cryogenic distillation. The studies of waste forms have been correspondingly diverse. In considering the technologies available for future development and implementation of both sorbents and waste forms, it will be necessary to use benchmarked measures of performance to objectively evaluate each sorbent system or waste form. This document is intended to provide initial guidance on the types of performance criteria for capture materials and waste forms intended for use in the recycling removal and disposal of UNF and, where possible, the minimum acceptable values for those criteria.

Radiative neutron capture on 242Pu in the resonance region at the CERN n_TOF-EAR1 facility

Science.gov (United States)

Lerendegui-Marco, J.; Guerrero, C.; Mendoza, E.; Quesada, J. M.; Eberhardt, K.; Junghans, A. R.; Krtička, M.; Aberle, O.; Andrzejewski, J.; Audouin, L.; Bécares, V.; Bacak, M.; Balibrea, J.; Barbagallo, M.; Barros, S.; Bečvář, F.; Beinrucker, C.; Berthoumieux, E.; Billowes, J.; Bosnar, D.; Brugger, M.; Caamaño, M.; Calviño, F.; Calviani, M.; Cano-Ott, D.; Cardella, R.; Casanovas, A.; Castelluccio, D. M.; Cerutti, F.; Chen, Y. H.; Chiaveri, E.; Colonna, N.; Cortés, G.; Cortés-Giraldo, M. A.; Cosentino, L.; Damone, L. A.; Diakaki, M.; Dietz, M.; Domingo-Pardo, C.; Dressler, R.; Dupont, E.; Durán, I.; Fernández-Domínguez, B.; Ferrari, A.; Ferreira, P.; Finocchiaro, P.; Furman, V.; Göbel, K.; García, A. R.; Gawlik, A.; Glodariu, T.; Gonçalves, I. F.; González-Romero, E.; Goverdovski, A.; Griesmayer, E.; Gunsing, F.; Harada, H.; Heftrich, T.; Heinitz, S.; Heyse, J.; Jenkins, D. G.; Jericha, E.; Käppeler, F.; Kadi, Y.; Katabuchi, T.; Kavrigin, P.; Ketlerov, V.; Khryachkov, V.; Kimura, A.; Kivel, N.; Kokkoris, M.; Leal-Cidoncha, E.; Lederer, C.; Leeb, H.; Lo Meo, S.; Lonsdale, S. J.; Losito, R.; Macina, D.; Marganiec, J.; Martínez, T.; Massimi, C.; Mastinu, P.; Mastromarco, M.; Matteucci, F.; Maugeri, E. A.; Mengoni, A.; Milazzo, P. M.; Mingrone, F.; Mirea, M.; Montesano, S.; Musumarra, A.; Nolte, R.; Oprea, A.; Patronis, N.; Pavlik, A.; Perkowski, J.; Porras, J. I.; Praena, J.; Rajeev, K.; Rauscher, T.; Reifarth, R.; Riego-Perez, A.; Rout, P. C.; Rubbia, C.; Ryan, J. A.; Sabaté-Gilarte, M.; Saxena, A.; Schillebeeckx, P.; Schmidt, S.; Schumann, D.; Sedyshev, P.; Smith, A. G.; Stamatopoulos, A.; Tagliente, G.; Tain, J. L.; Tarifeño-Saldivia, A.; Tassan-Got, L.; Tsinganis, A.; Valenta, S.; Vannini, G.; Variale, V.; Vaz, P.; Ventura, A.; Vlachoudis, V.; Vlastou, R.; Wallner, A.; Warren, S.; Weigand, M.; Weiss, C.; Wolf, C.; Woods, P. J.; Wright, T.; Žugec, P.; n TOF Collaboration

2018-02-01

The spent fuel of current nuclear reactors contains fissile plutonium isotopes that can be combined with uranium to make mixed oxide (MOX) fuel. In this way the Pu from spent fuel is used in a new reactor cycle, contributing to the long-term sustainability of nuclear energy. However, an extensive use of MOX fuels, in particular in fast reactors, requires more accurate capture and fission cross sections for some Pu isotopes. In the case of 242Pu there are sizable discrepancies among the existing capture cross-section measurements included in the evaluations (all from the 1970s) resulting in an uncertainty as high as 35% in the fast energy region. Moreover, postirradiation experiments evaluated with JEFF-3.1 indicate an overestimation of 14% in the capture cross section in the fast neutron energy region. In this context, the Nuclear Energy Agency (NEA) requested an accuracy of 8% in this cross section in the energy region between 500 meV and 500 keV. This paper presents a new time-of-flight capture measurement on 242Pu carried out at n_TOF-EAR1 (CERN), focusing on the analysis and statistical properties of the resonance region, below 4 keV. The 242Pu(n ,γ ) reaction on a sample containing 95(4) mg enriched to 99.959% was measured with an array of four C6D6 detectors and applying the total energy detection technique. The high neutron energy resolution of n_TOF-EAR1 and the good statistics accumulated have allowed us to extend the resonance analysis up to 4 keV, obtaining new individual and average resonance parameters from a capture cross section featuring a systematic uncertainty of 5%, fulfilling the request of the NEA.

Monte Carlo codes use in neutron therapy